Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation by Jones, Jeremy et al.
Health Technology Assessment 2009; Vol. 13: No. 35
Health Technology Assessment
NIHR HTA programme
www.hta.ac.uk
July 2009
DOI: 10.3310/hta13350
Adefovir dipivoxil and pegylated 
interferon alpha for the treatment 
of chronic hepatitis B: an updated 
systematic review and economic 
evaluation
J Jones, J Shepherd, L Baxter,  
E Gospodarevskaya, D Hartwell,  
P Harris, A PriceHow to obtain copies of this and other HTA programme reports
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of 
charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also 
available (see below). 
Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and 
private sector purchasers from our Despatch Agents.
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is 
£2 per monograph and for the rest of the world £3 per monograph.
You can order HTA monographs from our Despatch Agents:
– fax (with credit card or official purchase order) 
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).
Additionally the HTA website allows you either to pay securely by credit card or to print out your 
order and then post or fax it.
Contact details are as follows:
HTA Despatch  Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd  Tel: 02392 492 000
4 Oakwood Business Centre  Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK  Fax from outside the UK: +44 2392 478 555
NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of  
£100 for each volume (normally   comprising 30–40 titles). The commercial subscription rate is £300  
per volume. Please see our website for details. Subscriptions can be purchased only for the current or 
  forthcoming volume.
Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd 
and drawn on a bank with a UK address.
Paying by credit card 
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, 
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.
Paying by official purchase order 
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. 
We cannot at present accept purchase orders from commercial companies or from outside the UK.
How do I get a copy of HTA on CD?
Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see 
contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.
The website also provides information about the HTA programme and lists the membership of the   various 
  committees.
HTAAdefovir dipivoxil and pegylated 
interferon alpha for the treatment 
of chronic hepatitis B: an updated 
systematic review and economic 
evaluation
J Jones,1 J Shepherd,1* L Baxter,1 
E Gospodarevskaya,1 D Hartwell,1 
P Harris,1 A Price2
1Southampton Health Technology Assessments Centre (SHTAC), UK
2NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), 
Southampton, UK
*Corresponding author
Declared competing interests of authors: none
Published July 2009
DOI: 10.3310/hta13350
This report should be referenced as follows:
Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P , et al. Adefovir 
dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated 
systematic review and economic evaluation. Health Technol Assess 2009;13(35).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta 
Medica/EMBASE, Science Citation Expanded (SciSearch) and Current Contents/Clinical 
Medicine.
Abstract
Contents
List of abbreviations
Executive summary
Background
Methods
Results
Conclusions
Chapter 1  
Background
Description of underlying health problem
Incidence and prevalence
Vaccination
Morbidity and quality of life
Antiviral treatment
Current service provision
Chapter 2  
Methods
Search strategy
Inclusion and exclusion criteria
Data extraction strategy
Quality assessment strategy
Methods of analysis/synthesis
Chapter 3  
Clinical effectiveness
Results
Chapter 4  
Economic analysis
Methods for economic analysis
Chapter 5  
Discussion
Assessment of clinical effectiveness
Assessment of cost-effectiveness
Chapter 6  
Conclusions
Acknowledgements
References
Appendix 1  
Data extraction and critical 
appraisal of included RCTs
Appendix 2  
QUOROM flow chart of study inclusion 
(2007 update literature search)
Appendix 3  
Characteristics of RCTs included 
in original assessment report
Appendix 4  
Data extraction forms – economic evaluations
Appendix 5 
Transition probabilities used in 
published economic evaluations
Appendix 6  
Updated parameters in probabilistic 
sensitivity analysis
Appendix 7  
Costs and outcomes of sequential 
treatment strategies – HBeAg-positive 
and HBeAg-negative cohorts
Health Technology Assessment 
reports published to date
Health Technology Assessment  
programmeNIHR Health Technology Assessment programme
T
he Health Technology Assessment (HTA) programme, part of the National Institute for Health 
Research (NIHR), was set up in 1993. It produces high-quality research information on the 
effectiveness, costs and broader impact of health technologies for those who use, manage and provide care 
in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent 
and treat disease, and improve rehabilitation and long-term care.
The research findings from the HTA programme directly influence decision-making bodies such as the 
National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee 
(NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they 
form a key component of the ‘National Knowledge Service’.
The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three 
routes to the start of projects.
First is the commissioned route. Suggestions for research are actively sought from people working in the 
NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS 
trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service 
users). The HTA programme then commissions the research by competitive tender.
Second, the HTA programme provides grants for clinical trials for researchers who identify research 
questions. These are assessed for importance to patients and the NHS, and scientific rigour.
Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme 
commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together 
evidence on the value of specific technologies.
Some HTA research projects, including TARs, may take only months, others need several years. They 
can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, 
undertaking a trial, or other research collecting new data to answer a research problem.
The final reports from HTA projects are peer reviewed by a number of independent expert referees before 
publication in the widely read journal series Health Technology Assessment.
Criteria for inclusion in the HTA journal series
Reports are published in the HTA journal series if (1) they have resulted from work for the HTA 
programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and 
editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal 
and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication 
of the review by others.
The research reported in this issue of the journal was commissioned by the HTA programme as project 
number 07/15/01. The contractual start date was in December 2007. The draft report began editorial 
review in July 2008 and was accepted for publication in October 2008. As the funder, by devising a 
commissioning brief, the HTA programme specified the research question and study design. The authors 
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their 
work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would 
like to thank the referees for their constructive comments on the draft document. However, they do not 
accept liability for damages or losses arising from material published in this report.
The views expressed in this publication are those of the authors and not necessarily those of the HTA 
programme or the Department of Health.
Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Aileen Clarke, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsma and Professor 
Ken Stein
ISSN 1366-5278
© 2009 Queen’s Printer and Controller of HMSO
This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of 
Southampton Science Park, Southampton SO16 7NS, UK.
Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.
Printed on acid-free paper in the UK by Henry Ling Ltd, The Dorset Press, Dorchester.  GDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
iii
Objective: To update and extend a 2006 report on the 
clinical effectiveness and cost-effectiveness of adefovir 
dipivoxil (ADV) and pegylated interferon alpha (PEG-α) 
for the treatment of chronic hepatitis B (CHB).
Data sources: Thirteen bibliographic databases 
were searched including MEDLINE, EMBASE and 
the Cochrane Library. Searches were run from the 
beginning of 2005 to September 2007.
Review methods: For the clinical effectiveness review, 
randomised controlled trials (RCTs) comparing ADV, 
PEG-α-2a and PEG-α-2b with currently licensed 
treatments for CHB, including non-pegylated interferon 
alpha (IFN-α) and lamivudine (LAM), were included. 
Outcomes included biochemical, histological and 
virological response to treatment, drug resistance 
and adverse effects. A systematic review of economic 
evaluations of antiviral treatments for CHB was 
conducted. The economic Markov model used in the 
2006 report was updated in terms of utility values, 
discount rates and costs.
Results: Of the 82 papers retrieved for detailed 
screening, eight RCTs were included. Three evaluated 
ADV, four evaluated PEG-α-2b and one (from the 
original literature search) compared PEG-α-2b plus 
LAM with PEG-α-2b monotherapy. No RCTs of PEG-α-
2a were identified. One ADV trial showed a statistically 
significant difference between ADV and placebo in 
terms of ALT response and HBV DNA levels, favouring 
ADV. Following withdrawal of ADV, levels were similar 
to those in placebo patients. In the ADV versus ADV 
plus LAM trial, there was a statistically significant 
difference in favour of the combination treatment. In 
the PEG-α trials, there were statistically significant 
differences favouring PEG-α-2b plus LAM compared 
with either one of the drugs given as monotherapy. For 
the comparison between PEG-α-2b and IFN-α and 
the comparison between different staggered regimens 
of the commencement of PEG-α-2b and LAM, there 
were no statistically significant differences between 
groups. Four full economic evaluations were identified, 
in addition to one identified in the original report. Two 
assessed PEG-α-2a; the remainder assessed ADV. PEG-
α-2a was associated with increased treatment costs and 
gains in quality-adjusted life expectancy. In a UK study, 
the incremental cost-effectiveness ratio (ICER) for PEG-
α-2a was £10,444 per QALY gained compared with 
LAM. Evaluations of ADV found that LAM monotherapy 
was dominated; the ICER for ADV monotherapy 
compared with ‘doing nothing’ was $19,731. The 
results of the updated analysis were generally robust 
to changes in deterministic sensitivity analysis. In a 
probabilistic sensitivity analysis, the same sequence of 
treatments was identified as optimal. In a probabilistic 
sensitivity analysis, PEG-α-2b had a probability of being 
cost-effective of 79% at a willingness-to-pay threshold 
of £20,000 per QALY, and 86% at a willingness-to-pay 
threshold of £30,000 per QALY.
Conclusions: Both ADV and PEG-α are beneficial for 
patients with CHB in terms of suppressing viral load, 
reducing liver damage-associated biochemical activity, 
inducing HBeAg seroconversion, and reducing liver 
fibrosis and necroinflammation. The effects of long-
term treatment with ADV are generally durable, with 
relatively low rates of resistance. In most cases, cost-
effectiveness estimates were within acceptable ranges. 
Further research should assess the clinical effectiveness 
and cost-effectiveness of newer antiviral agents in 
relation to existing drugs, including the role of initiating 
treatment with combination therapy.
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Background
This short report is an update and extension of a 
technology assessment report published in 2006 on 
the clinical effectiveness and cost-effectiveness of 
adefovir dipivoxil (ADV) and pegylated interferon 
alpha (PEG-α) for the treatment of chronic 
hepatitis B (CHB).
Hepatitis B is an infectious disease caused by 
the hepatitis B virus (HBV). If not successfully 
treated, it can lead to progressive liver damage, 
including cirrhosis, hepatocellular carcinoma and 
death. Patients with CHB may be HBeAg positive 
or HBeAg negative, depending on the presence 
or absence of the ‘e’ antigen. It is estimated that 
around 180,000 people (0.3%) in the UK are 
chronically infected, with around 7000 new cases 
each year, primarily from immigrants, most of 
whom are asymptomatic.
Methods
Assessment of clinical 
effectiveness
We searched for studies of the clinical effectiveness 
of adefovir dipivoxil, pegylated interferon alpha-
2a (PEG-α-2a) and pegylated interferon alpha-2b 
(PEG-α-2b) (note that the latter was not included 
in the original report). Searches were run from the 
beginning of 2005 to September 2007. Thirteen 
bibliographic databases were searched, including 
MEDLINE, EMBASE and the Cochrane Library.
All studies were screened against a set of pre-
specified inclusion criteria. For the clinical 
effectiveness review, we included randomised 
controlled trials (RCTs) which compared 
ADV, PEG-α-2a, and PEG-α-2b with currently 
licensed treatments for CHB, including the 
immunomodulatory drug non-pegylated interferon 
alpha (IFN-α) and the nucleoside analogue 
lamivudine (LAM).
Outcomes included biochemical (alanine 
aminotransferase, ALT), histological (liver 
fibrosis and necroinflammation) and virological 
[HBV deoxyribonucleic acid (DNA)] response to 
treatment, drug resistance and adverse effects. 
The trials were reviewed in a narrative synthesis 
but meta-analysis was not undertaken because of 
heterogeneity in the interventions and comparators 
evaluated.
Assessment of cost-effectiveness
A systematic review of economic evaluations of 
antiviral treatments for CHB was conducted. In 
addition, the economic model devised for our 
previous report was updated using utility values 
based on a recent study eliciting health-state 
valuations from CHB-infected patients. The 
model was also updated to account for changes 
in methodological guidance on discount rates for 
costs and outcomes. Health-state and treatment 
costs were inflated to 2006–7 prices. Evidence for 
the clinical effectiveness of PEG-α-2b was used 
in the model to estimate the cost-effectiveness of 
PEG-α-2b compared with IFN-α.
Results
Clinical effectiveness
Literature searches yielded a total of 735 articles. 
Of these, 653 were excluded on the basis of title 
and, where available, abstract. Eighty-two papers 
were retrieved for detailed screening and eight 
randomised controlled trials (RCTs) were included 
in the systematic review:
•	 Three evaluated ADV, one of which was a 
long-term follow-up of a trial included in our 
original assessment report. In two trials ADV 
was compared with placebo, and in a third 
ADV was compared with ADV added to LAM in 
patients with LAM resistance.
•	 Four evaluated PEG-α-2b. In two of these PEG-
α-2b was combined with LAM and compared 
with either PEG-α-2b monotherapy or LAM 
monotherapy. Another compared three 
staggered regimens of PEG-α-2b combined 
with LAM. The fourth trial compared PEG-α-
2b monotherapy with IFN-α.
•	 A further PEG-α-2b RCT was included from 
our original literature search database (but not 
included in the original assessment report as it 
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was not in the scope of the review at that time). 
This RCT compared PEG-α-2b combined with 
LAM with PEG-α-2b monotherapy.
•	 No RCTs of PEG-α-2a were identified.
The trials varied in terms of aims, size and design 
characteristics. Five included only HBeAg-positive 
patients, with the remaining three including only 
HBeAg-negative patients.
Methodological quality also varied. Some 
trials reported adequate blinding, allocation 
concealment and randomisation methods, while 
other trials either failed to report such details or 
were judged inadequate.
ADV trials
In one trial there was a statistically significant 
difference between ADV and placebo in terms of 
ALT response and HBV DNA levels after 12 weeks, 
favouring ADV. Following withdrawal of ADV after 
40 weeks, the proportion of patients exhibiting 
HBV DNA and ALT responses declined to levels 
similar to those experienced by patients who had 
received placebo. There was no viral resistance 
to ADV. The rate of adverse events and dose 
discontinuations was low and generally similar 
between study groups.
In the trial that compared switching to ADV 
versus adding ADV to LAM in patients with LAM 
resistance there was a statistically significant 
difference in favour of the combination treatment 
in terms of zero resistance to ADV. For the other 
outcomes there were no statistically significant 
differences between groups.
A follow-up publication of an RCT included in our 
original assessment report, comparing ADV with 
placebo in HBeAg-negative patients, reported 
generally sustained HBV DNA and ALT response 
rates among those treated with ADV for 5 years. 
Cumulative probabilities of resistance to ADV in 
the cohort varied from 11% to 29% depending on 
how resistance was defined.
PEG-α trials
Where statistical testing was reported, there were 
statistically significant differences favouring PEG-
α-2b in combination with LAM compared with 
either one of the drugs given as monotherapy. This 
was the case for HBV DNA and ALT responses 
in two trials. However, another trial reported no 
significant differences between groups for these 
measures. There was a significant difference for 
HBeAg seroconversion, favouring combination 
therapy in one trial. For liver histology either there 
was no significant difference between groups or no 
statistical tests were performed.
For the comparison between PEG-α-2b and IFN-α 
and the comparison between different staggered 
regimens of the commencement of PEG-α-2b 
and LAM, there were no statistically significant 
differences between groups across the outcome 
measures where tests were reported.
Cost-effectiveness
The systematic review of cost-effectiveness studies 
identified four relevant full economic evaluations, 
in addition to one full economic evaluation 
identified and partially reviewed in our original 
assessment report. Two of the evaluations assessed 
PEG-α-2a; the remainder assessed ADV. Four of 
the five economic evaluations used Markov models, 
with lifetime horizons, while the other study used 
a decision tree with a 4-year time horizon. State-
transition diagrams in the evaluations were similar, 
identifying the treatment aim as inducing HBeAg 
seroconversion for patients with HBeAg-positive 
CHB and viral suppression for patients with either 
HBeAg-positive or HBeAg-negative CHB.
Economic evaluations of PEG-α-2a found that 
it was associated with increased treatment costs 
but also gains in quality-adjusted life expectancy. 
In a UK study, the incremental cost-effectiveness 
ratio (ICER) for PEG-α-2a was £10,444 per QALY 
gained compared with LAM. Evaluations of ADV 
found that LAM monotherapy was dominated, 
while the ICER for ADV monotherapy compared 
with ‘doing nothing’ was $19,731($14,342–
$24,224) at 2005 prices.
A review of health-state utility values used in 
economic evaluations of antiviral treatments for 
CHB showed that widely varying values were used, 
many of which were not specific to CHB patients. 
A recently published study reporting health-
state utilities for patients with CHB infection and 
for non-infected general population samples, 
derived using the standard gamble technique, was 
identified and reviewed.
The ICERs generated by the update of our 
economic model were generally less favourable 
than those reported in the original assessment 
report. However, it appears that much of 
the difference arises from recent changes to DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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methodological guidance (i.e. discounting costs 
and outcomes at 3.5% rather than 6% and 1.5% 
respectively) rather than from changes in costs or 
health-state utilities.
The sequential treatment strategies identified as 
optimal in our original report remained optimal 
in the updated model, i.e. interferon (pegylated 
or non-pegylated) followed by LAM, with ADV as 
salvage for patients who develop LAM resistance.
The results of the updated analysis were generally 
robust to changes in deterministic sensitivity 
analysis. The most notable changes were in the 
ICER for the strategy including ADV as salvage 
therapy for patients who develop resistance to 
LAM, in some cases increasing the ICER beyond 
the threshold conventionally used to indicate 
cost-effectiveness in the context of NHS decision 
making.
•	 The most influential structural assumption 
was excluding the possibility of HBeAg 
seroconversion (in HBeAg-positive CHB) in 
patients with compensated cirrhosis, which 
increased the ICER to £40,833 per QALY 
gained.
•	 In terms of the baseline characteristics of the 
treated cohort, decreasing the proportion with 
HBeAg-positive CHB and increasing age were 
associated with less favourable ICERs.
•	 The most influential parameter values related 
to the gain in utility associated with HBeAg 
seroconversion and loss of the surface antigen 
(HBsAg). This affected the ICERs for all 
strategies, but was most notable for the strategy 
including ADV as salvage for patients who 
develop resistance to LAM. If there is no utility 
gain for HBeAg seroconversion or loss of 
HBsAg, the ICER increases to £31,114.
In a probabilistic sensitivity analysis the same 
sequence of treatments was identified as optimal. 
However, the strategy including ADV as salvage 
becomes optimal only above a willingness-to-
pay threshold of £27,000 per QALY. This is at 
the upper limit of the range of ICERs regarded 
as cost-effective from an NHS decision-making 
perspective. Interferon (conventional or pegylated) 
followed by LAM is optimal for a willingness to 
pay of £9000–£26,000, compared with a range 
of £5000–£11,500 in our previous report. As 
discussed, much of this difference arises from 
changes in the practice of discounting rather than 
changes to input values in the model.
The ICER for PEG-α-2b, compared with IFN-α-2b, 
in patients with HBeAg-positive CHB was £9169, 
based on the results of a clinical trial of 24 weeks 
of interferon treatment. The trial did not include a 
placebo arm, so no ICER for PEG-α-2b compared 
with best supportive care was estimated. Results 
were generally robust to changes in deterministic 
sensitivity analysis.
•	 Increasing age of the cohort and lower utility 
gains from HBeAg seroconversion or loss of 
HBsAg were associated with less favourable 
ICERs.
•	 Alternative discount rates (6% for costs and 
1.5% for outcomes, as in our previous report, 
or 0% for both costs and outcomes) and a 
reduction in cost for PEG-α-2b were associated 
with more favourable ICERs.
•	 All ICERs in the one-way sensitivity analyses 
were below the threshold conventionally 
deemed as cost-effective.
In a probabilistic sensitivity analysis, PEG-α-2b had 
a probability of being cost-effective (compared with 
IFN-α-2b) of 79% at a willingness-to-pay threshold 
of £20,000 per QALY, and 86% at a willingness-to-
pay threshold of £30,000 per QALY.
Conclusions
Overall, the evidence from RCTs suggests that 
the effects of long-term treatment with ADV are 
generally durable, with relatively low rates of 
resistance. It is also apparent that beneficial effects 
are lost once ADV is withdrawn. Furthermore, in 
LAM-resistant HBeAg-negative patients there were 
no significant differences between adding ADV 
to ongoing LAM or switching from LAM to ADV, 
except for viral resistance where the combination 
was more favourable.
PEG-α-2a was associated with some benefit in 
terms of virological and biochemical response, 
HBeAg seroconversion and liver histology, relative 
to comparators. However, not all differences were 
statistically significant, and often significance tests 
were not reported at all. Consequently, there are 
uncertainties regarding the clinical effectiveness of 
this drug across different outcomes relevant to the 
control of CHB.
In terms of cost-effectiveness, optimum treatment 
strategies include IFN-α or PEG-α followed by 
LAM, with ADV used in patients who become Executive summary
xii
resistant to LAM. In most cases, cost-effectiveness 
estimates were within acceptable ranges.
Further high-quality RCTs are required to assess 
the durability of long-term antiviral treatment, 
optimum treatment of patients with LAM 
resistance, and the clinical effectiveness and cost-
effectiveness of initiating treatment with nucleoside 
combination therapy, including newer antiviral 
agents.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
1
Description of underlying 
health problem
Hepatitis B is an infectious disease caused by the 
hepatitis B virus (HBV), and was first identified 
in 1965. Key routes of transmission include 
sexual contact (via exposure to blood, saliva and 
other body fluids), injecting drug use, and from 
mother to child (particularly in South-east Asia). 
In health-care workers, needlestick injuries are 
also a relatively rare source of transmission. Some 
patients with haemophilia in the UK have been 
infected via contaminated blood products [as well 
as being infected with the hepatitis C virus (HCV)].
The virus infects cells in the liver (hepatocytes) 
and the immune system will at some point mount 
a response to try to remove the infection (in some 
cases after several years). If untreated, HBV can 
result in long-term complications such as cirrhosis 
and liver cancer (hepatocellular carcinoma, HCC). 
Carriers of the virus can remain asymptomatic for 
many years before presenting with symptoms of 
chronic liver disease.
In acute infection, the majority of cases are self-
limiting within 6 months, with patients developing 
lasting immunity to reinfection as the virus (surface 
antigen) is cleared from the blood and liver, 
although viral DNA can be detected in many cases.
There may be no or few symptoms (about 70% 
of patients are asymptomatic), and treatment is 
generally not indicated.
Chronic hepatitis B (CHB) results from an 
inadequate immune response to the primary 
infection, where viral replication continues and 
there is continuing presence of the surface antigen 
(HBsAg). It can follow acute hepatitis or be 
transmitted vertically from mother to baby (in the 
latter case there may be no acute infection). The 
hepatitis B surface antigen is present in all forms of 
the disease.
HBeAg-positive chronic 
hepatitis B
HBeAg-positive CHB (also referred to as ‘wild 
type’ CHB) is, for many, the first stage of chronic 
disease. This form of the disease prevails in 
Europe and North America. The first stage is the 
‘immunotolerant’ phase, during which the immune 
system does not actively fight the virus, and this 
may last for a number of years.1 Those who acquire 
the disease as neonates or in early childhood will 
undergo this phase, but adults and those infected 
during adolescence generally will not. During the 
immunotolerant phase, HBV deoxyribonucleic acid 
(DNA) levels are increased but aminotransferase 
levels remain normal. Treatment is not indicated in 
this phase.2
Progression to the ‘immunoactive’ phase (also 
referred to as the ‘immune clearance phase’) of 
chronic HBeAg-positive disease, whereby the 
immune system is actively fighting the virus, is 
characterised by HBV DNA replication and an 
increase in alanine aminotransferase (ALT) levels 
(ALT being an enzyme that indicates inflammation 
of the liver). Symptoms may appear during 
this phase, and ‘flares’ (short-lived rises in ALT 
levels) of aminotransferases may occur before 
seroconversion from HBeAg to anti-HBe in some 
patients.3 Treatment, the goal of which is to induce 
HBeAg seroconversion in the first instance, is 
indicated in this phase.2
HBeAg seroconversion results in the disease 
progressing either to an inactive carrier state (also 
referred to as the ‘low-’ or ‘non-replicative state’ 
or ‘immune control phase’) or to the HBeAg-
negative form of the disease. Between 50% and 
70% of patients with elevated aminotransferases 
spontaneously seroconvert within 5–10 years of 
diagnosis, with a mean annual rate of 8–15% in 
Western countries.3 HBeAg seroconversion is more 
likely to occur in older people, females and those 
with high aminotransferase levels. A proportion 
of seroconverted patients will also reacquire the 
e antigen (i.e. become HBeAg positive again), 
effectively reactivating the disease. Although, for 
most patients, HBeAg seroconversion results in 
transition to the inactive carrier state, between 1% 
and 5% of patients progress to the ‘immune escape 
phase’ whereby a pre-core viral mutation emerges.2 
This is characterised by undetectable HBeAg and 
detectable anti-HBe levels, high serum HBV DNA 
levels and elevated aminotransferase levels (see 
below).3
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The low- or non-replicative state is characterised 
by low HBV DNA levels and normal ALT. Unless 
cirrhosis is present, this stage usually has a benign 
prognosis, but around 3% of patients per annum 
may undergo reactivation and develop progressive 
liver disease.3
HBeAg-negative 
chronic hepatitis B
HBeAg-negative CHB (also known as ‘pre-core 
mutant’ or ‘variant’ hepatitis B) was identified 
relatively recently. It is a variant HBV strain 
carrying a mutation within the pre-core region of 
the HBV genome that permits viral replication 
but prevents production of HBeAg (or a mutation 
within the core region of the genome that 
diminishes HBeAg expression).4 Although some 
patients acquire HBeAg-negative infection on or 
following HBeAg seroconversion (as mentioned 
above), many develop the variant at an earlier stage 
or from the outset.
HBeAg-negative infection, common in 
Mediterranean areas and South-east Asia, 
is considered to be the most severe form of 
the disease. It is characterised by raised (but 
fluctuating) ALT and detectable HBV DNA levels.2 
There are three main patterns of ALT activity: 
recurrent flares with normalisation in between; 
recurrent flares with persistently abnormal 
serum aminotransferase levels in between; and 
persistently abnormal ALT without flares.3
HBsAg seroconversion
Around 0.5–2% of people with CHB (0.05–0.08% 
in Asia) each year lose the surface antigen 
(HBsAg) and develop antibodies (anti-HBs), 
thereby undergoing HBsAg seroconversion. This 
is most common in the year following HBeAg 
seroconversion (although patients can also 
seroconvert from the immunotolerant phase) and 
signifies resolution of chronic infection. Although 
HBsAg seroconversion is believed to be a relatively 
rare occurrence, it has been recommended that 
future clinical trials use it as an outcome measure 
as it represents the ultimate goal of therapy.2
Long-term complications
People with CHB, in common with chronic 
hepatitis C, are at increased risk of progressing 
to long-term complications, including cirrhosis 
(scarring) of the liver, decompensated liver disease 
and/or HCC. The risk of progression varies with 
geographical location and mode of transmission. 
Evidence suggests that 2–5.5% of HBeAg-positive 
people and 8–10% of those who are negative 
progress to cirrhosis annually.3 Decompensated 
liver disease occurs when the liver can no longer 
compensate for scarred tissue. It is characterised 
by ascites (fluid in the peritoneal cavity), variceal 
bleeding and hepatic encephalopathy, and is 
associated with irreversible liver failure, requiring 
liver transplantation. Death from liver disease 
and HCC is common in CHB. It is estimated that 
there are more than 1200 new cases of HCC in 
the UK each year, of which 430 are caused by viral 
hepatitis.
The 5-year mortality rate for CHB without cirrhosis 
is 0–2%, but this increases to 14–20% for those 
with compensated cirrhosis and 70–80% after the 
occurrence of decompensation.3
Incidence and prevalence
Approximately 400 million people worldwide 
are infected with chronic HBV, although levels 
vary geographically.5 In North-western Europe, 
North America and Australia there is a low level of 
endemic HBV, and the virus is usually transmitted 
by needle sharing among intravenous drug users 
(IDUs) and by sexual transmission. High levels 
of infection are found in Africa and Asia, where 
the virus is usually transmitted perinatally or 
during early childhood. The UK is considered 
to be a low prevalence country, with around 
156,000 people in England and Wales infected 
with CHB6 (180,000/0.3% in the UK) and around 
7000 estimated new chronic cases every year 
(mostly from immigration of established HBV 
carriers, many of whom are thought to be HBeAg 
negative and in the immunotolerant phase, and 
thus not currently symptomatic). The Hepatitis B 
Foundation recently estimated that the prevalence 
of CHB in the UK may have increased to 325,000 
and is thought likely to increase further as a 
consequence of increasing rates of immigration 
of people from countries with a high CHB 
prevalence.7
Vaccination
A safe and effective vaccine for hepatitis B has been 
available since 1982 and many countries operate a 
universal vaccination programme for newborns or 
adolescents. However, the UK has not introduced 
such a policy, instead offering selective vaccination 
to key risk groups (e.g. men who have sex with 
men, injecting drug users and health-care workers).DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Morbidity and quality of life
The impact of CHB on quality of life in the early 
stages of disease is not thought to be great. Many 
people do not know that they are infected and 
consequently may not present to health services for 
many years until symptoms of liver disease become 
evident.
However, quality of life becomes significantly 
impaired as the disease progresses to cirrhosis, 
decompensated liver disease and HCC.8 Patients 
who seroconvert into the low- or non-replicative 
state are thought to have a relatively good quality 
of life. There is evidence to suggest that quality of 
life impairment in CHB is not as great as it is with 
chronic HCV.9,10
Antiviral treatment
There are two modes of antiviral treatment for 
CHB:
1.  Short-term or finite, circumscribed therapy 
with interferon alpha (IFN-α). The goal is 
to achieve an immune response in terms of 
HBeAg seroconversion (for patients who are 
HBeAg positive), suppression of HBV DNA 
and, where possible, HBsAg seroconversion. 
This mode of treatment is a first-line attempt 
to ‘switch’ the immune system into clearing 
the infection or into remission. Although 
IFN-α appears to be commonly used in this 
scenario, some clinicians may use a nucleotide/
nucleoside analogue.
2.  Long-term maintenance treatment for patients 
who have failed IFN-α or for whom disease has 
advanced such that IFN-α is contraindicated. 
This would usually involve lamivudine (LAM), 
a nucleoside analogue. This mode of treatment 
may be particularly suitable for those HBeAg-
negative patients with high levels of HBV 
DNA and ALT. In these patients, long-term 
suppression of HBV replication with either 
nucleoside or nucleotide analogues will be 
necessary until the infected cells have been 
eliminated. The half-life of these cells may be 
10 years or more.11 Reducing levels to ‘normal’ 
will likely limit disease progression.
IFN-α was used as first-line treatment of CHB 
for a number of years. Versions available include 
IFN-α-2a (Roferon-A®; Hoffman–La Roche) and 
IFN-α-2b (IntronA®, Viraferon®; Schering–Plough). 
In 1998, LAM (Epivir, Zeffix; GlaxoSmithKline), 
an oral nucleoside reverse transcriptase inhibitor, 
was licensed for the treatment of CHB. In the last 
5 years, newer agents have been licensed, such as 
adefovir dipivoxil (ADV) and the pegylated form of 
IFN-α (PEG-α).
Adefovir dipivoxil (Hepsera®; Gilead Sciences), 
a prodrug of adefovir, was the first licensed 
nucleotide analogue for the treatment of CHB. It 
is currently licensed in the UK for CHB infection 
with either compensated liver disease with evidence 
of active viral replication, persistently elevated 
serum ALT levels and histological evidence 
of active liver inflammation and fibrosis, or 
decompensated liver disease. The recommended 
dose is 10 mg per day, taken orally.
A newer ‘pegylated’ derivative of IFN-α has 
become available recently. Pegylation involves 
the attachment of an inert polyethylene glycol 
polymer to the IFN-α molecule to produce a larger 
molecule with a prolonged half-life. Pegylation 
prolongs the biological effect and thus fewer 
injections are necessary.
Two versions are available: (1) 40 kD PEG-α-2a 
(Pegasys®; Hoffman–La Roche) and (2) 12 kD 
PEG-α-2b (PegIntron®, ViraferonPeg®; Schering–
Plough). Only the former is currently licensed in 
the UK.
Recently licensed drugs for CHB include 
nucleoside analogues entecavir (Baraclude®; 
Bristol–Myers Squibb) and telbivudine (Sebivo®; 
Novartis). These are not within the scope of the 
current report, but have undergone appraisal by 
the National Institute for Health and Clinical 
Excellence (NICE).
Current service provision
In 2006 NICE issued guidance to the health service 
in England and Wales on the use of PEG-α-2a 
and ADV, based on an independent technology 
assessment report (TAR).12 The guidance 
recommends:
•	 PEG-α-2a as an option for the initial treatment 
of adults with CHB, within its licensed 
indications.
•	 ADV as an option for the treatment of adults 
with CHB within its licensed indications if:
  – treatment with IFN-α or PEG-α-2a has 
been unsuccessful, or
  – a relapse occurs after successful initial 
treatment, or
  – treatment with IFN-α or PEG-α-2a is Background
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poorly tolerated or contraindicated.
The guidance also states that ADV should not 
normally be given before treatment with LAM. It 
may be used either alone or in combination with 
LAM when:
•	 treatment with LAM has resulted in viral 
resistance, or
•	 LAM resistance is likely to occur rapidly (e.g. 
in the presence of highly replicative hepatitis 
B disease) and development of LAM resistance 
is likely to have an adverse outcome (e.g. if 
a flare of the infection is likely to precipitate 
decompensated liver disease).
Our previous assessment report, which 
underpinned this guidance, was produced in 
early 2005.12 The current report is an update 
of the assessment for the National Institute for 
Health Research (NIHR) Health Technology 
Assessment (HTA) Programme (and is not intended 
to inform any NICE appraisal). The aim of 
the report is to update the systematic review of 
clinical effectiveness and the economic evaluation 
conducted in the original report. It also expands 
on the original report by including PEG-α-2b, 
which was not included in NICE’s appraisal 
because of its unlicensed status.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he methods used in this update are similar 
to those reported in the original assessment12 
(which can be downloaded free of charge from 
www.hta.ac.uk). A protocol outlining the scope 
and methods was published prior to the start of 
the project. This report was commissioned by the 
HTA programme as a ‘short technology assessment 
report’. Consequently the time and resources 
allocated to it were less than those allocated to the 
original report, which was commissioned as a ‘full 
technology assessment report’.
Search strategy
A sensitive search strategy was developed, tested 
and refined by an information scientist. Specific 
searches were conducted to identify studies of 
clinical effectiveness and cost-effectiveness. The 
strategies were the same as those used in our 
previous assessment report;12 please refer to that 
report for further detail.
The strategies were applied to the following 
electronic databases:
•	 Cochrane Systematic Reviews Database
•	 Cochrane Central Register of Controlled Trials
•	 NHS Centre for Reviews and Dissemination 
(CRD) (University of York) databases:
  – DARE (Database of Abstracts of Reviews of 
Effects)
  – Health Technology Assessment (HTA) 
database
  – NHS EED (Economic Evaluations 
Database)
•	 MEDLINE (Ovid)
•	 PREMEDLINE
•	 EMBASE (Ovid)
•	 EconLit (Silver Platter)
•	 National Research Register
•	 ISI Web of Science – Science Citation Index
•	 ISI Proceedings
•	 ISI BIOSIS
•	 Clinical trials.gov
•	 Current Controlled Trials.
In our original report, searches were carried out 
for the period 1995/1996 to April 2005. In this 
update they were run from the beginning of 2005 
to September 2007. All searches were limited to the 
English language.
We rescreened our original bibliographic database 
to identify any relevant trials of PEG-α-2b. 
Although not included in our original report, our 
search strategies were designed to identify studies 
of PEG-α-2a as well as PEG-α-2b.
Inclusion and 
exclusion criteria
Studies identified by the search strategy were 
assessed for inclusion in two stages. Firstly, the 
titles and abstracts of all identified studies were 
screened for possible inclusion by one reviewer, 
and a random sample of 10% of these were 
checked by a second reviewer. Any differences in 
opinion between reviewers were discussed and 
a final decision was reached. Secondly, full-text 
versions of relevant papers were retrieved, and an 
inclusion worksheet was applied independently 
by two reviewers. Any differences in judgement at 
either stage were resolved through discussion. The 
level of agreement between reviewers on selection 
decisions was not assessed.
The inclusion criteria, as specified in the study 
protocol, were as follows. (Note that the inclusion 
criteria for this update are the same as for the 
original assessment report with one key difference, 
i.e. studies of PEG-α-2b were eligible.)
�Interventions
•	 Interventions (alone and in combination with 
other treatment options):
  – PEG-α-2a†
  – PEG-α-2b†
  – ADV
•	 Comparators (alone and in combination with 
other treatment options):
  – PEG-α-2a*
  – PEG-α-2b*
  – ADV*
  – IFN-α-2a
  – IFN-α-2b
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  – LAM
  – best supportive care.
Note that † = not indicated for patients with 
decompensated liver disease; * = intervention was 
not compared with itself.
Patients
•	 Adults with CHB infection, including HBeAg-
positive and HBeAg-negative patients, with 
compensated or decompensated liver disease.
Types of studies
•	 Randomised controlled trials (RCTs) 
comparing the different drugs with placebo 
or each other or best supportive care. (Note 
that observational follow-up studies of RCTs 
included in our original report, where fully 
published, were eligible.)
•	 Unpublished material, including studies 
published as abstracts or conference 
presentations were not included.
•	 Full economic evaluations of the specified 
interventions in patients with CHB were 
included in the review of cost-effectiveness.
Outcomes
•	 The following outcome measures were 
included, where available:
  – survival
  – health-related quality of life
  – drug resistance
  – time to treatment failure
  – histological response (e.g. inflammation/
fibrosis – on biopsy)
  – biochemical response (e.g. liver function – 
aminotransferase)
  – virological response (e.g. seroconversion 
rate and viral replication – HBV DNA)
  – seroconversion (e.g. HBeAg loss/anti-HBe; 
HBsAg loss/anti-HBs)
  – adverse effects of treatment.
Data extraction strategy
Data were extracted from the included clinical 
effectiveness studies using a standardised template. 
Data extraction was undertaken by one reviewer 
and checked by a second, with any disagreements 
resolved through discussion. The level of 
agreement between reviewers was not assessed. The 
full data extraction forms of all the included studies 
can be seen in Appendix 1.
Quality assessment strategy
The methodological quality of RCTs was assessed 
using the CRD (University of York) criteria13 
(Appendix 1). Quality criteria were applied by 
one reviewer and checked by a second, with any 
disagreements resolved through discussion.
Methods of analysis/synthesis
A narrative synthesis was undertaken with the 
main results of the included clinical effectiveness 
and cost-effectiveness studies described 
qualitatively and in tabular form. A meta-analysis 
was not possible because of heterogeneity in the 
interventions and comparators evaluated by the 
included clinical trials.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
7
Results
Quantity and quality of 
research available
Appendix 2 illustrates the inclusion and exclusion 
of studies over the various stages of screening, 
adapted from the QUOROM flowchart. The 
literature searches yielded a total of 735 articles. Of 
these, 653 were excluded on the basis of title and, 
where available, abstract. In many cases, studies 
were excluded on the basis of inappropriate study 
design (i.e. they were not RCTs). The remaining 
82 papers were retrieved for detailed screening. Of 
these, 65 were excluded, again primarily because 
of inappropriate study design. The remaining 17 
papers were included, and of these:
•	 Four were follow-up publications relating to 
RCTs included in our original report.14–17 
These publications explored different aspects 
of the RCTs, such as predictors of treatment 
effect and subgroup analyses (e.g. based on 
genotype). As they do not report any updated 
findings on the main outcomes of the RCTs 
(e.g. long-term follow-up of HBV DNA, ALT, 
HBeAg seroconversion) they are not discussed 
further in the current report.
•	 Thirteen papers described a total of seven 
studies which met the inclusion criteria for the 
review. Of these seven studies:
  – three were RCTs of ADV, one of which was 
a long-term follow-up of an RCT included 
in our original assessment report
  – four were RCTs of PEG-α-2b (no RCTs of 
PEG-α-2a were identified in the update 
search).
•	 An additional RCT of PEG-α-2b from our 
original bibliographic database was also 
included in the review, to make a total of eight 
included RCTs.
In summary, a total of eight RCTs met the inclusion 
criteria as described by 13 publications. These are 
the focus of this report.
Characteristics of included 
studies from the update search
For details of the RCTs included in our original 
report see Appendix 3.
The key characteristics of the eight included 
studies, in terms of interventions, patients, 
methods and methodological quality, are described 
in the following sections.
Characteristics of ADV studies
Three fully published RCTs which evaluated 
treatment with ADV in CHB patients were 
identified and included.18–20 One trial, by Rapti 
and colleagues,18 recruited patients from a long-
term open-label study of LAM monotherapy 
and evaluated the efficacy of switching to ADV 
monotherapy or adding ADV to LAM.18 Results 
at 12 and 24 months are reported but the study 
is ongoing. The second trial, by Zeng and 
colleagues,19 had three arms, with participants 
receiving either ADV or placebo for 12 weeks, ADV 
for 28 weeks and ADV or placebo for a further 12 
weeks (52 weeks’ total treatment duration):
•	 placebo–ADV–ADV
•	 ADV–ADV–ADV
•	 ADV–ADV–placebo.
The rationale of both these studies was based 
upon the need for well-tolerated efficacious drugs 
that have a high barrier to the development 
of resistance, given that many CHB patients 
develop resistance to first-line LAM therapy. 
In the Rapti and colleagues study,18 this was 
investigated by evaluating long-term therapy for 
LAM-resistant patients by adding ADV to LAM, 
compared with switching to ADV. The trial by Zeng 
and colleagues19 tested the long-term antiviral 
efficacy and safety of ADV monotherapy, and also 
investigated the impact of cessation of therapy 
(placebo phases).
The third trial, by Hadziyannis and colleagues,20 
was a long-term follow-up of Study 438,21,22 an 
RCT that was included in our original assessment 
report.12 The trial compared ADV with placebo for 
48 weeks, at which point patients who had received 
ADV were re-randomised to ADV for a further 
48 weeks (n = 80, the ADV–ADV group) or to 
placebo (n = 40, the ADV–placebo group). Patients 
originally randomised to placebo switched to ADV 
(n = 60, the placebo–ADV group). At week 97, the 
ADV–placebo group discontinued treatment and all 
remaining patients (n = 125) entered an open-label 
Chapter 3  
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long-term safety and efficacy study until week 240. 
In the ADV–ADV group, 70 patients were analysed, 
while in the placebo–ADV group 55 patients were 
analysed. (Note that a 2005 publication reported 
interim results at week 144 for the ADV–ADV 
group, and results at week 96 for the ADV–placebo 
and placebo–ADV groups; these results are 
reported in our original assessment report,12 and 
can also be found in Appendix 1 of the current 
report). In all studies, the dose of ADV was 10 mg 
once daily.
The key characteristics of the trials and the 
participants involved are shown in Table 1. The 
Rapti and colleagues trial18 was a relatively small, 
single-centre, open-label study carried out in 
Greece. The source of funding was not reported 
by the authors but the ADV capsules used in 
the study were supplied on a ‘compassionate 
basis’ by Gilead Sciences. In contrast, the trial by 
Zeng and colleagues19 was a larger, multicentre 
study incorporating both double-blind and 
open-label phases, and was carried out across 
seven cities in China. The trial was supported by 
GlaxoSmithKline. The study by Hadziyannis and 
colleagues20 was supported by Gilead Sciences.
The primary outcome measure in the Zeng and 
colleagues trial19 was the reduction in serum 
HBV DNA after 12 weeks’ treatment. The main 
secondary efficacy end point was the proportion 
of patients with ALT normalisation in week 12. 
Other secondary outcome measures included HBV 
DNA change from baseline at end of treatment, 
the proportion of subjects with HBV DNA < 105 
copies/ml and with undetectable HBV DNA, ALT 
normalisation at end of treatment, HBeAg loss 
and seroconversion, and health-related quality of 
life. Rapti and colleagues18 did not specify which 
of their outcomes were primary and secondary 
measures, but reported median HBV DNA levels 
and non-detectability of HBV DNA at 6, 12 and 24 
months. Biochemical measures reported included 
ALT change from baseline and ALT normalisation. 
Both studies reported adverse effects. The 
outcomes reported by Hadziyannis and colleagues20 
were HBV DNA, ALT, histological response, HBsAg 
seroconversion and resistance to ADV.
Both trials included only adult patients, although 
the median age reported varied between trials 
[median 56 years (range 39–76)18 versus median 
30 years (range 17–61)19]. Participants were 
predominantly male in both trials, with the 
proportion ranging from 83% to 93%. Patients 
in the Rapti and colleagues trial18 were HBeAg 
negative while those in the Zeng and colleagues 
trial19 were HBeAg positive. In terms of ethnicity, 
one trial included 100% white Europeans,18 in 
another all patients were Chinese,19 and in the 
third around two-thirds were described as white, 
with the remaining patients being Asian or black.20
The majority of patients across the two trials had 
received previous antiviral therapy for CHB. All 
patients in the Rapti and colleagues trial18 had 
previously received LAM [for a median duration 
of 32 months (range 12–84)] and exhibited 
genotypical LAM resistance with virological and 
clinical breakthroughs. Prior to enrolment in the 
long-term LAM study, none had received any other 
antiviral drug other than IFN-α.
In the Zeng and colleagues trial,19 approximately 
one-third of patients had previously received 
treatment with LAM, one-third had previously 
received treatment with traditional Chinese 
medicines and one-third were treatment naïve. All 
patients in the included trials had compensated 
liver disease. In the Zeng and colleagues trial,19 
no patients had cirrhosis, while in the Rapti and 
colleagues trial18 about one-third of patients had 
histological evidence of cirrhosis. None of the 
patients had co-infection with hepatitis C, hepatitis 
D or HIV, or any co-morbidities.
Table 2 provides an overview of the methodological 
quality of two of the ADV RCTs. The third, the 
open-label follow-up study, is discussed below.
The two RCTs varied in terms of methodological 
quality. The trial by Zeng and colleagues19 
generally appeared to be of better quality than 
the trial by Rapti and colleagues18. It provided 
an adequate description of the method of 
randomisation; baseline characteristics were similar 
across the trial arms; the reporting of the primary 
outcome was adequate; and the study comprised 
both blinded and open-label phases (hence judged 
‘partial’). However, concealment of allocation 
was only partially met. The level of reporting in 
the trial by Rapti and colleagues was poor, and 
prohibited a full assessment of its methodological 
quality. Importantly, the methods of randomisation 
and concealment are unknown, although there 
were no reported statistically significant differences 
between study groups at baseline, suggesting that 
selection bias was unlikely.
The third study, the long-term open-label 
study by Hadziyannis and colleagues,20 became 
an observational study beyond the initial 48 DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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0
T
d
 
=
 
5
2
 
w
e
e
k
s
F
d
 
=
 
o
n
g
o
i
n
g
e
T
o
t
a
l
 
=
 
o
n
g
o
i
n
g
e
D
e
t
e
c
t
a
b
l
e
 
H
B
s
A
g
 
a
n
d
 
H
B
e
A
g
S
e
r
u
m
 
H
B
V
 
D
N
A
 
≥
 
1
0
6
 
c
o
p
i
e
s
/
m
l
S
e
r
u
m
 
A
L
T
 
l
e
v
e
l
 
>
 
1
 
×
 
U
L
N
 
(
a
n
d
 
>
 
2
 
×
 
U
L
N
 
s
o
m
e
t
i
m
e
 
w
i
t
h
i
n
 
t
h
e
 
p
r
e
v
i
o
u
s
 
6
 
m
o
n
t
h
s
)
C
o
m
p
e
n
s
a
t
e
d
 
l
i
v
e
r
 
d
i
s
e
a
s
e
C
h
i
n
e
s
e
 
p
o
p
u
l
a
t
i
o
n
A
v
e
r
a
g
e
 
a
g
e
:
 
≈
 
3
2
 
y
e
a
r
s
S
e
x
:
 
8
3
%
 
m
a
l
e
N
o
 
L
A
M
 
t
h
e
r
a
p
y
 
w
i
t
h
i
n
 
3
 
m
o
n
t
h
s
 
p
r
i
o
r
 
t
o
 
s
c
r
e
e
n
i
n
g
,
 
o
r
 
A
D
V
 
(
o
r
 
o
t
h
e
r
 
a
n
t
i
-
H
B
V
 
t
h
e
r
a
p
y
)
 
i
n
 
p
r
e
v
i
o
u
s
 
6
 
m
o
n
t
h
s
≈
 
o
n
e
-
t
h
i
r
d
 
t
r
e
a
t
m
e
n
t
 
n
a
i
v
e
N
o
 
c
i
r
r
h
o
s
i
s
N
o
 
c
o
-
i
n
f
e
c
t
i
o
n
 
w
i
t
h
 
h
e
p
a
t
i
t
i
s
 
C
 
o
r
 
H
I
V
P
A
A
P
l
a
c
e
b
o
 
(
1
2
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
2
8
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
1
2
 
w
e
e
k
s
)
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
4
0
 
w
e
e
k
s
)
(
n
 
=
 
1
2
0
)
A
A
A
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
1
2
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
2
8
 
w
e
e
k
s
)
A
D
V
 
1
0
m
g
/
d
a
y
 
(
1
2
 
w
e
e
k
s
)
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
5
2
 
w
e
e
k
s
)
(
n
 
=
2
 
4
0
)
A
A
P
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
1
2
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
2
8
 
w
e
e
k
s
)
P
l
a
c
e
b
o
 
(
1
2
 
w
e
e
k
s
)
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
4
0
 
w
e
e
k
s
)
(
n
 
=
 
1
2
0
)
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
:
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
f
 
o
f
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
a
t
 
w
e
e
k
 
1
2
S
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
:
V
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
H
B
V
 
D
N
A
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
f
 
a
t
 
w
e
e
k
s
 
4
0
 
a
n
d
 
5
2
H
B
V
 
D
N
A
 
<
 
1
0
5
 
c
o
p
i
e
s
/
m
l
U
n
d
e
t
e
c
t
a
b
l
e
 
H
B
V
 
D
N
A
 
(
<
 
3
0
0
 
c
o
p
i
e
s
/
m
l
)
B
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
:
A
L
T
 
n
o
r
m
a
l
i
s
a
t
i
o
n
 
a
t
 
w
e
e
k
s
 
1
2
,
 
4
0
 
a
n
d
 
5
2
A
L
T
 
fl
a
r
e
s
S
e
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
H
B
e
A
g
 
l
o
s
s
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
O
t
h
e
r
 
m
e
a
s
u
r
e
s
:
Q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
A
D
V
 
r
e
s
i
s
t
a
n
c
e
c
o
n
t
i
n
u
e
dClinical effectiveness
10
S
t
u
d
y
 
a
n
d
 
m
e
t
h
o
d
s
H
B
e
A
g
 
s
t
a
t
u
s
N
o
.
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
(
n
)
,
 
d
u
r
a
t
i
o
n
 
o
f
 
t
r
i
a
l
 
(
T
d
)
,
 
a
d
d
i
t
i
o
n
a
l
 
f
o
l
l
o
w
-
u
p
 
(
F
d
)
 
a
n
d
 
t
o
t
a
l
 
d
u
r
a
t
i
o
n
 
(
t
o
t
a
l
)
P
a
t
i
e
n
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
G
r
o
u
p
 
A
G
r
o
u
p
 
B
G
r
o
u
p
 
C
O
u
t
c
o
m
e
s
R
a
p
t
i
 
e
t
 
a
l
.
,
 
2
0
0
7
1
8
D
e
s
i
g
n
:
 
O
p
e
n
-
l
a
b
e
l
 
R
C
T
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
1
S
p
o
n
s
o
r
:
 
N
o
t
 
s
p
e
c
i
fi
e
d
 
(
d
r
u
g
s
 
s
u
p
p
l
i
e
d
 
b
y
 
G
i
l
e
a
d
 
S
c
i
e
n
c
e
s
)
C
o
u
n
t
r
y
:
 
G
r
e
e
c
e
N
e
g
a
t
i
v
e
n
 
=
 
4
2
T
d
 
=
 
3
7
.
5
 
m
o
n
t
h
s
a
F
d
 
=
 
o
n
g
o
i
n
g
b
T
o
t
a
l
 
=
 
o
n
g
o
i
n
g
H
B
s
A
g
 
+
v
e
 
o
r
 
H
b
e
A
g
 
–
v
e
/
a
n
t
i
-
H
B
e
 
+
v
e
 
f
o
r
 
≥
 
6
 
m
o
n
t
h
s
E
l
e
v
a
t
e
d
 
A
L
T
 
o
n
 
3
 
s
e
p
a
r
a
t
e
 
m
o
n
t
h
l
y
 
o
c
c
a
s
i
o
n
s
H
B
V
 
D
N
A
 
>
 
1
0
5
 
c
o
p
i
e
s
/
m
l
 
w
i
t
h
i
n
 
l
a
s
t
 
m
o
n
t
h
 
b
e
f
o
r
e
 
s
t
a
r
t
i
n
g
 
L
A
M
 
t
h
e
r
a
p
y
C
o
m
p
e
n
s
a
t
e
d
 
l
i
v
e
r
 
d
i
s
e
a
s
e
G
r
e
e
k
 
p
o
p
u
l
a
t
i
o
n
A
v
e
r
a
g
e
 
a
g
e
:
 
≈
 
5
6
 
y
e
a
r
s
S
e
x
:
 
9
3
%
 
m
a
l
e
P
r
e
v
i
o
u
s
 
L
A
M
 
m
o
n
o
t
h
e
r
a
p
y
 
(
a
l
l
 
L
A
M
-
r
e
s
i
s
t
a
n
t
)
N
o
 
c
o
-
i
n
f
e
c
t
i
o
n
 
w
i
t
h
 
H
I
V
 
o
r
 
h
e
p
a
t
i
t
i
s
 
C
A
D
V
1
0
 
m
g
 
d
a
i
l
y
(
n
 
=
 
1
4
)
A
D
V
1
0
 
m
g
 
d
a
i
l
y
 
+
 
L
A
M
 
(
d
o
s
e
 
n
o
t
 
s
p
e
c
i
fi
e
d
)
c
(
n
 
=
 
2
8
)
–
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
:
V
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
n
o
n
-
d
e
t
e
c
t
a
b
i
l
i
t
y
 
o
f
 
H
B
V
 
D
N
A
 
l
e
v
e
l
s
B
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
;
A
L
T
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
a
n
d
 
A
L
T
 
n
o
r
m
a
l
i
s
a
t
i
o
n
S
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
s
:
A
d
v
e
r
s
e
 
e
f
f
e
c
t
s
O
t
h
e
r
 
m
e
a
s
u
r
e
s
:
A
D
V
 
r
e
s
i
s
t
a
n
c
e
H
a
d
z
i
y
a
n
n
i
s
 
e
t
 
a
l
.
,
 
2
0
0
6
2
0
D
e
s
i
g
n
:
 
O
p
e
n
-
l
a
b
e
l
 
5
-
y
e
a
r
 
l
o
n
g
-
t
e
r
m
 
s
t
u
d
y
 
b
a
s
e
d
 
o
n
 
R
C
T
 
(
S
t
u
d
y
 
4
3
8
)
g
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
3
2
S
p
o
n
s
o
r
:
 
G
i
l
e
a
d
 
S
c
i
e
n
c
e
s
C
o
u
n
t
r
y
:
 
I
n
t
e
r
n
a
t
i
o
n
a
l
N
e
g
a
t
i
v
e
n
 
=
 
1
2
5
T
d
 
=
 
2
4
0
 
w
e
e
k
s
(
1
9
2
 
w
e
e
k
s
 
f
o
r
 
P
A
A
 
g
r
o
u
p
)
H
B
e
A
g
 
n
e
g
a
t
i
v
e
D
e
t
e
c
t
i
o
n
 
o
f
 
H
B
s
A
g
 
≥
 
6
 
m
o
n
t
h
s
C
o
m
p
e
n
s
a
t
e
d
 
l
i
v
e
r
 
d
i
s
e
a
s
e
S
e
r
u
m
 
H
B
V
 
D
N
A
 
≥
 
1
0
5
 
c
o
p
i
e
s
/
m
l
S
e
r
u
m
 
A
L
T
 
l
e
v
e
l
 
b
e
t
w
e
e
n
 
>
 
1
.
5
 
a
n
d
 
1
5
 
×
 
U
L
N
A
v
e
r
a
g
e
 
a
g
e
:
 
≈
 
4
6
 
y
e
a
r
s
S
e
x
:
 
≈
 
8
3
%
 
m
a
l
e
N
o
 
c
o
-
i
n
f
e
c
t
i
o
n
 
w
i
t
h
 
h
e
p
a
t
i
t
i
s
 
C
 
o
r
 
H
I
V
N
o
 
p
r
i
o
r
 
n
u
c
l
e
o
s
i
d
e
/
n
u
c
l
e
o
t
i
d
e
 
t
h
e
r
a
p
y
 
f
o
r
 
m
o
r
e
 
t
h
a
n
 
3
 
m
o
n
t
h
s
A
A
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
4
8
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
4
8
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
1
4
4
 
w
e
e
k
s
)
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
2
4
0
 
w
e
e
k
s
)
(
n
 
=
 
7
0
)
P
A
P
l
a
c
e
b
o
 
(
4
8
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
4
8
 
w
e
e
k
s
)
A
D
V
 
1
0
 
m
g
/
d
a
y
 
(
1
4
4
 
w
e
e
k
s
)
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
1
9
2
 
w
e
e
k
s
)
(
n
 
=
 
5
5
)
–
V
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
%
 
p
t
s
 
w
i
t
h
 
u
n
d
e
t
e
c
t
a
b
l
e
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
≤
 
1
0
0
0
 
c
o
p
i
e
s
 
p
e
r
 
m
l
B
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
:
N
o
r
m
a
l
i
s
a
t
i
o
n
 
o
f
 
A
L
T
 
l
e
v
e
l
s
S
e
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
H
B
s
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
H
i
s
t
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
C
h
a
n
g
e
 
i
n
 
K
n
o
d
e
l
l
 
n
e
c
r
o
i
n
fl
a
m
m
a
t
i
o
n
 
a
n
d
 
I
s
h
a
k
 
fi
b
r
o
s
i
s
 
s
c
o
r
e
s
T
A
B
L
E
 
1
 
S
t
u
d
y
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
–
 
A
D
V
 
s
t
u
d
i
e
s
 
(
c
o
n
t
i
n
u
e
d
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S
t
u
d
y
 
a
n
d
 
m
e
t
h
o
d
s
H
B
e
A
g
 
s
t
a
t
u
s
N
o
.
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
(
n
)
,
 
d
u
r
a
t
i
o
n
 
o
f
 
t
r
i
a
l
 
(
T
d
)
,
 
a
d
d
i
t
i
o
n
a
l
 
f
o
l
l
o
w
-
u
p
 
(
F
d
)
 
a
n
d
 
t
o
t
a
l
 
d
u
r
a
t
i
o
n
 
(
t
o
t
a
l
)
P
a
t
i
e
n
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
G
r
o
u
p
 
A
G
r
o
u
p
 
B
G
r
o
u
p
 
C
O
u
t
c
o
m
e
s
H
i
s
t
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
:
A
s
s
e
s
s
m
e
n
t
s
 
o
f
 
i
m
p
r
o
v
e
m
e
n
t
,
 
n
o
 
c
h
a
n
g
e
 
o
r
 
w
o
r
s
e
n
i
n
g
 
o
f
 
n
e
c
r
o
i
n
fl
a
m
m
a
t
i
o
n
 
a
n
d
 
fi
b
r
o
s
i
s
O
t
h
e
r
 
m
e
a
s
u
r
e
s
:
A
D
V
 
r
e
s
i
s
t
a
n
c
e
A
L
T
,
 
a
l
a
n
i
n
e
 
a
m
i
n
o
t
r
a
n
s
f
e
r
a
s
e
;
 
U
L
N
,
 
u
p
p
e
r
 
l
i
m
i
t
 
o
f
 
t
h
e
 
n
o
r
m
a
l
 
r
a
n
g
e
.
A
A
A
 
=
 
A
D
V
–
A
D
V
–
A
D
V
;
 
P
A
A
 
=
 
p
l
a
c
e
b
o
–
A
D
V
–
A
D
V
.
a
 
M
e
d
i
a
n
 
d
u
r
a
t
i
o
n
 
o
f
 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
a
l
l
 
p
a
r
t
i
c
i
p
a
n
t
s
.
b
 
R
e
s
u
l
t
s
 
a
r
e
 
p
r
e
s
e
n
t
e
d
 
a
t
 
6
,
 
1
2
 
a
n
d
 
2
4
 
m
o
n
t
h
s
;
 
s
t
u
d
y
 
i
s
 
o
n
g
o
i
n
g
.
c
 
P
a
t
i
e
n
t
s
 
w
e
r
e
 
t
a
k
e
n
 
f
r
o
m
 
a
 
p
r
e
v
i
o
u
s
 
l
o
n
g
-
t
e
r
m
 
s
t
u
d
y
 
o
f
 
L
A
M
 
m
o
n
o
t
h
e
r
a
p
y
 
a
n
d
 
e
i
t
h
e
r
 
s
w
i
t
c
h
e
d
 
t
o
 
A
D
V
 
o
r
 
a
d
d
e
d
 
A
D
V
;
 
d
e
t
a
i
l
s
 
o
f
 
L
A
M
 
d
o
s
a
g
e
 
n
o
t
 
r
e
p
o
r
t
e
d
 
i
n
 
t
h
i
s
 
p
u
b
l
i
c
a
t
i
o
n
.
d
 
S
t
u
d
y
 
d
e
s
i
g
n
 
w
a
s
 
1
2
 
w
e
e
k
s
 
d
o
u
b
l
e
-
b
l
i
n
d
 
a
n
d
 
r
a
n
d
o
m
i
s
e
d
 
t
o
 
A
D
V
 
o
r
 
p
l
a
c
e
b
o
,
 
t
h
e
n
 
2
8
 
w
e
e
k
s
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
;
 
t
h
e
 
o
r
i
g
i
n
a
l
 
A
D
V
 
g
r
o
u
p
 
w
a
s
 
t
h
e
n
 
r
e
-
r
a
n
d
o
m
i
s
e
d
 
t
o
 
A
D
V
 
o
r
 
p
l
a
c
e
b
o
 
f
o
r
 
1
2
 
w
e
e
k
s
 
a
n
d
 
t
h
e
 
o
r
i
g
i
n
a
l
 
p
l
a
c
e
b
o
 
g
r
o
u
p
 
r
e
m
a
i
n
e
d
 
o
n
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
 
f
o
r
 
1
2
 
w
e
e
k
s
.
e
 
5
2
-
w
e
e
k
 
r
e
s
u
l
t
s
 
a
r
e
 
p
r
e
s
e
n
t
e
d
;
 
t
h
e
 
s
t
u
d
y
 
i
s
 
o
n
g
o
i
n
g
 
f
o
r
 
a
n
 
a
d
d
i
t
i
o
n
a
l
 
4
 
y
e
a
r
s
.
f
 
L
o
g
1
0
 
r
e
d
u
c
t
i
o
n
 
f
r
o
m
 
b
a
s
e
l
i
n
e
.
g
 
P
a
t
i
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TABLE 2  Quality assessment – ADV randomised controlled trials
Zeng et al., 200619 Rapti et al., 200718
Randomisation Adequate Unknown
Concealment of allocation Partial Unknown
Baseline characteristics similar Adequate Reported
Blinding of assessors Partial Unknown
Care provider blinding Partial Unknown
Patient blinding Partial Unknown
Reporting outcomes Adequate  Partial
Intention-to-treat analysis Inadequate Adequate
Withdrawals explained Partial Adequate
weeks’ randomised double-blind treatment (the 
assessment of methodological quality of the 
original RCT is available in our earlier assessment 
report12). Results for most of the outcomes are 
presented for all 125 patients in the observational 
cohort, regardless of study group. The authors 
report two types of intention-to-treat (ITT) analysis 
for the analysis of HBV DNA and ALT. In the ‘ITT 
missing equals failure’ analysis (ITT; M = F), all 
patients who discontinued were considered to 
have failed treatment. In the ‘ITT missing equals 
failure for resistance or HCC’ analysis (ITT; M 
= F R/HCC), patients were considered failures if 
they (1) harboured HBV with an ADV-resistance 
mutation and either terminated the study or had 
LAM added (if a patient had HBV with a resistance 
mutation and remained in the study on ADV 
monotherapy, his or her serum HBV DNA and ALT 
values were included in analyses rather than being 
deemed failures), or (2) were diagnosed with HCC. 
Missing values from patients who left the study for 
other reasons were excluded. The ITT; M = F R/
HCC analysis was considered to provide a more 
realistic view of efficacy as drop-outs unrelated to 
efficacy are expected in a 5-year trial.
Characteristics of PEG-α-2b studies
Five published RCTs evaluating PEG-α-2b were 
included, all using similar inclusion and exclusion 
criteria. Four RCTs evaluated combined treatment 
of PEG-α-2b plus LAM,23–26 while one compared 
PEG-α-2b with IFN-α-2b.27 The studies had varied 
regimens and differing aims, as follows:
•	 Chan and colleagues (2007)23 included three 
treatment arms of combined PEG-α-2b, with 
arms differing in the commencement of 
LAM. One group received PEG-α-2b for 32 
weeks and LAM for 104 weeks concurrently. A 
second group received PEG-α-2b for 32 weeks, 
beginning 8 weeks before commencing LAM 
for 96 weeks. The third group received PEG-
α-2b for 32 weeks, beginning 8 weeks after 
commencing LAM, which they received for 104 
weeks. The rationale for this pilot study was to 
establish if staggered commencement would 
have a more potent HBV DNA suppression 
than simultaneous commencement of PEG-α-
2b plus LAM, with an extended LAM treatment 
of up to 2 years.
•	 Chan and colleagues (2005)24 compared 
combined treatment with LAM alone. A 
separate publication reported long-term 
sustained virological response outcomes.28 
The rationale was to ascertain if combination 
therapy increased HBeAg seroconversion rates 
and improved antiviral efficacy more than did 
LAM monotherapy.
•	 Kaymakoglu and colleagues25 compared 
PEG-α-2b and LAM with PEG-α-2b alone. 
The rationale of this trial was to discover if 
combination therapy could lead to an increased 
rate of sustained response.
•	 Janssen and colleagues26 evaluated combined 
PEG-α-2b and LAM with PEG-α-2b plus 
placebo. Separate publications report long-
term histology,29 safety results,30 and subgroup 
analyses (e.g. advanced fibrosis versus 
no advanced fibrosis;31 genotypes,32 early 
responders33). The aim was to assess whether 
combination therapy was associated with DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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increased rates of sustained response in CHB 
compared with PEG-α-2b monotherapy.
•	 Zhao and colleagues27 compared PEG-α-2b 
with IFN-α-2b. The authors aimed to establish 
factors predicting sustained combined response 
and adverse effects for a lower dose in patients 
with different genotypes (B versus C), in order 
to determine the most cost-effective treatment 
for developing countries with high HBV 
infection rates.
The key characteristics of the trials are shown in 
Table 3. Two trials were single-centre RCTs23,24 and 
three were multicentre studies,25–27 of which only 
one trial appeared to take place in more than 
one country.26 Two of the RCTs received funding 
(the Research Fund for the Control of Infections 
Diseases, Health, Welfare and Food Bureau;23 
the Rotterdam Foundation for Liver Research26). 
Schering–Plough supplied PEG-α-2b to three 
studies and the same studies also received LAM 
from GlaxoSmithKline.23,24,26
Outcome measures employed by the RCTs were 
similar, with differences in relation to participants’ 
HBeAg status, such as HBeAg seroconversion 
rates. Primary outcomes were changes from 
baseline in rate of serum HBV DNA,27 HBeAg 
seroconversion,24 loss of HBeAg at end of 
treatment,26 reduction of HBV DNA23 and levels 
of HBV DNA.25 Secondary outcome measures 
included ALT normalisation, development 
of genotypic LAM resistance, histological 
improvement (necroinflammatory and fibrosis 
score) using the Knodell score, adverse events and 
LAM-resistant mutations, as well as assessment of 
HBsAg and HBV genotypes.
All trials defined CHB by the presence of 
detectable HBsAg for a minimum of 6 months 
prior to enrolment. Serum HBV DNA levels were 
at least 105 copies/ml (106 in one study27) and ALT 
levels ranged between 1.3 and 10 times the upper 
limit of the normal range (ULN), although not all 
of the RCTs stated higher ALT limits.25,26 Three of 
the PEG-α-2b studies required participants to be 
HBeAg positive,23,24,27 one included both HBeAg-
positive and HBeAg-negative patients,27 and one 
included HBeAg-negative patients only.25 The trials 
generally excluded patients with decompensated/
advanced liver disease. A small proportion of 
participants with cirrhosis were included in two 
of the studies (4%;25 8%26). Comorbidities and 
co-infections were specifically excluded by three 
RCTs23,24,26 and were not remarked upon by the 
others.25,27
Trial size varied considerably, ranging from 30 
participants23 to 307.26 Duration of treatment also 
varied from 24 to 104 weeks, with an average 
24-week follow-up. All trials were carried out on 
adult patients. While Chan and colleagues23,24 
recruited only treatment-naive participants, two 
studies included participants with a mixture of 
prior and no prior treatment.26,27 Kaymakoglu 
and colleagues failed to mention prior treatment 
history.25 Previous IFN therapy was recorded for 
13%27 and about 20%26of participants, while 33% of 
participants had previous LAM therapy.26 However, 
no LAM resistance was reported.
Details of ethnicity were sparse. Chan and 
colleagues included Chinese participants,23 while 
the Kaymakoglu and colleagues trial primarily 
included white participants (74%) along with 20% 
Asian and 6% mixed.25 The mean age of study 
participants was between 30 and 43 years, and 
entailed a higher proportion of male participants 
(range 63–82%).
The methodological quality of the five PEG-α-2b 
trials was assessed using CRD criteria,13 and is 
shown in Table 4. Four of the five trials adequately 
reported the method of randomisation,23,24,26,27 and 
three of these adequately reported the concealment 
of allocation to treatment groups.23,24,26 The 
allocation process was unclear in the remaining two 
studies. All of the included RCTs reported patients’ 
baseline characteristics. Four of these reported 
that study groups were similar at baseline, with 
only Zhao and colleagues reporting a difference in 
previous treatment with interferon therapy between 
study groups, which was statistically significant 
(p < 0.05).27
Only one of the studies adequately described all 
aspects of blinding,26 stating, for example, that 
the placebo was similar in appearance to the study 
drug and that HBV markers were assessed at a 
central laboratory, with staff unaware of treatment 
allocation. Each of the remaining trials was open 
label. Two of these23,24 did report some blinding 
of outcome assessors. For example, in one of the 
studies, histological specimens were assessed by 
a single histopathologist who was unaware of the 
treatment assignments or the times at which the 
specimens were obtained.23
Reporting of primary outcomes was variable across 
the five studies, with only two adequately reporting 
point estimates and measures of variability.25,26 
Three studies adequately described an ITT 
method of data analysis. The other two studies Clinical effectiveness
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TABLE 4  Quality assessment – PEG-α-2b randomised controlled trials
Chan et al., 
200723
Chan et al., 
200524
Janssen et al., 
200526
Kaymakoglu et 
al., 200725
Zhao et al., 
200727
Randomisation Adequate Adequate Adequate Unknown Adequate
Concealment of 
allocation
Adequate Adequate Adequate Unknown Unknown
Baseline 
characteristics 
similar
Adequate Adequate Adequate Adequate Partial
Blinding of 
assessors
Partial Partial Adequate Inadequate Inadequate
Care provider 
blinding
Unknown Unknown Adequate Inadequate  Inadequate
Patient blinding Inadequate  Inadequate  Adequate Inadequate Inadequate
Reporting 
outcomes
Inadequate Partial Adequate Adequate Partial
Intention-to-treat 
analysis
Inadequate Adequate Inadequate  Adequate Adequate
Withdrawals 
explained
Adequate Adequate Partial Inadequate Partial
reported a ‘modified’ ITT analysis. For example, 
in Janssen and colleagues’ study, 41 (13%) of the 
307 randomised patients were excluded from the 
modified ITT. Of these, 24 patients from one 
study centre (12 from each arm) were excluded 
because of ‘misconduct’; 10 lost HBeAg before the 
start of the study; and seven did not receive any 
study medication. It is unclear whether all of those 
excluded received at least one dose of the study 
medication, therefore it is recorded as ‘inadequate’ 
in the table.26
Withdrawals were fully described in two of the five 
studies. One study reported early withdrawals, with 
no other details given. Studies are described in 
Table 4 as partially explaining withdrawals where 
early attrition or withdrawals due to adverse events 
were reported, but where later losses to follow-up 
are not fully explained.26,34
Assessment of effectiveness
Virological response
Proportion of patients achieving an 
HBV DNA response – ADV studies
Table 5 presents the proportion of patients 
achieving a defined threshold of HBV DNA 
response in the two trials. In the trial by Zeng and 
colleagues,19 the proportion of patients whose HBV 
DNA level dropped below 105 copies/ml reached 
67% by week 52 in patients treated continuously 
with ADV [the adefovir–adefovir–adefovir 
(AAA) group]. For the group who commenced 
open-label ADV after 12 weeks of placebo [the 
placebo–adefovir–adefovir (PAA) group], the 
proportion reached 70% at week 52. For the 
group who initially received ADV and were then 
re-randomised to placebo at week 40 [the adefovir–
adefovir–placebo (AAP) group], the proportion fell 
to 11% at week 52, having previously reached 59%. 
Zeng and colleagues19 also reported the proportion 
of patients whose HBV DNA was undetectable, 
defined as HBV DNA < 300 copies/ml. At week 
52, the proportions were similar in the AAA and 
the PAA groups (28% and 30% respectively). In the 
AAP group, the proportion fell from 59% at week 
40 to 11% by week 52, following the withdrawal of 
ADV. No statistical tests were reported for any of 
these comparisons.
In the trial by Rapti and colleagues,18 the 
proportion of patients with HBV DNA ≤ 1000 
copies/ml after 24 months of therapy was higher 
in the group treated with ADV and LAM than in 
the group treated with ADV monotherapy (82.6% 
versus 75% respectively). However, this difference 
did not reach statistical significance.Clinical effectiveness
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TABLE 5  Proportion of patients achieving an HBV DNA response – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +ve
HBV DNA < 105 copies/ml, week 
12, n/N (%)
4/115 (3) 113/227 (50) 55/116 (47) NR
HBV DNA < 105 copies/ml, week 
40, n/N (%)
75/115 (65) 147/231 (64) 68/115 (59) NR
HBV DNA < 105 copies/ml, week 
52, n/N (%)
81/115 (70) 155/231 (67) 13/115 (11) NR
HBV DNA undetectable, week 
12, n/N (%)a
0/119 (0) 11/232 (5) 7/120 (6) NR
HBV DNA undetectable, week 
40, n/N (%)a
23/119 (19) 42/236 (18) 23/119 (19) NR
HBV DNA undetectable, week 
52, n/N (%)a
36/119 (30) 67/236 (28) 1/119 (1) NR
Rapti et al., 200718 ADV ADV + LAM
HBeAg –ve
HBV DNA ≤ 1000 copies/ml at 6 
months, %
45.5 57.1 0.723
HBV DNA ≤ 1000 copies/ml at 12 
months, %
78.6 68 0.713
HBV DNA ≤ 1000 copies/ml at 24 
months, %
75 82.6 0.670
a  HBV DNA < 300 copies/ml.
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
Table 6 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to 
the ADV–ADV group as the placebo–ADV group 
commenced ADV only after week 48.)
In the ‘ITT missing data = failure for resistance 
or HCC’ analysis (i.e. missing values from patients 
who left the study for other reasons were excluded), 
the proportion of patients whose HBV DNA levels 
were < 1000 copies/ml peaked after 96 weeks, 
after which they gradually fell to 67%. In the ‘ITT 
missing data = failure’ analysis, the proportion 
peaked after 144 weeks, and fell to 53% after 240 
weeks.
In summary, a greater proportion of ADV-treated 
patients experienced an HBV DNA response 
relative to comparators, although this was 
not confirmed statistically. The proportion of 
responders was generally maintained during long-
term treatment.
Proportion of patients achieving an 
HBV DNA response – PEG-α-2b studies
Table 7 shows the proportion of patients achieving 
an HBV DNA response as reported in four of the 
five studies. Response was measured by reductions 
in HBV DNA levels to a given threshold. Each of 
the studies of PEG-α-2b used differing thresholds 
of HBV DNA response. These proportions also vary 
across the studies.
Chan and colleagues23 report HBV DNA response 
for three groups of patients, receiving staggered 
regimens of PEG-α-2b and LAM. At week 52, 
Group A had a higher proportion of patients 
(44%) with negative HBV DNA than either Group 
B (22%) or Group C (10%). Neither of these 
differences was statistically significant (p = 0.62 and 
p = 0.24). At end of treatment (week 104) Group B 
had the highest proportion of patients (56%) with 
negative HBV DNA, compared with Group A (33%) 
and Group C (40%). Baseline HBV DNA had been 
significantly lower in this group. At end of follow-DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 6  Proportion of patients achieving an HBV DNA response – long-term ADV follow-up study
Study, patient type, outcome
Weeks of ADV treatment
48 96 144 192 240a
Hadziyannis et al., 200620
HBeAg –ve
HBV DNA < 1000 copies/ml, % of enrolled 
patientsb
72 80 77 73 67
HBV DNA < 1000 copies/ml, % of enrolled 
patientsc
71 71 73 62 53
HCC, hepatocellular carcinoma; ITT, intention to treat.
a  Includes only patients in the ADV–ADV group.
b  ITT missing data = failure for resistance or HCC.
c  ITT missing data = failure.
TABLE 7  Proportion of patients achieving an HBV DNA ‘response’ – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value 
Chan et al., 200723
Group A
PEG-α-2b 
+LAM
Group B
PEG-α-2b 
+ LAM
Group C
PEG-α-2b 
+LAM
HBeAg +ve
Negative HBV DNA at week 52, n/N (%) 4/9 (44) 2/9 (22) 1/10 (10) Group B vs Group A: 0.62
Group C vs Group A: 0.24
Negative HBV DNA at week 104, n/N (%) 3/9 (33) 5/9 (56) 4/10 (40) NR
Undetectable HBV DNA at follow-up (week 
128), n/N (%)
2/9 (22) 1/9 (11) 2/10 (20) NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG- α-2b + placebo
HBeAg +ve
HBV DNA < 200,000 copies/ml, EOT (week 
52), n/N (%)
96/130 (74) 40/136 (29) < 0.0001
HBV DNA < 200,000 copies/ml (week 78), 
n/N (%)
41/130 (32) 37/136 (27) 0.44
HBV DNA < 400 copies/ml (week 52), n/N 
(%)
43/130 (33) 13/136 (10) < 0.0001
HBV DNA < 400 copies/ml (week 78), n/N 
(%)
12/130 (9) 9/136 (7) 0.43
Kaymakoglu et al., 200725
Group A
PEG-α-2b
Group B
PEG-α-2b +LAM
HBeAg –ve
HBV DNA < 4 pg/ml, EOT (week 48), n/N 
(%)
12/19 (63) 23/29 (79) > 0.05
HBV DNA < 4 pg/ml, EOF-U (week 72), n/N 
(%)
7/19(37) 10/29 (34) > 0.05
HBV DNA < 400 copies/ml, EOF-U (week 
72), n/N (%)
5/19 (26) 7/29 (24) >0.05
continuedClinical effectiveness
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Study, patient type, outcome Treatment group p-value 
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
HBV DNA level < 5 log10 copies/ml, EOF-U 
(week 48), n/N (%)
34/115 (29.6) 22/115 (19.1) 0.06
HBV DNA level < 3 log10 copies/ml, EOF-U 
(week 48), n/N (%)
14/115 (12.2) 14/115 (12.2) 1.00
EOF-U, end of follow-up; EOT, end of treatment; NR, not reported; pg, picograms.
TABLE 7  Proportion of patients achieving an HBV DNA ‘response’ – PEG-α-2b studies (continued)
up (week 128), Group A had a slightly higher 
proportion of patients reaching ‘undetectable’ HBV 
DNA of 22%, compared with Group B at 11% and 
Group C at 20%. Statistical significance was not 
given for these results. Definitions of ‘negative’ and 
‘undetectable’ are not reported, and so it is unclear 
how these differ.
The trial by Janssen and colleagues26 compares 
a group receiving PEG-α-2b and LAM (Group 
A), and a group receiving PEG-α-2b and placebo 
(Group B). At end of treatment (week 52) the 
proportion of patients in Group A reaching 
< 200,000 copies/ml was 74%, compared with 29% 
in Group B (p < 0.0001). At end of follow-up this 
had fallen in Group A to 32% and in Group B to 
27% (p = 0.44). Thirty-three per cent of patients in 
Group A at end of treatment reached < 400 copies/
ml, compared with 10% in Group B (p < 0.0001). 
This, again, fell by end of follow-up to 9% in Group 
A and 7% in Group B (p = 0.43).
In the trial by Kaymakoglu and colleagues,25 a 
higher proportion of patients receiving PEG-
α-2b and LAM achieved HBV DNA < 4 pg/ml 
(picograms per millilitre; in this paper defined as 
the ‘lower limit of detection’) at end of treatment 
(week 48) than of those receiving PEG-α-2b 
alone: 79% versus 63% respectively. At end of 
follow-up, the proportions reaching 400 copies/
ml were similar for both groups: 24% versus 26%. 
However, none of these differences was statistically 
significant.
Zhao and colleagues27 compared patients receiving 
PEG-α-2b (Group A) with those taking IFN-α 
(Group B). A higher proportion of patients in 
Group A (29.6%) reached < 5 log10 copies/ml at end 
of follow-up (week 48), compared with 19.1% in 
Group B (p = 0.06). In both groups, 12.2% reached 
< 3 log10 copies/ml (p = 1.00).
In summary, the results of these studies show 
that there was no significant difference between 
concurrent and staggered commencement of 
PEG-α-2b and LAM; and no consistent statistically 
significant differences between the combination 
of PEG-α-2b and LAM versus PEG-α-2b 
monotherapy, or between PEG-α-2b and IFN-α.
Changes in HBV DNA 
levels – ADV studies
Table 8 reports the median changes in HBV DNA 
from baseline in the trial by Zeng and colleagues.27
At week 12 there was a statistically significant 
difference between the patients randomised to ADV 
(the AAA group) and those randomised to placebo 
(the PAA group) (p < 0.001). At week 40, median 
reductions in HBV DNA appeared to be similar for 
all three groups (all three had been receiving open-
label ADV since week 12). At week 52, median HBV 
DNA reductions appeared to be similar for the 
patients who had received ADV continuously (the 
AAA group) and those who had switched to ADV 
from placebo after week 12 (the PAA group) (–4.5 
and –5.0 log10 copies/ml respectively). However, 
those who had received ADV until week 40 and 
were then re-randomised to placebo had a smaller 
reduction (–0.2 log10 copies/ml).
Changes in HBV DNA levels 
– PEG-α-2b studies
Changes in HBV DNA levels are shown in Table 9.
Chan and colleagues (2007)23 report the median 
log HBV DNA reduction from baseline at weeks 
4, 8, 52 and 104. The median difference between 
Group A and Group B was 3.59 (95% CI 1.49–5.65, 
p < 0.0001) at week 4 (at this stage, because of 
the staggered regimen, Group A was receiving 
PEG-α-2b and LAM, Group B was receiving PEG-
α-2b monotherapy and Group C received LAM DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
21
TABLE 8  Changes in HBV DNA levels – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +ve
HBV DNA change (log10 copies/ml) from 
baseline to week 12, median range [25%, 75% 
(interquartile values)]
–0.1, –5.2 to 3.1 
(–0.7 to 0.3)
–3.4, –7.7 to 0.5 
(–4.6 to –2.6)
–3.3, –6.8 to –1.0 
(–4.3 to –2.7)
< 0.001a 
HBV DNA change (log10 copies/ml) from 
baseline to week 40, median range [25%, 75% 
(interquartile values)]
–4.6, –7.7 to 2.0 
(–5.6 to –3.1)
–4.2, –8.0 to 0.5 
(–5.5 to –3.0)
–4.0, –8.6 to 0.7 
(–5.3 to –3.0)
NR
HBV DNA change (log10 copies/ml) from 
baseline to week 52, median range [25%, 75% 
(interquartile values)]
–5.0, –8.0 to 2.1 
(–6.0 to –3.3)
–4.5, –8.0 to 0.7 
(–5.8 to –3.1)
–0.2, –6.1 to 
2.1(–1.6 to 0.3)
NR
NR, not reported.
a  For AAA vs PAA.
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
monotherapy). At week 52, the point at which the 
primary outcome was measured, the difference 
between Groups A and B was significant (6.38 
versus 3.43, p = 0.030), but the difference between 
Groups A and C was not (p = 0.06). By end of 
treatment, week 104, there were no significant 
differences in median log HBV DNA reduction 
between any of the groups.
In the trial by Chan and colleagues (2005),24 
there were greater reductions in HBV DNA for 
combination treatment than for monotherapy. 
The median difference between groups at end of 
treatment was reported as 1.24 copies/ml (95% 
CI 0.78–1.66); however, no statistical tests were 
reported for this outcome.
The HBV DNA change from baseline in Janssen 
and colleagues26 was estimated by the reviewers 
from a figure in the paper, and showed a similar 
reduction in mean log HBV DNA copies/ml of 2.3 
for Group A and 2.2 for Group B at end of follow-
up.
Zhao and colleagues27 reported the HBV DNA 
mean reduction from baseline, log10 copies/ml 
at end of treatment and end of follow-up. The 
difference was significant at week 24 (end of 
treatment) (Group A 2.22 versus Group B 1.66, 
p = 0.03), but again was not statistically significant 
by end of follow-up (p = 0.34). At end of follow-up, 
the ‘mean reduction’ in Group A was –1.4 ± 2.2, 
and in Group B it was –1.1 ± 2.1, indicating that 
overall there had been an increase in the HBV 
DNA level in both groups from baseline.
In summary, the results of the trials show that PEG-
α-2b is generally associated with greater reductions 
in HBV DNA levels than are comparators. This was 
the case when PEG-α-2b was added to LAM, or 
vice versa, and for PEG-α-2b versus IFN. However, 
there were no consistent statistically significant 
differences between treatments. The results 
suggested a greater reduction in HBV DNA for 
those who received concurrent commencement of 
PEG-α-2b and LAM, but by the end of treatment 
there were no statistically significant differences 
between this and the staggered regimens.
Biochemical response (ALT)
ALT normalisation – ADV studies
Table 10 reports the proportion of patients with 
normal ALT levels in two of the studies.
Four of the trials reported changes in HBV 
DNA. In the trial by Zeng and colleagues,19 the 
proportion of patients with normal ALT appeared 
similar at week 12 in the groups randomised to 
receive ADV (42% and 44% in the AAA and AAP 
groups respectively). There was a statistically 
significant difference between the AAA and AAP 
groups combined compared with the group 
randomised to placebo (the PAA group). The 
proportion of responders in the AAA and AAP 
groups remained similar to each other at week 40 
after 28 weeks of open-label ADV (73% and 74% 
respectively). At week 40, in the group randomised 
to placebo in the first 12 weeks and who had 
subsequently received open-label ADV for 28 weeks 
(the PAA group), the proportion of ALT responders 
was slightly lower than in the other two groups Clinical effectiveness
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TABLE 9  Changes in HBV DNA levels – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200723
Group A
PEG-α-2b 
+LAM
Group B
PEG-α-2b 
+LAM
Group C
PEG-α-2b + 
LAM
HBeAg +ve
Median log HBV DNA reduction, week 4a,b 4.21 1.39 2.95 < 0.0001 (Groups A and B)
0.027 (Groups A and C)
Median log HBV DNA reduction, week 8b,c 5.46 1.55 3.14 < 0.0001 (Groups A and B)
0.004 (Groups A and C)
Median log HBV DNA reduction, week 52d 6.38 3.43 4.44 0.030 (Groups A and B)
0.060 (Groups A and C)
Median log HBV DNA reduction, EOT, week 104e 6.13 5.24 5.15 0.20 (Groups A and B)
0.46 (Groups A and C)
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
HBV DNA median log10 reduction, copies/ml 
(range), EOTf
3.89 (1.59–6.35) 2.74 (–0.10 to 
5.68)
NR
HBV DNA median log10 reduction, copies/ml 
(range), week 48g
4.65 (–0.84 to 7.83) 3.62 (1.32–7.33) NR
Janssen et al., 200526
HBeAg +ve
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + 
placebo
HBV DNA change from baseline: mean log HBV 
DNA, copies/ml (estimated from paper), EOF-U
2.3h 2.2h NR
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
Mean reduction of HBV DNA level from baseline, 
log10 copies/ml week 24 (EOT)
2.22 1.66 0.03
Mean reduction of HBV DNA level from baseline, 
log10 copies/ml, week 48 (EOF-U) ± SD
–1.4 ± 2.2 –1.1 ± 2.1 0.34
EOF-U, end of follow-up; EOT, end of treatment; NR, not reported.
a  Median difference between Groups A and B was 3.59 (95% CI 1.49–5.65) and between Groups A and C was 1.45 (95% 
CI 0.11–2.78).
b  Due to staggered regimes, at weeks 4 and 8, Group A was PEG + LAM, Group B was PEG monotherapy and Group C 
was LAM monotherapy.
c  Median difference between Groups A and B was 3.91 (95% CI 2.06–6.34) and between Groups A and C was 1.95 (95% 
CI 0.79–3.09).
d  Median difference between Groups A and B was 2.07 (95 CI 0.31–3.96) and between Groups A and C was 1.61 (95 CI 
–0.07–2.08).
e  Median difference between Groups A and B was 0.90 (95% CI –1.05 to 2.63) and between Groups A and C was 0.56 
(95% CI –0.97 to 2.07). 
f  Median difference 1.24 (95% CI 0.78–1.66).
g  Median difference 1.10 (95% CI 0.55–1.65).
h  These results are estimated from a figure in the paper.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 10  Proportion of patients with normal ALT – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +vea,b
ALT normalisation at week 12, n/N (%) 15/108 (14) 92/220 (42) 48/110 (44) 0.001c
ALT normalisation at week 40, n/N (%) 69/106 (65) 163/223 (73) 81/109 (74) NR
ALT normalisation at week 52, n/N (%) 74/107 (69) 176/224 (79) 23/109 (21) NR
Rapti et al., 200718 ADV ADV + LAM
HBeAg –ve
% of patients with ALT ≤ 49 IU/l (ULN) at 24 months 72.7 91 0.304
ALT, alanine aminotransferase; IU/l = international units per litre; NR, not reported; ULN, upper limit of normal.
a  ULN was 49 IU/l.
b  Subjects with elevated serum ALT at baseline.
c  For the AAA and AAP groups combined compared with the PAA group.
PAA, placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
(65%). At week 52, the proportion of responders 
in the PAA group had increased to 69%, while 
the proportion of responders of those who had 
received ADV continuously (the AAA group) had 
increased to 79%. The proportion of responders 
fell to 21% in the group re-randomised at week 40 
to placebo (the AAP group). No statistical tests were 
reported for these comparisons.
In the trial by Rapti and colleagues, there was a 
higher proportion of responders in the group who 
received ADV and LAM compared with the group 
that received ADV monotherapy (91% versus 72.7% 
respectively). However, the difference was not 
statistically significant.
Table 11 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to 
the ADV–ADV group as the placebo–ADV group 
commenced ADV only after week 48.)
The proportion of patients with normal ALT values 
declined from 75% after 48 weeks to 69% and 59% 
at week 240 for the ‘ITT missing data = failure 
for resistance or HCC’ and ‘ITT missing data = 
failure’ analyses respectively.
In summary, a greater proportion of ADV-treated 
patients experienced ALT normalisation relative 
to comparators, although this was not always 
TABLE 11  Proportion of patients achieving an HBV DNA response – long-term ADV follow-up study
Study, patient type, outcome
Weeks of ADV treatment
48 96 144 192 240a
Hadziyannis et al., 200620
HBeAg –ve
ALT normalisation, % of enrolled 
patientsb
75 74 71 73 69
ALT normalisation, % of enrolled 
patientsc
75 65 68 63 59
ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; ITT, intention to treat.
a  Includes only patients in the ADV–ADV group.
b  ITT, missing data = failure for resistance or HCC.
c  ITT, missing data = failure.Clinical effectiveness
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statistically significant. The proportion of ALT 
responders was generally maintained during long-
term treatment.
ALT normalisation – PEG-α-2b studies
Table 12 reports the proportions of patients with 
ALT normalisation in the PEG-α-2b studies.
All five of the PEG-α-2b trials reported 
results of the proportion of patients with ALT 
normalisation.23–27 All reported ALT normalisation 
at end of follow-up, and four also reported 
results at end of treatment.23–26 None stated the 
‘normalisation’ threshold used.
In the trial by Chan and colleagues (2007),23 
three groups of patients on staggered regimens 
of PEG-α-2b and LAM had similar rates of ALT 
normalisation at end of treatment [Group A 9 
(100%), Group B 9 (100%), Group C 9 (90%)]. At 
end of follow-up these numbers had decreased 
to Group A 4/9 (44%), Group B 5/9 (56%) and 
Group C 4/9 (40%). There were no statistical tests 
reported.
In the study by Chan and colleagues (2005),24 a 
slightly higher proportion (90%) of Group A (PEG-
α-2b and LAM), had normal ALT levels compared 
with 78% of Group B (LAM alone) at end of 
treatment. This was similar at follow-up (Group A 
50% versus Group B 30%). No statistical tests were 
reported for these differences.
The trial by Janssen and colleagues26 found a 
significant difference between Group A (PEG-α-2b 
and LAM) and Group B (PEG-α-2b and placebo) 
in ALT normalisation at end of treatment (51% 
and 34% respectively, p = 0.005). By end of follow-
up, the difference between groups was no longer 
significant (35% and 32% respectively, p = 0.60).
There were no significant differences in the 
proportions of patients reaching normal ALT levels 
at end of treatment or end of follow-up in the trial 
by Kaymakoglu and colleagues.25 The proportions 
of patients with normal ALT at these points were 
slightly higher in Group B (PEG-α-2b and LAM) 
(p > 0.05). Again, these proportions had decreased 
between end of treatment and end of follow-up, 
e.g. 53% of patients in Group A (PEG-α-2b) at end 
of treatment and 42% at end of follow-up.
The proportion of patients reaching ALT 
normalisation in the trial by Zhao and colleagues27 
was very similar at end of follow-up for the two 
study groups (33.9% in Group A receiving PEG-
α-2b versus 34.8% in Group B receiving IFN-α; 
p = 0.93).
In summary, the proportion of patients with 
normalised ALT tended to be greater for the 
combination of PEG-α-2b and LAM compared 
with either as monotherapy. The proportions 
were generally similar when comparing different 
commencement regimens of PEG and LAM, or 
PEG-α-2b with IFN-α. Rates of normalisation 
usually fell between end of treatment and follow-
up. Few statistically significant differences between 
treatments were reported.
Changes in ALT levels – ADV studies
Table 13 presents median ALT levels in the two 
ADV trials which reported this outcome.
In the trial by Zeng and colleagues,19 median ALT 
was similar at week 12 in the groups randomised 
to receive ADV (1.1 × ULN, in both the AAA and 
AAP groups). Median ALT remained similar in the 
AAA and AAP groups at week 40, after 28 weeks of 
open-label ADV (0.7 and 0.9 × ULN respectively). 
At week 40, in the group randomised to placebo 
in the first 12 weeks and who had subsequently 
received open-label ADV for 28 weeks (the PAA 
group), median ALT was similar to the other two 
groups (0.9 × ULN). At week 52, median ALT 
levels remained similar in the PAA and AAA 
groups, but increased to 3.0 × ULN in the group 
who were re-randomised to placebo at week 40 (the 
AAP group). No statistical tests were reported for 
these comparisons.
In the trial by Rapti and colleagues,18 median ALT 
fell to around 24 IU/l in both treatment groups 
at 24 months of treatment, with no statistically 
significant difference between groups.
Changes in ALT levels – 
PEG-α-2b studies
Only one of the PEG-α-2b studies reported this 
outcome (Table 14). In the trial by Chan and 
colleagues,24 medial ALT fell to around 60–70 IU/l 
at 24 weeks’ post-treatment follow-up.
HBeAg loss/seroconversion
HBeAg loss/seroconversion 
– ADV studies
Table 15 presents rates of HBeAg loss and 
seroconversion for the Zeng and colleagues trial.19 
(This outcome was not reported in the study by 
Rapti and colleagues,18 and was not applicable to 
the study of HBeAg-negative patients in the study 
by Hadziyannis and colleagues.20)DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 12  ALT normalisation – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value 
Chan et al., 200723
Group A
PEG-α-2b + 
LAM
Group B
PEG-α-2b + 
LAM
Group C
PEG-α-2b + LAM
HBeAg +ve
Normal ALT levels, EOT (week 104),a n/N (%) 9/9 (100) 9/9 (100) 9/10 (90) NR
Normal ALT levels at follow-up (week 128),a 
n/N (%)
4/9 (44) 59 (56) 4/10 (40) NR
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
Normalisation of ALT levels, EOT, n/N (%)b 45/50 (90) 39/50 (78) NR
Normalisation of ALT levels at follow-up (24 
weeks after treatment), n/N (%)c
25/50 (50) 15/50 (30) NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + placebo
HBeAg +ve
ALT returned to normal, EOT (week 52), n/N 
(%)
66/130 (51) 46/136 (34) 0.005
ALT returned to normal, EOF-U (week 78), 
n/N (%)
46/130 (35) 44/136 (32) 0.60
Kaymakoglu et al., 200725
Group A
PEG-α-2b
Group B
PEG-α-2b + LAM
HBeAg –ve
ALT normalisation EOT, n/N (%) 10/19 (53) 19/29 (66) > 0.05
ALT normalisation EOF-U, n/N (%) 8/19 (42) 14/29 (48) > 0.05
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
ALT level normalisation, week 48 n/N (%) 39/115 (33.9) 40/115 (34.8) 0.93
ALT, alanine aminotransferase; EOF-U, end of follow-up; EOT, end of treatment; NR, not reported.
a  Two patients in Group B and two in Group C had post-treatment ALT reactivation to > 5 times ULN (range 465–1980 
IU/I) between weeks 120 and 128.
b  Absolute difference 12% points (95% CI –2 to 26).
c  Absolute difference 20% points (95% CI 1–39).
At week 52, rates of HBeAg loss and seroconversion 
were highest for patients randomised to placebo 
in the first 12 weeks and who then received open-
label ADV until week 52 (the PAA group). The 
authors attribute this to the six cases of HBeAg 
loss in this group within the first 12 weeks (actual 
date not recorded) which, it is suggested, represent 
spontaneous cases. At week 40, 16 of the 114 
patients (14%) in the AAP group lost HBeAg. 
Following re-randomisation to placebo at week 40, 
nine of them regained HBeAg between week 40 
and week 52. The higher rate of seroconversion in 
the PAA group at week 52 compared with the AAA 
group is again attributed by the study authors to 
the six patients who spontaneously seroconverted 
on placebo in the first 12 weeks. The authors also 
acknowledged that the seroconversion rate in 
the AAA group was lower than achieved in other 
trials. In summary, the results of this study suggest 
that HBeAg seroconversion rates are generally 
maintained with continued ADV treatment, and are 
reduced when treatment is withdrawn.Clinical effectiveness
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TABLE 13  Median ALT – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +ve
Median (range) ALT (× ULN), week 12 2.4 (0.1–14.4) 1.1 (0.3–9.1) 1.1 (0.2–5.9) NR
Median (range) ALT (× ULN), week 40 0.8 (0.2–4.1) 0.7 (0.1–4.4) 0.9 (0.3–30)
Median (range) ALT (× ULN), week 52 0.7 (0.2–4.0) 0.6 (0.2–5.1) 3.0 (0.2–36.4)
Rapti et al., 200718 ADV ADV + LAM
HBeAg –ve
Median ALT at baseline, IU/l (range) 135 (74–608) 108 (52–1004) 0.088
Median ALT at 24 months, IU/l (range) 24 (15–55) 24.5 (12–69) 0.863
ALT, alanine aminotransferase; IU/l = international units per litre; NR, not reported; ULN = upper limit of normal.
PAA, placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
HBeAg loss/seroconversion 
– PEG-α-2b studies
Table 16 reports the results for HBeAg loss and 
seroconversion in four of the PEG-α-2b studies. 
This outcome was not applicable in the trial 
of HBeAg-negative patients by Kaymakoglu 
and colleagues.25 All four trials reports HBeAg 
seroconversion at end of follow-up; three of these 
report rates at end of treatment.
Chan and colleagues (2007)23 compared three 
groups who received staggered regimens of PEG-
α-2b and LAM as described above. At end of 
treatment (week 104) 56% of patients in Group A, 
33% of patients in Group B and 60% of patients 
in Group C had seroconverted. At week 128, 
these figures remained the same in Groups A and 
B and had fallen in Group C to 40%. None of 
the between-group differences were statistically 
significant.
Chan and colleagues (2005)24 report the rate of 
seroconversion at end of treatment in Group A 
receiving PEG-α-2b and LAM (8 weeks of PEG-
α-2b only, followed by 24 weeks of combination 
and then 28 weeks of LAM only) compared with 
Group B receiving LAM alone. In Group A, 60% 
of patients had seroconverted during the last 28 
weeks of LAM therapy; in Group B this figure was 
28%. No statistical tests were reported for these 
results.
Janssen and colleagues26 reported HBeAg loss and 
HBeAg seroconversion at end of treatment (week 
52) and end of follow-up (week 78). At week 52, 
44% of patients in Group A (PEG-α-2b and LAM) 
lost HBeAg compared with 29% in Group B (PEG-
α-2b and placebo) (p = 0.01). Also at this time, 
25% of patients in Group A and 22% of patients in 
Group B had seroconverted (p = 0.52). At week 78, 
35% of patients in Group A and 36% of patients in 
Group B had lost HBeAg (p = 0.91). At this time, 
TABLE 14  Changes in ALT levels – PEG-α-2b studies
Study, patient type, outcome
Group A
PEG-α-2b + LAM
Group B
LAM p-value
Chan et al., 200524
HBeAg +ve
Median ALT at baseline, IU/l (range) 144 (48–1179) 119 (36–461) NR
Median ALT at 24 weeks’ follow-up, IU/l (range)a 60 70 NR
IU/l, international units per litre; NR, not reported.
a  Estimated by the reviewers from a graph in the study publication.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 15  HBeAg loss and seroconversion – ADV studies
Study, patient type, outcome Treatment group
Zeng et al., 200619 PAA AAA AAP
HBeAg +ve
HBeAg loss at week 12, n/N (%) 6/119 (5) 14/239 (6) 6/115 (5)
HBeAg loss at week 40, n/N (%) 22/118 (18) 25/233 (11) 16/114 (14)
HBeAg loss at week 52, n/N (%) 24/118 (20) 30/233 (13) 10/114 (9)
HBeAg seroconversion at week 12, n/N (%) 6/119 (5) 14/229 (6) 6/115 (5)
HBeAg seroconversion at week 40, n/N (%) 22/118 (18) 23/233 (10) 13/114 (11)
HBeAg seroconversion at week 52, n/N (%) 21/118 (18) 19/233 (8) 8/114 (7)
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
38 patients (29%) in Group A and 29 patients 
(29%) in Group B had seroconverted (p = 0.92).
Zhao and colleagues27 reported that the difference 
between groups in the rate of HBeAg loss at end 
of treatment (week 24) was not significant: Group 
A (PEG-α-2b monotherapy) 22.6% versus Group 
B (IFN-α monotherapy) 17.4% (actual p-value 
not reported). At end of follow-up (week 48) this 
number had decreased in Group B (i.e. some of the 
patients re-acquired HBeAg; Group A 24.4% versus 
Group B 13.9%) and the difference was statistically 
significant (p = 0.04). HBeAg seroconversion rates 
at end of follow-up were 21.7% in Group A and 
13.9% in Group B (p = 0.92).
In summary, the results for HBeAg seroconversion 
and loss were mixed. In one trial, higher rates 
of HBeAg seroconversion were reported for the 
combination of PEG-α-2b and LAM compared 
with LAM monotherapy, although these were not 
confirmed statistically. In another trial, HBeAg 
seroconversion rates were similar for PEG-α-2b 
and LAM compared with PEG-α-2b monotherapy. 
There were higher rates of seroconversion for 
PEG-α-2b compared with IFN-α, but the difference 
was not statistically significant. There was also 
no significant difference between staggered 
commencement regimens of PEG-α-2b and LAM.
HBsAg loss/seroconversion
HBsAg loss/seroconversion 
– ADV studies
This outcome was reported in only one of the three 
ADV studies, the long-term open-label follow-up 
study by Hadziyannis and colleagues.20
Six patients (5%) had HBsAg loss after a median 
of 196 weeks (range 20–260) of ADV. Five of these 
patients developed antibody to hepatitis B surface 
antigen (anti-HBs) at their last measurement.
HBsAg loss/seroconversion 
– PEG-α-2b studies
Table 17 reports HBsAg loss or seroconversion as 
reported in three of the PEG-α-2b studies.24,26,27
Chan and colleagues24 reported that five patients 
in Group A (staggered regimen of PEG-α-2b 
and LAM) and seven in Group B (LAM alone) 
underwent HBsAg clearance. No statistical test was 
reported.
Janssen and colleagues26 reported results for 
HBsAg loss and seroconversion at both end 
of treatment (week 52) and end of follow-
up (week 78). The results show very similar, 
small proportions of patients from each group 
undergoing HBsAg loss or seroconversion. For 
example, HBsAg loss at end of treatment had 
occurred in nine patients (7%) in Group A and in 
seven (5%) in Group B (p = 0.54). By end of follow-
up this was nine (7%) in both groups (p = 0.92).
In the trial by Zhao and colleagues,27 none of the 
patients in Group A (receiving PEG-α-2b alone) 
had experienced HBsAg seroconversion, compared 
with two (1.7%) in Group B (receiving IFN 
therapy alone). This difference was not statistically 
significant (p = 0.50).
In summary, rates of HBsAg loss/seroconversion 
were comparatively low (< 15%) and there were 
no consistent statistically significant differences 
between treatment groups. However, statistical 
differences are less likely to be reported for a 
relatively rare outcome.Clinical effectiveness
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TABLE 16  HBeAg loss and seroconversion – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200723
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + 
LAM
Group C
PEG-α-2b + 
LAM
HBeAg +ve
Rate of HBeAg seroconversion, week 52, 
n/N (%)
6/9 (67) 3/9 (33) 1/10 (10) 0.35 (Groups A 
and B)
0.037 (Groups A 
and C)
Rate of HBeAg seroconversion, EOT 
(week 104), n/N (%)
5/9 (56) 3/9 (33) 6/10 (60) 0.64 (Groups A 
and B)
1.00 (Groups A 
and C)
Rate of HBeAg seroconversion at follow-
up (week 128), n/N (%)
5/9 (56) 3/9 (33) 4/10 (40) 0.64 (Groups A 
and B)
0.83 (Groups A 
and C)
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
Rate of HBeAg seroconversion, week 8 
(before commencement of LAM in Group 
A), n/N (%)
9/50 (18) 0/50 NR
Rate of HBeAg seroconversion, week 32 
(after 24 weeks of LAM in both groups), 
n/N (%)
20/50 (40) 11/50 (22) NR
Rate of HBeAg seroconversion, last 28 
weeks of extended LAM, n/N (%)
30/50 (60) 14/50 (28) NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + placebo
HBeAg +ve
HBeAg loss, EOT (week 52), n/N (%) 57/130 (44) 40/136 (29) 0.01
HBeAg loss, EOF-U (week 78), n/N (%) 46/130 (35) 49/136 (36) 0.91
HBeAg seroconversion, EOT (week 52), 
n/N (%)
33/130 (25) 30/136 (22) 0.52
HBeAg seroconversion, EOF-U (week 78), 
n/N (%)
38/130 (29) 39/136 (29) 0.92
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
HBeAg loss, EOT (week 24), n/N (%) 26/115 (22.6) 20/115 (17.4) NS
HBeAg loss, EOF-U (week 48), n/N (%) 28/115 (24.4) 16/115 (13.9) 0.04
HBeAg seroconversion, EOF-U (week 48), 
n/N (%)
25/115 (21.7) 16/115 (13.9) 0.12
EOF-U, end of follow-up; EOT, end of treatment; NR, not reported; NS, not significant.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Liver histological response
Of the three ADV trials, only the long-term open-
label ADV study20 reported this outcome. Table 
18 presents histological results for a subset of 45 
patients who had a liver biopsy at the end of the 
study. (Note that there is a discrepancy in the 
journal publication for this study, such that the 
total number of patients is reported as being 45 as 
well as 44.)
Compared with pre-treatment biopsy, there were 
improvements in necroinflammation in the range 
of 83–86% of patients, and in improvements 
in fibrosis in the range of 73–75% of patients. 
There were similar reductions in median Knodell 
necroinflammation scores (in the range –5.0 to –4.5 
points) and in median Ishak fibrosis scores.
Liver histological response 
– PEG-α-2b studies
Liver histological response, as reported in three of 
the PEG-α-2b studies,23,24,26 is shown in Table 19. 
One of these trials reported using both the Ishak 
and the Knodell classification systems,24 another 
used the Ishak system26 and the third trial did not 
state which system was used.23
Chan and colleagues (2007)23 reported no 
significant differences across their three groups 
receiving staggered regimens of PEG-α-2b and 
LAM (described above), although group B had 
a slightly lower proportion of patients for each 
change: six (75%) for both necroinflammation 
improvement and fibrosis change, compared 
with eight (89%) in Group A for both results, 
and eight (89%) and nine (100%) in Group C for 
necroinflammation and fibrosis change respectively.
In the trial by Chan and colleagues (2005),24 the 
results across groups were again broadly similar, 
for both improvements and worsening in the 
necroinflammatory score; e.g. four (10%) in Group 
A (PEG-α-2b) versus four (9%) in Group B (LAM) 
for a ≥ 2-point decrease in this score. For both 
improvement and worsening in fibrosis scores, 
Group A had the highest proportion of patients: six 
(15%) versus four (9%) for a ≥ 2-point decrease, for 
example. No p-values are reported for these results.
Janssen and colleagues26 reported improvement, 
no change and deterioration for both fibrosis 
and inflammation. A higher proportion in Group 
A (PEG-α-2b and LAM) improved their fibrosis 
scores: 33% versus 22% in Group B (PEG-α-2b 
and placebo). A higher proportion in Group B 
experienced no change, and the proportions were 
equal for deterioration (38% in each group). There 
was no statistically significant difference between 
groups for improvement or no change versus 
worsening (p = 0.22).
This pattern was reversed for the inflammation 
results, with Group B having a higher proportion 
of patients with improvement. The groups were 
again equal for the proportion that deteriorated. 
Again, the differences between groups for 
improvement and no change versus worsening 
were not statistically significant. The authors of 
this study advise caution with these results as post-
treatment biopsies were optional and selection bias 
may have occurred.26
A follow-up paper to this study29 reported the 
improvements in necroinflammatory and fibrosis 
scores (mean ± SD, range) and these are presented 
in Table 19. Results show that Group B had a 
smaller reduction in necroinflammatory score than 
Group A (–1.5 and –1.7 respectively). While the 
improvements in these scores within groups were 
significant, no p-value is given for the difference 
between groups. This is repeated for the changes in 
fibrosis score, where again improvements within the 
groups were significant, but the difference between 
groups in improvements was not (p = 0.59).
In summary, there were mixed results for liver 
histology. In some instances, differences between 
treatments in necroinflammation and fibrosis 
favoured PEG-α-2b and LAM combination 
therapy, while in other instances, PEG-α-2b or 
LAM monotherapy appeared more favourable. 
Where statistical tests were reported there were no 
significant differences between treatments.
Combined outcomes
Combined outcomes – ADV studies
None of the ADV studies reported combined 
outcome measures.
Combined outcomes – 
PEG-α-2b studies
Table 20 reports results for the two PEG-α-2b trials 
that reported combined outcome measures. In 
the trial by Chan and colleagues,24 a virological 
response was defined as HBeAg seroconversion, 
detection of antibody to HBeAg and HBV DNA 
level < 500,000 copies/ml and normalisation of 
ALT. In a follow-up study,28 sustained virological 
response (SVR) was defined as persistent HBeAg Clinical effectiveness
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TABLE 17  HBsAg loss and seroconversion – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
HBsAg clearance, n/N 5/50 7/50 NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG- α-2b + placebo
HBeAg +ve
HBsAg loss, EOT (week 52), n/N (%) 9/130 (7) 7/136 (5) 0.54
HBsAg loss, EOF-U (week 78), n/N (%) 9/130 (7) 9/136 (7) 0.92
HBsAg seroconversion, EOT (week 52), 
n/N (%)
8/130 (6) 6/136 (4) 0.53
HBsAg seroconversion, EOF-U (week 
78), n/N (%)
9/130 (7) 7/136 (5) 0.54
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
HBsAg seroconversion, n/N (%)  0/115 (0) 2/115 (1.7) 0.50
EOF-U, end of follow-up; EOT, end of treatment; NR, not reported.
TABLE 18  Histological results – long-term ADV follow-up study
Study, patient type, outcome
Study group
240 weeks, ADV–ADV 
(n = 24)
192 weeks, placebo–ADV 
(n = 22)
Hadziyannis et al., 200620
HBeAg –ve
Ranked assessment
Improved necroinflammation, % 83 86
Improved fibrosis, % 75 73
Median change in Knodell necroinflammation score from baseline –5.0 points –4.5 points
Median change in Ishak fibrosis score –1.0 points –1.0 points
% improvement in Ishak fibrosis scorea 71 55
a  Proportion of patients with at least a 1-point improvement in Ishak fibrosis score.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 19  Liver histological response – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200723
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + 
LAM
Group C
PEG-α-2b 
+ LAM
HBeAg +ve
Necroinflammatory score, ≥ 2-point 
improvement, week 104, n/N (%)
8/9 (89) 6/8 (75) 8/9 (89) Group A vs Group B: 0.91
Group A vs Group C: 1.00
Fibrosis score, ≤ 1-point change, week 
104, n/N (%)
8/9 (89) 6/8 (75) 9/9 (100) Group A vs Group B: 0.91
Group A vs Group C: 1.00
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
≥ 2-point increase in necroinflammatory 
score, EOT, n/N (%)a
24/40 (60) 26/44 (59) NR
≥ 2-point decrease in necroinflammatory 
score, EOT, n/N (%)
4/40 (10) 4/44 (9) NR
≥ 2-point increase in fibrosis scores, 
EOT, n/N (%)b
6/40 (15) 4/44 (9)  NR
≥ 2-point decrease in fibrosis scores, 
EOT, n/N (%)c
4/40 (10) 2/44 (5) NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + placebo
HBeAg +ve
Fibrosisf
Improvement, EOT (week 52), n/N 
(%)
17/52 (33) 13/58 (22)  0.22 for improvement or 
no change vs worsening
No change, EOT (week 52), n/N (%) 15/52 (29) 23/58 (40)
Deteriorated, EOT (week 52), n/N (%) 20/52 (38) 22/58 (38)
Inflammationd
Improvement, EOT (week 52), n/N 
(%)
25/52 (48) 31/58 (53) 0.57 for improvement or 
no change vs worsening
No change, EOT (week 52), n/N (%) 22/52 (42) 21/58 (36)
Deteriorated, EOT (week 52), n/N (%) 5/52 (10) 6/58 (10)
Necroinflammatory score, EOT (week 
52)e
Pre-treatment, mean ± SD (range) 5.4 ± 2.0 (2–9) 5.6 ± 2.2 (1–10) <0.001 for pre-treatment 
vs post-treatment Post-treatment, mean ± SD (range) 3.7 ± 2.0 (1–8) 4.1 ± 1.8 (1–9)
Change, mean ± SD (range) –1.7 ± 2.6 (–7 to 3) –1.5 ± 2.3 (–7 to 4)
continuedClinical effectiveness
32
Study, patient type, outcome Treatment group p-value
Fibrosis score, EOT (week 52)f
Pre-treatment, mean ± SD (range) 2.6 ± 1.5 (0–6) 2.3 ± 1.6 (0–6) Group A: 0.23 for 
pre-treatment vs post-
treatment
Group B: 0.07 for 
pre-treatment vs post-
treatment
Post-treatment, mean ± SD (range) 2.8 ± 1.8 (0–6) 2.7 ± 1.6 (0–6)
Change, mean ± SD (range) 0.2 ± 1.4 (–3 to 3) 0.4 ± 1.5 (–2 to 5)
EOF-U, end of follow-up; EOT, end of treatment; NR, not reported.
a  Absolute difference 1% point (95% CI –20 to 22).
b  Absolute difference 6% points (95% CI –8 to 20).
c  Absolute difference 5% points (95% CI –6 to 17).
d  Improvement in histology was defined as a decrease of ≥ 2 points for the necroinflammatory score (range 0–18) and 1 
point for the fibrosis score (range 0–6); worsening was defined as an increase of ≥ 2 points for the necroinflammatory 
score and 1 point for the fibrosis score.
e  Overall mean necroinflammatory score improved by 1.6 points, a significant improvement in both groups (p < 0.001). 
Largest improvements were in focal inflammation (mean 0.7 points) and interface hepatitis (mean 0.6 points). 
Necroinflammation score improved in 51% of patients (decrease ≥ 2 points) and only 10% showed worsening (increase 
≥ 2 points). Inflammation improved in 48% of patients in Group A and 53% of patients in Group B (p = 0.57).
f  Overall mean fibrosis score increased by 0.3 points (p = 0.03). Fibrosis score improved in 27% of patients (decrease ≥ 
2 points). Improvement in fibrosis was found in 33% of patients in Group A and 22% of patients in Group B (p = 0.23), 
while mean fibrosis score increased by 0.2 points in Group A and by 0.4 points in Group B (p = 0.59).
TABLE 19  Liver histological response – PEG-α-2b studies (continued)
loss and HBV DNA < 100,000 copies/ml from 
treatment cessation until the end of follow-up (up 
to 124 weeks). In the Zhao and colleagues trial,27 
a ‘sustained combined response’ was defined as 
serum HBV DNA level < 105 copies/ml, HBeAg loss 
and normal ALT levels.
In the study by Chan and colleagues,24 60% of 
patients taking the combination of PEG-α-2b and 
LAM (Group A) achieved the virological response 
at week 52, compared with 28% in the LAM group 
(Group B) (p = 0.001). Results are also given for 
SVR at both follow-up and long-term follow-up. A 
higher proportion of patients in Group A (18/50, 
36%) achieved an SVR at 24 weeks’ follow-up than 
of those in Group B (7/50, 14%) (p = 0.011). At end 
of long-term follow-up, these numbers decreased 
in Groups A and B (29% and 8% respectively). No 
statistical test is reported for this difference.
In the trial by Zhao and colleagues,27 a slightly 
higher proportion of patients receiving PEG-α-2b 
(17.4%) achieved the sustained combined response 
than of those receiving IFN-α (10.4%). This 
difference was not statistically significant.
Viral resistance
Viral resistance – ADV studies
Table 21 presents rates of viral resistance in two of 
the ADV studies.
No participants in the trial by Zeng and 
colleagues19 developed a resistance to ADV during 
the course of the study. Those included in analysis 
for resistance were patients with an increase in 
serum HBV DNA of at least 1 log10 copies/ml while 
on ADV from their lowest point during treatment 
and therefore had isolates analysed for the 
presence of ADV associated-mutations at week 52. 
These totalled 45 in the study, and are distributed 
among treatment groups as shown Table 21.
In the trial by Rapti and colleagues,18 a higher 
proportion of patients (21%) developed resistance 
in the group receiving ADV alone, compared with 
0% of patients in the groups receiving ADV and 
LAM combination therapy. This difference was 
statistically significant (p = 0.0182).
Table 22 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to the 
ADV–ADV group as the placebo–ADV group only 
commenced ADV after week 48.)
The incidence of three definitions of resistance 
was measured: (1) ADV resistance mutations 
(N236T or A181V); (2) ADV-resistant mutations 
with HBV DNA increased from nadir by at least 1 
log10 copies/ml (confirmed or last measurement) 
or never suppressed to less than 3 log10 copies/ml DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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(‘virological resistance’); and (3) ADV resistance 
mutations with virological resistance and 
ALT elevations (ALT greater than ULN after 
normalising ALT; ‘clinical resistance’). At 240 weeks 
of ADV treatment, the cumulative probabilities of 
ADV resistance were 29%, 20% and 11% for the 
three definitions of resistance respectively.
In summary, rates of ADV reported in these studies 
were relatively low and tended to remain so over 
long-term treatment.
Viral resistance – PEG-α-2b studies
Table 23 presents rates of LAM resistance rates in 
three of the four PEG-α-2b trials that included 
LAM.23–26
Chan and colleagues (2007)23 reported low rates 
of LAM resistance. In Group C there were two 
patients with LAM resistance, compared with one 
patient in each of Groups A and B at week 104 
(end of treatment).
In the trial by Chan and colleagues (2005),24 
a higher proportion of patients exhibited 
LAM resistance in the group receiving LAM 
monotherapy than in the group receiving PEG-α-
2b and LAM (40% versus 21%). No statistical test 
was reported for these results.
In the trial by Janssen and colleagues,26 14 patients 
(11%) in Group A (PEG-α-2b and LAM) exhibited 
LAM resistance at the end of treatment. The 
comparison group in this trial did not receive 
LAM. Seven of the 14 had previously been treated 
with LAM and had a mutant from the start of 
therapy.
In summary, the addition of LAM to PEG-α-2b 
was associated with lower rates of LAM resistance, 
although this was not confirmed statistically.
Adverse events
Adverse events – ADV studies
Table 24 reports dose discontinuations, reductions 
and incidence of serious adverse events in the ADV 
studies.
Zeng and colleagues19 reported that two patients in 
the AAA group and one patient in the AAP group 
discontinued the study drug because of adverse 
events. The authors state that adverse events were 
similar in nature and severity between treatment 
groups. No patients died during the trial. The 
authors stated that adverse events rarely occurred 
at a frequency of 5% or greater in any treatment 
group. The incidence of CHB-related adverse 
events was reported, with 9% in the AAP group, 
compared with < 1% in the AAA and PAA groups. 
TABLE 20  Combined outcomes – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
HBV DNA virological response, EOT 
(week 52), n/N (%)
30/50 (60) 14/50 (28) 0.001
HBV DNA virological response, week 48, 
n/N (%)
25/50 (50) 14/50 (28) NR
SVR at follow-up (24 weeks after 
treatment), n/N (%)
18/50 (36) 7/50 (14) 0.011
SVR at long-term follow-up, n/N (%) 14/48 (29) 4/47 (8) NR
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
Sustained combined response at week 48 
n/N (%)
20/115 (17.4) 12/115 (10.4) 0.13
EOT, end of treatment; NR, not reported; SVR, sustained virological response.Clinical effectiveness
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TABLE 21  Viral resistance – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +vea
Viral resistance at week 52, N236T or A181V 
mutation, n/N
0/11 0/28 0/6
Rapti et al., 200718 ADV ADV + LAM
HBeAg –ve
Genotypic ADV resistance, % 21 0 0.0182
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
a  A total of 45 subjects (28 from AAA, 11 from PAA and 6 from AAP) had an increase in serum HBV DNA of at least 1 
log10 copies per ml while on ADV from their lowest point during treatment and therefore had isolates analysed for the 
presence of ADV-associated mutations at week 52.
The authors report that these events all occurred 
after patients in the AAP group were randomised to 
placebo at week 40.
There were no dose discontinuations in the trial 
by Rapti and colleagues,18 but two patients in the 
group receiving ADV and LAM had their ADV 
dose reduced, compared with zero reductions 
in the ADV monotherapy group. Three patients 
experienced HCC during the course of the trial, 
all in the ADV and LAM group. There was no 
statistically significant difference between groups 
(p = 0.545). Only serious adverse events were 
reported.
In summary, the incidence of adverse events was 
low and generally similar between treatment 
groups.
Adverse events – PEG-α-2b studies
Table 25 reports dose discontinuations, reductions 
and incidence of serious adverse events in the 
PEG-α-2b studies.
Chan and colleagues (2007)23 compared three 
groups receiving staggered regimens of PEG-α-2b 
and LAM as described above. Two patients in both 
Group A and Group C had their dose of PEG-α-2b 
halved owing to neutropenia (0.7–0.9 × 109/ml) at 
doses 6–19. While no patients in Group B had a 
dose reduction, one experienced a serious adverse 
event (hysterectomy for menorraghia). The authors 
state that this was unrelated to the study drug, 
and the study medication was uninterrupted. No 
patients in this study died. Each of the groups in 
this trial experienced generally similar numbers 
of adverse events; however, Group B (receiving 
PEG-α-2b for 8 weeks prior to commencing LAM) 
experienced the fewest adverse events. The largest 
apparent difference was in upper respiratory tract 
symptoms, where one incident occurred in Group 
B, compared with five (50%) in Group A and seven 
(70%) in Group C (not shown in Table 25; for more 
information refer to Appendix 1).
In the trial by Chan and colleagues (2005),24 Group 
A (PEG-α-2b and LAM) had a larger proportion 
TABLE 22  Drug resistance – long-term open-label ADV study
Study, patient type, outcome
Weeks of ADV treatment
48 96 144 192 240
Hadziyannis et al., 200620
HBeAg –ve
Mutation, % of enrolled patients 0 3 11 18 29
Mutation with virological resistance, % of enrolled 
patients
0 3 8 14 20
Mutation with virological resistance and ALT 
elevation (clinical resistance), % of enrolled patients
0 2 6 10 11DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 23  Viral resistance – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200723
Group A
PEG-α-2b +LAM
Group B
PEG-α-2b +LAM
Group C
PEG-α-2b +LAM
HBeAg +ve
Resistance to LAM at week 104, 
rtM204V, n/N
1/9 1/8 1/9 NR
Resistance to LAM at week 104, 
rtL108M and rtM205I, n/N 
0 0 1/9 NR
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
LAM-resistant mutants, EOT, n/N (%)a 10/48 (21) 19/48 (40) NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + placebo
HBeAg +ve
YMDD mutation (resistance to LAM), 
EOT, n/N (%)
14/130 (11) Not applicable
EOT, end of treatment; NR, not reported; YMDD, tyrosine-methionine-aspartate-aspartate.
a  Absolute difference 19% points (CI 8–37).
TABLE 24  Adverse events – ADV studies
Study, patient type, outcome Treatment group p-value
Zeng et al., 200619 PAA AAA AAP
HBeAg +ve
Dose discontinuation for any adverse event, n/N 2/240 1/120 NR
Incidence of hepatitis B-related adverse events, % < 1 < 1 9a NR
Rapti et al., 200718 ADV ADV + LAM
HBeAg –ve
Dose discontinuation for any adverse event, n/N 0/14 0/28 NR
Dose reduction for any adverse event, n/N 0/14 2/28b NR
a  All events occurred after re-randomisation to placebo at week 40.
b  ADV dose reduced to 10 mg every other day.
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
than Group B (LAM monotherapy) of patients 
discontinuing the study drug (4 versus 0), dose 
reduction (5 versus 0) and serious adverse events 
(4 versus 0). The authors report that most adverse 
events were transient and related to the use of 
PEG-α-2b. No patient died or required liver 
transplantation. Reduction of the PEG-α-2b dose 
to 50 μg/week (if body weight > 65 kg) or 1.0 μg/
kg/week if < 65kg) was due to anaemia (n = 1), 
neutropenia (n = 3) and/or thrombocytopenia 
(n = 4). PEG-α-2b was discontinued in all four 
cases of serious adverse events, which were: bipolar 
disorder, pulmonary tuberculosis, thyrotoxicosis 
and severe local reaction at injection sites. Three 
patients continued with LAM through to week 60, 
while the fourth patient withdrew from the study 
and was considered a treatment failure.
The most common adverse events in Groups A and 
B were upper respiratory tract symptoms, which Clinical effectiveness
36
TABLE 25  Adverse events – PEG-α-2b studies
Study, patient type, outcome Treatment group p-value
Chan et al., 200723
Group A
PEG-α-2b + 
LAM
Group B
PEG-α-2b + 
LAM
Group C
PEG-α-2b + 
LAM
HBeAg +ve
Dose reduction for any adverse event, n/N  2/9 0/8 2/9 NR
Serious adverse event, n/N 0/9 1/8 0/9 NR
Total number of adverse events, n 42 34 45
Chan et al., 200524
Group A
PEG-α-2b + LAM
Group B
LAM
HBeAg +ve
Dose discontinuation (PEG-α-2b) for any adverse 
event, n/N (%)
4/40 (8) 0/44 NR
Dose reduction (PEG-α-2b) for any adverse event, 
n/N (%)
5/40 (10) 0/44 NR
Serious adverse events, n/N (%) 4/40 (8) 0/44 NR
Total number of adverse events, n 429  55 NR
Janssen et al., 200526
Group A
PEG-α-2b + LAM
Group B
PEG-α-2b + placebo
HBeAg +ve
Dose reduction (PEG-α-2b) for any adverse event, 
n/N (%)
37/148 (54) 32/152 (47) NS
Blinded drug reduction – 0
Blinded drug discontinuation – 24
Incidents of common adverse events, n 557 539
Kaymakoglu et al., 200725
Group A
PEG-α-2
Group B
PEG-α-2b + LAM
HBeAg –ve
Dose discontinuation for any adverse event, n/N 0/19 0/29
Dose reduction for any adverse event, n/N 0/19 0/29
Zhao et al., 200727
Group A
PEG-α-2b
Group B
IFN
HBeAg +ve
Dose discontinuation for any adverse event, n/N 0/115 4/115 NR
Dose reduction for any adverse event, n/N (%) 0/115 0/115
Adverse events experienced (%) 75 75
NR, not reported; NS, not significant.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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included cough, running nose and sore throat. 
Group A had a higher proportion of patients 
experiencing adverse events across all types, and 
all of these differences between the two groups 
were statistically significant, apart from vomiting 
and diarrhoea, weight loss > 10% and abdominal 
discomfort (not shown in Table 25, for more 
information refer to Appendix 1).
A follow-up publication30 of the trial by Janssen 
and colleagues26 reported that a slightly higher 
percentage of patients in Group A (PEG-α-2b and 
LAM) than Group B (PEG-α-2b and placebo) had 
the dose of PEG-α-2b reduced for any adverse 
event: 37 (54%) and 32 (47%) respectively. There 
was no significant difference between treatment 
groups, for these and for all side effects. The 
authors of this study reported discontinuations of 
PEG-α-2b across the two groups of patients (28, 
9%) but not how these were distributed between 
groups. Neutropenia was the most common reason 
for dose reduction in this trial (n = 36, 52%). The 
most common reason for early discontinuation was 
local reaction (n = 10, 36%). There were no dose 
reductions of LAM or placebo. Fifty per cent of 
the dose reductions occurred within the first 10 
weeks, with numbers of dose reductions decreasing 
thereafter and only two reported after week 32, 
when the scheduled dose reduction took place. 
Discontinuation of therapy was reported more 
frequently before the scheduled dose reduction of 
PEG-α-2b at week 32.
There were 33 serious adverse events in the trial by 
Janssen and colleagues;26 the authors state that 17 
(53%) were probably related to therapy, and that all 
were reversible after treatment had stopped. The 
frequency of all side effects is reported as not being 
statistically significant between groups.
Kaymakoglu and colleagues25 reported that no 
patients from either treatment group had their 
dose reduced or discontinued for any adverse 
event. Of the adverse events experienced, 71% 
were of flu-like symptoms. The authors do not 
comment on severity or likelihood of relation to the 
study drug.
The study drug was discontinued in four patients 
in the group receiving IFN-α, and in no patients in 
the group receiving PEG-α-2b in the trial by Zhao 
and colleagues.27 There were no dose reductions 
in either group. The authors report that 75% of 
patients in each group experienced ‘various forms’ 
of drug-related adverse events, the most common 
of which, again, were flu-like symptoms and fever.
In summary, there were mixed findings for adverse 
events. In some trials, the incidence of events 
and dose discontinuations was generally similar 
between treatments. In at least one trial, there was 
a higher incidence of events and discontinuations 
for PEG-α-2b and LAM compared with LAM. 
Common adverse events included flu-like 
symptoms and upper respiratory tract infections.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Methods for economic 
analysis
The aim of this section is to provide an update of 
the cost-effectiveness assessment of PEG-α and 
ADV in our original report.12 The economic analysis 
comprises:
•	 a systematic review of the 2005–7 publications 
on the cost-effectiveness of PEG-α and ADV
•	 an update of our previously published 
economic model.12
Systematic review of 
economic evaluations
Search strategy
This review was guided by the general principles 
for conducting a systematic review outlined in 
the CRD Report 4.13 Details on the literature 
search methods to identify published economic 
evaluations are described in Chapter 2.
Titles and abstracts of studies identified by the 
search strategy were independently assessed for 
potential eligibility by two health economists. Full 
economic evaluations were eligible for inclusion if 
they reported on the cost-effectiveness of PEG-α 
(2a and 2b) and/or ADV versus the specified 
comparators (IFN-α and LAM or best supportive 
care) in adults with CHB. Studies reporting the 
economic evaluation of comparator treatments 
were also identified. In addition, recently published 
studies on health-related quality of life in patients 
with CHB were considered for potential use in 
the update of our economic model (see below). 
Health-related quality of life literature searches 
were run in MEDLINE, PREMEDLINE, EMBASE 
and PsycINFO Ovid databases. The searches were 
limited to 2005 to September 2007 and to English 
language only.
Data extraction strategy
Data were extracted from the included cost-
effectiveness studies using a standardised template. 
Data extraction was undertaken by one reviewer 
and checked by a second, with any disagreements 
resolved through discussion. Full data extraction 
forms of all the included studies can be found in 
Appendix 4.
Quality assessment strategy
Economic evaluations were assessed using 
the critical appraisal checklist for economic 
evaluations. The checklist was consistent with 
methodology proposed by Drummond and 
colleagues36 and Philips and colleagues37 for 
assessing good practice in decision-analytic 
modelling in published economic evaluations. See 
Appendix 4 for details.
Results of the systematic 
review: cost-effectiveness
Our previously published assessment report12 
included:
•	 one fully published economic evaluation 
of treatments for CHB, including ADV as 
monotherapy and as a salvage strategy for 
LAM-resistant patients38
•	 six fully published economic evaluations of 
antiviral treatments for CHB (IFN-α and 
LAM)8,39–43
•	 two unpublished drug manufacturers’ 
submissions to NICE – the Roche submission 
evaluating PEG-α-2a versus IFN-α, LAM, 
ADV and best supportive care; and the Gilead 
Sciences submission evaluating ADV as first- 
and second-line treatment versus LAM as first- 
or second-line treatment.
The characteristics and results of these studies 
are not presented in the current report. However, 
where appropriate, two of these evaluations, 
Kanwal and colleagues38 and the Roche submission, 
are discussed. For clarity of presentation, the 
outcomes reported by Kanwal and colleagues38 
are presented separately for HBeAg-positive and 
HBeAg-negative patients. The original model used 
in the Roche submission remains unpublished and 
is not reviewed here. A description is available in 
our previous report.12
A total of 67 publications of the cost-effectiveness 
of PEG-α and/or ADV in CHB were identified 
through our updated searches. Four fully published 
economic evaluations met the inclusion criteria 
and were included.44–47 In addition, one systematic 
review of economic evidence of cost-effectiveness 
of antiviral therapies in CHB patients (Sun and 
colleagues48) was included.
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The studies by Veenstra and colleagues44 
and Sullivan and colleagues45 estimated cost-
effectiveness of PEG-α-2a compared with LAM 
in HBeAg-positive patients. The same model was 
used in both studies; however, the perspective in 
Veenstra and colleagues44 was that of the UK NHS, 
while in Sullivan and colleagues45 the perspective 
was of the Taiwan Bureau of National Health 
Insurance. The newly identified study by Kanwal 
and colleagues (2006)46 used the model first 
presented in Kanwal and colleagues (2005)38 to 
estimate cost-effectiveness of alternative treatments 
for CHB in the subgroup of patients with cirrhosis 
(both compensated and decompensated). Buti and 
colleagues47 conducted an economic evaluation 
comparing ADV with LAM in HBeAg-negative 
patients.
A systematic review of cost-effectiveness of antiviral 
therapies (Sun and colleagues48) described studies 
published from 2000 to 2007, including three 
studies described here (Kanwal and colleagues38, 
Buti and colleagues47 and Sullivan and colleagues45) 
and some of the studies identified in our previous 
review.12 Sun and colleagues48 also reviewed other 
cost studies based on randomised, non-randomised 
and retrospective cohort data that did not meet 
the inclusion criteria of the present or previous 
reviews and were generally assessed by Sun and 
colleagues48 as being of moderate or poor quality. 
These studies are therefore not discussed any 
further in the present review.
Description of the published 
economic evaluations
Table 26 provides a summary of characteristics of 
the identified economic evaluations reporting the 
cost-effectiveness of antiviral treatments for CHB.
Four of the five economic evaluations presented in 
Table 26 employed a Markov state-transition model; 
Buti and colleagues 47 used a decision tree analysis. 
All modelled economic evaluations incorporate 
health states that correspond to the natural history 
of the disease. The model presented in Buti and 
colleagues47 has a 4-year time horizon; other 
models have a lifetime horizon as appropriate for 
the chronic nature of the disease.
The state-transition diagrams presented in 
each of these evaluations are broadly similar. 
Typically, patients enter the model in the ‘chronic 
HBV’ health state and receive the evaluated 
intervention, one of the comparator treatments 
or best supporting care. In accordance with the 
natural history of the disease, patients may then 
remain in this state, achieve treatment-induced 
response (HBeAg seroconversion in HBeAg-
positive patients or viral suppression that can be 
achieved by both HBeAg-positive and -negative 
patients) or experience treatment relapse (return 
to CHB). Patients could also develop resistance to 
the active treatment (a virological breakthrough). 
Patients who do not achieve a response can also 
enter more progressive stages of liver disease (such 
as compensated or decompensated cirrhosis or 
hepatocellular carcinoma). Patients in the study 
by Kanwal and colleagues46 enter the model at the 
cirrhotic stage, which can be either compensated or 
decompensated. The best outcome in this subgroup 
of CHB patients is to remain in the compensated 
cirrhosis stage or revert from decompensated 
to compensated cirrhosis either as a result of 
treatment or spontaneously.
With the exception of the model reported by Buti 
and colleagues,47 the models presented here allow 
TABLE 26  Model structure and assumptions of economic evaluations for antiviral treatment of hepatitis B
Veenstra et al., 
200744
Sullivan et al., 
200745 Buti et al., 200647
Kanwal et al., 
200538
Kanwal et al., 
200646
Type of model Adapted from 
Crowley42 and 
Crowley et al.43 
and Pwu and 
Chan.49 Two 
additional health 
states – ‘liver 
transplantation’ 
and ‘post-liver 
transplant’ – 
were added
Adapted from 
Crowley42 and 
Crowley et al.43 
and Pwu and 
Chan49. Two 
additional health 
states – ‘liver 
transplantation’ 
and ‘post-liver 
transplant’ – 
were added
A new decision-analytic 
model
A new hybrid 
modela consisting 
of two submodels
Adapted from 
Kanwal et al.38 
for the subgroup 
of patients with 
cirrhosisDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Veenstra et al., 
200744
Sullivan et al., 
200745 Buti et al., 200647
Kanwal et al., 
200538
Kanwal et al., 
200646
Health states/
stages of 
treatment 
pathway
Seroconversion
Chronic hepatitis 
B 
Compensated 
cirrhosis
Decompensated 
cirrhosis
Hepatocellular 
carcinoma
Liver 
transplantation
Post-liver 
transplant
Death
Seroconversion
Chronic 
hepatitis B
Compensated 
cirrhosis
Decompensated 
cirrhosis
Hepatocellular 
carcinoma
Liver 
transplantation
Post-liver 
transplant
Death
Over 4 years patients 
may progress though 
the following stages:
Receiving initial 
active treatment with 
response
Continuing initial 
active treatment with 
response
Developing resistance 
to initial active 
treatment
Receiving ADV 
treatment and 
continuing with 
response (applies 
to LAM-refractory 
patients)
Developing resistance 
and no response to 
ADV salvage therapy
No active treatment 
after developing 
resistanceb
Chronic HBV 
infection
Virological 
response (either 
spontaneously or 
due to treatment)
Virological relapse
Developing viral 
resistance
Compensated 
cirrhosis
Decompensated 
cirrhosis
Liver transplant
Hepatocellular 
carcinoma
Death
Compensated 
cirrhosis
Decompensated 
cirrhosis
Successful liver 
transplant
Hepatocellular 
carcinoma
Death
Characteristics 
of baseline 
cohort 
32 years old
78% male
87% Asian
17% with 
compensated 
cirrhosis or 
transition to 
cirrhosis
32 years of age
78% male
87% Asian
17% with 
compensated 
cirrhosis or 
transition to 
cirrhosis
Mean age of patients 
varied from 45 to 49 
years
Proportion of males 
varied from 74% to 
83%
Proportion of patients 
with cirrhosis, wherever 
reported, varied from 
23% to 54% across 
four studies that were 
used to obtain estimates 
of outcome
40 years of age
Elevated ALT, 
no evidence of 
cirrhosis and no 
previous CHB 
treatment
55% of the cohort 
were HBeAg –ve
50 years of age
50% with 
compensated 
cirrhosis and 
50% with 
decompensated 
cirrhosis
Cycle length 1 year 1 year 1 year 1 year 1 year
Time horizon Lifetime Not reported, 
appears to be 
lifetime
4 years Lifetime Lifetime
a  Patient progression through pre-cirrhotic health states is analysed with decision-analytic model. Progression through 
cirrhotic health states is analysed by means of a Markov model.
b  Although not clearly identified, ‘progressing to decompensated liver disease’ is used as an implicit outcome that only 
applies to patients who received no treatment as a result of developing resistance to LAM and/or ADV. This outcome is not 
associated with a defined health state but is associated with additional costs.
TABLE 26  Model structure and assumptions of economic evaluations for antiviral treatment of hepatitis BEconomic analysis
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the possibility of patients with progressive liver 
disease to undergo liver transplantation. Kanwal 
and colleagues (2006)46 specified that patients in 
decompensated cirrhosis health states (ascites, 
variceal haemorrhage and hepatic encephalopathy) 
and HCC could undergo liver transplantation. 
According to the assumptions of the model 
reported in Veenstra and colleagues44 and Sullivan 
and colleagues,45 patients with HCC do not receive 
a liver transplant. Table 27 presents further details 
of the included economic evaluations including 
base-case results.
Details of economic evaluations 
based on the Roche model
As noted earlier, two economic evaluations 
(Veenstra and colleagues44 and Sullivan and 
colleagues45) use the same model to evaluate PEG-
α-2a versus LAM in HBeAg-positive patients. This 
model uses the structure and some of the transition 
probabilities presented in 2005 in the Roche 
submission to NICE for their appraisal of PEG-α-
2a. The model evaluated a 48-week course of PEG-
α-2a versus comparators IFN-α, LAM, ADV and 
best supportive care. (For a fuller description see 
our previous report.12) However, unlike the Roche 
model, economic evaluations reported in Veenstra 
and colleagues44 and Sullivan and colleagues45 
apply exclusively to an HBeAg-positive population.
The 48-week outcomes of the RCT of PEG-α-2a 
versus LAM reported by Lau and colleagues50 
provided short-term clinical effectiveness data for 
the base-case analysis in all three of these models. 
Long-term clinical effectiveness data (rates of 
seroconversion, relapse and LAM resistance) were 
taken from previously published studies (Liaw and 
colleagues,51 Leung and colleagues 52 and Lok 
and colleagues53). The Roche model estimated 
cost-effectiveness of a 48-week course of PEG-
α-2a versus two LAM treatment alternatives: 
treatment for 48 weeks and for 4 years. Veenstra 
and colleagues44 estimated cost-effectiveness of a 
48-week course of PEG-α-2a versus up to 4 years of 
LAM treatment (i.e. patients who do not achieve a 
sustained seroconversion after 48 weeks continue 
LAM treatment for up to 4 years or until they 
achieve seroconversion). Sullivan and colleagues45 
assumed that a 48-week course duration is applied 
to both PEG-α-2a and the comparator, LAM.
Demographic and clinical characteristics of the 
hypothetical cohort of patients in Veenstra and 
colleagues44 and Sullivan and colleagues45 mirrored 
the baseline characteristics of patients enrolled 
in the RCT reported by Lau and colleagues.50 
Of note, 87% of patients in the modelled cohort 
of CHB patients were Asian. This population 
may not be representative of the general 
population in England and Wales, which may 
limit generalisability of the outcomes of the cost-
effectiveness analysis.
All three studies use a Markov model 
consisting of the following health states 
(CHB, HBeAg seroconversion, compensated 
cirrhosis, decompensated cirrhosis, HCC, liver 
transplantation, post-liver transplantation and 
death). A health state not included in these studies 
is HBsAg seroconversion, a state which has been 
included in other economic evaluations (e.g. 
Crowley42 and Crowley and colleagues43). The 
outcomes are expressed as incremental cost per 
quality-adjusted life-year (QALY) in these studies. 
Sensitivity analysis is performed in all three studies.
As in the model presented in the Roche submission 
to NICE, Veenstra and colleagues44 and Sullivan 
and colleagues45 did not include the short-term 
effect of antiviral therapy on progression to 
compensated cirrhosis, such as that estimated in 
recent economic evaluations of LAM (Orlewska,41 
Crowley42 and Crowley and colleagues43 The base-
case analyses in Veenstra and colleagues44 and 
Sullivan and colleagues45 did not include the effect 
of LAM resistance. Drug resistance was explored 
in the scenario analysis reported in Veenstra and 
colleagues44 but not in Sullivan and colleagues45 
In the base-case analysis of these models, it was 
assumed that by taking HBeAg seroconversion 
rates from long-term follow-up (which show 
reducing denominators over time), some of the 
effects of drug resistance, as indicated by reduced 
seroconversion rates, will have been captured.
Drug acquisition costs were taken from the most 
recent (at the time of writing) British National 
Formulary in Veenstra and colleagues44 and in 
the Roche model, and from the 2004 Taiwan Fee 
Schedule for Medical Service in Sullivan and 
colleagues45
As stated in our previous review,12 in the Roche 
model the health-state costs were developed by 
means of a combination of methods, including 
assumption, bottom-up costing using protocols 
based on expert opinion and extrapolation from 
costs developed for previous submissions. These 
costs were not adjusted for the differences in the 
intensity of medical management between the 
treatment groups. We previously12 also noted that 
the assumption that the HBeAg seroconverted Economic analysis
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health state has zero costs and does not correspond 
with current clinical guidelines that suggest that 
seroconverted patients should be reviewed every 
6–12 months, during which time their serological 
status/HBV DNA should be assessed and a screen 
for HCC should be undertaken.
In the recent publication by Veenstra and 
colleagues,44 estimates of the costs of management 
of patients in different health states were taken 
directly from the economic evaluation in our 
previous report.12 Health-state costs used in our 
previous economic evaluation were estimated 
specifically for the assessment. The costs were 
a combination of values from published cost 
estimates for the progressive stages of liver disease 
and estimates based on treatment protocols 
developed with expert advisors to the project. Unit 
costs for health-care resources were obtained from 
the finance department at Southampton University 
Hospitals Trust.
Sullivan and colleagues45 obtained cost estimates 
for the disease states of CHB and compensated 
and decompensated cirrhosis by applying the 2004 
Taiwan Fee Schedule for Medical Service unit costs 
to the resource use reported by treating clinicians 
(no further details are provided). Cost estimates 
for HCC were taken from the published literature 
(Wang and Kowdley54). Liver transplantation and 
post-transplantation costs were obtained from the 
Chang Gung Memorial Hospital in 2004.
Veenstra and colleagues44 and the Roche 
submission used the same approach to estimating 
utility values. This was based principally on values 
reported by Wong and colleagues.8 Sullivan and 
colleagues45 used higher estimates of utility in four 
health states (seroconversion, CHB, compensated 
cirrhosis and HCC), based on Pwu and Chan49 and 
Bennett and colleagues55 (see Table 28 below).
Sullivan and colleagues45 concluded that treatment 
with PEG-α-2a compared with LAM results in 
higher total cost but longer quality-adjusted life 
expectancy, yielding an ICER of NTD381,000 
or US$12,000 at 2004 prices). As in the Roche 
submission, Veenstra and colleagues44 confirmed 
that PEG-α-2a is associated with higher discounted 
total health-care cost but also with additional 
discounted QALYs compared with long-term (up 
to 4 years) LAM treatment. The estimated ICER 
of £10,444 is almost twice as high as the ICER of 
£5948 reported in the Roche original submission. 
The difference most likely relates to the different 
method of cost estimation and the difference in the 
population cohort.
Details of economic evaluations based 
on the Kanwal and colleagues38 model
The original model was published in 2005 (Kanwal 
and colleagues38) and assessed in our earlier 
report.12 Kanwal and colleagues concluded that 
in the base-case analysis (with 55% of patients 
being HBeAg negative at baseline), neither LAM 
nor ADV monotherapy is cost-effective in chronic 
HBV infection. However, depending on financial 
restrictions, either IFN or a hybrid strategy that 
reserves ADV as a salvage therapy only for LAM-
resistant patients may be cost-effective. The 
objective of the more recent publication of Kanwal 
and colleagues46 was to estimate cost-effectiveness 
of alternative therapies in the subgroup of the CHB 
population with cirrhosis, and, in particular, to 
test whether the newer and more expensive agents 
such as ADV and entecavir become cost-effective 
in this subgroup. The structure and transition 
probabilities in the model reported by Kanwal and 
colleagues38 were adjusted for the subgroup of CHB 
patients with cirrhosis.
At baseline, 50% of patients in the cohort 
have compensated cirrhosis and 50% have 
decompensated cirrhosis, and in each treatment 
arm separate transition probabilities are assigned 
to patients in the compensated and decompensated 
cirrhosis groups as they progress through the stages 
of the disease. The baseline ratio of patients with 
compensated versus decompensated cirrhosis was 
tested in the sensitivity analysis.
As noted earlier, in the study by Kanwal and 
colleagues,46 the best outcome in the subgroup 
of cirrhotic patients is either to remain in the 
compensated cirrhosis stage or to revert from 
decompensated to compensated cirrhosis as a 
result of treatment or spontaneously. Patients 
reverting to compensated cirrhosis were eligible 
to decompensate a second time. The rate of 
subsequent decompensation was higher than 
the initial rate. Hepatocellular carcinoma 
could develop at any stage and all patients with 
decompensated cirrhosis or HCC were eligible for 
a liver transplant.
The study evaluated cost-effectiveness of six 
strategies in treatment of cirrhosis in CHB patients:
•	 strategy 1: no pharmacological treatment of 
chronic HBV (‘do nothing’ strategy)DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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•	 strategy 2: LAM monotherapy 100 mg once 
daily for an indefinite period
•	 strategy 3: ADV monotherapy 10 mg once daily 
for an indefinite period
•	 strategy 4: LAM with crossover to ADV on 
development of resistance (‘ADV salvage’ 
strategy)
•	 strategy 5: entecavir monotherapy 0.5 mg once 
daily for an indefinite period
•	 strategy 6: LAM with crossover to entecavir on 
development of resistance (‘entecavir salvage’ 
strategy).
The first four strategies are relevant to the scope of 
this report.
Unlike the 2005 study by Kanwal and colleagues,38 
the 2006 study46 did not include a treatment 
strategy based on IFN-α, as this is not approved 
for patients with decompensated cirrhosis. In both 
studies, the perspective is of a US third-party payer.
In both studies38,46 estimates of costs of health-care 
resources were obtained by (1) calculating direct 
cost estimates by multiplying unit prices for the 
drugs and medical services by the estimated use of 
these resources in natural units, and (2) combining 
these costs with other cost estimates (e.g. costs of 
complications) obtained from the literature. In 
particular, in Kanwal and colleagues,46 costs of 
physician services and procedures were obtained 
from the 2005 American Medical Association 
Current Procedural Terminology codebook and the 
2005 Medicare Fee Schedule. Pharmaceutical costs 
were obtained from the average wholesale prices 
(AWPs) listed in the 2006 Red Book. Cost estimates 
for cirrhosis and related health states were obtained 
from a published study of detailed, itemised 
inpatient and outpatient direct costs incurred by 
patients with cirrhosis (Bennett and colleagues55). 
While the model first presented in the Roche 
submission has only one health state corresponding 
to decompensated cirrhosis, the structure of the 
model in Kanwal and colleagues38,46 differentiates 
between different types of decompensation (i.e. 
variceal haemorrhage, ascites and encephalopathy), 
which allowed for a more precise estimation of the 
associated costs in the first and subsequent years.
In both studies,38,46 transition probabilities were 
obtained from a systematic review of the literature. 
Appendix 5 compares transition probabilities used 
in studies assessed in our previous report12 and 
those in the present report (the study by Buti and 
colleagues47 is not included in this appendix, as 
explained below).
The model reported in Kanwal and colleagues38,46 
used utility values obtained from the literature 
that reported utilities for chronic liver disease 
associated with hepatitis C. Kanwal and colleagues 
argue that both hepatitis C and hepatitis B lead 
to cirrhosis and related complications and there is 
no a priori reason to believe that the quality of life 
decrements assigned to the corresponding health 
states would depend on the underlying aetiology. 
(The same approach was used in the economic 
evaluation conducted in our previous report.12 
Table 28 compares utility values used in studies 
assessed in our previous report12 and in the present 
report, with the exception of the study by Buti and 
colleagues47).
The result of economic modelling in Kanwal and 
colleagues (2006)46 indicated that:
•	 LAM monotherapy is dominated.
•	 The ICER of ADV monotherapy versus ‘doing 
nothing’ is $19,731($14,342–$24,224) at 2005 
prices.
•	 The ICER of ADV monotherapy versus 
entecavir monotherapy is $25,626 ($19,637–
$31,184) at 2005 prices.
•	 ADV salvage strategy is dominated.
•	 Entecavir salvage strategy is dominated.
The sensitivity analysis showed that the model 
outcomes were sensitive to the cost of ADV and 
entecavir; the annual rate of progression from 
compensated to decompensated cirrhosis with 
LAM resistance; the annual rate of progression 
from compensated to decompensated cirrhosis 
with entecavir (no resistance); the annual rate of 
progression from compensated to decompensated 
cirrhosis with ADV (no resistance); and the 
annual rate of progression from compensated to 
decompensated cirrhosis with ADV resistance. 
For example, if the incidence of progression from 
compensated to decompensated cirrhosis in LAM-
resistant patients is less than the threshold of 3.5% 
(8% in the base-case analysis), than LAM becomes 
cost-effective. The results were robust with respect 
to the baseline ratio of patients with compensated 
versus decompensated cirrhosis.
Details of economic evaluation 
reported by Buti and colleagues47
Buti and colleagues47 estimate cost-effectiveness 
of a 4-year LAM with ADV as a salvage therapy 
strategy for LAM-resistant patients compared with 
ADV monotherapy.Economic analysis
48
In the decision tree model, different health states 
in two treatment groups are assigned to describe 
patient progression:
•	 In the LAM arm, these are: receiving LAM 
treatment with response; continuing LAM 
treatment with response; developing resistance 
to LAM, followed by receiving ADV as a 
salvage therapy; receiving ADV treatment with 
response; and developing resistance and no 
response to ADV treatment, in which case no 
other active treatment is received.
•	 In the ADV arm, these are: receiving ADV 
treatment with response; continuing ADV 
treatment with response; and developing 
resistance to ADV, in which case no other active 
treatment is received.
Other health states that characterise disease 
progression (e.g. compensated and decompensated 
cirrhosis, HCC, liver transplant) are not 
explicitly included in the model. Nevertheless, 
a certain proportion of patients who do not 
receive treatment are assumed to develop a 
‘decompensated CHB’, which includes cirrhosis, 
hepatic encephalopathy, varicose haemorrhage, 
ascites and hepatocarcinoma, and is associated 
with the aggregated ‘cost of decompensation’ of 
€172.50. Buti and colleagues47 do not provide 
a clear explanation of either the proportion of 
patients with decompensation or the monetary 
value of health-care resources associated with 
treatment of decompensated CHB. In particular, 
it is not clear what proportion of patients (if any) 
start at the compensated cirrhosis state from which 
decompensated cirrhosis is later developed. It does 
not appear that a systematic review of the clinical 
evidence used in the model was undertaken. 
The probability of response, non-response and 
resistance seem to have been derived from 
averaging the response rate across a few selected 
studies, including non-randomised observational 
studies (see Appendix 4 for details). It assumed 
that patients receiving an active treatment, 
including those with compensated cirrhosis at 
baseline, do not develop decompensated CHB. 
This assumption is not consistent with assumptions 
used in other economic evaluations.12,38,44–46
Although the systematic review by Sun and 
colleagues48 assessed the economic evaluation 
reported in Buti and colleagues 47 as being of 
high quality in comparison with the other models 
discussed above, it is characterised by a number 
of shortcomings, in addition to the issues outlined 
earlier. It has a short time horizon of just 4 years 
rather than a lifetime horizon, as is appropriate 
in a chronic disease. A discounting factor is 
applied only to costs and not to the outcomes. 
The outcome of cost-effectiveness analysis is 
expressed in terms of additional cost per patient 
with response [defined as decrease of serum HBV 
DNA to undetectable levels by polymerase chain 
reaction (PCR) assay] instead of the conventional 
incremental cost per incremental QALY. Another 
methodological shortcoming is that clinical 
effectiveness data used in the two treatment 
groups come from different clinical trials and may 
therefore involve patient populations with different 
baseline characteristics. These shortcomings may 
potentially introduce a bias to the cost-effectiveness 
estimates, which may compromise the outcomes of 
the cost-effectiveness analysis.
Buti and colleagues47 estimated an incremental 
cost of ADV per additional patient with response 
at €27,872 at 2003 prices. Notwithstanding the 
shortcomings listed above, the results expressed 
in units other than QALYs renders the study 
outcomes of limited use for decision making in the 
area of allocating the limited health-care resources 
across the treatment alternatives.
Health-related quality of life in 
patients with chronic hepatitis B
The models reported in Kanwal and 
colleagues,38,46 Veenstra and colleagues 44 and 
Sullivan and colleagues45 assume that health 
states corresponding to the stages of natural 
disease progression (CHB, response, resistance, 
compensated cirrhosis, decompensated cirrhosis, 
HCC, liver transplantation and post-liver 
transplantation) determine the patients’ quality 
of life. This is consistent with approaches used in 
previous published economic evaluations of CHB 
treatments (Wong and colleagues8, Shepherd and 
colleagues12). The study by Buti and colleagues47 
does not include outcomes assessed in terms of 
QALYs.
A recent study by Levy and colleagues56 was 
identified during the literature search. In this 
study, standard gamble utilities were elicited 
using an interviewer-administered survey from 
populations in six countries, with a total of 534 
HBV-infected patients and a total of 600 uninfected 
respondents. The study aimed to recruit 100 HBV-
infected and 100 uninfected respondents from each 
country. Chronic hepatitis B was not differentiated 
with respect to its variants (i.e. HBeAg positive or 
negative). Utility values were obtained in relation 
to six CHB states: CHB, compensated cirrhosis, DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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decompensated cirrhosis, liver transplantation, 
post-liver transplantation and HCC. Utility values 
for other health states that are typically included in 
the models (e.g. response to treatment or resistance 
to treatment) were not elicited.
Although the study by Levy and colleagues56 
included a representative sample of the population 
from six countries, it is uncertain whether the UK 
sample consisting of 100 HBV-infected patients 
and 100 uninfected respondents is representative 
of the UK population. Levy and colleagues56 
observed that uninfected respondents had higher 
mean utility values than infected respondents for 
most of the health states.
Table 28 presents the age- and sex-adjusted utility 
values elicited from 100 HBV-infected patients and 
100 uninfected respondents in the UK study by 
Levy and colleagues,56 alongside the baseline values 
used in the economic evaluation presented in our 
original report.12
The utility weights, reported by Levy and 
colleagues,56 elicited from the compensated 
cirrhosis state, liver transplant and post-liver 
transplant health states are markedly higher than 
the utility weights used in our previous economic 
evaluation.12 Another observation is that, according 
to Levy and colleagues,56 there is a substantial 
decrease in utility in patients in transition from 
compensated to decompensated cirrhosis. In 
our economic model,12 the largest decrease in 
utility occurs in patients in transition from CHB 
to compensated cirrhosis. The effect of these 
differences on the cost-effectiveness analysis of 
alternative treatments for CHB is explored in the 
update of our economic model, below.
Comparison of estimates of 
health-related quality of life
Table 29 compares health-state utilities used 
in different economic evaluations of antiviral 
treatment for patients with CHB. For completeness, 
the methodologically robust studies that used utility 
weights and were assessed in our previous report12 
are included, along with the economic evaluations 
identified in our update search.
Economic evaluations by Wong and colleagues,8 
Crowley,42 Crowley and colleagues43 and Dusheiko 
and Roberts39 applied health-state utility estimates 
derived from clinicians’ opinion rather than 
from patients’ preferences. These estimates 
are characterised by a large variation. Some 
of these estimates were subsequently reused in 
our previous model,12 and in models by Kanwal 
and colleagues38,46 Veenstra and colleagues44 
and Sullivan and colleagues,45 along with utility 
weights elicited from patients with hepatitis C (see 
Appendix 4 for details). The utility values elicited 
by Levy and colleagues56 from the HBV population 
generally fall within this broad range of estimates 
used in different economic evaluations.
Summary
We identified four recently published economic 
evaluations in our update search. The studies 
assessed the cost-effectiveness of PEG-α-2a, LAM, 
ADV, entecavir and best supportive care. None of 
the studies featured PEG-α-2b.
The economic evaluation reported in Kanwal 
and colleagues (2006),46 based on the evaluation 
by Kanwal and colleagues (2005),38 was strongest 
methodologically. They conducted comprehensive 
economic evaluations across the broad range 
TABLE 28  Utility values assigned to CHB patients in different health states as reported in Levy et al.56 and Shepherd et al.12
Health state 
Values elicited from 
uninfected/infected UK 
respondents56
Values at baseline in 
HBeAg +ve model12
Values at baseline in 
HBeAg –ve model12
CHB 0.88/0.69 0.89 0.87
Compensated cirrhosis 0.87/0.68 0.49 0.47
Decompensated cirrhosis 0.36/0.35 0.39 0.37
Hepatocellular carcinoma 0.42/0.42 0.39 0.37
Liver transplant 0.69/0.57 0.38 0.36
Post-liver transplant 0.82/0.66 0.61 0.59
CHB, chronic hepatitis B.Economic analysis
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of HBV therapies using a population that was 
representative of the patient mix observed in 
practice. In contrast, Veenstra and colleagues,44 
Sullivan and colleagues45 and Buti and colleagues47 
undertook only a pairwise comparison of treatment 
alternatives in a particular subgroup of patients.
However, the results reported by Kanwal and 
colleagues38,46 are not likely to be fully generalisable 
to the NHS. This is because they were conducted 
from the perspective of the US health-care system 
which differs in prices, structure of resource use 
and economic incentives. The same disadvantage 
applies to the results reported in Sullivan and 
colleagues45 and Buti and colleagues,47 which were 
conducted from the Taiwanese and Spanish health 
system perspectives respectively. The study by 
Buti and colleagues47 is also characterised by the 
number of methodological shortcomings.
The study by Veenstra and colleagues,44, the only 
one conducted from the UK perspective, reported 
that PEG-α-2a is associated with higher discounted 
total health-care cost but also with additional 
discounted QALYs compared with long-term (up 
to 4 years) of LAM treatment in HBeAg-positive 
patients. The estimated ICER was £10,444. Our 
original report12 estimated the ICER of PEG-
α-2a versus IFN-α in line with the scope of the 
assessment.
The estimates of utility values reported in Levy 
and colleagues56 were obtained in relation to 
six CHB states: CHB, compensated cirrhosis, 
decompensated cirrhosis, liver transplantation, 
post-liver transplantation and HCC. Although 
utility values for the health states ‘response to 
treatment’ or ‘resistance to treatment’ were not 
assessed, the important contribution of the 
study by Levy and colleagues56 lies in eliciting 
utility estimates directly from patients. Previous 
models, in contrast, derived utility estimates from 
either clinician opinion or patients with hepatitis 
C.12,38,44–46
Update of the Southampton 
Health Technology Assessments 
Centre (SHTAC) economic model
Summary of methods and 
results of economic modelling 
in the assessment report
Our previous report12 presented estimates of the 
cost-effectiveness of PEG-α-2a and ADV using a 
state-transition model. Development of the model 
was informed by systematic review of the literature 
on natural history, epidemiology and quality of 
life for patients with CHB and on the clinical and 
cost-effectiveness of antiviral treatment. It has not 
been possible to repeat all of the methodological 
detail of the model here. Readers are therefore 
encouraged to consult the original report which 
is freely available to download from the internet 
(www.hta.ac.uk).
The model included eight health states (CHB, 
HBeAg seroconversion/remission, HBsAg 
seroconversion, compensated cirrhosis, 
decompensated cirrhosis, HCC, liver 
transplantation and death) and used ‘tunnel states’ 
to account for previous treatment history (such 
as switching drugs owing to the development of 
resistance). The model was used to extrapolate 
long-term outcomes (in terms of life expectancy 
and quality-adjusted life expectancy) and lifetime 
costs (including costs of managing progressive liver 
disease as well as costs of antiviral treatment) based 
on short-term outcomes included in the clinical 
effectiveness review (HBeAg seroconversion for 
HBeAg-positive patients and ALT normalisation 
for HBeAg-negative patients).
Published, age-specific quality of life weights for 
healthy populations were used to estimate utility 
values for patients who achieved HBsAg or HBeAg 
seroconversion. Utility values for other health 
states were estimated relative to these values, based 
on the published literature (not all of which were 
specific to patients with CHB).
The model had a lifetime horizon and the 
analysis adopted the perspective of the NHS and 
Personal Social Services, in accordance with NICE 
methodological guidance. The base-case results 
reported were for a mixed cohort of patients, with 
70% having HBeAg-positive and the remainder 
HBeAg-negative CHB. The mean age at start of 
treatment was assumed to be 32 years for patients 
with HBeAg-positive CHB and 40 years for those 
with HBeAg-negative CHB. The majority of 
patients in both groups were male. Incremental 
cost-effectiveness ratios were calculated for each 
intervention compared with its closest comparator 
(for PEG-α-2a this was IFN-α-2a and for ADV 
it was LAM). The ICERs for individual antiviral 
agents were within the range considered to 
represent good value for money by NHS decision-
makers:
•	 £5994 per QALY gained for IFN-α compared 
with best supportive care and £6119 per QALY 
gained for PEG-α-2a compared with IFN-α-2a. Economic analysis
52
•	 £3685 per QALY gained for LAM compared 
with best supportive care and £16,569 per 
QALY gained for ADV compared with LAM.
In addition, a number of sequential treatment 
scenarios (IFN-α-2a or PEG α-2a as first-line 
treatment followed by LAM or ADV until resistance 
develops) were modelled (Table 30). A similar logic 
to that adopted for individual antiviral agents 
(identifying the closest comparator, for calculating 
ICERs) was applied to the cost-effectiveness 
analysis of sequential treatment strategies:
•	 Strategies using IFN-α as first-line treatment 
followed by LAM or ADV were compared with 
IFN-α alone.
•	 The strategy using IFN-α as first-line treatment 
followed by LAM, with ADV for patients 
developing LAM resistance was compared with 
IFN-α followed by LAM.
•	 Strategies using PEG-α-2a as first-line 
treatment followed by nucleoside/nucleotide 
analogue were compared with the equivalent 
strategy using conventional IFN as first-line 
treatment.
ICERs derived for these comparisons are reported 
in Table 30.
To simplify the analysis, Figure 1 shows an optimal 
treatment sequence consisting of IFN-α or PEG-
α-2a followed by LAM, with ADV reserved as a 
salvage strategy for patients who develop LAM 
resistance. The dashed line in Figure 1 indicates 
the cost-effectiveness frontier, joining the optimal 
treatment strategies (those which provide a 
given output at minimum cost). Other sequences 
were excluded using the principle of extended 
dominance, i.e. points above the cost-effectiveness 
frontier are non-optimal and can be eliminated, as 
the same output can theoretically be provided at 
lower cost by a combination of strategies that are 
found on the frontier.
Incremental cost-effectiveness ratios estimated 
using the optimal strategies are: IFN followed by 
LAM (ICER = £4772 per QALY gained relative 
to best supportive care); PEG-α-2a followed by 
LAM (ICER = £6765 relative to IFN-α followed by 
LAM); and PEG-α-2a followed by LAM followed 
by ADV (ICER = £11,460 relative to PEG-α-2a 
followed by LAM).
Deterministic sensitivity analyses showed that 
the results were robust to assumptions about the 
baseline cohort, but were sensitive to assumptions 
regarding:
TABLE 30  Cost-effectiveness results for sequential treatment strategies (previous report12)
Strategy Cost (£)
Discounted life 
expectancy
Discounted 
QALYs ICER
Best supportive care 8555 22.29 17.07
IFN-α 12,609 22.98 17.75 5994
IFN-α followed by LAM 15,159 23.76 18.45 3604a
IFN-α followed by ADV 27,442 24.81 19.40 8987b
IFN-α followed by LAM followed by ADV 27,740 25.00 19.56 11,402c
PEG-α-2a 15,745 23.51 18.26 6119
PEG-α-2a followed by LAM 18,053 24.20 18.88 6766d
PEG-α-2a followed by ADV 28,907 25.13 19.71 4649e
PEG-α-2a followed by LAM followed by 
ADV
28,976 25.28 19.83 4452f
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
a  Comparing IFN-α-2a followed by LAM with IFN-α-2a alone.
b  Comparing IFN-α-2a followed by ADV with IFN-α-2a alone.
c  Comparing IFN-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM.
d  Comparing PEG-α-2a followed by LAM with IFN-α-2a followed by LAM.
e  Comparing PEG-α-2a followed by ADV with IFN-α-2a followed by ADV.
f  Comparing PEG-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM followed by ADV 
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FIGURE 1  Incremental cost-effectiveness and cost-effectiveness frontier results (previous report12).
•	 efficacy of long-term treatment with ADV 
(whether or not treatment effects observed in 
clinical trials were extrapolated beyond the 
time horizon of the trials)
•	 relapse of HBeAg-negative patients following 
treatment with PEG-α-2a
•	 HBeAg seroconversion probability of patients 
with compensated cirrhosis receiving antiviral 
treatment, particularly for strategies including 
ADV.
Summary of findings of current review 
and implications for economic model
This update has identified:
•	 a recently published study of health-related 
quality of life in patients with CHB which 
estimated relevant state-specific utility weights 
using a preference-based method56 suitable for 
updating our model (see earlier in this chapter)
•	 RCT evidence on the clinical effectiveness 
of PEG-α-2b, compared with IFN-α-2b (see 
Chapter 3, HBeAg loss/seroconversion), which 
can be used in our model to estimate the cost-
effectiveness of PEG α-2b.
Costs and outcomes in our previous report were 
discounted at different rates (6% for costs and 
1.5% for outcomes) in accordance with NICE 
methodological guidance applicable at the time 
the review was conducted. Since then it has become 
accepted practice (including in updated NICE 
methodological guidance) to discount both costs 
and outcomes at 3.5%. These rates were applied in 
this update.
In addition, while the cost of all drug treatments 
have not changed since our previous report was 
completed, we have updated monitoring and 
health-state costs used in the original report to 
2006–7 prices. This enables an assessment of the 
robustness of the original report’s findings to 
changes in costs as well as to assumptions over 
quality of life for treated patients.
The update identified no requirement to change 
assumptions regarding disease progression in the 
model.
Estimation of cost-effectiveness
Specification of changed inputs
Health-state utilities applied in the updated 
model are reported in Table 31. The first set of 
values adopted is based on the age- and sex- 
adjusted valuations for UK infected patients 
reported by Levy and colleagues.56 As discussed 
earlier, Levy and colleagues56 did not elicit 
health-state valuations for treatment response or 
seroconversion states. We have assumed, in this 
first set of valuations, that there is a 0.1-point 
increase in health-state utility for patients who 
HBeAg seroconvert or who lose the surface 
antigen (see Table 31, set 1). This was based on the 
difference between the average utility estimated 
for uninfected respondents’ current health (mean 
= 0.87 and median = 0.95) and the average utility 
estimated for CHB in the same group (mean 
= 0.76 and median = 0.85). This utility gain is 
more than double the value of 0.04 applied in 
our original model, based on values estimated by 
Wong and colleagues.8 We assessed the robustness 
of our results to this assumption using two further 
sets of weights in a sensitivity analysis. These utility Economic analysis
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weights were identical to those in set 1 with the 
following exceptions:
•	 In the first sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion or 
losing the surface antigen (i.e. the health-state 
utility value of 0.69, for chronic hepatitis B, 
was also applied to HBeAg-seroconverted and 
HBsAg-seroconverted health states).
•	 In a second sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion, but 
it was assumed that patients who lose the 
surface antigen have the same utility as the 
uninfected population (i.e. the 0.10 utility gain 
was applied only to the HBsAg-seroconverted 
health state).
•	 In a third sensitivity analysis, the smaller gain 
of 0.04 was applied for both HBeAg- and 
HBsAg-seroconverted health states.
The utility weights in set 1 were not related to age, 
in contrast to the approach adopted in the model 
developed for our previous report. To examine 
the robustness of the results to this assumption, 
we derived a further set of health-state utility 
weights, based on the valuations reported by Levy 
and colleagues,56 but estimated as state-specific 
utility decrements (see Table 31, set 2). These utility 
decrements were applied to age-specific utility 
values, as in the previous report. As before, we 
assumed a 0.1-point increase in utility for patients 
who HBeAg seroconvert or who lose the surface 
antigen (compared with patients in the chronic 
hepatitis B health state). The robustness of our 
results to this assumption was tested in sensitivity 
analyses:
•	 In the first sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion or 
losing the surface antigen (i.e. the –0.10 utility 
decrement for chronic hepatitis B was also 
applied to the age-specific utility values for 
patients in the HBeAg-seroconverted and 
HBsAg-seroconverted health states).
•	 In a second sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion, but it 
was assumed that patients who lose the surface 
antigen experience have the same utility as 
the general populations (i.e. the –0.10 utility 
decrement for chronic hepatitis B was also 
applied to the age-specific utility values only 
for patients in the HBeAg-seroconverted health 
state).
•	 In a third sensitivity analysis, the smaller gain 
of 0.04 adopted in our previous report was 
applied.
TABLE 31  Health-state utilities applied in updated model 
(based on Levy et al.56)
Health state
Health-state utility
Set 1 Set 2a
HBsAg seroconverted 0.79 0.00
HBeAg seroconverted 0.79 0.00
Chronic hepatitis B 0.69 –0.10
Compensated cirrhosis  0.68 –0.11
Decompensated cirrhosis 0.35 –0.44
Hepatocellular carcinoma 0.42 –0.37
Liver transplantation
Year of transplantation 0.57 –0.22
Years following year of 
transplantation
0.66 –0.13
a  State-specific utility decrements.
TABLE 32  Updated treatment monitoring costs adopted in 
model (2006–7 prices)
Health state Cost (£)
Evaluation of a new patient 376
Tests prior to initiation of treatment 1024
Monitoring/management for 24 weeks of 
conventional IFN
464
Monitoring/management for 48 weeks of 
PEG-α
890
Monitoring/management for each year of LAM 
or ADV treatment
524
TABLE 33  Updated health-state costs adopted in model (2006–
7 prices)
Health state Cost (£)
HBsAg seroconverted 0
HBeAg seroconverted 290
Chronic hepatitis B 584
Compensated cirrhosis  1341
Decompensated cirrhosis 10,750
Hepatocellular carcinoma 9580
Liver transplantation
Cost of transplant 32,215
First year following transplant 11,149
Subsequent years following transplant 1633DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 34  Response to treatment with PEG-α-2b
PEG-α-2b  IFN-α
HBeAg seroconversion (24 
weeks’ treatment, follow-up at 48 
weeks),27 n/N (%)
25/115 
(21.7)
16/115 
(13.9)
Tables 32 and 33 report the inflated costs applied 
in the model. Costs derived for the previous report 
were inflated to 2006–7 prices using the Hospital 
and Community Health Services (HCHS) Pay and 
Prices Index.61
Table 34 reports treatment responses to PEG-α-
2b included in the model, based on the results of 
the RCT by Zhao and colleagues27 as reported in 
Chapter 3, HBeAg loss/seroconversion.
The frequency and intensity of monitoring of 
patients being treated with IFN-α-2b or PEG-α-2b 
were based on protocols developed for 24 weeks of 
treatment with IFN-α, described in our previous 
report.12 Updated costs for monitoring patients 
receiving 24 weeks of IFN-α are reported in Table 
32. In this costing we assumed that patients would 
be seen 10 times, during a 24-week treatment 
period, corresponding to weekly visits for the 
first month of treatment, then fortnightly for 
the second month and then monthly visits. The 
protocol stated that full blood counts, liver function 
tests, urea and electrolytes and blood clotting 
tests would be assessed at each consultation, with 
a more detailed assessment undertaken every 3 
months (during which HBeAg and HBsAg serology, 
HBV DNA and thyroid function were assessed). 
The detailed assessments also included screening 
for hepatocellular carcinoma using abdominal 
ultrasound and α-fetoprotein tests. Standard 
consultations were assumed to take 30 minutes, 
whereas the detailed assessments were assumed to 
require 1 hour of clinical time. All assessments for 
treated patients were assumed to be performed by 
specialist nurses.
Drug costs for IFN-α-2b were calculated for a 
dosage of 3 million units of IntronA® (Schering–
Plough), self-administered by patients three times 
per week, as used in the trial reported by Zhao 
and colleagues.27 Unit costs of £77.76 for a 1.5-
ml multidose cartridge (at a concentration of 15 
million units/ml, which delivers six doses of 0.2 ml) 
were taken from the British National Formulary.62 
This corresponds to a cost per 3-million-unit 
injection of £12.96, a weekly cost of £38.88 and a 
total drug cost of £933.12 for a 24-week course of 
treatment.
Drug costs for PEG-α-2b were calculated for a 
dosage of 1.0 mg/kg of PegIntron® (Schering–
Plough), self-administered by patients once per 
week. Assuming an average body weight of 79 kg, 
this would require one 80 μg vial per week. The 
unit cost, from the British National Formulary, is 
£108.00, which includes injection equipment 
and water for injections. This corresponds to a 
total drug cost of £2592 for a 24-week course of 
treatment.
Results from updated model
Applying alternative utility 
sets – base case
Table 35 reports total cost, discounted life 
expectancy and discounted QALYs for the overall 
cohort of patients with HBeAg-positive and 
HBeAg-negative CHB modelled in our previous 
report, using updated assumptions on health-
state utility (utility set 1), updated costs and 
applying a discount rate of 3.5% for both costs and 
benefits. Incremental cost-effectiveness ratios are 
substantially higher than for the base case reported 
in our previous report (see Table 30). Total costs are 
between 23% and 45% higher, while discounted 
QALYs are 27–28% lower. However, much of this 
difference arises from the change in discount 
rates, rather than from changes in utility weights 
or inflating costs to current prices. For example, 
for IFN-α the same analysis, but using discount 
rates of 6% for costs and 1.5% for QALYs, yields 
total costs of £13,768, total QALYs of 16.96 and 
an ICER of £6981 relative to best supportive care, 
which is broadly comparable to the ICER of £5994 
from our previous report.
The cost-effectiveness frontier in Figure 2 shows 
that allowable interventions (in cost-effectiveness 
terms) are the same as for the analysis based on 
our previous report (shown in Figure 1). These are: 
IFN-α followed by LAM (ICER = £8552 per QALY 
gained relative to best supportive care), PEG-α-
2a followed by LAM (ICER = £12,801 relative to 
IFN-α followed by LAM) and PEG-α-2a followed 
by LAM followed by ADV (ICER = £26,379 relative 
to PEG-α-2a followed by LAM).
Again, much of the difference with the results 
based on our previous model (reported earlier in 
this chapter) is due to changes in discount rate. As 
an example, ICERs for these strategies, discounted 
at 6% for costs and 1.5% for outcomes are: IFN-α Economic analysis
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TABLE 35  Cost-effectiveness results applying updated utility set 1 (derived from Levy et al.56)
Strategy Cost (£)
Discounted life 
expectancy
Discounted 
QALYs ICER
Best supportive care 12,433 16.42 11.97  
IFN-α 16,482 16.86 12.35 10,492
IFN-α followed by LAM 19,376 17.35 12.78 6794a
IFN-α followed by ADV 34,268 17.97 13.31 18,615b
IFN-α followed by LAM followed by ADV 35,494 18.08 13.39 26,271c
PEG-α-2a 19,564 17.18 12.62 11,459
PEG-α-2a followed by LAM 22,228 17.62 13.00 12,800d
PEG-α-2a followed by ADV 35,557 18.16 13.47 7833e
PEG-α-2a followed by LAM followed by ADV 36,398 18.25 13.54 6173f
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
a  Comparing IFN-α-2a followed by LAM with IFN-α-2a alone.
b  Comparing IFN-α-2a followed by ADV with IFN-α-2a alone.
c  Comparing IFN-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM.
d  Comparing PEG-α-2a followed by LAM with IFN-α-2a followed by LAM.
e  Comparing PEG-α-2a followed by ADV with IFN-α-2a followed by ADV.
f  Comparing PEG-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM followed by ADV 
salvage.
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FIGURE 2  Incremental cost-effectiveness and cost-effectiveness frontier, applying utility set 1.
followed by LAM (ICER = £5367 per QALY gained 
relative to best supportive care), PEG-α-2a followed 
by LAM (ICER = £8192 relative to IFN-α followed 
by LAM) and PEG-α-2a followed by LAM followed 
by ADV (ICER = £12,171 relative to PEG-α-2a 
followed by LAM).
Results for separate cohorts of HBeAg-positive and 
HBeAg-negative patients are reported in Appendix 
7.
Applying alternative utility sets – 
deterministic sensitivity analysis
A series of one-way sensitivity analyses was 
conducted using the updated model, based on 
the range of values and sources of uncertainty 
reported in sensitivity analyses in our previous 
review.12 These are reported in Table 36. To simplify 
the presentation and interpretation of the cost-
effectiveness estimates in the sensitivity analyses, DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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we report ICERs only for the optimal strategies in 
each analysis (using the methods for identifying 
the cost-effectiveness frontier and for excluding 
strategies using the principle of extended 
dominance, as described for Figure 1.
In this sensitivity analysis, the selection of optimal 
strategies is generally robust to changes in 
structural assumptions, baseline characteristics and 
parameter values. As with the base-case analysis, 
the optimal treatment sequence was generally 
identified as IFN-α or PEG-α-2a, followed by LAM, 
reserving ADV as a salvage strategy for patients 
who develop LAM resistance. The estimated ICERs 
are also generally robust to changes applied in 
the sensitivity analysis. However, changes in some 
key assumptions produce less favourable cost-
effectiveness estimates than the base case adopted 
for this analysis:
•	 Assuming that patients with compensated 
cirrhosis cannot achieve HBeAg seroconversion 
produces a significantly less favourable 
ICER for the treatment strategy containing 
ADV as salvage for patients who develop 
LAM resistance. In contrast, the ICERs for 
IFN-α or PEG-α-2a followed by LAM are 
largely insensitive to this changed structural 
assumption.
•	 Reducing the proportion of the baseline cohort 
that has HBeAg-positive CHB also produces a 
less favourable ICER for the strategy including 
ADV (relative to PEG-α-2a followed by LAM), 
while the cost-effectiveness of PEG-α-2a 
followed by LAM improves (relative to IFN-α 
followed by LAM).
•	 Cost-effectiveness estimates for all treatment 
strategies are less favourable with increasing 
patient age at start of treatment. QALY gains 
from interventions are reduced by 15–20%, 
whereas incremental costs are reduced by 
2–6%.
•	 Reducing the utility gain from seroconversion 
(to either no utility gain or using the lower 
value of 0.04 used in our previous report) gives 
a less favourable ICER than for the base case.
Reducing drug costs for PEG-α-2a leads to the 
elimination of ‘IFN-α followed by LAM’ from the 
sequence of optimal strategies and leads to an 
improvement in the cost-effectiveness of PEG-α-2a 
followed by LAM (relative to best supportive care).
Applying alternative discount rates (6% for costs 
and 1.5% for outcomes, as in our previous report, 
or 0% for both costs and outcomes) produces more 
favourable ICERs than the base case – reducing the 
ICER for PEG-α-2a followed by LAM with ADV as 
salvage from £26,379 to £12,171 (relative to PEG-
α-2a followed by LAM).
Applying alternative utility sets – 
probabilistic sensitivity analysis
A probabilistic sensitivity analysis was undertaken 
using utility set 1 (see Table 31), updated costs 
(see Tables 32 and 33) and a discount rate of 3.5% 
for both costs and outcomes. The utilities were 
sampled from beta distributions with parameters 
calculated using the method of moments63 (using 
the reported mean values and standard errors 
derived from 95% CIs reported for UK infected 
patients by Levy and colleagues56) (see Appendix 
6 for full details). Health-state costs were sampled 
from gamma distributions with parameters 
calculated using the method of moments (see 
Appendix 6 for full details).
Table 37 reports the mean cost and QALYs (with 
percentile-based 95% CIs) and the ICERs for 
the sequential strategies from the probabilistic 
sensitivity analysis. The mean discounted QALYs 
are close to those in the deterministic base-case 
analysis. However, the mean costs are around 
£1500 lower for each strategy.
Figure 3 shows the cost-effectiveness acceptability 
curves (CEACs) for all interventions included in the 
analysis of sequential treatment strategies. As with 
our previous report, this suggests that IFN-α-2a or 
PEG-α-2a followed by LAM would be the optimal 
strategy at lower threshold values of willingness to 
pay, but as the threshold increases the sequential 
treatment strategy including ADV salvage is 
increasingly likely to be the optimal intervention.
In contrast with our previous report,12 this strategy 
(interferon followed by LAM with ADV as salvage) 
becomes optimal only at the upper range of 
ICERs conventionally deemed as cost-effective 
from an NHS decision-making perspective. 
This is reinforced by Figure 4 which shows the 
cost-effectiveness acceptability frontier64 for the 
analysis based on our previous report (Figure 4a) 
and using the updated model (Figure 4b). The 
cost-effectiveness acceptability frontier comprises 
those portions of the CEAC where interventions 
are deemed optimal (using the maximum net 
benefit criterion) over a range of willingness-to-pay 
values. This clearly illustrates that interferon alpha 
followed by LAM is optimal, using the updated 
model, over a wider range of willingness-to-pay 
values (£9000–£12,000 for IFN-α followed by LAM Economic analysis
60
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FIGURE 3  Cost-effectiveness acceptability curves for sequential treatment strategies in overall cohort of patients with HBeAg-positive 
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effectiveness acceptability frontier based on analysis in original assessment report. (b) Cost-effectiveness acceptability frontier based on 
updated model.
and £13,000–£26,000 for PEG-α followed by LAM) 
than in the analysis based on the previous report 
(£5000–£6500 for conventional IFN followed by 
LAM and £7000–£11,500 for PEG-α followed by 
LAM). As discussed earlier, this arises largely as a 
result of the change in discount rates applied in the 
updated model.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 37  Costs and outcomes from probabilistic analysis of sequential strategies
Strategy
Discounted costs  
[£ (95% CI)]
Discounted QALYs  
(95% CI)
ICER 
(£ per QALY 
gained)
Best supportive care 11,007 (9079–13,335) 11.99 (11.07–12.77)
IFN-α 15,024 (13,164–17,289) 12.38 (11.46–13.16) 10,334
IFN-α followed by LAM 17,881 (15,881–20,184) 12.80 (11.86–13.61) 6759a
IFN-α followed by ADV 32,713 (28,737–37,153) 13.32 (12.40–14.11) 18,815b
IFN-α followed by LAM 
followed by ADV
33,946 (29,470–39,012) 13.40 (12.47–14.20) 26,762c
PEG-α-2a 18,128 (16,265–20,309) 12.65 (11.74–13.45) 11,336
PEG-α-2a followed by LAM 20,744 (18,745–23,119) 13.03 (12.09–13.86) 12,578d
PEG-α-2a followed by ADV 33,966 (29,677–38,788) 13.48 (12.56–14.29) 7412e
PEG-α-2a followed by LAM 
followed by ADV
34,810 (30,068–40,213) 13.55 (12.62–14.33) 5,732f
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
a  Comparing IFN-α-2a followed by LAM with IFN-α-2a alone.
b  Comparing IFN-α-2a followed by ADV with IFN-α-2a alone.
c  Comparing IFN-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM.
d  Comparing PEG-α-2a followed by LAM with IFN-α-2a followed by LAM.
e  Comparing PEG-α-2a followed by ADV with IFN-α-2a followed by ADV.
f  Comparing PEG-α-2a followed by LAM followed by ADV salvage with IFN-α-2a followed by LAM followed by ADV 
salvage.
TABLE 38  Cost-effectiveness results for PEG-α-2b
Strategy Cost (£)
Discounted life 
expectancy Discounted QALYs
ICER (£ per QALY 
gained)
IFN-α-2b 12,610 18.20 13.57  
PEG-α-2b 14,067 18.35 13.73 9169
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Cost-effectiveness of PEG-
α-2b – base case
Table 38 reports total cost, discounted life 
expectancy and discounted QALYs for a cohort of 
patients with HBeAg-positive CHB receiving 24 
months of PEG-α-2b compared with 24 months of 
IFN-α-2b (based on HBeAg seroconversion rates 
reported by Zhao and colleagues27). This is based 
on the clinical effectiveness review (see Chapter 3).
The results suggest that PEG-α-2b is a cost-effective 
alternative to IFN-α-2b for the treatment of 
patients with CHB. In the absence of a comparison 
with best supportive care, this analysis implicitly 
assumes that IFN-α-2b is a cost-effective option 
and a current standard of care. Supportive care 
has not been included in this analysis as the 
trial reported by Zhao and colleagues27 did not 
include a placebo or no treatment arm. No trials 
comparing IFN-α-2b with placebo or no treatment 
were included in the clinical effectiveness review 
reported in Chapter 3.
Cost-effectiveness of PEG-α-2b – 
deterministic sensitivity analysis
Table 39 reports a series of one-way sensitivity 
analyses based on the range of values and sources 
of uncertainty reported in sensitivity analyses in 
our previous review.12
The ICERs are generally robust to changes in 
structural assumptions, baseline characteristics 
and parameter values. However, changes in some 
key assumptions produce less favourable cost-
effectiveness estimates than the base case adopted 
for this analysis:Economic analysis
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TABLE 39  Deterministic sensitivity analysis of cost-effectiveness of PEG-α-2b compared with IFN-α2b
IFN-α-2b PEG-α-2b
Cost (£) QALY Cost (£) QALY
ICER (£ per 
QALY gained)
Baseline analysis 12,610 13.57 14,067 13.73 9169
Structural assumptions
Zero transition probability from compensated 
cirrhosis to HBeAg-seroconverted state
13,801 12.62 15,222 12.81 7454
Zero transition probability from HBeAg-
seroconverted state to HCC
12,545 13.65 13,998 13.81 8805
Zero transition probability to HBsAg-
seroconverted state
14,853 12.91 16,325 13.08 8935
Discount rates (6% for costs and 1.5% for 
outcomes)
10,267 19.08 11,745 19.32 6225
Discount rates (0% for costs and 0% for 
outcomes)
19,124 26.07 20,559 26.41 4218
Baseline cohort characteristics
HBeAg-positive cohort, 50% male 12,646 13.66 14,103 13.82 9090
Change age of cohort at 
start of simulation
– 5 years 12,772 14.02 14,230 14.19 8779
+ 5 years 12,392 13.03 13,848 13.18 9673
+ 10 years 12,102 12.38 13,557 12.52 10,340
Parameter uncertainty
No utility gain from seroconversion (HBeAg or 
HBsAg)
12,610 12.45 14,067 12.56 13,415
No utility gain from HBeAg seroconversion, but 
0.1 utility gain from HBsAg seroconversion
12,610 12.89 14,067 13.01 12,647
Utility gain (+ 0.04) from seroconversion 12,610 12.90 14,067 13.03 11,311
Age-specific utilities (with health-state 
decrements based on Levy et al.56)
12,610 14.91 14,067 15.07 8884
Age-specific utilities, as above (no utility gain 
from HBeAg or HBsAg seroconversion)
12,610 13.79 14,067 13.91 12,814
Age-specific utilities, as above (no gain from 
HBeAg but 0.1 utility gain from HBsAg 
seroconversion)
12,610 14.23 14,067 14.35 12,111
Double cost for compensated cirrhosis state (to 
£2683)
14,661 13.57 16,056 13.73 8780
Reduce PEG-α-2b cost by 20% 12,610 13.57 13,548 13.73 5906
HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 40  Costs and outcomes from probabilistic analysis of PEG-α-2b compared with IFN-α-2b
Strategy Discounted costs [£ (95% CI)] Discounted QALYs (95% CI) ICER (£ per QALY gained)
IFN-α-2b 12,669 (10,524–15,252) 13.58 (12.41–14.57)
PEG-α-2b 14,119 (12,066–16,617) 13.74 (12.57–14.71) 8930DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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•	 Cost-effectiveness estimates for all treatment 
strategies are less favourable with increasing 
patient age at start of treatment. QALY gains 
from interventions are reduced by 5–12%, 
whereas incremental costs reduce by less than 
1%.
•	 Reducing the utility gain from HBeAg 
seroconversion (to either no utility gain or 
using the lower value of 0.04 used in our 
previous report) gives a less favourable ICER 
than for the base case.
Reductions in drug costs for PEG-α-2b and the use 
of alternative discount rates are associated with 
more favourable cost-effectiveness estimates in the 
sensitivity analysis. Reducing drug costs for PEG-
α-2b by 20% leads to a 4% reduction in total costs 
associated with PEG-α-2b, reducing the ICER to 
£5906. Using discount rates that applied at the 
time we conducted our previous review (6% for 
costs and 1.5% for outcomes), the ICER reduces 
to £6225. Applying zero discount rates, the ICER 
reduces to £4218.
In all analyses the ICER is below the threshold 
usually taken to define cost-effectiveness from an 
NHS decision-making perspective.
Cost-effectiveness of PEG-α-2b – 
probabilistic sensitivity analysis
A probabilistic sensitivity analysis was undertaken 
using utility set 1 (see Table 31), updated costs 
(see Tables 32 and 33) and a discount rate of 3.5% 
for both costs and outcomes. The utilities were 
sampled from beta distributions with parameters 
calculated using the method of moments63 (using 
the reported mean values and standard errors 
derived from 95% CIs reported for UK infected 
patients by Levy and colleagues56) (see Appendix 
6 for full details). Health-state costs were sampled 
from gamma distributions with parameters 
calculated using the method of moments (see 
Appendix 6 for full details).
Table 40 reports the mean discounted cost and 
mean discounted QALYs (with percentile-based 
95% CIs) for IFN-α-2b and PEG-α-2b from the 
probabilistic evaluation of the model. Table 40 also 
reports the ICER for PEG-α-2b compared with 
IFN-α-2b, based on the mean discounted cost and 
mean discounted QALYs. The results from the 
probabilistic evaluation of the model are similar to 
those in the deterministic base-case analysis.
Figure 5 shows the CEACs for PEG-α-2b for 
patients with HBeAg-positive CHB. This suggests 
that PEG-α-2b is likely to be a cost-effective option 
for the treatment of HBeAg-positive CHB, in 
comparison with IFN-α-2b.
In the probabilistic sensitivity analysis PEG-α-2b 
had a probability of being cost-effective (compared 
with IFN-α-2b) of 79% at a willingness-to-pay 
threshold of £20,000 per QALY, and 86% at a 
willingness-to-pay threshold of £30,000 per QALY.
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Assessment of clinical 
effectiveness
The trials included in this report were diverse 
in terms of aims, comparators and design 
characteristics. This prohibited quantitative meta-
analysis and also made it difficult to provide an 
overall narrative summary of outcomes. The 
general finding is that both ADV and PEG-α-2b are 
associated with benefits across a range of outcomes 
(virological, biochemical and histological), with 
relatively few adverse effects and, in the case of 
ADV, relatively low viral resistance. This finding is 
similar to that of our previous assessment report of 
ADV and PEG-α-2a.12
Although both drugs appeared to be superior 
to their comparators, there were no consistent 
statistically significant differences. In many cases, 
no statistical tests were reported to confirm 
superiority, and some trials were small and 
probably underpowered. Uncertainties therefore 
exist regarding comparative efficacy and safety.
Benefits were not always sustained after treatment 
cessation, suggesting the need for ongoing 
treatment. This report was able to include 
evidence on the durability of effects of continued 
treatment from follow-up studies included in our 
original report. The 5-year follow-up study, based 
on the RCT by Hadziyannis and colleagues,20 
reported that favourable changes in viral load, 
biochemical markers and liver histology were 
generally sustained. After 5 years of ADV, the 
cumulative resistance rate was 29%, lower than 
the 60% rate associated with LAM after 4 years of 
treatment.20  The relatively low rates of resistance 
to ADV are encouraging, particularly as HBeAg-
negative patients are likely to require maintenance 
treatment over a long period. However, caution is 
required in the interpretation of these results as 
they were derived from an observational cohort 
study arising from an RCT.
Other RCTs included in our original assessment 
report were ongoing and fully published results 
would have been expected at the time of our 
update search. For example, at the termination of 
the double-blind phase of the RCT of ADV versus 
placebo in HBeAg-positive patients (Marcellin and 
colleagues,65 ADV Study 437, see Appendix 3), all 
patients were assigned to receive ADV for up to 
5 years. This was similar in design to the follow-
up study in HBeAg-negative patients conducted 
by Hadziyannis and colleagues. Fully published 
results of this study, if and when available, would 
complement those already reported, illustrating 
durability in HBeAg-positive patients. This is a 
group of patients who, in the absence of HBeAg 
seroconversion, are likely to require ongoing 
treatment.
This report identified fully published RCT 
evidence for the effectiveness of adding ADV to 
LAM in LAM-resistant HBeAg-negative patients.18 
Our previous report identified RCTs of this kind 
only in HBeAg-positive patients.66,67 The RCT 
included in this update failed to identify any 
significant differences between treatments in 
clinical outcomes, although there was a statistically 
significant difference between groups favouring 
combination therapy in terms of ADV resistance 
(a zero rate). Caution is advised as the trial 
appeared to be small, underpowered and generally 
methodologically weak, in common with the 
previous trials.66,67 Therefore, the evidence base for 
treatment of LAM-resistant patients is generally 
poor and good quality RCTs are needed.
PEG-α-2b is associated with some degree of 
benefit, although the results of the trials were 
inconsistent, which may be partly the result of 
variable methodological quality. In terms of HBeAg 
seroconversion, which expert clinical opinion 
suggests would be one of the goals of IFN-based 
treatment, PEG-α-2b appears broadly comparable 
to PEG-α-2a. For example, in the trial by Janssen 
and colleagues,26 the proportion of seroconverted 
patients who received 1 year of PEG-α-2b and LAM 
was 25% at follow-up, compared to 27% for those 
who received 1 year of PEG-α-2a and LAM (Lau 
and colleagues50). Caution is advised as no head-
to-head RCTs have been identified and this is not a 
formal statistical indirect comparison.
In terms of initiating therapy with a combination 
therapy, the only studies identified by our update 
search were those featuring PEG-α-2b and LAM. 
Chapter 5  
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Such trials have limited applicability as PEG-α is 
indicated only in patients with compensated liver 
disease, and may not be tolerated by all patients. 
There has been much interest in the initiation 
of therapy with combined nucleoside/nucleotide 
agents, particularly as a way of minimising the 
risk of drug resistance. No such trials were found 
in our search; however, as this report was being 
finalised, an RCT of LAM in combination with 
ADV, versus ADV and placebo in HBeAg-positive 
treatment-naive patients was published (Sung and 
colleagues68). (Note that a conference abstract 
reporting interim results of this trial was described 
in our previous report.) Combination therapy 
was more effective than monotherapy on some 
measures, including LAM resistance. This trial 
will be fully included in any future updates of this 
report.
It has been argued that use of sequential 
monotherapies increases the risk of drug resistance 
and may potentially limit treatment options, as 
has been the case in the management of other 
infectious diseases such as HIV.69 Given the 
interest in de novo combination therapy as a 
means of reducing the likelihood of multidrug 
resistance in CHB, there is a need for further 
trials of this modality, particularly of nucleoside/
nucleotide analogues. Fortunately, there is 
an increasing number of potential treatment 
options open to clinicians and patients. Newer 
nucleoside analogues are becoming available, 
including entecavir, telbivudine and tenofovir. 
Licensing trials of these drugs have tended 
to assess the efficacy and safety of their use as 
monotherapies.70–73 High-quality RCTs are needed 
to assess appropriate combinations of these and 
other drugs in treatment-naive patients, and these 
should be carefully designed to minimise the risk 
of cross-resistance (e.g. entecavir and telbivudine in 
combination). Trials should be conducted in both 
HBeAg-positive and -negative patients, with long-
term treatment, particularly for negative patients 
(e.g. at least 5 years).
Few other systematic reviews have been published 
to which the results of this review can be compared. 
None featuring ADV was identified in the 
production of this report, and only one of PEG-α 
was located (Hui and colleagues74). The latter 
included RCTs of both PEG-α-2a and -2b, and 
its results were comparable with our current and 
previous reports.12
A limitation of this report is the fact that only 
published evidence was considered for inclusion. 
Conference abstracts reporting long-term follow-
up of some of the RCTs included in our original 
report are available, but have not been included in 
the current report. A more detailed discussion of 
uncertainties and limitations can be found in our 
previous assessment report.12
Assessment of cost-
effectiveness
Systematic review of 
economic evaluations
The majority of the cost-effectiveness studies 
reviewed in this report were direct evaluations of 
PEG-α-2a versus LAM (Veenstra and colleagues44 
and Sullivan and colleagues45) or LAM (with or 
without ADV salvage for LAM-resistant patients) 
versus ADV (Buti and colleagues47 and Kanwal 
and colleagues38). There are no published 
economic evaluations of the entire spectrum of 
alternative therapies for CHB (i.e. including the 
new pharmacotherapies entecavir and telbivudine) 
conducted from the NHS perspective, nor any 
evaluations of combinations of nucleotide/
nucleoside analogues in LAM-naive patients. 
Evaluation of the new medications was outside 
the scope of this report. Contrary to expectations, 
our searches did not capture studies reporting 
the effectiveness (in terms of drug resistance) 
of nucleoside/nucleotide analogue combination 
therapy in LAM-naive (or non-resistant) patients 
on which to base further modelling.
The most comprehensive published economic 
evaluation that compares the broader range of 
alternative therapies in the general population 
of CHB patients was conducted in the US,38 
using a mix of health-care resources and prices 
that are unlikely to be applicable in the NHS 
context. The recently published adaptation of the 
unpublished Roche model,44 while adopting an 
NHS perspective, includes only two medications 
(PEG-α-2a and LAM). There is, therefore, 
uncertainty remaining about the relative costs and 
effects of the entire range of treatment alternatives 
for CHB. A comprehensive economic evaluation of 
alternative antiviral treatments for CHB should be 
undertaken, from an NHS perspective, including 
new treatments [entecavir and telbivudine, which 
have received European marketing authorisation, 
and tenofovir, which has received a positive opinion 
from the Committee for Medicinal Products for 
Human Use (CHMP)].
The recently published multinational study 
of assessment of quality of life by Levy and 
colleagues56 is an important contribution to the DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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area. The study employed a preference-based 
method (standard gamble), based on patients’ 
rather than clinicians’ ratings. However, the UK 
sample size was small (about 200 people) and may 
not be representative of the entire population. 
While the results of the study are generally 
consistent with utility estimates used in previously 
published economic evaluations, this is mainly 
because of the large variation between the estimates 
used in previous studies, each of which involved a 
small number of clinicians to evaluate utility weight 
for each of the health states included in the model. 
There is a substantial disparity, in both absolute 
and relative terms, between utility values reported 
by Levy and colleagues56 and those used in our 
previous economic evaluation.12
Update of SHTAC 
economic model
The model developed for our previous report12 was 
updated to include:
•	 utility values based on those reported in Levy 
and colleagues56
•	 treatment monitoring and health-state costs 
updated to 2006–7 prices
•	 current discounting practice
•	 a separate analysis to include PEG-α-2b.
The ICERs in the updated analysis are generally 
less favourable than in our previous report. 
However, the same optimal treatment sequence 
[IFN (conventional or pegylated) followed by 
LAM with ADV salvage for patients who develop 
resistance] was identified in both analyses. 
Sensitivity analyses indicate that much of the 
difference between the results in the two reports 
arises from the change in discounting practice.
Key uncertainties in the model, identified in the 
sensitivity analyses, that affect the cost-effectiveness 
estimates were:
•	 Outcomes for patients with compensated 
cirrhosis who receive treatment – if the 
probability of HBeAg seroconversion is set 
to zero the ICER of strategies including ADV 
increases sharply.
•	 The size of utility gain from HBeAg 
seroconversion or loss of the surface antigen 
(HBsAg) – if there is no gain in utility, the 
incremental cost-effectiveness of all strategies 
is poorer.
While it is relatively common in trials of antiviral 
treatment for hepatitis C to report outcomes by 
stage of disease – identifying cirrhotic and non-
cirrhotic patients separately – this is less common 
in CHB. Clearer identification of patients’ outcome 
by stage of disease may enable more reliable and 
transparent modelling of the cost-effectiveness of 
antiviral treatments in this group of patients.
Uncertainty over the existence and size of the 
utility gain associated with response to treatment 
cannot be addressed using studies included in this 
review. The study by Levy and colleagues56 did not 
include utility estimates for patients who HBeAg 
seroconverted or lost the surface antigen, nor did 
it consider quality of life for patients who remain 
chronically infected, but have low viral levels 
(which would characterise response to treatment 
in patients with HBeAg-negative CHB). Further 
research is required to derive utility estimates 
across the full range of health states relevant to 
HBeAg-negative and HBeAg-positive variants of 
CHB, using appropriate preference-based methods 
in a representative sample of the UK population.
A further source of uncertainty in the model 
concerns the relationship between patients with 
HBeAg-positive and HBeAg-negative CHB. The 
latter group have only recently been included 
in economic models of antiviral treatment and 
have traditionally had a limited evidence base on 
natural history and epidemiology. The two groups 
of patients have typically been enrolled in separate 
clinical trials or have been analysed separately, 
leading to them being included as two separate 
populations in economic models. However, it 
has been suggested that HBeAg-negative CHB 
may represent a late stage of CHB (reflected by 
the older average age for patients with HBeAg-
negative CHB).75 The implication of this for 
economic models of cohorts of CHB patients is 
that a proportion of patients who begin the model 
with HBeAg-positive CHB should move into the 
HBeAg-negative cohort. Currently, there is limited 
evidence on which to base such transitions. More 
robust evidence on the natural history of CHB and 
development of HBeAg-negative disease is needed 
to improve the robustness of economic models of 
antiviral treatments.
The absence of reliable evidence on the 
effectiveness (in terms of treatment resistance 
rather than HBeAg seroconversion or viral 
suppression) of combination treatments limits 
the scope for robust modelling of their long-
term effectiveness and cost-effectiveness. Given 
that patients with HBeAg-negative CHB are 
likely to require long-term maintenance therapy, 
this is a major gap in knowledge and limits Discussion
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reliable selection of optimal treatment strategies. 
The potential benefits offered by new antiviral 
treatments (in terms of reduced resistance profiles 
in comparison with LAM) may be compromised by 
the use of a well-tolerated, comparatively low-cost 
drug (LAM), with a poor resistance profile which 
may induce cross-resistance or promote more 
rapid development of resistance on switching to 
alternative therapies (such as ADV). However, in 
the absence of evidence of benefit, it is difficult to 
make a case for adopting a combination treatment 
that may cost up to four times as much as LAM 
monotherapy.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 6  
Conclusions
In terms of cost-effectiveness, the optimal 
treatment strategy is PEG-α followed by LAM, 
followed by ADV for patients developing LAM 
resistance. Further research should assess the 
clinical effectiveness and cost-effectiveness of 
newer antiviral agents in relation to existing drugs, 
including the role of initiating treatment with 
combination therapy.
B
oth ADV and PEG-α are beneficial for patients 
with CHB in terms of suppressing viral load, 
reducing liver damage-associated biochemical 
activity, inducing HBeAg seroconversion, and 
reducing liver fibrosis and necroinflammation. 
Emerging evidence suggests that benefits are 
durable when patients are treated with ADV for up 
to 5 years, with relatively low risk of resistance.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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s
p
o
n
s
e
 
a
t
 
m
o
n
t
h
 
1
2
A
f
t
e
r
 
t
h
e
 
fi
r
s
t
 
y
e
a
r
 
o
f
 
t
h
e
r
a
p
y
,
 
2
1
%
 
o
f
 
p
a
t
i
e
n
t
s
 
i
n
 
G
r
o
u
p
 
A
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
0
%
 
i
n
 
G
r
o
u
p
 
B
 
d
e
v
e
l
o
p
e
d
 
g
e
n
o
t
y
p
i
c
 
A
D
V
 
r
e
s
i
s
t
a
n
c
e
 
w
i
t
h
 
v
i
r
o
l
o
g
i
c
a
l
 
b
r
e
a
k
t
h
r
o
u
g
h
s
 
(
p
 
=
 
0
.
0
1
8
2
)
A
D
V
 
w
a
s
 
g
e
n
e
r
a
l
l
y
 
w
e
l
l
 
t
o
l
e
r
a
t
e
d
.
 
N
o
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
 
w
a
s
 
s
e
e
n
 
i
n
 
t
h
e
 
r
a
t
e
 
o
f
 
H
C
C
 
d
e
v
e
l
o
p
m
e
n
t
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
(
p
 
=
 
0
.
5
4
5
)
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
R
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
i
n
 
a
 
1
:
2
 
r
a
t
i
o
 
A
D
V
 
:
 
A
D
V
 
+
 
L
A
M
.
 
R
a
n
d
o
m
i
s
a
t
i
o
n
 
m
e
t
h
o
d
 
n
o
t
 
s
p
e
c
i
fi
e
d
A
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
:
 
N
o
t
 
r
e
p
o
r
t
e
d
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
:
 
O
r
i
g
i
n
a
l
 
l
o
n
g
-
t
e
r
m
 
s
t
u
d
y
 
f
r
o
m
 
w
h
i
c
h
 
t
h
e
s
e
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
t
a
k
e
n
 
w
a
s
 
o
p
e
n
-
l
a
b
e
l
.
 
N
o
 
f
u
r
t
h
e
r
 
d
e
t
a
i
l
s
 
r
e
g
a
r
d
i
n
g
 
b
l
i
n
d
i
n
g
 
w
e
r
e
 
r
e
p
o
r
t
e
d
A
n
a
l
y
s
i
s
 
b
y
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
:
 
Y
e
s
.
 
N
o
t
 
s
p
e
c
i
fi
e
d
 
p
e
r
 
s
e
,
 
b
u
t
 
t
h
e
 
a
n
a
l
y
s
i
s
 
w
a
s
 
p
e
r
f
o
r
m
e
d
 
o
n
 
a
l
l
 
4
2
 
p
a
t
i
e
n
t
s
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
a
t
 
p
r
e
-
t
r
e
a
t
m
e
n
t
:
 
G
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
f
o
r
 
a
l
l
 
r
e
p
o
r
t
e
d
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
.
 
p
-
v
a
l
u
e
s
 
p
r
e
s
e
n
t
e
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M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
M
a
n
n
–
W
h
i
t
n
e
y
 
T
e
s
t
 
u
s
e
d
 
f
o
r
 
c
o
m
p
a
r
i
s
o
n
s
 
o
f
 
q
u
a
n
t
i
t
a
t
i
v
e
 
v
a
r
i
a
b
l
e
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
,
 
W
i
l
c
o
x
o
n
 
m
a
t
c
h
e
d
-
p
a
i
r
s
 
s
i
g
n
e
d
-
r
a
n
k
s
 
t
e
s
t
 
f
o
r
 
e
v
a
l
u
a
t
i
o
n
 
o
f
 
c
h
a
n
g
e
s
 
o
f
 
v
a
r
i
a
b
l
e
s
 
w
i
t
h
i
n
 
t
h
e
 
s
a
m
e
 
g
r
o
u
p
,
 
a
n
d
 
t
h
e
 
c
o
r
r
e
c
t
e
d
 
c
h
i
-
s
q
u
a
r
e
d
 
o
r
 
t
w
o
-
t
a
i
l
e
d
 
F
i
s
h
e
r
’
s
 
e
x
a
c
t
 
t
e
s
t
 
f
o
r
 
q
u
a
l
i
t
a
t
i
v
e
 
d
a
t
a
.
 
T
h
e
 
K
a
p
l
a
n
–
M
e
i
e
r
 
w
a
s
 
u
s
e
d
 
t
o
 
e
s
t
i
m
a
t
e
 
b
o
t
h
 
v
i
r
o
l
o
g
i
c
a
l
 
a
n
d
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
m
i
s
s
i
o
n
 
r
a
t
e
s
 
d
u
r
i
n
g
 
t
h
e
 
s
t
u
d
y
 
p
e
r
i
o
d
 
a
n
d
 
C
o
x
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
i
s
 
t
o
 
e
v
a
l
u
a
t
e
 
t
h
e
 
a
s
s
o
c
i
a
t
i
o
n
 
o
f
 
s
e
v
e
r
a
l
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
w
i
t
h
 
t
h
e
 
m
a
i
n
t
e
n
a
n
c
e
 
o
f
 
r
e
m
i
s
s
i
o
n
.
 
I
n
 
a
l
l
 
c
a
s
e
s
,
 
a
 
t
w
o
-
t
a
i
l
e
d
 
p
 
<
 
0
.
0
5
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
P
o
w
e
r
 
a
n
a
l
y
s
i
s
:
 
N
o
t
 
r
e
p
o
r
t
e
d
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
N
o
n
e
 
r
e
p
o
r
t
e
d
 
t
o
 
d
a
t
e
;
 
a
l
l
 
p
a
t
i
e
n
t
s
 
s
t
i
l
l
 
u
n
d
e
r
g
o
i
n
g
 
t
h
e
r
a
p
y
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
H
B
e
A
g
-
n
e
g
a
t
i
v
e
 
H
B
V
 
c
h
r
o
n
i
c
 
l
i
v
e
r
 
d
i
s
e
a
s
e
.
 
P
a
t
i
e
n
t
s
 
h
a
d
 
n
o
 
c
o
-
i
n
f
e
c
t
i
o
n
s
 
a
n
d
 
w
e
r
e
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
o
n
l
y
 
w
i
t
h
 
I
F
N
-
α
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
F
u
n
d
i
n
g
 
n
o
t
 
s
t
a
t
e
d
.
 
A
D
V
 
s
u
p
p
l
i
e
d
 
o
n
 
c
o
m
p
a
s
s
i
o
n
a
t
e
 
b
a
s
i
s
 
b
y
 
G
i
l
e
a
d
 
S
c
i
e
n
c
e
s
;
 
R
o
c
h
e
 
A
n
a
l
y
t
i
c
a
l
 
d
o
n
a
t
e
d
 
C
o
b
a
s
 
T
a
q
M
a
n
 
H
B
V
 
r
e
a
g
e
n
t
s
D
e
fi
n
i
t
i
o
n
s
:
 
U
p
p
e
r
 
l
i
m
i
t
 
o
f
 
n
o
r
m
a
l
 
f
o
r
 
A
L
T
 
w
a
s
 
4
9
 
I
U
/
l
.
 
I
n
i
t
i
a
l
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
a
s
 
n
o
n
-
d
e
t
e
c
t
a
b
l
e
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
b
y
 
P
C
R
 
a
n
d
 
i
n
i
t
i
a
l
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
 
a
s
 
t
h
e
 
d
e
c
l
i
n
e
 
o
f
 
A
L
T
 
w
i
t
h
i
n
 
t
h
e
 
n
o
r
m
a
l
 
r
a
n
g
e
 
i
n
 
t
w
o
 
c
o
n
s
e
c
u
t
i
v
e
 
d
e
t
e
r
m
i
n
a
t
i
o
n
s
 
d
u
r
i
n
g
 
t
h
e
r
a
p
y
a
 
P
a
t
i
e
n
t
s
 
w
e
r
e
 
t
a
k
e
n
 
f
r
o
m
 
a
 
p
r
e
v
i
o
u
s
 
l
o
n
g
-
t
e
r
m
 
s
t
u
d
y
 
o
f
 
L
A
M
 
m
o
n
o
t
h
e
r
a
p
y
 
a
n
d
 
e
i
t
h
e
r
 
s
w
i
t
c
h
e
d
 
t
o
 
A
D
V
 
o
r
 
g
i
v
e
n
 
a
d
d
e
d
 
A
D
V
 
–
 
d
e
t
a
i
l
s
 
o
f
 
L
A
M
 
d
o
s
a
g
e
 
n
o
t
 
p
r
o
v
i
d
e
d
 
i
n
 
t
h
i
s
 
p
u
b
l
i
c
a
t
i
o
n
.
b
 
N
o
t
 
s
t
a
t
e
d
 
a
s
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
s
 
p
e
r
 
s
e
.
Q
u
a
l
i
t
y
 
a
s
s
e
s
s
m
e
n
t
 
f
o
r
 
R
C
T
s
 
(
q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
–
 
C
R
D
 
r
e
p
o
r
t
 
4
)
 
C
r
i
t
e
r
i
o
n
J
u
d
g
e
m
e
n
t
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
U
n
k
n
o
w
n
2
.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
U
n
k
n
o
w
n
3
.
 
W
e
r
e
 
t
h
e
 
g
r
o
u
p
s
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
A
d
e
q
u
a
t
e
4
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
U
n
k
n
o
w
n
5
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
6
.
 
W
a
s
 
t
h
e
 
p
a
t
i
e
n
t
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
n
7
.
 
W
e
r
e
 
t
h
e
 
p
o
i
n
t
 
e
s
t
i
m
a
t
e
s
 
a
n
d
 
m
e
a
s
u
r
e
 
o
f
 
v
a
r
i
a
b
i
l
i
t
y
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
?
P
a
r
t
i
a
l
8
.
 
D
i
d
 
t
h
e
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
 
a
n
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
 
a
n
a
l
y
s
i
s
?
A
d
e
q
u
a
t
e
9
.
 
W
e
r
e
 
w
i
t
h
d
r
a
w
a
l
s
 
a
n
d
 
d
r
o
p
-
o
u
t
s
 
c
o
m
p
l
e
t
e
l
y
 
d
e
s
c
r
i
b
e
d
?
A
d
e
q
u
a
t
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R
e
f
e
r
e
n
c
e
 
a
n
d
 
d
e
s
i
g
n
I
n
t
e
r
v
e
n
t
i
o
n
 
P
a
r
t
i
c
i
p
a
n
t
s
O
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
Z
e
n
g
 
e
t
 
a
l
.
,
 
2
0
0
6
1
9
T
r
i
a
l
 
d
e
s
i
g
n
:
 
M
u
l
t
i
c
e
n
t
r
e
,
 
d
o
u
b
l
e
-
b
l
i
n
d
/
o
p
e
n
-
l
a
b
e
l
 
R
C
T
N
u
m
b
e
r
 
o
f
 
c
e
n
t
r
e
s
:
 
7
C
o
u
n
t
r
y
:
 
C
h
i
n
a
F
u
n
d
i
n
g
:
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
G
r
o
u
p
 
A
:
 
P
A
A
n
 
=
 
1
2
0
P
l
a
c
e
b
o
D
o
s
e
:
 
n
/
a
D
u
r
a
t
i
o
n
:
 
1
2
 
w
e
e
k
s
A
d
e
f
o
v
i
r
 
d
i
p
i
v
o
x
i
l
D
o
s
e
:
 
1
0
 
m
g
/
d
a
y
D
u
r
a
t
i
o
n
:
 
2
8
 
w
e
e
k
s
A
d
e
f
o
v
i
r
 
d
i
p
i
v
o
x
i
l
D
o
s
e
:
 
1
0
 
m
g
/
d
a
y
D
u
r
a
t
i
o
n
:
 
1
2
 
w
e
e
k
s
(
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
4
0
 
w
e
e
k
s
)
G
r
o
u
p
 
B
:
 
A
A
A
n
 
=
 
2
4
0
A
d
e
f
o
v
i
r
 
d
i
p
i
v
o
x
i
l
 
D
o
s
e
:
 
1
0
 
m
g
/
d
a
y
D
u
r
a
t
i
o
n
:
 
1
2
 
w
e
e
k
s
A
d
e
f
o
v
i
r
 
d
i
p
i
v
o
x
i
l
D
o
s
e
:
 
1
0
 
m
g
/
d
a
y
D
u
r
a
t
i
o
n
:
 
2
8
 
w
e
e
k
s
A
d
e
f
o
v
i
r
 
d
i
p
i
v
o
x
i
l
D
o
s
e
:
 
1
0
m
g
/
d
a
y
D
u
r
a
t
i
o
n
:
 
1
2
 
w
e
e
k
s
 
T
o
t
a
l
 
A
D
V
 
d
u
r
a
t
i
o
n
:
 
5
2
 
w
e
e
k
s
T
o
t
a
l
 
n
u
m
b
e
r
s
 
i
n
v
o
l
v
e
d
:
 
4
8
0
T
o
t
a
l
 
r
a
n
d
o
m
i
s
e
d
:
 
4
8
0
n
 
i
n
 
e
a
c
h
 
g
r
o
u
p
:
 
G
r
o
u
p
 
A
 
1
2
0
,
 
G
r
o
u
p
 
B
 
2
4
0
,
 
G
r
o
u
p
 
C
 
1
2
0
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
P
a
t
i
e
n
t
s
 
≥
 
1
8
 
y
e
a
r
s
 
w
h
o
,
 
a
t
 
s
c
r
e
e
n
i
n
g
 
(
u
p
 
t
o
 
2
8
 
d
a
y
s
 
p
r
i
o
r
 
t
o
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
a
n
d
,
 
f
o
r
 
H
B
s
A
g
,
 
≥
 
6
 
m
o
n
t
h
s
 
p
r
i
o
r
 
t
o
 
s
t
u
d
y
 
e
n
r
o
l
m
e
n
t
)
,
 
h
a
d
 
d
e
t
e
c
t
a
b
l
e
 
h
e
p
a
t
i
t
i
s
 
B
 
s
u
r
f
a
c
e
 
a
n
t
i
g
e
n
 
(
H
B
s
A
g
)
;
 
d
e
t
e
c
t
a
b
l
e
 
h
e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
 
(
H
B
e
A
g
)
;
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
≥
 
1
0
6
 
c
o
p
i
e
s
/
m
l
;
a
 
s
e
r
u
m
 
A
L
T
 
l
e
v
e
l
 
>
 
1
 
×
 
U
L
N
 
(
a
n
d
 
>
 
2
 
×
 
U
L
N
 
s
o
m
e
t
i
m
e
 
w
i
t
h
i
n
 
t
h
e
 
p
r
e
v
i
o
u
s
 
6
 
m
o
n
t
h
s
)
E
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
H
e
p
a
t
o
c
e
l
l
u
l
a
r
 
c
a
r
c
i
n
o
m
a
;
 
l
i
v
e
r
 
d
e
c
o
m
p
e
n
s
a
t
i
o
n
;
 
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
 
>
 
1
.
5
 
m
g
/
d
l
 
(
≥
 
1
3
0
 
μ
m
o
l
/
L
)
;
 
A
L
T
 
>
 
1
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1
%
1
1
 
(
9
%
)
A
d
v
e
r
s
e
 
e
v
e
n
t
s
 
a
f
t
e
r
 
r
e
-
r
a
n
d
o
m
i
s
a
t
i
o
n
 
t
o
 
p
l
a
c
e
b
o
 
a
t
 
w
e
e
k
 
4
0
R
e
a
c
t
i
v
a
t
i
o
n
 
o
f
 
h
e
p
a
t
i
t
i
s
 
B
1
/
1
2
0
 
(
<
 
1
%
)
1
/
2
4
0
 
(
<
 
1
%
)
1
1
/
1
2
0
 
(
9
%
)
U
p
p
e
r
 
r
e
s
p
i
r
a
t
o
r
y
 
i
n
f
e
c
t
i
o
n
1
0
/
1
2
0
 
(
8
%
)
2
0
/
2
4
0
 
(
8
%
)
9
/
1
2
0
 
(
8
%
)
F
a
t
i
g
u
e
7
/
1
2
0
 
(
6
%
)
6
/
2
4
0
 
(
3
%
)
8
/
1
2
0
 
(
7
%
)
N
a
s
o
p
h
a
r
y
n
g
i
t
i
s
6
/
1
2
0
 
(
5
%
)
1
1
/
2
4
0
 
(
5
%
)
2
/
1
2
0
 
(
2
%
)
V
i
r
a
l
 
r
e
s
i
s
t
a
n
c
e
 
a
t
 
w
e
e
k
 
5
2
k
P
A
A
 
(
n
 
=
 
1
1
)
A
A
A
 
(
n
 
=
 
2
8
)
A
A
P
 
(
n
 
=
 
6
)
N
2
3
6
T
 
o
r
 
A
1
8
1
V
 
m
u
t
a
t
i
o
n
0
0
0
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
a
r
t
i
c
i
p
a
n
t
s
 
r
a
n
d
o
m
i
s
e
d
 
b
y
 
c
e
n
t
r
a
l
 
t
e
l
e
p
h
o
n
e
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
s
y
s
t
e
m
 
(
R
A
M
O
S
)
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
a
s
s
i
g
n
m
e
n
t
 
v
i
a
 
r
a
n
d
o
m
 
n
u
m
b
e
r
 
g
e
n
e
r
a
t
i
o
n
 
i
n
 
b
l
o
c
k
s
 
o
f
 
8
 
(
3
:
1
 
r
a
t
i
o
 
f
o
r
 
1
2
 
w
e
e
k
s
,
 
r
e
-
r
a
n
d
o
m
i
s
a
t
i
o
n
 
a
t
 
w
e
e
k
 
4
0
,
 
2
:
1
 
r
a
t
i
o
 
f
o
r
 
1
2
 
w
e
e
k
s
;
 
w
h
e
n
 
c
o
n
s
i
d
e
r
i
n
g
 
t
h
e
 
t
h
r
e
e
 
g
r
o
u
p
s
,
 
t
h
e
 
r
a
t
i
o
 
w
o
u
l
d
 
a
p
p
e
a
r
 
t
o
 
b
e
 
1
:
2
:
1
)
.
 
P
l
a
c
e
b
o
 
p
a
t
i
e
n
t
s
 
e
x
p
e
r
i
e
n
c
i
n
g
 
p
r
o
g
r
e
s
s
i
o
n
 
o
f
 
l
i
v
e
r
 
d
i
s
e
a
s
e
 
w
e
r
e
 
e
l
i
g
i
b
l
e
 
t
o
 
r
e
c
e
i
v
e
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
.
 
A
l
l
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
a
n
d
o
m
i
s
e
d
 
t
o
 
p
l
a
c
e
b
o
 
o
r
 
A
D
V
 
f
o
r
 
1
2
 
w
e
e
k
s
,
 
f
o
l
l
o
w
e
d
 
b
y
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
 
f
o
r
 
2
8
 
w
e
e
k
s
.
 
T
h
o
s
e
 
w
h
o
 
r
e
c
e
i
v
e
d
 
A
D
V
 
i
n
 
t
h
e
 
fi
r
s
t
 
1
2
 
w
e
e
k
s
 
w
e
r
e
 
r
e
-
r
a
n
d
o
m
i
s
e
d
 
t
o
 
A
D
V
 
o
r
 
p
l
a
c
e
b
o
,
 
w
h
e
r
e
a
s
 
t
h
o
s
e
 
w
h
o
 
r
e
c
e
i
v
e
d
 
p
l
a
c
e
b
o
 
i
n
 
t
h
e
 
fi
r
s
t
 
1
2
 
w
e
e
k
s
 
c
o
n
t
i
n
u
e
d
 
o
n
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
A
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
:
 
D
o
u
b
l
e
-
b
l
i
n
d
 
s
t
u
d
y
 
d
r
u
g
 
a
n
d
 
o
p
e
n
-
l
a
b
e
l
 
s
u
p
p
l
i
e
s
 
w
e
r
e
 
p
a
c
k
a
g
e
d
,
 
l
a
b
e
l
l
e
d
 
a
n
d
 
n
u
m
e
r
i
c
a
l
l
y
 
c
o
d
e
d
 
f
o
r
 
e
a
c
h
 
t
r
e
a
t
m
e
n
t
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
c
o
m
p
u
t
e
r
-
g
e
n
e
r
a
t
e
d
 
r
a
n
d
o
m
 
c
o
d
e
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
:
 
P
a
t
i
e
n
t
s
 
w
e
r
e
 
b
l
i
n
d
e
d
 
u
n
t
i
l
 
w
e
e
k
 
1
2
.
 
A
l
l
 
t
h
e
n
 
r
e
c
e
i
v
e
d
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
 
f
o
r
 
2
8
 
w
e
e
k
s
.
 
T
h
e
 
P
A
A
 
g
r
o
u
p
 
r
e
c
e
i
v
e
d
 
o
p
e
n
-
l
a
b
e
l
 
A
D
V
 
f
o
r
 
t
h
e
 
n
e
x
t
 
1
2
 
w
e
e
k
s
,
 
w
h
i
l
e
 
t
h
e
 
A
A
A
 
a
n
d
 
A
A
P
 
g
r
o
u
p
s
 
w
e
r
e
 
r
e
-
r
a
n
d
o
m
i
s
e
d
 
a
n
d
 
b
l
i
n
d
e
d
 
t
o
 
w
h
e
t
h
e
r
 
t
h
e
y
 
w
e
r
e
 
r
e
c
e
i
v
i
n
g
 
A
D
V
 
o
r
 
p
l
a
c
e
b
o
A
n
a
l
y
s
i
s
 
b
y
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
:
 
S
t
u
d
y
 
s
t
a
t
e
s
 
t
h
a
t
 
t
h
e
 
p
r
i
m
a
r
y
 
p
o
p
u
l
a
t
i
o
n
 
f
o
r
 
e
f
fi
c
a
c
y
 
a
n
a
l
y
s
e
s
 
w
a
s
 
a
l
l
 
r
a
n
d
o
m
i
s
e
d
 
s
u
b
j
e
c
t
s
 
r
e
g
a
r
d
l
e
s
s
 
o
f
 
w
h
e
t
h
e
r
 
t
h
e
 
s
t
u
d
y
 
d
r
u
g
 
w
a
s
 
t
a
k
e
n
 
o
r
 
i
f
 
t
h
e
 
s
u
b
j
e
c
t
 
c
o
m
p
l
e
t
e
d
 
t
h
e
 
s
t
u
d
y
.
 
H
o
w
e
v
e
r
,
 
r
e
s
u
l
t
s
 
a
r
e
 
n
o
t
 
a
v
a
i
l
a
b
l
e
 
f
o
r
 
a
l
l
 
s
u
b
j
e
c
t
s
 
i
n
 
t
h
e
 
e
f
fi
c
a
c
y
 
r
e
s
u
l
t
s
 
t
a
b
l
e
.
 
T
h
e
 
p
o
p
u
l
a
t
i
o
n
 
f
o
r
 
t
h
e
 
s
a
f
e
t
y
 
a
n
a
l
y
s
e
s
 
w
a
s
 
a
l
l
 
s
u
b
j
e
c
t
s
 
f
o
r
 
w
h
o
m
 
n
o
 
c
l
e
a
r
 
e
v
i
d
e
n
c
e
 
o
f
 
f
a
i
l
u
r
e
 
t
o
 
t
a
k
e
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
 
w
a
s
 
a
v
a
i
l
a
b
l
e
.
 
N
o
 
a
d
j
u
s
t
m
e
n
t
 
w
a
s
 
m
a
d
e
 
f
o
r
 
m
i
s
s
i
n
g
 
d
a
t
a
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
a
t
 
p
r
e
-
t
r
e
a
t
m
e
n
t
:
 
G
r
o
u
p
s
 
a
p
p
e
a
r
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
;
 
o
n
l
y
 
t
w
o
 
p
-
v
a
l
u
e
s
 
g
i
v
e
n
,
 
f
o
r
 
A
D
V
 
a
n
d
 
p
l
a
c
e
b
o
 
g
r
o
u
p
s
 
a
t
 
w
e
e
k
 
1
2
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
M
e
a
n
 
±
 
S
D
 
s
t
a
t
e
d
 
f
o
r
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
.
 
M
e
d
i
a
n
 
(
r
a
n
g
e
 
2
5
–
7
5
%
)
 
s
t
a
t
e
d
 
f
o
r
 
H
B
V
 
D
N
A
 
r
e
s
u
l
t
s
.
 
R
e
s
u
l
t
s
 
f
o
r
 
t
h
e
 
w
e
e
k
 
1
2
 
a
n
a
l
y
s
i
s
 
a
r
e
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
e
 
t
w
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
A
D
V
 
(
n
 
=
 
3
6
0
)
 
a
n
d
 
p
l
a
c
e
b
o
 
(
n
 
=
 
1
2
0
)
.
 
T
h
e
 
r
e
s
u
l
t
s
 
o
f
 
s
u
b
s
e
q
u
e
n
t
 
a
n
a
l
y
s
e
s
 
a
r
e
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
t
h
r
e
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
P
A
A
 
(
n
 
=
 
1
2
0
)
,
 
A
A
A
 
(
n
 
=
 
2
4
0
)
 
a
n
d
 
A
A
P
 
(
n
 
=
 
1
2
0
)
P
o
w
e
r
 
a
n
a
l
y
s
i
s
:
 
T
h
e
 
s
t
u
d
y
 
w
a
s
 
d
e
s
i
g
n
e
d
 
t
o
 
e
n
r
o
l
 
4
8
0
 
s
u
b
j
e
c
t
s
 
a
n
d
 
e
x
p
e
c
t
e
d
 
t
o
 
p
r
o
v
i
d
e
 
g
r
e
a
t
e
r
 
t
h
a
n
 
9
5
%
 
p
o
w
e
r
 
t
o
 
d
e
t
e
c
t
 
a
 
m
e
a
n
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
t
h
e
 
c
h
a
n
g
e
 
i
n
 
H
B
V
 
D
N
A
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
t
o
 
w
e
e
k
 
1
2
 
b
e
t
w
e
e
n
 
A
D
V
 
a
n
d
 
p
l
a
c
e
b
o
 
o
f
 
1
.
5
 
l
o
g
1
0
 
c
o
p
i
e
s
/
m
l
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
S
i
x
 
s
u
b
j
e
c
t
s
 
d
i
s
c
o
n
t
i
n
u
e
d
 
s
t
u
d
y
 
d
r
u
g
 
p
r
e
m
a
t
u
r
e
l
y
,
 
t
h
r
e
e
 
o
f
 
t
h
e
s
e
 
f
o
r
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
.
 
S
o
m
e
 
r
e
s
u
l
t
s
 
m
i
s
s
i
n
g
 
f
r
o
m
 
t
a
b
l
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G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
P
r
e
d
o
m
i
n
a
n
t
l
y
 
m
a
l
e
,
 
H
B
e
A
g
-
p
o
s
i
t
i
v
e
 
C
H
B
 
C
h
i
n
e
s
e
 
p
o
p
u
l
a
t
i
o
n
 
w
i
t
h
o
u
t
 
c
i
r
r
h
o
s
i
s
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
G
S
K
 
f
u
n
d
e
d
 
t
h
e
 
s
t
u
d
y
,
 
a
n
d
 
c
o
m
p
l
e
t
e
d
 
t
h
e
 
s
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
i
s
;
 
h
o
w
e
v
e
r
 
t
h
e
y
 
d
o
 
n
o
t
 
m
a
n
u
f
a
c
t
u
r
e
 
t
h
i
s
 
d
r
u
g
a
 
L
o
w
e
r
 
l
i
m
i
t
 
o
f
 
d
e
t
e
c
t
i
o
n
 
2
0
0
 
c
o
p
i
e
s
/
m
l
,
 
r
e
v
i
s
e
d
 
t
o
 
3
0
0
 
c
o
p
i
e
s
/
m
l
 
d
u
r
i
n
g
 
t
h
e
 
c
o
u
r
s
e
 
o
f
 
t
h
e
 
s
t
u
d
y
.
b
 
L
o
g
1
0
 
r
e
d
u
c
t
i
o
n
 
c
o
p
i
e
s
/
m
l
.
c
 
S
u
b
j
e
c
t
s
 
w
i
t
h
 
e
l
e
v
a
t
e
d
 
s
e
r
u
m
 
A
L
T
 
a
t
 
b
a
s
e
l
i
n
e
.
d
 
>
5
 
×
 
U
L
N
 
a
n
d
 
>
 
2
 
×
 
b
a
s
e
l
i
n
e
 
(
f
o
r
 
fi
r
s
t
 
1
2
 
w
e
e
k
s
)
 
o
r
 
>
 
2
 
×
 
n
a
d
i
r
 
f
o
r
 
s
u
b
s
e
q
u
e
n
t
 
i
n
t
e
r
v
a
l
s
.
e
 
D
e
fi
n
e
d
 
a
s
 
a
 
d
e
c
r
e
a
s
e
 
i
n
 
H
B
e
A
g
 
t
o
 
a
n
 
u
n
d
e
t
e
c
t
a
b
l
e
 
l
e
v
e
l
 
a
n
d
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
H
B
e
A
b
 
t
o
 
a
 
d
e
t
e
c
t
a
b
l
e
 
l
e
v
e
l
.
f
 
N
o
 
a
d
j
u
s
t
m
e
n
t
 
m
a
d
e
 
f
o
r
 
m
i
s
s
i
n
g
 
d
a
t
a
.
 
g
 
H
B
V
 
D
N
A
 
<
3
0
0
 
c
o
p
i
e
s
/
m
l
.
h
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
e
l
e
v
a
t
e
d
 
s
e
r
u
m
 
A
L
T
 
a
t
 
b
a
s
e
l
i
n
e
.
i
 
>
 
5
 
×
 
U
L
N
 
>
 
2
 
×
 
b
a
s
e
l
i
n
e
 
(
f
o
r
 
t
h
e
 
fi
r
s
t
 
1
2
 
w
e
e
k
s
)
 
o
r
 
>
 
2
 
x
 
n
a
d
i
r
 
(
f
o
r
 
s
u
b
s
e
q
u
e
n
t
 
i
n
t
e
r
v
a
l
s
)
.
j
 
T
h
e
s
e
 
e
v
e
n
t
s
 
a
l
l
 
o
c
c
u
r
r
e
d
 
f
o
l
l
o
w
i
n
g
 
r
e
-
r
a
n
d
o
m
i
s
a
t
i
o
n
 
o
f
 
s
u
b
j
e
c
t
s
 
t
o
 
p
l
a
c
e
b
o
 
a
t
 
w
e
e
k
 
4
0
.
 
A
l
l
 
e
i
g
h
t
 
c
a
s
e
s
 
o
f
 
d
i
s
e
a
s
e
 
e
x
a
c
e
r
b
a
t
i
o
n
 
o
c
c
u
r
r
e
d
 
a
f
t
e
r
 
s
u
b
j
e
c
t
s
 
w
e
r
e
 
r
e
-
r
a
n
d
o
m
i
s
e
d
 
t
o
 
p
l
a
c
e
b
o
 
a
t
 
w
e
e
k
 
4
0
.
k
 
A
 
t
o
t
a
l
 
o
f
 
4
5
 
s
u
b
j
e
c
t
s
 
(
2
8
 
f
r
o
m
 
A
A
A
,
 
1
1
 
f
r
o
m
 
P
A
A
 
a
n
d
 
6
 
f
r
o
m
 
A
A
P
)
 
h
a
d
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
o
f
 
a
t
 
l
e
a
s
t
 
1
 
l
o
g
1
0
 
c
o
p
i
e
s
/
m
l
 
w
h
i
l
e
 
o
n
 
a
d
e
f
o
v
i
r
 
f
r
o
m
 
t
h
e
i
r
 
l
o
w
e
s
t
 
p
o
i
n
t
 
d
u
r
i
n
g
 
t
r
e
a
t
m
e
n
t
,
 
a
n
d
 
t
h
e
r
e
f
o
r
e
 
h
a
d
 
i
s
o
l
a
t
e
s
 
a
n
a
l
y
s
e
d
 
f
o
r
 
t
h
e
 
p
r
e
s
e
n
c
e
 
o
f
 
A
D
V
-
a
s
s
o
c
i
a
t
e
d
 
m
u
t
a
t
i
o
n
s
 
a
t
 
w
e
e
k
 
5
2
.
 
I
n
 
t
h
e
 
m
a
j
o
r
i
t
y
 
o
f
 
s
u
b
j
e
c
t
s
 
(
2
8
/
4
5
)
,
 
t
h
i
s
 
i
n
c
r
e
a
s
e
 
i
n
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
w
a
s
 
l
e
s
s
 
t
h
a
n
 
2
 
l
o
g
1
0
 
c
o
p
i
e
s
/
m
l
.
Q
u
a
l
i
t
y
 
a
s
s
e
s
s
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b
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c
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i
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c
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c
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c
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c
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c
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i
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c
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i
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b
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i
e
n
t
s
 
(
1
.
6
%
)
 
a
p
p
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a
 
2
:
1
 
r
a
t
i
o
.
 
C
e
n
t
r
a
l
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
w
a
s
 
s
t
r
a
t
i
fi
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
fi
v
e
 
g
e
o
g
r
a
p
h
i
c
 
r
e
g
i
o
n
s
.
 
P
e
r
m
u
t
e
d
 
b
l
o
c
k
s
 
(
w
i
t
h
 
a
 
b
l
o
c
k
 
s
i
z
e
 
o
f
 
6
)
 
w
e
r
e
 
u
s
e
d
 
i
n
 
e
a
c
h
 
s
t
r
a
t
u
m
.
 
A
t
 
w
e
e
k
 
4
8
,
 
t
r
e
a
t
m
e
n
t
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
t
o
 
r
e
c
e
i
v
e
 
e
i
t
h
e
r
 
c
o
n
t
i
n
u
i
n
g
 
t
r
e
a
t
m
e
n
t
 
o
r
 
p
l
a
c
e
b
o
 
f
o
r
 
t
h
e
 
r
e
m
a
i
n
d
e
r
 
o
f
 
t
h
e
 
s
t
u
d
y
 
a
n
d
 
p
l
a
c
e
b
o
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
e
a
s
s
i
g
n
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
.
 
T
h
i
s
 
p
a
r
t
 
o
f
 
t
h
e
 
s
t
u
d
y
 
i
s
 
o
n
g
o
i
n
g
 
a
n
d
 
r
e
m
a
i
n
s
 
b
l
i
n
d
e
d
.
 
W
e
e
k
s
 
9
7
–
2
4
0
 
o
f
 
t
h
e
 
l
o
n
g
-
t
e
r
m
 
f
o
l
l
o
w
-
u
p
 
s
t
u
d
y
 
w
e
r
e
 
o
p
e
n
-
l
a
b
e
l
B
l
i
n
d
i
n
g
:
 
C
l
i
n
i
c
a
l
 
d
a
t
a
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
,
 
m
o
n
i
t
o
r
e
d
 
a
n
d
 
e
n
t
e
r
e
d
 
i
n
t
o
 
a
 
d
a
t
a
b
a
s
e
 
b
y
 
a
 
c
o
n
t
r
a
c
t
 
r
e
s
e
a
r
c
h
 
o
r
g
a
n
i
s
a
t
i
o
n
.
 
L
a
b
 
t
e
s
t
s
 
w
e
r
e
 
c
o
n
d
u
c
t
e
d
 
b
y
 
C
o
v
a
n
c
e
 
a
n
d
 
t
h
e
 
s
p
o
n
s
o
r
 
h
e
l
d
 
t
h
e
 
d
a
t
a
 
a
n
d
 
c
o
n
d
u
c
t
e
d
 
t
h
e
 
s
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
e
s
.
 
K
n
o
d
e
l
l
 
s
c
o
r
e
s
 
w
e
r
e
 
a
s
s
e
s
s
e
d
 
b
y
 
a
n
 
i
n
d
e
p
e
n
d
e
n
t
 
h
i
s
t
o
p
a
t
h
o
l
o
g
i
s
t
 
w
h
o
 
w
a
s
 
u
n
a
w
a
r
e
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
s
’
 
t
r
e
a
t
m
e
n
t
 
a
s
s
i
g
n
m
e
n
t
s
 
a
n
d
 
t
h
e
 
t
i
m
i
n
g
 
o
f
 
l
i
v
e
r
 
b
i
o
p
s
y
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
a
r
e
 
r
e
p
o
r
t
e
d
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
’
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
s
.
 
F
o
r
 
t
h
e
 
l
o
n
g
-
t
e
r
m
 
f
o
l
l
o
w
-
u
p
 
p
a
p
e
r
,
 
b
a
s
e
l
i
n
e
 
d
e
m
o
g
r
a
p
h
i
c
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
a
n
d
 
t
h
o
s
e
 
r
e
l
a
t
e
d
 
t
o
 
h
e
p
a
t
i
t
i
s
 
B
 
i
n
f
e
c
t
i
o
n
 
w
e
r
e
 
n
o
t
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
d
i
f
f
e
r
e
n
t
 
a
m
o
n
g
 
t
h
e
 
t
h
r
e
e
 
g
r
o
u
p
s
.
 
F
o
r
 
t
h
e
 
o
p
e
n
-
l
a
b
e
l
 
p
h
a
s
e
 
c
o
h
o
r
t
,
 
l
o
w
e
r
 
H
B
V
 
D
N
A
 
a
n
d
 
A
L
T
 
l
e
v
e
l
s
 
p
r
i
o
r
 
t
o
 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
p
l
a
c
e
b
o
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
e
p
o
r
t
e
d
.
 
T
h
e
 
a
u
t
h
o
r
s
 
s
u
g
g
e
s
t
 
t
h
a
t
 
t
h
i
s
 
c
o
u
l
d
 
b
e
 
d
u
e
 
t
o
 
v
i
r
a
l
 
r
e
p
l
i
c
a
t
i
o
n
 
a
n
d
 
d
i
s
e
a
s
e
 
a
c
t
i
v
i
t
y
 
fl
u
c
t
u
a
t
i
o
n
s
 
p
r
e
v
i
o
u
s
l
y
 
o
b
s
e
r
v
e
d
 
i
n
 
H
b
e
A
g
-
n
e
g
a
t
i
v
e
 
p
a
t
i
e
n
t
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M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
S
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
d
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
1
 
d
o
s
e
 
o
f
 
t
h
e
 
s
t
u
d
y
 
d
r
u
g
.
 
T
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
h
i
s
t
o
l
o
g
i
c
a
l
 
e
n
d
 
p
o
i
n
t
s
 
i
n
c
l
u
d
e
d
 
a
 
s
u
b
g
r
o
u
p
 
o
f
 
t
h
i
s
 
p
o
p
u
l
a
t
i
o
n
 
t
h
a
t
 
h
a
d
 
a
n
 
a
s
s
e
s
s
a
b
l
e
 
b
a
s
e
l
i
n
e
 
b
i
o
p
s
y
 
s
p
e
c
i
m
e
n
.
 
T
o
t
a
l
 
n
 
v
a
r
i
e
s
 
f
o
r
 
e
a
c
h
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
,
 
s
o
 
t
r
u
e
 
I
T
T
 
w
a
s
 
n
o
t
 
p
e
r
f
o
r
m
e
d
.
 
A
n
 
u
n
s
t
r
a
t
i
fi
e
d
 
C
o
c
h
r
a
n
–
M
a
n
t
e
l
–
H
a
e
n
s
z
e
l
 
t
e
s
t
 
w
a
s
 
u
s
e
d
 
f
o
r
 
t
h
e
 
p
r
i
m
a
r
y
 
e
f
fi
c
a
c
y
 
e
n
d
 
p
o
i
n
t
,
 
c
o
n
d
u
c
t
e
d
 
a
s
 
a
 
n
o
m
i
n
a
l
 
t
w
o
-
s
i
d
e
d
 
α
 
l
e
v
e
l
 
o
f
 
0
.
0
5
.
 
A
l
l
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
s
,
 
s
i
g
n
i
fi
c
a
n
c
e
 
t
e
s
t
s
 
a
n
d
 
r
e
s
u
l
t
i
n
g
 
p
-
v
a
l
u
e
s
 
w
e
r
e
 
t
w
o
-
s
i
d
e
d
,
 
w
i
t
h
 
a
n
 
α
 
l
e
v
e
l
 
o
f
 
0
.
0
5
.
 
S
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
s
 
a
r
e
 
g
i
v
e
n
 
f
o
r
 
a
l
l
 
m
e
a
n
 
v
a
l
u
e
s
.
 
F
o
r
 
t
h
e
 
l
o
n
g
-
t
e
r
m
 
f
o
l
l
o
w
-
u
p
 
p
a
p
e
r
,
 
s
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
d
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
1
 
d
o
s
e
 
o
f
 
t
h
e
 
s
t
u
d
y
 
d
r
u
g
 
i
n
 
t
h
e
 
s
e
c
o
n
d
 
2
 
w
e
e
k
s
.
 
A
l
l
 
t
e
s
t
s
 
f
o
r
 
s
i
g
n
i
fi
c
a
n
c
e
 
a
n
d
 
r
e
s
u
l
t
i
n
g
 
p
-
v
a
l
u
e
s
 
w
e
r
e
 
t
w
o
-
s
i
d
e
d
 
w
i
t
h
 
a
 
0
.
0
5
 
l
e
v
e
l
 
o
f
 
s
i
g
n
i
fi
c
a
n
c
e
.
 
E
x
c
e
p
t
 
f
o
r
 
t
h
e
 
t
r
e
n
d
 
t
e
s
t
,
 
t
h
i
s
 
i
s
 
t
h
e
 
s
a
m
e
 
f
o
r
 
t
h
e
 
o
p
e
n
-
l
a
b
e
l
 
p
h
a
s
e
 
c
o
h
o
r
t
.
 
H
B
V
 
D
N
A
 
a
n
d
 
A
L
T
 
l
e
v
e
l
s
 
w
e
r
e
 
a
n
a
l
y
s
e
d
 
b
y
 
I
T
T
,
 
m
i
s
s
i
n
g
 
e
q
u
a
l
s
 
f
a
i
l
u
r
e
 
(
I
T
T
;
 
M
 
=
 
F
)
,
 
a
n
d
 
I
T
T
,
 
m
i
s
s
i
n
g
 
e
q
u
a
l
s
 
f
a
i
l
u
r
e
 
f
o
r
 
r
e
s
i
s
t
a
n
c
e
 
o
r
 
h
e
p
a
t
o
c
e
l
l
u
l
a
r
 
c
a
r
c
i
n
o
m
a
,
 
m
i
s
s
i
n
g
 
i
s
 
e
x
c
l
u
d
e
d
 
f
o
r
 
o
t
h
e
r
 
r
e
a
s
o
n
s
 
(
I
T
T
;
 
M
 
=
 
F
 
R
/
H
C
C
)
 
t
o
 
p
r
o
v
i
d
e
 
a
 
m
o
r
e
 
r
e
a
l
i
s
t
i
c
 
v
i
e
w
 
o
f
 
e
f
fi
c
a
c
y
 
(
d
r
o
p
-
o
u
t
s
 
u
n
r
e
l
a
t
e
d
 
t
o
 
e
f
fi
c
a
c
y
 
a
r
e
 
e
x
p
e
c
t
e
d
 
i
n
 
a
 
5
-
y
e
a
r
 
t
r
i
a
l
)
.
 
I
n
 
t
h
i
s
 
s
e
c
o
n
d
 
a
n
a
l
y
s
i
s
 
(
I
T
T
;
 
M
 
=
 
F
 
R
/
H
C
C
)
,
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
c
o
n
s
i
d
e
r
e
d
 
f
a
i
l
u
r
e
s
 
i
f
 
t
h
e
y
 
(
1
)
 
h
a
r
b
o
u
r
e
d
 
H
B
V
 
w
i
t
h
 
a
n
 
A
D
V
-
r
e
s
i
s
t
a
n
c
e
 
m
u
t
a
t
i
o
n
 
a
n
d
 
e
i
t
h
e
r
 
t
e
r
m
i
n
a
t
e
d
 
t
h
e
 
s
t
u
d
y
 
o
r
 
h
a
d
 
l
a
m
i
v
u
d
i
n
e
 
a
d
d
e
d
 
(
i
f
 
a
 
p
a
t
i
e
n
t
 
h
a
d
 
H
B
V
 
w
i
t
h
 
a
 
r
e
s
i
s
t
a
n
c
e
 
m
u
t
a
t
i
o
n
 
a
n
d
 
r
e
m
a
i
n
e
d
 
i
n
 
t
h
e
 
s
t
u
d
y
 
o
n
 
A
D
V
 
m
o
n
o
t
h
e
r
a
p
y
,
 
h
i
s
 
o
r
 
h
e
r
 
s
e
r
u
m
 
H
B
V
 
D
N
A
 
a
n
d
 
A
L
T
 
v
a
l
u
e
s
 
w
e
r
e
 
i
n
c
l
u
d
e
d
 
i
n
 
a
n
a
l
y
s
e
s
 
r
a
t
h
e
r
 
t
h
a
n
 
b
e
i
n
g
 
d
e
e
m
e
d
 
f
a
i
l
u
r
e
s
)
 
o
r
 
(
2
)
 
w
e
r
e
 
d
i
a
g
n
o
s
e
d
 
w
i
t
h
 
h
e
p
a
t
o
c
e
l
l
u
l
a
r
 
c
a
r
c
i
n
o
m
a
.
 
M
i
s
s
i
n
g
 
v
a
l
u
e
s
 
f
r
o
m
 
p
a
t
i
e
n
t
s
 
w
h
o
 
l
e
f
t
 
t
h
e
 
s
t
u
d
y
 
f
o
r
 
o
t
h
e
r
 
r
e
a
s
o
n
s
 
w
e
r
e
 
e
x
c
l
u
d
e
d
.
 
T
o
 
a
s
s
e
s
s
 
s
t
a
t
i
s
t
i
c
a
l
 
s
i
g
n
i
fi
c
a
n
c
e
 
i
n
 
t
h
e
 
s
t
e
p
w
i
s
e
 
l
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
,
 
t
h
e
 
W
a
l
d
 
χ
2
 
t
e
s
t
 
w
a
s
 
u
s
e
d
.
 
I
t
 
i
s
 
a
s
s
u
m
e
d
 
t
h
a
t
 
p
a
t
i
e
n
t
s
 
h
a
v
e
 
t
h
e
 
s
a
m
e
 
l
e
n
g
t
h
 
o
f
 
f
o
l
l
o
w
-
u
p
 
a
n
d
 
p
o
t
e
n
t
i
a
l
 
p
r
e
d
i
c
t
o
r
s
 
o
f
 
r
e
s
i
s
t
a
n
c
e
 
w
e
r
e
 
e
v
a
l
u
a
t
e
d
 
f
o
r
 
p
a
t
i
e
n
t
s
 
t
r
e
a
t
e
d
 
u
p
 
t
o
 
1
9
2
 
w
e
e
k
s
 
t
o
 
m
a
x
i
m
i
s
e
 
t
h
e
 
n
u
m
b
e
r
 
o
f
 
a
n
a
l
y
s
e
d
 
p
a
t
i
e
n
t
s
S
a
m
p
l
e
 
s
i
z
e
/
p
o
w
e
r
 
c
a
l
c
u
l
a
t
i
o
n
:
 
T
h
e
 
s
t
u
d
y
 
w
a
s
 
d
e
s
i
g
n
e
d
 
t
o
 
e
n
r
o
l
 
1
8
0
 
p
a
t
i
e
n
t
s
 
a
n
d
 
t
o
 
h
a
v
e
 
a
t
 
l
e
a
s
t
 
9
0
%
 
p
o
w
e
r
 
t
o
 
d
e
t
e
c
t
 
a
n
 
a
b
s
o
l
u
t
e
 
d
i
f
f
e
r
e
n
c
e
 
o
f
 
3
0
%
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
(
6
0
%
 
v
s
 
3
0
%
)
 
w
i
t
h
 
r
e
s
p
e
c
t
 
t
o
 
t
h
e
 
p
r
i
m
a
r
y
 
e
n
d
 
p
o
i
n
t
,
 
a
s
s
u
m
i
n
g
 
t
h
a
t
 
2
5
%
 
o
f
 
p
a
t
i
e
n
t
s
 
w
o
u
l
d
 
h
a
v
e
 
m
i
s
s
i
n
g
 
b
i
o
p
s
y
 
s
p
e
c
i
m
e
n
s
 
a
t
 
w
e
e
k
 
4
8
 
o
r
 
b
a
s
e
l
i
n
e
 
K
n
o
d
e
l
l
 
s
c
o
r
e
s
 
<
 
2
 
a
n
d
 
w
o
u
l
d
 
t
h
e
r
e
f
o
r
e
 
b
e
 
c
o
u
n
t
e
d
 
a
s
 
h
a
v
i
n
g
 
n
o
 
r
e
s
p
o
n
s
e
,
 
a
n
d
 
t
h
a
t
 
8
%
 
w
o
u
l
d
 
h
a
v
e
 
m
i
s
s
i
n
g
 
b
i
o
p
s
y
 
s
p
e
c
i
m
e
n
s
 
a
t
 
b
a
s
e
l
i
n
e
 
a
n
d
 
w
o
u
l
d
 
t
h
u
s
 
b
e
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
t
h
e
 
p
r
i
m
a
r
y
 
e
f
fi
c
a
c
y
 
a
n
a
l
y
s
i
s
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
O
n
e
 
p
l
a
c
e
b
o
 
p
a
t
i
e
n
t
 
d
r
o
p
p
e
d
 
o
u
t
 
b
e
f
o
r
e
 
r
e
c
e
i
v
i
n
g
 
a
n
y
 
d
r
u
g
 
a
n
d
 
w
a
s
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
a
n
a
l
y
s
i
s
.
 
A
n
o
t
h
e
r
 
i
s
 
s
a
i
d
 
t
o
 
h
a
v
e
 
d
r
o
p
p
e
d
 
o
u
t
 
a
f
t
e
r
 
H
I
V
 
i
n
f
e
c
t
i
o
n
 
w
a
s
 
d
i
a
g
n
o
s
e
d
.
 
N
o
 
o
t
h
e
r
 
d
r
o
p
-
o
u
t
s
 
a
r
e
 
m
e
n
t
i
o
n
e
d
.
 
F
o
r
 
t
h
e
 
l
o
n
g
-
t
e
r
m
 
f
o
l
l
o
w
-
u
p
 
p
a
p
e
r
,
 
o
n
e
 
p
a
t
i
e
n
t
 
i
n
 
G
r
o
u
p
 
A
1
 
(
i
.
e
.
 
c
o
n
t
i
n
u
a
t
i
o
n
 
o
f
 
A
D
V
)
 
w
i
t
h
d
r
e
w
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
b
e
f
o
r
e
 
t
a
k
i
n
g
 
m
e
d
i
c
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R
 
a
s
s
a
y
 
a
t
 
2
4
 
w
e
e
k
s
 
a
f
t
e
r
 
t
r
e
a
t
m
e
n
t
A
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
h
a
d
 
l
o
s
t
 
H
B
e
A
g
 
d
e
v
e
l
o
p
e
d
 
a
n
t
i
b
o
d
i
e
s
 
t
o
 
H
B
e
A
g
F
o
l
l
o
w
-
u
p
 
s
t
u
d
y
:
 
O
n
l
y
 
1
/
3
0
 
p
a
t
i
e
n
t
s
 
w
h
o
 
h
a
d
 
H
B
e
A
g
 
l
o
s
s
 
a
f
t
e
r
 
c
o
m
b
i
n
a
t
i
o
n
 
t
r
e
a
t
m
e
n
t
 
d
i
d
 
n
o
t
 
d
e
v
e
l
o
p
 
a
n
t
i
-
H
B
e
 
a
n
t
i
b
o
d
y
;
 
o
t
h
e
r
w
i
s
e
 
a
l
l
 
p
a
t
i
e
n
t
s
 
d
e
v
e
l
o
p
e
d
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
t
o
 
+
v
e
 
a
n
t
i
-
H
B
e
.
 
O
f
 
p
a
t
i
e
n
t
s
 
a
c
h
i
e
v
i
n
g
 
a
n
 
S
V
R
 
(
G
r
o
u
p
 
A
 
=
 
1
4
,
 
G
r
o
u
p
 
B
 
=
 
4
)
,
 
a
l
l
 
h
a
d
 
+
v
e
 
a
n
t
i
-
H
B
e
 
a
n
t
i
b
o
d
i
e
s
 
a
t
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
f
o
l
l
o
w
-
u
p
.
 
T
w
o
 
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
d
e
r
s
 
i
n
 
t
h
e
 
P
E
G
 
+
 
L
A
M
 
g
r
o
u
p
 
h
a
d
 
t
r
a
n
s
i
e
n
t
 
e
l
e
v
a
t
i
o
n
 
o
f
 
H
B
V
 
D
N
A
 
t
o
 
>
 
1
0
0
,
0
0
0
 
c
o
p
i
e
s
/
m
l
 
a
t
 
w
e
e
k
s
 
8
 
a
n
d
 
1
6
 
a
f
t
e
r
 
t
r
e
a
t
m
e
n
t
.
 
A
l
l
 
f
o
u
r
 
S
V
R
 
p
a
t
i
e
n
t
s
 
i
n
 
t
h
e
 
L
A
M
 
g
r
o
u
p
 
h
a
d
 
t
r
a
n
s
i
e
n
t
 
e
l
e
v
a
t
i
o
n
 
o
f
 
H
B
V
 
D
N
A
 
>
 
1
0
0
,
0
0
0
 
c
o
p
i
e
s
/
m
l
 
(
t
h
r
e
e
 
p
a
t
i
e
n
t
s
 
a
t
 
w
e
e
k
 
8
 
a
n
d
 
o
n
e
 
p
a
t
i
e
n
t
 
a
t
 
w
e
e
k
 
1
0
0
 
a
f
t
e
r
 
t
r
e
a
t
m
e
n
t
)
.
 
I
f
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
h
o
 
h
a
d
 
a
 
s
i
n
g
l
e
 
t
r
a
n
s
i
e
n
t
 
H
B
V
 
D
N
A
 
e
l
e
v
a
t
i
o
n
 
w
e
r
e
 
r
e
g
a
r
d
e
d
 
a
s
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
,
 
t
h
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
S
V
R
 
o
f
 
P
E
G
 
+
 
L
A
M
 
w
a
s
 
s
t
i
l
l
 
h
i
g
h
e
r
 
t
h
a
n
 
L
A
M
 
(
l
o
g
-
r
a
n
k
 
t
e
s
t
,
 
p
 
<
 
0
.
0
0
0
1
)
.
 
A
l
l
 
n
o
n
-
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
H
B
V
 
D
N
A
 
1
0
0
,
0
0
0
 
c
o
p
i
e
s
/
m
l
 
a
t
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
l
a
p
s
e
.
 
A
m
o
n
g
 
p
a
t
i
e
n
t
s
 
w
h
o
 
h
a
d
 
H
B
e
A
g
 
l
o
s
s
 
a
t
 
E
O
T
,
 
1
2
/
1
6
 
(
7
5
%
)
 
P
E
G
 
+
 
L
A
M
 
v
s
 
8
/
9
 
(
9
8
%
)
 
L
A
M
 
a
l
s
o
 
h
a
d
 
H
B
e
A
g
 
r
e
v
e
r
s
i
o
n
c
o
n
t
i
n
u
e
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B
i
o
c
h
e
m
i
c
a
l
O
f
 
t
h
o
s
e
 
w
i
t
h
 
S
V
R
,
 
a
l
l
 
e
x
c
e
p
t
 
o
n
e
 
p
a
t
i
e
n
t
 
i
n
 
G
r
o
u
p
 
A
 
h
a
d
 
s
u
s
t
a
i
n
e
d
 
n
o
r
m
a
l
i
s
a
t
i
o
n
 
o
f
 
A
L
T
 
l
e
v
e
l
s
 
(
A
L
T
 
1
.
1
 
×
 
U
L
N
)
H
i
s
t
o
l
o
g
i
c
a
l
A
m
o
n
g
 
t
h
e
 
1
6
 
p
a
t
i
e
n
t
s
 
(
1
0
 
i
n
 
G
r
o
u
p
 
A
,
 
s
i
x
 
i
n
 
G
r
o
u
p
 
B
)
 
w
i
t
h
o
u
t
 
e
v
a
l
u
a
b
l
e
 
p
a
i
r
e
d
 
l
i
v
e
r
 
b
i
o
p
s
y
 
s
p
e
c
i
m
e
n
s
,
 
s
i
x
 
p
a
t
i
e
n
t
s
 
(
f
o
u
r
 
i
n
 
G
r
o
u
p
 
A
,
 
t
w
o
 
i
n
 
G
r
o
u
p
 
B
)
 
h
a
d
 
E
O
T
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
,
 
a
n
d
 
t
w
o
 
p
a
t
i
e
n
t
s
 
(
G
r
o
u
p
 
A
)
 
h
a
d
 
a
n
 
S
V
R
D
r
u
g
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
s
A
m
o
n
g
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
L
A
M
,
 
s
e
v
e
n
 
h
a
d
 
a
 
L
A
M
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
 
a
n
d
 
1
2
 
h
a
d
 
b
o
t
h
 
w
i
d
e
-
t
y
p
e
 
a
n
d
 
L
A
M
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
s
.
 
A
m
o
n
g
 
P
E
G
 
+
 
L
A
M
 
p
a
t
i
e
n
t
s
,
 
fi
v
e
 
h
a
d
 
a
 
L
A
M
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
 
a
n
d
 
fi
v
e
 
h
a
d
 
m
i
x
e
d
 
w
i
d
e
-
t
y
p
e
 
a
n
d
 
L
A
M
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
s
A
d
v
e
r
s
e
 
e
v
e
n
t
s
M
o
s
t
 
A
E
s
 
w
e
r
e
 
t
r
a
n
s
i
e
n
t
 
a
n
d
 
w
e
r
e
 
r
e
l
a
t
e
d
 
t
o
 
t
h
e
 
u
s
e
 
o
f
 
P
E
G
-
α
-
2
b
.
 
N
o
 
p
a
t
i
e
n
t
s
 
d
i
e
d
 
o
r
 
r
e
q
u
i
r
e
d
 
l
i
v
e
r
 
t
r
a
n
s
p
l
a
n
t
a
t
i
o
n
S
e
r
i
o
u
s
 
A
E
s
 
–
 
o
n
e
 
p
a
t
i
e
n
t
 
i
n
 
e
a
c
h
 
o
f
 
t
h
e
 
f
o
l
l
o
w
i
n
g
:
 
b
i
p
o
l
a
r
 
d
i
s
o
r
d
e
r
 
r
e
q
u
i
r
i
n
g
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
t
h
e
r
a
p
y
 
(
w
e
e
k
 
2
1
)
,
 
p
u
l
m
o
n
a
r
y
 
t
u
b
e
r
c
u
l
o
s
i
s
 
r
e
q
u
i
r
i
n
g
 
a
n
t
i
-
t
u
b
e
r
c
u
l
o
s
i
s
 
t
r
e
a
t
m
e
n
t
 
(
w
e
e
k
 
1
1
)
,
 
t
h
y
r
o
t
o
x
i
c
o
s
i
s
 
r
e
q
u
i
r
i
n
g
 
p
r
o
p
y
l
u
r
a
c
i
l
 
t
r
e
a
t
m
e
n
t
 
(
w
e
e
k
 
1
7
)
 
a
n
d
 
s
e
v
e
r
e
 
l
o
c
a
l
 
r
e
a
c
t
i
o
n
 
a
t
 
i
n
j
e
c
t
i
o
n
 
s
i
t
e
s
 
(
w
e
e
k
 
8
)
 
t
h
a
t
 
r
e
s
o
l
v
e
d
 
s
p
o
n
t
a
n
e
o
u
s
l
y
.
 
P
E
G
 
w
a
s
 
d
i
s
c
o
n
t
i
n
u
e
d
 
i
n
 
a
l
l
 
f
o
u
r
 
c
a
s
e
s
;
 
t
h
r
e
e
 
p
a
t
i
e
n
t
s
 
c
o
n
t
i
n
u
e
d
 
w
i
t
h
 
L
A
M
 
t
h
r
o
u
g
h
 
t
o
 
w
e
e
k
 
6
0
 
w
h
i
l
e
 
t
h
e
 
f
o
u
r
t
h
 
p
a
t
i
e
n
t
 
w
i
t
h
d
r
e
w
 
f
r
o
m
 
t
h
e
 
s
t
u
d
y
 
a
n
d
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
a
 
t
r
e
a
t
m
e
n
t
 
f
a
i
l
u
r
e
R
e
d
u
c
t
i
o
n
 
o
f
 
P
E
G
 
d
o
s
e
 
t
o
 
5
0
 
μ
g
/
w
e
e
k
 
(
i
f
 
b
o
d
y
 
w
e
i
g
h
t
 
>
 
6
5
 
k
g
)
 
o
r
 
1
.
0
 
μ
g
/
k
g
/
w
e
e
k
 
i
f
 
<
 
6
5
 
k
g
)
 
w
a
s
 
d
u
e
 
t
o
 
a
n
a
e
m
i
a
 
(
n
 
=
 
1
)
,
 
n
e
u
t
r
o
p
e
n
i
a
 
(
n
 
=
 
3
)
 
a
n
d
/
o
r
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
 
(
n
 
=
 
4
)
O
n
e
 
p
a
t
i
e
n
t
 
(
G
r
o
u
p
 
A
)
 
h
a
d
 
P
E
G
 
w
i
t
h
h
e
l
d
 
f
o
r
 
t
w
o
 
d
o
s
e
s
 
a
t
 
w
e
e
k
s
 
4
 
a
n
d
 
5
 
o
w
i
n
g
 
t
o
 
s
e
v
e
r
e
 
h
e
p
a
t
i
t
i
s
 
fl
a
r
e
-
u
p
 
(
A
L
T
 
l
e
v
e
l
 
1
7
6
2
 
U
/
l
)
 
a
n
d
 
r
e
s
u
m
e
d
 
f
u
l
l
 
d
o
s
e
 
a
t
 
w
e
e
k
 
6
 
w
h
e
n
 
A
L
T
 
l
e
v
e
l
 
d
e
c
r
e
a
s
e
d
 
t
o
 
a
 
l
o
w
e
r
 
l
e
v
e
l
 
(
2
4
2
 
U
/
l
)
F
i
v
e
 
p
a
t
i
e
n
t
s
 
(
1
0
%
)
 
i
n
 
G
r
o
u
p
 
A
 
a
n
d
 
1
1
 
p
a
t
i
e
n
t
s
 
(
2
3
%
)
 
i
n
 
G
r
o
u
p
 
B
 
d
e
v
e
l
o
p
e
d
 
s
e
v
e
r
e
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
r
e
l
a
p
s
e
 
o
f
 
C
H
B
 
(
a
b
s
o
l
u
t
e
 
d
i
f
f
e
r
e
n
c
e
 
–
1
3
%
 
p
o
i
n
t
s
 
(
9
5
%
 
C
I
 
–
2
7
 
t
o
 
 
2
)
.
 
T
w
o
 
G
r
o
u
p
 
B
 
p
a
t
i
e
n
t
s
 
h
a
d
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
r
e
l
a
p
s
e
 
l
e
a
d
i
n
g
 
t
o
 
e
l
e
v
a
t
i
o
n
 
o
f
 
s
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
l
e
v
e
l
s
 
t
o
 
8
2
 
μ
m
o
l
/
l
 
a
n
d
 
1
5
3
 
μ
m
o
l
/
l
.
 
L
A
M
 
w
a
s
 
r
e
s
u
m
e
d
 
a
n
d
 
a
l
l
 
p
a
t
i
e
n
t
s
 
r
e
s
p
o
n
d
e
d
F
o
l
l
o
w
-
u
p
 
s
t
u
d
y
:
 
S
e
v
e
n
 
P
E
G
 
+
 
L
A
M
 
v
s
 
1
4
 
L
A
M
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
o
p
e
n
-
l
a
b
e
l
 
L
A
M
 
f
o
r
 
s
e
v
e
r
e
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
l
a
p
s
e
 
–
 
o
n
e
 
p
a
t
i
e
n
t
 
(
G
r
o
u
p
 
A
)
 
d
e
v
e
l
o
p
e
d
 
a
c
u
t
e
 
d
u
o
d
e
n
a
l
 
u
l
c
e
r
 
b
l
e
e
d
i
n
g
 
c
o
m
p
l
i
c
a
t
e
d
 
b
y
 
s
h
o
c
k
 
a
n
d
 
a
s
p
i
r
a
t
i
o
n
 
p
n
e
u
m
o
n
i
a
,
 
a
n
d
 
d
i
e
d
 
a
t
 
w
e
e
k
 
6
4
 
a
f
t
e
r
 
t
r
e
a
t
m
e
n
t
.
 
N
o
 
p
a
t
i
e
n
t
s
 
d
e
v
e
l
o
p
e
d
 
a
s
c
i
t
e
s
 
o
r
 
h
e
p
a
t
i
c
 
e
n
c
e
p
h
a
l
o
p
a
t
h
y
.
 
T
w
o
 
P
E
G
 
+
 
L
A
M
 
p
a
t
i
e
n
t
s
 
d
e
v
e
l
o
p
e
d
 
d
e
c
o
m
p
e
n
s
a
t
i
o
n
 
a
t
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
l
a
p
s
e
 
w
i
t
h
 
s
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
e
l
e
v
a
t
e
d
 
t
o
 
1
4
0
 
I
U
/
l
 
a
t
 
w
e
e
k
 
3
2
 
a
n
d
 
1
3
8
 
I
U
/
l
 
a
t
 
w
e
e
k
 
6
3
;
 
f
o
u
r
 
L
A
M
 
p
a
t
i
e
n
t
s
 
h
a
d
 
e
l
e
v
a
t
e
d
 
s
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
f
r
o
m
 
5
2
–
1
5
3
 
I
U
/
l
 
a
t
 
w
e
e
k
s
 
1
2
–
2
2
 
a
f
t
e
r
 
t
r
e
a
t
m
e
n
t
 
(
fi
v
e
 
o
f
 
t
h
e
s
e
 
s
i
x
 
p
a
t
i
e
n
t
s
 
h
a
d
 
a
 
h
i
s
t
o
l
o
g
i
c
a
l
 
fi
b
r
o
s
i
s
 
s
c
o
r
e
 
o
f
 
1
 
a
n
d
 
t
h
e
 
r
e
m
a
i
n
i
n
g
 
p
a
t
i
e
n
t
s
 
h
a
d
 
a
 
fi
b
r
o
s
i
s
 
s
c
o
r
e
 
o
f
 
4
 
b
e
f
o
r
e
 
c
o
m
m
e
n
c
e
m
e
n
t
 
o
f
 
t
r
e
a
t
m
e
n
t
)
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
A
 
c
o
m
p
u
t
e
r
-
g
e
n
e
r
a
t
e
d
 
l
i
s
t
 
w
a
s
 
u
s
e
d
 
f
o
r
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
g
r
o
u
p
s
.
 
R
a
n
d
o
m
i
s
e
d
 
1
:
1
A
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
:
 
R
e
s
e
a
r
c
h
 
s
t
a
f
f
,
 
w
h
o
 
w
e
r
e
 
n
o
t
 
i
n
v
o
l
v
e
d
 
i
n
 
p
a
t
i
e
n
t
 
m
a
n
a
g
e
m
e
n
t
,
 
p
l
a
c
e
d
 
t
h
e
 
r
a
n
d
o
m
 
n
u
m
b
e
r
s
 
i
n
 
o
p
a
q
u
e
 
e
n
v
e
l
o
p
e
s
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
:
 
A
 
r
e
s
e
a
r
c
h
 
n
u
r
s
e
 
p
r
e
s
c
r
i
b
e
d
 
s
t
u
d
y
 
d
r
u
g
s
 
a
f
t
e
r
 
r
e
c
e
i
v
i
n
g
 
t
h
e
 
i
n
f
o
r
m
a
t
i
o
n
 
a
b
o
u
t
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
a
t
 
t
h
e
 
b
a
s
e
l
i
n
e
 
v
i
s
i
t
.
 
O
n
e
 
h
i
s
t
o
p
a
t
h
o
l
o
g
i
s
t
,
 
b
l
i
n
d
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
a
s
s
i
g
n
m
e
n
t
s
 
o
r
 
t
h
e
 
t
i
m
e
s
 
a
t
 
w
h
i
c
h
 
t
h
e
 
s
p
e
c
i
m
e
n
s
 
w
e
r
e
 
o
b
t
a
i
n
e
d
,
 
a
s
s
e
s
s
e
d
 
a
l
l
 
h
i
s
t
o
l
o
g
i
c
a
l
 
s
p
e
c
i
m
e
n
s
.
 
A
l
l
 
l
a
b
 
a
s
s
a
y
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
i
n
-
h
o
u
s
e
.
 
I
n
v
e
s
t
i
g
a
t
o
r
s
 
a
s
s
e
s
s
i
n
g
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
e
r
e
 
n
o
t
 
b
l
i
n
d
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
a
s
 
t
h
e
y
 
w
e
r
e
 
a
b
l
e
 
t
o
 
r
e
d
u
c
e
 
t
h
e
 
P
E
G
 
d
o
s
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
A
E
 
e
x
p
e
r
i
e
n
c
e
d
.
 
N
o
 
i
n
f
o
r
m
a
t
i
o
n
 
r
e
p
o
r
t
e
d
 
r
e
g
a
r
d
i
n
g
 
t
h
e
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
t
h
e
 
p
r
i
m
a
r
y
 
o
r
 
o
t
h
e
r
 
s
e
c
o
n
d
a
r
y
 
o
u
t
c
o
m
e
 
m
e
a
s
u
r
e
s
A
n
a
l
y
s
i
s
 
b
y
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
:
 
M
o
d
i
fi
e
d
 
I
T
T
 
a
n
a
l
y
s
i
s
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
r
e
s
p
o
n
s
e
s
,
 
i
n
c
l
u
d
e
d
 
a
l
l
 
r
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
p
a
t
i
e
n
t
s
 
h
a
v
i
n
g
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
d
r
u
g
 
d
o
s
e
.
 
F
o
r
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
v
i
r
o
l
o
g
i
c
a
l
 
a
n
d
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
s
,
 
o
r
 
a
n
a
l
y
s
e
s
 
o
f
 
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
s
e
s
,
 
e
a
r
l
y
 
w
i
t
h
d
r
a
w
a
l
s
 
(
w
e
e
k
 
5
2
 
f
o
r
 
L
A
M
 
a
n
d
 
w
e
e
k
 
6
0
 
f
o
r
 
P
E
G
 
+
 
L
A
M
)
 
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
m
i
s
s
i
n
g
 
d
a
t
a
 
w
e
r
e
 
c
l
a
s
s
i
fi
e
d
 
a
s
 
h
a
v
i
n
g
 
a
 
f
a
i
l
e
d
 
r
e
s
p
o
n
s
e
.
 
T
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
i
n
c
l
u
d
e
d
 
a
l
l
 
p
a
t
i
e
n
t
s
 
r
a
n
d
o
m
l
y
 
a
s
s
i
g
n
e
d
 
t
o
 
e
i
t
h
e
r
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
,
 
h
a
v
i
n
g
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
d
r
u
g
 
d
o
s
e
.
 
O
n
e
 
p
a
t
i
e
n
t
 
i
n
 
G
r
o
u
p
 
B
 
h
a
d
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
b
e
f
o
r
e
 
c
o
m
m
e
n
c
e
m
e
n
t
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
w
a
s
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
a
n
a
l
y
s
i
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C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
a
t
 
p
r
e
-
t
r
e
a
t
m
e
n
t
:
 
B
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
w
e
r
e
 
w
e
l
l
 
m
a
t
c
h
e
d
 
b
e
t
w
e
e
n
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
(
n
o
 
p
-
v
a
l
u
e
s
 
p
r
e
s
e
n
t
e
d
)
,
 
b
u
t
 
s
e
v
e
r
a
l
 
p
a
t
i
e
n
t
s
 
h
a
d
 
e
i
t
h
e
r
 
n
o
r
m
a
l
 
A
L
T
 
l
e
v
e
l
s
 
o
r
 
l
e
v
e
l
s
 
t
h
a
t
 
w
e
r
e
 
g
r
e
a
t
e
r
 
t
h
a
n
 
5
 
×
 
U
L
N
 
a
t
 
b
a
s
e
l
i
n
e
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
v
i
s
i
t
.
 
M
e
d
i
a
n
 
A
L
T
 
l
e
v
e
l
s
 
f
o
r
 
G
r
o
u
p
 
A
 
w
e
r
e
 
h
i
g
h
e
r
 
t
h
a
n
 
t
h
o
s
e
 
f
o
r
 
G
r
o
u
p
 
B
 
(
p
 
=
 
0
.
0
2
)
,
 
b
u
t
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
(
p
 
>
 
0
.
2
)
 
i
n
 
d
i
f
f
e
r
e
n
t
 
A
L
T
 
c
a
t
e
g
o
r
i
e
s
 
(
1
–
2
 
×
,
 
2
–
5
 
×
 
o
r
 
>
 
5
 
×
 
U
L
N
)
 
d
i
d
 
n
o
t
 
d
i
f
f
e
r
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
P
a
t
i
e
n
t
s
 
i
n
 
G
r
o
u
p
 
A
,
 
w
h
o
 
s
t
o
p
p
e
d
 
p
e
g
y
l
a
t
e
d
 
i
n
t
e
r
f
e
r
o
n
 
p
r
e
m
a
t
u
r
e
l
y
,
 
h
a
d
 
a
s
s
e
s
s
m
e
n
t
s
 
o
f
 
v
i
r
o
l
o
g
i
c
a
l
 
a
n
d
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
s
 
i
f
 
l
a
m
i
v
u
d
i
n
e
 
t
r
e
a
t
m
e
n
t
 
w
a
s
 
c
o
n
t
i
n
u
e
d
 
t
o
 
t
h
e
 
e
n
d
.
 
C
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
 
w
e
r
e
 
e
x
p
r
e
s
s
e
d
 
a
s
 
t
h
e
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
.
 
H
e
p
a
t
i
t
i
s
 
B
 
v
i
r
u
s
 
D
N
A
 
w
a
s
 
l
o
g
a
r
i
t
h
m
i
c
a
l
l
y
 
t
r
a
n
s
f
o
r
m
e
d
 
f
o
r
 
a
n
a
l
y
s
i
s
.
 
C
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
,
 
i
n
c
l
u
d
i
n
g
 
p
a
t
i
e
n
t
 
a
g
e
,
 
l
i
v
e
r
 
b
i
o
c
h
e
m
i
s
t
r
y
,
 
l
o
g
1
0
 
H
B
V
 
D
N
A
 
l
e
v
e
l
s
,
 
a
n
d
 
h
i
s
t
o
l
o
g
i
c
a
l
 
s
c
o
r
e
s
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
t
h
e
 
M
a
n
n
–
W
h
i
t
n
e
y
 
U
-
t
e
s
t
.
 
C
a
t
e
g
o
r
i
c
a
l
 
v
a
r
i
a
b
l
e
s
 
a
n
d
 
t
h
e
 
p
r
o
p
o
r
t
i
o
n
s
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
v
i
r
o
l
o
g
i
c
a
l
 
a
n
d
 
b
i
o
c
h
e
m
i
c
a
l
 
r
e
s
p
o
n
s
e
s
,
 
h
i
s
t
o
l
o
g
i
c
a
l
 
i
m
p
r
o
v
e
m
e
n
t
s
,
 
l
a
m
i
v
u
d
i
n
e
-
r
e
s
i
s
t
a
n
t
 
m
u
t
a
n
t
s
 
a
n
d
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
t
h
e
 
P
e
a
r
s
o
n
 
c
h
i
-
s
q
u
a
r
e
d
 
t
e
s
t
 
o
r
 
F
i
s
h
e
r
’
s
 
e
x
a
c
t
 
t
e
s
t
,
 
a
s
 
a
p
p
r
o
p
r
i
a
t
e
.
 
T
h
e
 
t
i
m
i
n
g
 
o
f
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
w
a
s
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
K
a
p
l
a
n
–
M
e
i
e
r
 
s
u
r
v
i
v
a
l
 
a
n
a
l
y
s
i
s
.
 
A
 
l
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
 
m
o
d
e
l
 
w
a
s
 
u
s
e
d
 
t
o
 
c
o
m
p
a
r
e
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
 
w
i
t
h
 
a
d
j
u
s
t
m
e
n
t
 
f
o
r
 
b
a
s
e
l
i
n
e
 
i
m
b
a
l
a
n
c
e
 
i
n
 
A
L
T
 
l
e
v
e
l
s
.
 
A
 
p
-
v
a
l
u
e
 
<
 
0
.
0
5
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
.
 
A
l
l
 
s
t
a
t
i
s
t
i
c
a
l
 
t
e
s
t
s
 
w
e
r
e
 
t
w
o
-
s
i
d
e
d
.
 
H
B
V
 
D
N
A
 
w
a
s
 
l
o
g
a
r
i
t
h
m
i
c
 
t
r
a
n
s
f
o
r
m
e
d
 
t
o
 
n
o
r
m
a
l
 
d
i
s
t
r
i
b
u
t
i
o
n
 
f
o
r
 
a
n
a
l
y
s
i
s
.
 
C
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
 
w
i
t
h
 
n
o
r
m
a
l
 
d
i
s
t
r
i
b
u
t
i
o
n
 
w
e
r
e
 
e
x
p
r
e
s
s
e
d
 
a
s
 
m
e
a
n
 
±
 
S
D
 
a
n
d
 
v
a
r
i
a
b
l
e
s
 
w
i
t
h
 
s
k
e
w
e
d
 
d
i
s
t
r
i
b
u
t
i
o
n
 
a
s
 
m
e
d
i
a
n
 
a
n
d
 
r
a
n
g
e
.
 
B
a
s
e
l
i
n
e
 
c
a
t
e
g
o
r
i
c
a
l
 
v
a
r
i
a
b
l
e
s
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
u
s
i
n
g
 
P
e
a
r
s
o
n
’
s
 
c
h
i
-
s
q
u
a
r
e
d
 
t
e
s
t
,
 
a
n
d
 
c
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
b
y
 
S
t
u
d
e
n
t
 
t
-
t
e
s
t
 
a
n
d
 
M
a
n
n
-
W
h
i
t
n
e
y
 
U
-
t
e
s
t
 
a
s
 
a
p
p
r
o
p
r
i
a
t
e
.
 
K
a
p
l
a
n
–
M
e
i
e
r
 
w
a
s
 
u
s
e
d
 
f
o
r
 
s
u
r
v
i
v
a
l
 
a
n
a
l
y
s
i
s
 
t
o
 
c
o
m
p
a
r
e
 
t
h
e
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
S
V
R
 
a
s
 
w
e
l
l
 
a
s
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
a
m
o
n
g
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
.
 
T
h
e
 
C
o
x
 
p
r
o
p
o
r
t
i
o
n
a
l
 
h
a
z
a
r
d
 
m
o
d
e
l
 
w
a
s
 
u
s
e
d
 
t
o
 
a
s
s
e
s
s
 
t
h
e
 
p
r
e
d
i
c
t
o
r
s
 
o
f
 
S
V
R
 
a
m
o
n
g
 
p
a
t
i
e
n
t
s
 
i
n
 
G
r
o
u
p
 
A
.
 
S
t
a
t
i
s
t
i
c
a
l
 
t
e
s
t
s
 
a
n
d
 
s
i
g
n
i
fi
c
a
n
c
e
 
a
s
 
a
b
o
v
e
P
o
w
e
r
 
a
n
a
l
y
s
i
s
:
 
T
h
e
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
m
o
n
o
t
h
e
r
a
p
y
 
w
h
o
 
a
c
h
i
e
v
e
 
S
V
R
 
w
a
s
 
a
r
o
u
n
d
 
1
5
%
 
a
n
d
 
f
o
r
 
P
E
G
 
+
 
L
A
M
 
u
p
 
t
o
 
3
3
%
.
 
I
t
 
w
a
s
 
a
n
t
i
c
i
p
a
t
e
d
 
t
h
a
t
 
t
h
e
 
u
s
e
 
o
f
 
P
E
G
 
+
 
L
A
M
 
t
r
e
a
t
m
e
n
t
 
h
a
d
 
s
u
p
e
r
i
o
r
 
e
f
fi
c
a
c
y
 
a
n
d
 
t
h
a
t
 
t
h
e
 
r
a
t
e
 
o
f
 
S
V
R
 
w
a
s
 
3
0
%
 
h
i
g
h
e
r
 
t
h
a
n
 
t
h
a
t
 
o
f
 
m
o
n
o
t
h
e
r
a
p
y
 
(
S
V
R
 
i
n
 
G
r
o
u
p
 
A
 
v
s
 
G
r
o
u
p
 
B
,
 
4
5
%
 
v
s
 
1
5
%
)
.
 
G
i
v
e
n
 
t
h
e
s
e
 
e
s
t
i
m
a
t
e
d
 
r
e
s
p
o
n
s
e
 
r
a
t
e
s
,
 
i
t
 
w
a
s
 
c
a
l
c
u
l
a
t
e
d
 
t
h
a
t
 
9
4
 
p
a
t
i
e
n
t
s
 
w
o
u
l
d
 
b
e
 
r
e
q
u
i
r
e
d
 
t
o
 
p
r
o
v
i
d
e
 
a
 
p
o
w
e
r
 
o
f
 
8
0
%
 
a
t
 
a
n
 
α
 
l
e
v
e
l
 
o
f
 
0
.
0
5
,
 
a
l
l
o
w
i
n
g
 
f
o
r
 
a
 
d
r
o
p
-
o
u
t
 
r
a
t
e
 
o
f
 
1
0
%
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
T
o
t
a
l
 
=
 
2
0
 
(
7
 
G
r
o
u
p
 
A
,
 
1
3
 
G
r
o
u
p
 
B
)
.
 
T
w
o
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
g
r
o
u
p
 
d
i
d
 
n
o
t
 
c
o
m
p
l
e
t
e
 
t
r
e
a
t
m
e
n
t
 
–
 
e
a
r
l
y
 
w
i
t
h
d
r
a
w
a
l
 
d
u
e
 
t
o
 
l
a
c
k
 
o
f
 
i
n
t
e
r
e
s
t
 
=
 
2
 
(
o
n
e
 
G
r
o
u
p
 
A
,
 
o
n
e
 
G
r
o
u
p
 
B
)
,
 
a
l
l
e
r
g
i
c
 
r
e
a
c
t
i
o
n
 
=
 
1
 
(
G
r
o
u
p
 
A
)
,
 
p
r
e
g
n
a
n
c
y
 
=
 
1
 
(
G
r
o
u
p
 
B
)
.
 
A
 
f
u
r
t
h
e
r
 
1
6
 
p
a
t
i
e
n
t
s
 
d
i
d
 
n
o
t
 
c
o
m
p
l
e
t
e
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
f
o
l
l
o
w
-
u
p
 
b
e
c
a
u
s
e
 
o
f
 
s
e
v
e
r
e
 
r
e
l
a
p
s
e
 
w
h
i
l
e
 
r
e
c
e
i
v
i
n
g
 
l
a
m
i
v
u
d
i
n
e
 
(
fi
v
e
 
G
r
o
u
p
 
A
,
 
1
1
 
G
r
o
u
p
 
B
)
.
 
O
n
e
 
p
a
t
i
e
n
t
 
i
n
 
G
r
o
u
p
 
B
 
h
a
d
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
b
e
f
o
r
e
 
c
o
m
m
e
n
c
e
m
e
n
t
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
w
a
s
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
a
n
a
l
y
s
i
s
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
C
h
i
n
e
s
e
 
t
r
e
a
t
m
e
n
t
-
n
a
i
v
e
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
h
e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
 
(
H
B
e
A
g
)
,
 
p
o
s
i
t
i
v
e
 
c
h
r
o
n
i
c
 
h
e
p
a
t
i
t
i
s
 
B
 
a
n
d
 
m
o
d
e
r
a
t
e
l
y
 
e
l
e
v
a
t
e
d
 
A
L
T
 
l
e
v
e
l
s
C
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b
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c
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c
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p
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o
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i
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s
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e
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r
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e
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B
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e
d
 
a
s
 
a
n
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L
T
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v
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l
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N
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V
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p
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i
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i
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;
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B
,
 
c
h
r
o
n
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c
 
h
e
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a
t
i
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s
 
B
;
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T
,
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n
d
 
o
f
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a
t
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n
t
;
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B
e
A
g
,
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e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
;
 
H
B
V
,
 
h
e
p
a
t
i
t
i
s
 
B
 
v
i
r
u
s
;
 
S
V
R
,
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u
s
t
a
i
n
e
d
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
s
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n
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e
;
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N
,
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p
p
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r
 
l
i
m
i
t
 
o
f
 
n
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r
m
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.
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e
c
r
o
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n
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a
m
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t
i
o
n
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r
e
 
–
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d
u
c
t
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n
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f
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t
 
l
e
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t
 
2
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o
i
n
t
s
 
c
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i
c
a
l
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y
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n
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l
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r
 
o
f
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c
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l
 
c
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n
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.
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i
v
e
r
 
b
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o
p
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y
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e
s
u
l
t
s
 
w
i
t
h
 
a
t
 
l
e
a
s
t
 
t
h
r
e
e
 
p
o
r
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l
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c
t
s
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u
f
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c
i
e
n
t
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o
r
 
h
i
s
t
o
l
o
g
i
c
a
l
 
s
c
o
r
i
n
g
.
 
A
L
T
 
fl
a
r
e
 
d
u
r
i
n
g
 
t
r
e
a
t
m
e
n
t
 
d
e
fi
n
e
d
 
a
s
 
p
r
e
-
t
r
e
a
t
m
e
n
t
 
b
a
s
e
l
i
n
e
 
l
e
v
e
l
 
p
l
u
s
 
A
L
T
 
i
n
c
r
e
a
s
e
 
>
 
1
1
6
 
I
U
/
l
 
(
i
.
e
.
 
2
 
×
 
U
L
N
)
 
a
t
 
a
n
y
 
t
i
m
e
 
d
u
r
i
n
g
 
t
r
e
a
t
m
e
n
t
.
 
V
i
r
o
l
o
g
i
c
a
l
 
r
e
l
a
p
s
e
 
d
e
fi
n
e
d
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s
 
e
i
t
h
e
r
 
H
B
V
 
D
N
A
 
>
 
1
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0
0
0
 
c
o
p
i
e
s
 
o
n
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y
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o
 
o
r
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o
r
e
 
o
c
c
a
s
i
o
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s
 
o
r
 
H
B
e
A
g
 
r
e
v
e
r
s
i
o
n
 
d
u
r
i
n
g
 
e
n
t
i
r
e
 
p
o
s
t
-
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r
e
a
t
m
e
n
t
 
f
o
l
l
o
w
-
u
p
 
p
e
r
i
o
d
.
 
T
i
m
i
n
g
 
o
f
 
v
i
r
o
l
o
g
i
c
a
l
 
r
e
l
a
p
s
e
 
t
a
k
e
n
 
a
s
 
t
i
m
i
n
g
 
o
f
 
fi
r
s
t
 
H
B
V
 
D
N
A
 
e
l
e
v
a
t
i
o
n
 
o
r
 
H
B
e
A
g
 
r
e
v
e
r
s
i
o
n
,
 
w
h
i
c
h
e
v
e
r
 
w
a
s
 
e
a
r
l
i
e
r
.
 
B
i
o
c
h
e
m
i
c
a
l
 
r
e
l
a
p
s
e
 
d
e
fi
n
e
d
 
a
s
 
A
L
T
 
e
l
e
v
a
t
i
o
n
 
t
o
 
>
 
2
 
t
i
m
e
s
 
u
p
p
e
r
 
l
i
m
i
t
 
o
f
 
l
a
b
o
r
a
t
o
r
y
 
n
o
r
m
a
l
.
 
D
e
c
o
m
p
e
n
s
a
t
i
o
n
 
d
e
fi
n
e
d
 
a
s
 
e
l
e
v
a
t
e
d
 
s
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
>
 
5
0
 
I
U
/
l
 
a
c
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o
m
p
a
n
i
e
d
 
b
y
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o
c
h
e
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i
c
a
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Q
u
a
l
i
t
y
 
a
s
s
e
s
s
m
e
n
t
 
f
o
r
 
R
C
T
s
 
(
q
u
a
l
i
t
y
 
c
r
i
t
e
r
i
a
 
–
 
C
R
D
 
r
e
p
o
r
t
 
4
)
 
C
r
i
t
e
r
i
o
n
J
u
d
g
e
m
e
n
t
1
.
 
W
a
s
 
t
h
e
 
a
s
s
i
g
n
m
e
n
t
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
r
e
a
l
l
y
 
r
a
n
d
o
m
?
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d
e
q
u
a
t
e
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.
 
W
a
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
e
d
?
A
d
e
q
u
a
t
e
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.
 
W
e
r
e
 
t
h
e
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r
o
u
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s
 
s
i
m
i
l
a
r
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t
 
b
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s
e
l
i
n
e
 
i
n
 
t
e
r
m
s
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
?
A
d
e
q
u
a
t
e
4
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
e
d
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
?
P
a
r
t
i
a
l
5
.
 
W
a
s
 
t
h
e
 
c
a
r
e
 
p
r
o
v
i
d
e
r
 
b
l
i
n
d
e
d
?
U
n
k
n
o
w
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.
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s
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h
e
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t
i
e
n
t
 
b
l
i
n
d
e
d
?
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n
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d
e
q
u
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t
e
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.
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e
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e
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h
e
 
p
o
i
n
t
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s
t
i
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p
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p
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t
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e
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e
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u
r
e
?
P
a
r
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l
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.
 
D
i
d
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h
e
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y
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n
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.
 
W
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w
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d
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e
n
c
e
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e
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c
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u
t
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e
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s
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n
s
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n
 
e
t
 
a
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.
,
 
2
0
0
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,
2
6
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n
 
Z
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n
n
e
v
e
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d
 
e
t
 
a
l
.
,
 
2
0
0
6
2
9
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d
 
v
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n
 
Z
o
n
n
e
v
e
l
d
 
e
t
 
a
l
.
,
 
2
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0
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r
i
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l
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e
s
i
g
n
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D
o
u
b
l
e
-
b
l
i
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d
 
R
C
T
N
u
m
b
e
r
 
o
f
 
c
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o
u
n
t
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i
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1
5
 
(
N
e
t
h
e
r
l
a
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,
 
B
e
l
g
i
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,
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e
r
m
a
n
y
,
 
D
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n
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r
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,
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o
l
a
n
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,
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c
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r
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r
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d
i
n
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o
t
t
e
r
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o
u
n
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t
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o
n
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o
r
 
L
i
v
e
r
 
R
e
s
e
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r
c
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n
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n
c
i
a
l
 
s
u
p
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o
r
t
 
f
r
o
m
 
S
c
h
e
r
i
n
g
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P
l
o
u
g
h
 
I
n
t
e
r
n
a
t
i
o
n
a
l
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d
 
G
l
a
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o
S
m
i
t
h
K
l
i
n
e
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&
D
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r
o
u
p
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:
 
P
E
G
/
L
A
M
n
 
=
 
1
3
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D
r
u
g
 
1
:
 
P
e
g
y
l
a
t
e
d
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n
t
e
r
f
e
r
o
n
 
a
l
p
h
a
-
2
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(
P
E
G
-
I
F
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o
s
e
:
 
1
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0
 
μ
g
/
w
e
e
k
a
D
u
r
a
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o
n
:
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2
 
w
e
e
k
s
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o
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w
e
e
k
a
D
u
r
a
t
i
o
n
:
 
2
0
 
w
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w
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e
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u
g
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d
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w
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E
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/
p
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3
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D
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u
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e
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e
r
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o
s
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μ
g
/
w
e
e
k
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D
u
r
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t
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o
n
:
 
3
2
 
w
e
e
k
s
D
o
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e
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:
 
5
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μ
g
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w
e
e
k
a
D
u
r
a
t
i
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n
:
 
2
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w
e
e
k
s
 
(
w
e
e
k
s
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–
5
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)
 
D
r
u
g
 
2
:
 
P
l
a
c
e
b
o
D
u
r
a
t
i
o
n
:
 
5
2
 
w
e
e
k
s
T
o
t
a
l
 
n
u
m
b
e
r
s
 
i
n
v
o
l
v
e
d
:
 
3
0
7
T
o
t
a
l
 
r
a
n
d
o
m
i
s
e
d
:
 
3
0
7
 
(
G
r
o
u
p
 
A
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n
 
=
 
1
5
2
;
 
G
r
o
u
p
 
B
 
n
 
=
 
1
5
5
)
n
 
i
n
 
e
a
c
h
 
g
r
o
u
p
:
 
G
r
o
u
p
 
A
 
1
3
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;
 
G
r
o
u
p
 
B
 
1
3
6
n
 
i
n
 
e
a
c
h
 
g
r
o
u
p
 
i
n
 
h
i
s
t
o
l
o
g
y
 
s
t
u
d
y
:
 
G
r
o
u
p
 
A
 
5
2
;
 
G
r
o
u
p
 
B
 
5
8
 
(
t
o
t
a
l
 
=
 
1
1
0
)
.
 
n
 
i
n
 
e
a
c
h
 
g
r
o
u
p
 
i
n
 
s
a
f
e
t
y
 
s
t
u
d
y
:
 
G
r
o
u
p
 
A
 
1
4
8
;
 
G
r
o
u
p
 
B
 
1
4
8
 
(
t
o
t
a
l
 
=
 
3
0
0
)
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
C
H
B
,
 
≥
 
1
6
 
y
e
a
r
s
.
 
H
B
s
A
g
 
p
o
s
i
t
i
v
e
 
l
o
n
g
e
r
 
t
h
a
n
 
6
 
m
o
n
t
h
s
;
 
p
o
s
i
t
i
v
e
 
H
B
e
A
g
 
o
n
 
t
w
o
 
o
c
c
a
s
i
o
n
s
 
w
i
t
h
i
n
 
8
 
w
e
e
k
s
 
o
f
 
r
a
n
d
o
m
i
s
a
t
i
o
n
;
 
t
w
o
 
e
p
i
s
o
d
e
s
 
o
f
 
r
a
i
s
e
d
 
s
e
r
u
m
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
A
L
T
 
(
2
 
×
 
U
L
N
)
 
w
i
t
h
i
n
 
8
 
w
e
e
k
s
 
o
f
 
r
a
n
d
o
m
i
s
a
t
i
o
n
P
r
e
v
i
o
u
s
 
l
i
v
e
r
 
b
i
o
p
s
y
 
i
f
 
t
a
k
e
n
 
<
 
1
 
y
e
a
r
 
p
r
i
o
r
 
t
o
 
t
r
e
a
t
m
e
n
t
 
o
r
 
b
i
o
p
s
y
 
a
t
 
s
t
a
r
t
 
o
f
 
t
h
e
r
a
p
y
 
(
s
e
c
o
n
d
 
o
p
t
i
o
n
a
l
 
b
i
o
p
s
y
 
E
O
T
)
.
 
B
i
o
p
s
y
 
s
a
m
p
l
e
s
 
a
d
e
q
u
a
t
e
 
f
o
r
 
e
v
a
l
u
a
t
i
o
n
 
i
f
 
a
t
 
l
e
a
s
t
 
0
.
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c
m
 
l
o
n
g
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h
a
d
 
a
t
 
l
e
a
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t
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o
u
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u
a
b
l
e
 
p
o
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l
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c
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t
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r
e
S
a
f
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u
d
y
:
 
P
a
t
i
e
n
t
s
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o
 
h
a
d
 
r
e
c
e
i
v
e
d
 
a
t
 
l
e
a
s
t
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e
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o
s
e
 
o
f
 
s
t
u
d
y
 
m
e
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x
c
l
u
s
i
o
n
 
c
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r
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r
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s
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n
c
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o
f
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e
r
u
m
 
a
n
t
i
b
o
d
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e
s
 
a
g
a
i
n
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t
 
h
e
p
a
t
i
t
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s
 
C
 
o
r
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y
 
b
e
f
o
r
e
 
t
h
e
 
s
c
h
e
d
u
l
e
d
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
f
 
P
E
G
 
a
t
 
w
e
e
k
 
3
2
.
 
F
l
a
r
e
s
:
 
G
r
o
u
p
 
A
,
 
n
 
=
 
3
7
/
1
4
8
 
(
2
5
%
)
;
 
G
r
o
u
p
 
B
,
 
n
 
=
 
3
4
/
1
5
2
 
(
2
2
%
)
;
 
p
 
=
 
0
.
5
.
c
 
S
a
f
e
t
y
 
s
t
u
d
y
A
d
d
i
t
i
o
n
a
l
 
r
e
s
u
l
t
s
A
l
s
o
 
r
e
p
o
r
t
e
d
 
H
B
e
A
g
 
l
o
s
s
 
b
y
 
H
B
V
 
g
e
n
o
t
y
p
e
 
a
n
d
 
Y
M
D
D
 
m
u
t
a
n
t
 
a
t
 
E
O
T
.
 
T
w
o
 
(
1
4
%
)
 
p
a
t
i
e
n
t
s
 
h
a
d
 
r
e
s
p
o
n
d
e
d
 
t
o
 
t
h
e
r
a
p
y
 
w
i
t
h
 
l
o
s
s
 
o
f
 
H
B
e
A
g
,
 
w
h
i
l
e
 
s
e
v
e
n
 
(
5
0
%
)
 
o
f
 
h
a
d
 
b
e
e
n
 
p
r
e
v
i
o
u
s
l
y
 
t
r
e
a
t
e
d
 
w
i
t
h
 
L
A
M
 
a
n
d
 
h
a
d
 
h
a
d
 
a
 
m
u
t
a
n
t
 
f
r
o
m
 
t
h
e
 
s
t
a
r
t
 
o
f
 
t
h
e
r
a
p
y
.
 
R
e
s
u
l
t
s
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
r
e
s
p
o
n
s
e
 
b
y
 
H
B
V
 
g
e
n
o
t
y
p
e
 
w
e
r
e
 
a
l
s
o
 
r
e
p
o
r
t
e
d
.
 
O
t
h
e
r
 
b
a
s
e
l
i
n
e
 
f
a
c
t
o
r
s
 
t
h
a
t
 
w
e
r
e
 
p
r
e
d
i
c
t
i
v
e
 
o
f
 
r
e
s
p
o
n
s
e
 
w
i
t
h
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
w
e
r
e
 
l
o
w
 
v
i
r
a
l
 
l
o
a
d
 
[
1
.
6
 
(
1
.
3
–
1
.
8
)
,
 
p
 
=
 
0
.
0
0
9
]
,
 
h
i
g
h
 
A
L
T
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
[
1
.
1
 
(
1
.
0
–
1
.
2
)
,
 
p
 
=
 
0
.
0
2
]
 
a
n
d
 
a
b
s
e
n
c
e
 
o
f
 
p
r
e
v
i
o
u
s
 
I
F
N
 
t
h
e
r
a
p
y
 
[
2
.
2
 
(
1
.
1
–
4
.
5
)
,
 
p
 
=
 
0
.
0
4
]
.
 
L
o
w
 
H
B
V
 
D
N
A
 
l
e
v
e
l
s
 
(
p
 
=
 
0
.
0
0
2
)
 
a
n
d
 
l
o
w
 
B
M
I
 
(
p
 
=
 
0
.
0
2
)
 
w
e
r
e
 
t
w
o
 
b
a
s
e
l
i
n
e
 
f
a
c
t
o
r
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
i
m
p
r
o
v
e
m
e
n
t
 
o
f
 
n
e
c
r
o
i
n
fl
a
m
m
a
t
o
r
y
 
s
c
o
r
e
s
 
a
n
d
 
s
t
a
b
l
e
 
o
r
 
i
m
p
r
o
v
e
d
 
fi
b
r
o
s
i
s
 
s
t
a
g
e
.
 
A
l
s
o
 
r
e
p
o
r
t
e
d
 
H
B
V
 
g
e
n
o
t
y
p
e
 
o
n
 
h
i
s
t
o
l
o
g
i
c
a
l
 
r
e
s
p
o
n
s
e
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
:
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
E
l
i
g
i
b
l
e
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
a
n
d
o
m
i
s
e
d
 
o
n
 
a
 
1
:
1
 
b
a
s
i
s
 
t
o
 
P
E
G
/
L
A
M
 
o
r
 
P
E
G
/
p
l
a
c
e
b
o
.
 
R
a
n
d
o
m
i
s
a
t
i
o
n
 
w
a
s
 
d
o
n
e
 
c
e
n
t
r
a
l
l
y
 
a
n
d
 
s
t
r
a
t
i
fi
e
d
 
b
y
 
s
t
u
d
y
 
c
e
n
t
r
e
A
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
:
 
T
r
e
a
t
m
e
n
t
 
w
a
s
 
a
l
l
o
c
a
t
e
d
 
i
n
 
b
l
o
c
k
s
 
o
f
 
s
i
x
 
p
e
r
 
c
e
n
t
r
e
.
 
C
e
n
t
r
e
s
 
w
e
r
e
 
m
o
n
i
t
o
r
e
d
 
b
y
 
a
n
 
i
n
d
e
p
e
n
d
e
n
t
 
c
o
m
p
a
n
y
,
 
w
h
i
c
h
 
l
e
d
 
t
o
 
t
h
e
 
w
i
t
h
d
r
a
w
a
l
 
o
f
 
o
n
e
 
c
e
n
t
r
e
 
w
h
e
r
e
 
s
o
u
r
c
e
 
d
a
t
a
 
c
o
u
l
d
 
n
o
t
 
b
e
 
v
e
r
i
fi
e
d
.
 
T
h
e
 
t
r
i
a
l
 
w
a
s
 
d
o
u
b
l
e
-
b
l
i
n
d
e
d
.
 
T
h
e
 
p
l
a
c
e
b
o
 
w
a
s
 
s
i
m
i
l
a
r
 
i
n
 
a
p
p
e
a
r
a
n
c
e
 
t
o
 
L
A
M
 
a
n
d
 
a
d
m
i
n
i
s
t
r
a
t
e
d
 
d
a
i
l
y
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
:
 
A
l
l
 
H
B
V
 
m
a
r
k
e
r
s
 
w
e
r
e
 
a
s
s
e
s
s
e
d
 
a
t
 
c
e
n
t
r
a
l
 
l
a
b
o
r
a
t
o
r
y
,
 
w
i
t
h
 
s
t
a
f
f
 
u
n
a
w
a
r
e
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
l
l
o
c
a
t
i
o
n
.
 
R
o
u
t
i
n
e
 
b
i
o
c
h
e
m
i
c
a
l
 
a
n
d
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
e
s
t
s
 
w
e
r
e
 
d
o
n
e
 
b
y
 
a
u
t
o
m
a
t
e
d
 
t
e
c
h
n
i
q
u
e
s
 
a
t
 
p
a
r
t
i
c
i
p
a
t
i
n
g
 
c
e
n
t
r
e
s
.
 
H
i
s
t
o
l
o
g
i
c
a
l
 
s
a
m
p
l
e
s
 
w
e
r
e
 
s
c
o
r
e
d
 
c
e
n
t
r
a
l
l
y
 
b
y
 
a
 
p
a
t
h
o
l
o
g
i
s
t
 
u
n
a
w
a
r
e
 
o
f
 
t
r
e
a
t
m
e
n
t
 
r
e
g
i
m
e
n
;
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
o
t
h
e
r
 
o
u
t
c
o
m
e
s
 
w
a
s
 
n
o
t
 
d
i
s
c
u
s
s
e
d
.
 
T
r
e
a
t
i
n
g
 
p
h
y
s
i
c
i
a
n
 
a
s
s
e
s
s
e
d
 
a
n
d
 
r
e
p
o
r
t
e
d
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
u
s
i
n
g
 
s
t
a
n
d
a
r
d
 
c
a
s
e
-
r
e
c
o
r
d
 
f
o
r
m
s
,
 
v
e
r
i
fi
e
d
 
b
y
 
t
r
i
a
l
 
c
e
n
t
r
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A
n
a
l
y
s
i
s
 
b
y
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
:
 
M
o
d
i
fi
e
d
 
I
T
T
 
n
 
=
 
2
6
6
,
 
8
7
%
 
(
a
l
l
 
r
a
n
d
o
m
i
s
e
d
 
p
a
t
i
e
n
t
s
 
m
e
e
t
i
n
g
 
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
 
a
n
d
 
h
a
v
i
n
g
 
h
a
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
d
o
s
e
 
o
f
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
)
.
 
O
n
e
 
s
t
u
d
y
 
c
e
n
t
r
e
 
w
a
s
 
w
i
t
h
d
r
a
w
n
 
b
e
c
a
u
s
e
 
o
f
 
‘
m
i
s
c
o
n
d
u
c
t
’
 
(
s
e
e
 
a
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
 
a
b
o
v
e
)
 
a
n
d
 
2
4
 
(
8
%
)
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
I
T
T
,
 
b
u
t
 
i
t
 
i
s
 
u
n
c
l
e
a
r
 
h
o
w
 
f
a
r
 
i
n
t
o
 
t
h
e
 
s
t
u
d
y
 
t
h
i
s
 
o
c
c
u
r
r
e
d
 
(
a
s
s
e
s
s
m
e
n
t
 
o
f
 
p
r
i
m
a
r
y
 
a
n
d
 
s
e
c
o
n
d
a
r
y
 
e
n
d
 
p
o
i
n
t
s
 
w
a
s
 
n
o
t
 
p
o
s
s
i
b
l
e
 
f
o
r
 
t
h
e
s
e
 
p
a
t
i
e
n
t
s
,
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
s
a
m
p
l
e
s
 
b
e
i
n
g
 
t
h
a
w
e
d
 
f
o
r
 
a
 
l
o
n
g
 
p
e
r
i
o
d
)
.
 
A
 
f
u
r
t
h
e
r
 
1
0
 
(
3
%
)
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
e
x
c
l
u
d
e
d
 
b
e
c
a
u
s
e
 
t
h
e
y
 
h
a
d
 
l
o
s
t
 
H
B
e
A
g
 
b
e
f
o
r
e
 
t
h
e
 
s
t
a
r
t
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
s
e
v
e
n
 
(
2
%
)
 
p
a
t
i
e
n
t
s
 
d
i
d
 
n
o
t
 
t
a
k
e
 
a
n
y
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
.
 
P
a
t
i
e
n
t
s
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
t
h
e
 
fi
n
a
l
 
a
n
a
l
y
s
i
s
 
w
e
r
e
 
r
e
p
o
r
t
e
d
 
t
o
 
b
e
 
e
q
u
a
l
l
y
 
d
i
s
t
r
i
b
u
t
e
d
 
a
m
o
n
g
 
a
s
s
i
g
n
e
d
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
C
o
m
p
a
r
a
b
i
l
i
t
y
 
o
f
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
a
t
 
p
r
e
-
t
r
e
a
t
m
e
n
t
:
 
G
r
o
u
p
s
 
a
p
p
e
a
r
 
s
i
m
i
l
a
r
 
a
t
 
b
a
s
e
l
i
n
e
,
 
b
u
t
 
n
o
 
p
-
v
a
l
u
e
s
 
a
r
e
 
g
i
v
e
n
.
 
P
o
p
u
l
a
t
i
o
n
 
i
n
 
h
i
s
t
o
l
o
g
i
c
a
l
 
s
t
u
d
y
 
r
e
p
o
r
t
e
d
 
t
o
 
b
e
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
 
o
f
 
t
h
e
 
o
r
i
g
i
n
a
l
 
s
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
,
 
w
i
t
h
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
b
e
t
w
e
e
n
 
t
h
o
s
e
 
i
n
c
l
u
d
e
d
 
a
n
d
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
h
i
s
t
o
l
o
g
i
c
a
l
 
a
s
s
e
s
s
m
e
n
t
 
(
n
o
 
p
-
v
a
l
u
e
s
 
a
r
e
 
g
i
v
e
n
)
M
e
t
h
o
d
 
o
f
 
d
a
t
a
 
a
n
a
l
y
s
i
s
:
 
W
i
t
h
d
r
a
w
a
l
s
 
w
e
r
e
 
c
l
a
s
s
i
fi
e
d
 
a
s
 
t
r
e
a
t
m
e
n
t
 
f
a
i
l
u
r
e
s
.
 
T
h
e
 
e
f
f
e
c
t
s
 
o
f
 
P
E
G
 
a
n
d
 
P
E
G
/
L
A
M
 
t
h
e
r
a
p
y
 
o
n
 
r
e
s
p
o
n
s
e
 
w
e
r
e
 
c
o
m
p
a
r
e
d
 
b
y
 
t
h
e
 
c
h
i
-
s
q
u
a
r
e
d
 
t
e
s
t
.
 
R
e
s
p
o
n
s
e
 
r
a
t
e
s
 
a
r
e
 
t
h
o
s
e
 
a
s
s
e
s
s
e
d
 
b
y
 
%
 
H
B
e
A
g
 
l
o
s
s
,
 
H
B
V
 
D
N
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
<
 
2
0
0
,
0
0
0
 
c
o
p
i
e
s
/
m
l
,
 
H
B
V
 
D
N
A
 
n
e
g
a
t
i
v
e
 
b
y
 
P
C
R
 
o
r
 
n
o
r
m
a
l
 
A
L
T
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
t
 
E
O
T
 
a
n
d
 
E
O
F
-
U
.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
m
i
s
s
i
n
g
 
d
a
t
a
 
a
t
 
w
e
e
k
 
5
2
 
o
r
 
w
e
e
k
 
7
8
 
w
e
r
e
 
c
l
a
s
s
i
fi
e
d
 
a
s
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
a
t
 
E
O
T
 
o
r
 
E
O
F
-
U
 
r
e
s
p
e
c
t
i
v
e
l
y
.
 
T
h
e
 
r
e
l
a
t
i
o
n
s
h
i
p
 
b
e
t
w
e
e
n
 
p
a
t
i
e
n
t
s
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
a
n
d
 
H
B
e
A
g
 
l
o
s
s
 
a
t
 
E
O
F
-
U
 
(
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
s
e
)
 
w
a
s
 
e
x
a
m
i
n
e
d
 
b
y
 
l
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
e
s
.
 
U
n
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
w
a
s
 
u
s
e
d
 
t
o
 
a
s
s
e
s
s
 
t
h
e
 
i
m
p
o
r
t
a
n
c
e
 
o
f
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
.
 
M
u
l
t
i
p
l
e
 
l
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
e
s
 
w
e
r
e
 
d
o
n
e
 
w
i
t
h
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
t
o
 
c
h
e
c
k
 
t
h
e
 
i
n
d
e
p
e
n
d
e
n
c
e
 
o
f
 
t
h
e
s
e
 
f
a
c
t
o
r
s
.
 
I
n
d
e
p
e
n
d
e
n
c
e
 
o
f
 
g
e
n
o
t
y
p
e
 
a
s
 
a
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
 
w
a
s
 
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
.
 
A
l
l
 
p
-
v
a
l
u
e
s
 
w
e
r
e
 
t
w
o
-
s
i
d
e
d
.
 
C
o
m
p
a
r
i
s
o
n
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
w
e
r
e
 
m
a
d
e
 
u
s
i
n
g
 
t
h
e
 
c
h
i
-
s
q
u
a
r
e
d
 
t
e
s
t
 
f
o
r
 
c
a
t
e
g
o
r
i
c
a
l
 
v
a
r
i
a
b
l
e
s
 
a
n
d
 
t
h
e
 
M
a
n
n
–
W
h
i
t
n
e
y
 
t
e
s
t
 
f
o
r
 
c
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
.
 
L
o
g
i
s
t
i
c
 
r
e
g
r
e
s
s
i
o
n
 
w
a
s
 
u
s
e
d
 
f
o
r
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
.
 
B
a
s
e
l
i
n
e
 
v
a
r
i
a
b
l
e
s
 
(
i
m
p
r
o
v
e
m
e
n
t
s
 
o
f
 
n
e
c
r
o
i
n
fl
a
m
m
a
t
i
o
n
 
a
n
d
 
fi
b
r
o
s
i
s
,
 
w
o
r
s
e
n
i
n
g
 
o
f
 
fi
b
r
o
s
i
s
:
 
s
e
x
,
 
r
a
c
e
,
 
a
g
e
,
 
B
M
I
,
 
t
r
a
n
s
m
i
s
s
i
o
n
 
r
o
u
t
e
,
 
g
e
n
o
t
y
p
e
 
o
f
 
H
B
V
,
 
A
L
T
,
 
l
o
g
 
H
B
V
 
D
N
A
,
 
p
r
e
v
i
o
u
s
 
t
h
e
r
a
p
y
 
w
i
t
h
 
L
A
M
 
o
r
 
P
E
G
)
 
w
e
r
e
 
e
v
a
l
u
a
t
e
d
 
a
s
 
p
r
o
g
n
o
s
t
i
c
 
f
a
c
t
o
r
s
.
 
A
 
s
e
p
a
r
a
t
e
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
e
v
a
l
u
a
t
e
d
 
w
h
i
c
h
 
t
r
e
a
t
m
e
n
t
 
e
n
d
 
p
o
i
n
t
s
 
(
A
L
T
 
n
o
r
m
a
l
i
s
a
t
i
o
n
,
 
H
B
V
 
D
N
A
 
<
 
2
0
0
,
0
0
0
 
c
o
p
i
e
s
/
m
l
,
 
H
B
V
 
D
N
A
 
P
C
R
 
n
e
g
a
t
i
v
i
t
y
,
 
H
B
e
A
g
 
l
o
s
s
 
a
n
d
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
)
 
w
e
r
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
i
m
p
r
o
v
e
m
e
n
t
 
o
f
 
n
e
c
r
o
i
n
fl
a
m
m
a
t
i
o
n
 
a
n
d
 
fi
b
r
o
s
i
s
,
 
o
r
 
w
i
t
h
 
w
o
r
s
e
n
i
n
g
 
o
f
 
fi
b
r
o
s
i
s
.
 
K
a
p
l
a
n
–
M
e
i
e
r
 
a
n
a
l
y
s
i
s
 
w
a
s
 
u
s
e
d
 
t
o
 
a
s
s
e
s
s
 
t
i
m
e
 
u
n
t
i
l
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
r
 
p
r
e
m
a
t
u
r
e
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
o
f
 
t
h
e
r
a
p
y
.
 
C
h
i
-
s
q
u
a
r
e
d
 
a
n
a
l
y
s
i
s
 
w
a
s
 
c
a
r
r
i
e
d
 
o
u
t
 
t
o
 
c
o
m
p
a
r
e
 
f
r
e
q
u
e
n
c
i
e
s
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
.
 
F
o
r
 
a
l
l
 
a
n
a
l
y
s
i
s
 
i
n
 
t
h
e
 
s
a
f
e
t
y
 
s
t
u
d
y
,
 
t
h
e
 
d
a
t
a
 
o
f
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
w
e
r
e
 
c
o
m
b
i
n
e
d
P
o
w
e
r
 
a
n
a
l
y
s
i
s
:
 
T
h
e
 
s
t
u
d
y
 
w
a
s
 
p
o
w
e
r
e
d
 
t
o
 
a
c
c
o
u
n
t
 
f
o
r
 
a
 
m
i
x
e
d
 
p
o
p
u
l
a
t
i
o
n
 
w
i
t
h
 
5
0
%
 
o
f
 
p
a
t
i
e
n
t
s
 
p
r
e
v
i
o
u
s
l
y
 
n
o
n
-
r
e
s
p
o
n
s
i
v
e
 
t
o
 
I
F
N
 
t
h
e
r
a
p
y
 
a
n
d
 
5
0
%
 
w
h
o
 
h
a
d
 
n
o
t
 
r
e
c
e
i
v
e
d
 
I
F
N
 
p
r
e
v
i
o
u
s
l
y
,
 
w
i
t
h
 
a
 
b
a
s
e
l
i
n
e
 
A
L
T
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
>
 
t
w
i
c
e
 
U
L
N
.
 
T
o
 
o
b
t
a
i
n
 
a
 
p
o
w
e
r
 
o
f
 
m
o
r
e
 
t
h
a
n
 
8
0
%
 
(
α
 
=
 
0
.
0
5
)
,
 
a
n
 
e
s
t
i
m
a
t
e
d
 
2
7
0
 
p
a
t
i
e
n
t
s
 
w
o
u
l
d
 
b
e
 
n
e
e
d
e
d
,
 
o
n
 
a
s
s
u
m
p
t
i
o
n
 
o
f
 
r
a
t
e
s
 
o
f
 
H
B
e
A
g
 
l
o
s
s
 
a
t
 
t
h
e
 
e
n
d
 
o
f
 
f
o
l
l
o
w
-
u
p
 
o
f
 
2
0
%
 
f
o
r
 
P
E
G
 
a
n
d
 
3
6
%
 
f
o
r
 
P
E
G
/
L
A
M
 
t
h
e
r
a
p
y
.
 
S
a
m
p
l
e
-
s
i
z
e
 
c
a
l
c
u
l
a
t
i
o
n
 
w
a
s
 
b
a
s
e
d
 
o
n
 
a
n
 
e
s
t
i
m
a
t
e
d
 
w
i
t
h
d
r
a
w
a
l
 
r
a
t
e
 
o
f
 
2
0
%
.
 
F
e
w
e
r
 
P
E
G
-
e
x
p
e
r
i
e
n
c
e
d
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
r
e
c
r
u
i
t
e
d
 
t
h
a
n
 
e
x
p
e
c
t
e
d
 
(
n
 
=
 
5
5
,
 
2
1
%
)
 
b
u
t
 
i
t
 
i
s
 
r
e
p
o
r
t
e
d
 
t
h
a
t
 
w
i
t
h
 
a
 
t
o
t
a
l
 
o
f
 
2
6
6
 
p
a
t
i
e
n
t
s
 
i
n
 
t
h
e
 
m
o
d
i
fi
e
d
 
I
T
T
 
p
o
p
u
l
a
t
i
o
n
,
 
t
h
e
 
s
t
u
d
y
 
r
e
m
a
i
n
e
d
 
a
d
e
q
u
a
t
e
l
y
 
p
o
w
e
r
e
d
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
2
2
 
w
i
t
h
d
r
a
w
a
l
s
 
f
r
o
m
 
G
r
o
u
p
 
A
 
(
f
o
u
r
 
d
i
d
 
n
o
t
 
s
t
a
r
t
 
t
r
e
a
t
m
e
n
t
,
 
s
i
x
 
H
B
e
A
g
-
n
e
g
a
t
i
v
e
 
a
t
 
s
t
a
r
t
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
1
2
 
i
n
 
c
e
n
t
r
e
 
w
i
t
h
d
r
a
w
n
 
f
o
r
 
m
i
s
c
o
n
d
u
c
t
)
 
a
n
d
 
1
9
 
w
i
t
h
d
r
a
w
a
l
s
 
f
r
o
m
 
G
r
o
u
p
 
B
 
(
t
h
r
e
e
 
d
i
d
 
n
o
t
 
s
t
a
r
t
 
t
r
e
a
t
m
e
n
t
,
 
f
o
u
r
 
H
B
e
A
g
 
n
e
g
a
t
i
v
e
 
a
t
 
s
t
a
r
t
 
o
f
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
1
2
 
i
n
 
c
e
n
t
r
e
 
w
i
t
h
d
r
a
w
n
 
f
o
r
 
m
i
s
c
o
n
d
u
c
t
)
.
 
T
h
e
s
e
 
w
e
r
e
 
n
o
t
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
m
o
d
i
fi
e
d
 
I
T
T
.
 
O
f
 
t
h
o
s
e
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
m
o
d
i
fi
e
d
 
I
T
T
,
 
1
2
 
p
a
t
i
e
n
t
s
 
d
i
s
c
o
n
t
i
n
u
e
d
 
b
e
c
a
u
s
e
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
,
 
o
n
e
 
f
o
r
 
o
t
h
e
r
 
r
e
a
s
o
n
s
 
a
n
d
 
t
h
r
e
e
 
w
e
r
e
 
l
o
s
t
 
t
o
 
f
o
l
l
o
w
 
u
p
 
i
n
 
G
r
o
u
p
 
A
,
 
w
h
i
l
e
 
1
1
 
p
a
t
i
e
n
t
s
 
d
i
s
c
o
n
t
i
n
u
e
d
 
a
s
 
a
 
r
e
s
u
l
t
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
a
n
d
 
s
e
v
e
n
 
w
e
r
e
 
l
o
s
t
 
t
o
 
f
o
l
l
o
w
-
u
p
 
i
n
 
G
r
o
u
p
 
B
.
 
B
i
o
p
s
y
 
p
a
i
r
s
:
 
n
 
=
 
1
5
1
 
p
a
t
i
e
n
t
s
 
(
4
0
%
 
r
e
s
p
o
n
s
e
)
,
 
4
1
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
e
x
c
l
u
d
e
d
 
(
=
 
4
5
 
b
i
o
p
s
i
e
s
)
 
f
o
r
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
r
e
a
s
o
n
s
:
 
b
i
o
p
s
y
 
s
a
m
p
l
e
 
w
a
s
 
t
o
o
 
s
m
a
l
l
 
(
1
6
)
,
 
n
o
t
 
e
n
o
u
g
h
 
p
o
r
t
a
l
 
t
r
a
c
t
s
 
(
1
2
)
,
 
t
o
o
 
f
r
a
g
m
e
n
t
e
d
 
(
1
4
)
 
o
r
 
t
e
c
h
n
i
c
a
l
 
r
e
a
s
o
n
s
 
(
3
)
.
 
1
1
5
 
p
a
t
i
e
n
t
s
 
h
a
d
 
n
o
 
f
o
l
l
o
w
-
u
p
 
b
i
o
p
s
y
 
(
r
e
s
p
o
n
s
e
 
3
2
%
)
S
a
f
e
t
y
 
p
a
p
e
r
 
r
e
p
o
r
t
s
 
2
8
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
s
 
f
o
r
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
H
B
e
A
g
-
p
o
s
i
t
i
v
e
 
C
H
B
 
p
a
t
i
e
n
t
s
 
f
r
o
m
 
E
u
r
o
p
e
,
 
E
a
s
t
 
A
s
i
a
 
a
n
d
 
N
o
r
t
h
 
A
m
e
r
i
c
a
,
 
s
o
m
e
 
w
i
t
h
 
c
i
r
r
h
o
s
i
s
.
 
A
u
t
h
o
r
s
 
a
d
v
i
s
e
 
c
a
u
t
i
o
n
 
w
i
t
h
 
t
h
e
 
h
i
s
t
o
l
o
g
i
c
a
l
 
r
e
s
u
l
t
s
 
a
s
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
 
b
i
o
p
s
i
e
s
 
w
e
r
e
 
o
p
t
i
o
n
a
l
 
a
n
d
 
s
e
l
e
c
t
i
o
n
 
m
a
y
 
h
a
v
e
 
o
c
c
u
r
r
e
d
C
o
n
fl
i
c
t
 
o
f
 
i
n
t
e
r
e
s
t
s
:
 
T
h
e
 
s
t
u
d
y
 
r
e
c
e
i
v
e
d
 
fi
n
a
n
c
i
a
l
 
s
u
p
p
o
r
t
 
f
r
o
m
 
S
c
h
e
r
i
n
g
–
P
l
o
u
g
h
 
I
n
t
e
r
n
a
t
i
o
n
a
l
 
a
n
d
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
 
R
&
D
.
 
T
h
r
e
e
 
a
u
t
h
o
r
s
 
h
a
v
e
 
s
e
r
v
e
d
 
a
s
 
c
o
n
s
u
l
t
a
n
t
s
 
o
r
 
r
e
c
e
i
v
e
d
 
g
r
a
n
t
s
 
f
r
o
m
 
S
c
h
e
r
i
n
g
–
P
l
o
u
g
h
 
I
n
t
e
r
n
a
t
i
o
n
a
l
 
a
n
d
 
G
l
a
x
o
S
m
i
t
h
K
l
i
n
e
 
a
n
d
 
o
t
h
e
r
 
m
a
j
o
r
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
c
o
m
p
a
n
i
e
s
.
 
T
h
e
 
a
u
t
h
o
r
s
 
s
t
a
t
e
 
t
h
a
t
 
c
o
m
p
a
n
i
e
s
 
p
r
o
v
i
d
i
n
g
 
fi
n
a
n
c
i
a
l
 
s
u
p
p
o
r
t
 
t
o
 
t
h
e
 
F
o
u
n
d
a
t
i
o
n
 
f
o
r
 
L
i
v
e
r
 
R
e
s
e
a
r
c
h
 
(
F
u
n
d
e
r
)
 
a
p
p
r
o
v
e
d
 
t
h
e
 
s
t
u
d
y
 
d
e
s
i
g
n
.
 
T
h
e
y
 
s
t
a
t
e
 
t
h
a
t
 
n
o
 
f
u
n
d
i
n
g
 
s
o
u
r
c
e
 
h
a
d
 
a
n
y
 
r
o
l
e
 
i
n
 
t
h
e
 
c
o
l
l
e
c
t
i
o
n
,
 
m
a
n
a
g
e
m
e
n
t
,
 
a
n
a
l
y
s
i
s
 
o
r
 
i
n
t
e
r
p
r
e
t
a
t
i
o
n
 
o
f
 
t
h
e
 
d
a
t
a
,
 
w
r
i
t
i
n
g
 
o
f
 
t
h
e
 
r
e
p
o
r
t
 
o
r
 
d
e
c
i
s
i
o
n
 
t
o
 
s
u
b
m
i
t
 
f
o
r
 
p
u
b
l
i
c
a
t
i
o
n
.
 
D
a
t
a
 
c
o
l
l
e
c
t
i
o
n
 
a
n
d
 
m
a
n
a
g
e
m
e
n
t
 
w
a
s
 
c
a
r
r
i
e
d
 
o
u
t
 
a
t
 
t
h
e
 
t
r
i
a
l
 
c
o
o
r
d
i
n
a
t
i
n
g
 
c
e
n
t
r
e
 
i
n
 
t
h
e
 
N
e
t
h
e
r
l
a
n
d
s
c
o
n
t
i
n
u
e
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O
t
h
e
r
:
 
B
e
c
a
u
s
e
 
t
h
e
r
e
 
w
a
s
 
n
o
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
s
e
r
i
o
u
s
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
o
r
 
n
e
e
d
 
f
o
r
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
r
 
p
r
e
m
a
t
u
r
e
 
t
r
e
a
t
m
e
n
t
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
,
 
t
h
e
 
d
a
t
a
 
f
o
r
 
t
h
e
 
t
w
o
 
g
r
o
u
p
s
 
w
e
r
e
 
c
o
m
b
i
n
e
d
 
i
n
 
t
h
e
 
p
a
p
e
r
 
o
n
 
s
a
f
e
t
y
D
e
fi
n
i
t
i
o
n
s
:
 
A
L
T
,
 
a
l
a
n
i
n
e
 
a
m
i
n
o
t
r
a
n
s
f
e
r
a
s
e
;
 
B
M
I
,
 
b
o
d
y
 
m
a
s
s
 
i
n
d
e
x
;
 
C
H
B
,
 
c
h
r
o
n
i
c
 
h
e
p
a
t
i
t
i
s
 
B
;
 
E
O
F
-
U
,
 
e
n
d
 
o
f
 
f
o
l
l
o
w
-
u
p
;
 
E
O
T
,
 
e
n
d
 
o
f
 
t
r
e
a
t
m
e
n
t
;
 
H
B
e
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
;
 
H
B
s
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
s
u
r
f
a
c
e
 
a
n
t
i
g
e
n
,
 
H
B
V
 
D
N
A
,
 
h
e
p
a
t
i
t
i
s
 
B
 
v
i
r
u
s
 
D
N
A
;
 
L
A
M
,
 
l
a
m
i
v
u
d
i
n
e
;
 
P
E
G
-
α
-
2
b
,
 
p
e
g
i
n
t
e
r
f
e
r
o
n
 
α
-
2
b
;
 
U
L
N
,
 
u
p
p
e
r
 
l
i
m
i
t
 
o
f
 
n
o
r
m
a
l
A
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
e
r
e
 
g
r
a
d
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
t
h
e
 
W
H
O
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
a
s
 
m
i
l
d
/
m
o
d
e
r
a
t
e
/
s
e
v
e
r
e
/
l
i
f
e
-
t
h
r
e
a
t
e
n
i
n
g
,
 
a
n
d
 
r
e
p
o
r
t
e
d
 
i
n
 
r
e
l
a
t
i
o
n
 
t
o
 
t
h
e
r
a
p
y
 
a
s
 
u
n
r
e
l
a
t
e
d
/
p
o
s
s
i
b
l
y
 
r
e
l
a
t
e
d
/
p
r
o
b
a
b
l
y
 
r
e
l
a
t
e
d
 
o
r
 
r
e
l
a
t
e
d
 
t
o
 
t
h
e
r
a
p
y
.
 
T
h
e
 
e
f
f
e
c
t
 
o
n
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
 
w
a
s
 
n
o
n
e
/
d
o
s
e
 
r
e
d
u
c
t
i
o
n
/
t
r
e
a
t
m
e
n
t
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
.
 
S
e
r
i
o
u
s
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
e
r
e
 
d
e
fi
n
e
d
 
a
s
 
e
v
e
n
t
s
 
r
e
s
u
l
t
i
n
g
 
i
n
 
d
e
a
t
h
,
 
l
i
f
e
-
t
h
r
e
a
t
e
n
i
n
g
,
 
r
e
q
u
i
r
e
/
p
r
o
l
o
n
g
 
p
a
t
i
e
n
t
 
h
o
s
p
i
t
a
l
i
s
a
t
i
o
n
,
 
e
v
e
n
t
s
 
w
h
i
c
h
 
r
e
s
u
l
t
 
i
n
 
p
e
r
s
i
s
t
e
n
t
/
s
i
g
n
i
fi
c
a
n
t
 
d
i
s
a
b
i
l
i
t
y
/
i
n
c
a
p
a
c
i
t
y
,
 
p
r
e
g
n
a
n
c
y
,
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c
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3
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p
 
A
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o
u
p
 
B
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u
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e
 
(
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(
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.
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.
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.
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.
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p
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.
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.
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.
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.
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A
d
v
e
r
s
e
 
e
v
e
n
t
s
D
o
s
e
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
f
o
r
 
a
n
y
 
a
d
v
e
r
s
e
 
e
v
e
n
t
0
4
b
D
o
s
e
 
r
e
d
u
c
t
i
o
n
 
f
o
r
 
a
n
y
 
a
d
v
e
r
s
e
 
e
v
e
n
t
0
0
A
d
v
e
r
s
e
 
e
v
e
n
t
s
 
e
x
p
e
r
i
e
n
c
e
d
c
7
5
%
7
5
%
a
 
D
a
t
a
 
a
r
e
 
n
 
(
%
)
 
o
f
 
p
a
t
i
e
n
t
s
,
 
u
n
l
e
s
s
 
o
t
h
e
r
w
i
s
e
 
i
n
d
i
c
a
t
e
d
.
b
 
T
w
o
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
e
l
e
v
a
t
e
d
 
A
L
T
 
w
i
t
h
 
n
a
u
s
e
a
 
a
n
d
 
v
o
m
i
t
i
n
g
,
 
o
n
e
 
p
a
t
i
e
n
t
 
w
i
t
h
 
e
l
e
v
a
t
e
d
 
A
L
T
 
a
n
d
 
t
o
t
a
l
 
b
i
l
i
r
u
b
i
n
 
l
e
v
e
l
s
,
 
o
n
e
 
p
a
t
i
e
n
t
 
w
i
t
h
 
e
l
e
v
a
t
e
d
 
t
o
t
a
l
 
b
i
l
i
r
u
b
i
n
 
l
e
v
e
l
s
.
c
 
V
a
r
i
o
u
s
 
c
l
i
n
i
c
a
l
 
f
o
r
m
s
 
o
f
 
d
r
u
g
-
r
e
l
a
t
e
d
 
a
d
v
e
r
s
e
 
e
f
f
e
c
t
s
,
 
fl
u
-
l
i
k
e
 
s
y
m
p
t
o
m
s
 
a
n
d
 
f
e
v
e
r
 
w
e
r
e
 
t
h
e
 
m
o
s
t
 
c
o
m
m
o
n
.
A
d
d
i
t
i
o
n
a
l
 
r
e
s
u
l
t
s
:
 
R
e
s
u
l
t
s
 
w
e
r
e
 
a
l
s
o
 
p
r
e
s
e
n
t
e
d
 
f
o
r
 
H
B
V
 
g
e
n
o
t
y
p
e
-
a
s
s
o
c
i
a
t
e
d
 
r
e
s
p
o
n
s
e
,
 
a
n
d
 
p
r
e
d
i
c
t
i
v
e
 
f
a
c
t
o
r
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
s
u
s
t
a
i
n
e
d
 
c
o
m
b
i
n
e
d
 
r
e
s
p
o
n
s
e
R
a
t
e
s
 
o
f
 
s
u
s
t
a
i
n
e
d
 
c
o
m
b
i
n
e
d
 
r
e
s
p
o
n
s
e
,
 
H
B
e
A
g
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
 
a
n
d
 
A
L
T
 
n
o
r
m
a
l
i
s
a
t
i
o
n
 
w
e
r
e
 
s
i
m
i
l
a
r
 
f
o
r
 
b
o
t
h
 
t
r
e
a
t
m
e
n
t
 
a
r
m
s
 
a
t
 
E
O
T
 
(
d
a
t
a
 
n
o
t
 
s
h
o
w
n
)
T
w
o
 
p
a
t
i
e
n
t
s
 
(
G
r
o
u
p
 
B
)
 
s
e
r
o
c
o
n
v
e
r
t
e
d
 
a
f
t
e
r
 
2
4
 
w
e
e
k
s
;
 
t
h
i
s
 
w
a
s
 
m
a
i
n
t
a
i
n
e
d
 
t
o
 
t
h
e
 
4
8
-
w
e
e
k
 
f
o
l
l
o
w
-
u
p
7
5
%
 
o
f
 
p
a
t
i
e
n
t
s
 
i
n
 
e
a
c
h
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
 
e
x
p
e
r
i
e
n
c
e
d
 
v
a
r
i
o
u
s
 
c
l
i
n
i
c
a
l
 
f
o
r
m
s
 
o
f
 
d
r
u
g
-
r
e
l
a
t
e
d
 
a
d
v
e
r
s
e
 
e
f
f
e
c
t
s
.
 
F
l
u
-
l
i
k
e
 
s
y
m
p
t
o
m
s
 
a
n
d
 
f
e
v
e
r
 
w
e
r
e
 
t
h
e
 
m
o
s
t
 
c
o
m
m
o
n
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
M
e
t
h
o
d
o
l
o
g
i
c
a
l
 
c
o
m
m
e
n
t
s
A
l
l
o
c
a
t
i
o
n
 
t
o
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
A
 
c
e
n
t
r
a
l
 
c
o
m
p
u
t
e
r
i
s
e
d
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
m
e
t
h
o
d
 
w
a
s
 
u
s
e
d
 
o
n
 
a
 
r
a
t
i
o
 
o
f
 
1
:
1
A
l
l
o
c
a
t
i
o
n
 
c
o
n
c
e
a
l
m
e
n
t
:
 
N
o
 
d
e
t
a
i
l
s
 
r
e
p
o
r
t
e
d
B
l
i
n
d
i
n
g
 
o
f
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
:
 
B
i
o
c
h
e
m
i
c
a
l
 
a
n
d
 
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
l
a
b
 
a
s
s
a
y
s
 
w
e
r
e
 
p
e
r
f
o
r
m
e
d
 
i
n
-
h
o
u
s
e
 
a
t
 
t
h
e
 
p
a
r
t
i
c
i
p
a
t
i
n
g
 
c
e
n
t
r
e
s
.
 
I
n
v
e
s
t
i
g
a
t
o
r
s
 
a
s
s
e
s
s
i
n
g
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
w
e
r
e
 
n
o
t
 
b
l
i
n
d
e
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
a
s
 
t
h
e
y
 
w
e
r
e
 
a
b
l
e
 
t
o
 
r
e
d
u
c
e
 
t
h
e
 
P
E
G
 
o
r
 
I
F
N
 
d
o
s
e
 
a
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o
r
d
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n
g
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a
d
v
e
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e
 
e
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e
n
t
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x
p
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r
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e
n
c
e
d
.
 
N
o
 
i
n
f
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r
m
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i
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n
 
r
e
p
o
r
t
e
d
 
r
e
g
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r
d
i
n
g
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h
e
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s
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e
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o
f
 
t
h
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h
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p
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b
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e
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b
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w
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.
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i
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b
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p
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p
r
e
v
i
o
u
s
l
y
 
r
e
c
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c
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.
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p
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i
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(
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b
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e
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o
n
t
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n
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o
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s
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a
r
i
a
b
l
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w
e
r
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c
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p
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f
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t
a
 
w
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a
r
s
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c
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w
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o
c
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.
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t
w
o
-
w
a
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a
l
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v
a
r
i
a
n
c
e
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w
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m
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t
,
 
c
e
n
t
r
e
 
a
n
d
 
t
r
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a
t
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t
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c
e
n
t
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e
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c
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w
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m
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c
h
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n
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H
B
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D
N
A
 
l
e
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r
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b
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e
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w
e
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b
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e
e
n
 
t
h
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g
r
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u
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s
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T
h
e
 
i
n
c
i
d
e
n
c
e
 
o
f
 
a
d
v
e
r
s
e
 
e
f
f
e
c
t
s
 
w
a
s
 
c
o
m
p
a
r
e
d
 
b
e
t
w
e
e
n
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
u
s
i
n
g
 
C
o
c
h
r
a
n
–
M
a
n
t
e
l
–
H
a
e
n
s
z
e
l
 
s
t
a
t
i
s
t
i
c
s
,
 
c
o
n
t
r
o
l
l
i
n
g
 
f
o
r
 
c
e
n
t
r
e
 
(
p
 
<
 
0
.
0
5
 
w
a
s
 
c
o
n
s
i
d
e
r
e
d
 
t
o
 
b
e
 
s
i
g
n
i
fi
c
a
n
t
)
P
o
w
e
r
 
a
n
a
l
y
s
i
s
:
 
N
o
t
 
r
e
p
o
r
t
e
d
A
t
t
r
i
t
i
o
n
/
d
r
o
p
-
o
u
t
:
 
D
r
o
p
-
o
u
t
s
 
w
e
r
e
 
r
e
p
o
r
t
e
d
 
a
t
 
e
a
c
h
 
s
t
a
g
e
 
i
n
 
a
 
fl
o
w
-
c
h
a
r
t
.
 
R
e
a
s
o
n
s
 
w
e
r
e
 
g
i
v
e
n
 
f
o
r
 
f
o
u
r
 
(
G
r
o
u
p
 
B
)
 
w
h
o
 
d
i
s
c
o
n
t
i
n
u
e
d
 
b
e
c
a
u
s
e
 
o
f
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
;
 
t
w
o
 
o
t
h
e
r
s
 
(
G
r
o
u
p
 
B
)
 
d
i
s
c
o
n
t
i
n
u
e
d
 
f
o
r
 
n
o
n
-
s
t
u
d
y
 
r
e
a
s
o
n
s
.
 
R
e
a
s
o
n
s
 
f
o
r
 
l
o
s
s
 
t
o
 
f
o
l
l
o
w
-
u
p
 
w
e
r
e
 
n
o
t
 
g
i
v
e
n
.
 
C
o
m
p
l
e
t
e
d
 
t
r
e
a
t
m
e
n
t
:
 
G
r
o
u
p
 
A
,
 
1
1
5
;
 
G
r
o
u
p
 
B
,
 
1
0
9
.
 
C
o
m
p
l
e
t
e
d
 
f
o
l
l
o
w
-
u
p
:
 
G
r
o
u
p
 
A
,
 
1
0
8
;
 
G
r
o
u
p
 
B
,
 
9
5
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G
e
n
e
r
a
l
 
c
o
m
m
e
n
t
s
G
e
n
e
r
a
l
i
s
a
b
i
l
i
t
y
:
 
C
h
i
n
e
s
e
 
p
a
t
i
e
n
t
s
,
 
H
B
e
A
g
 
a
n
d
 
H
B
s
A
g
 
p
o
s
i
t
i
v
e
,
 
p
r
e
v
i
o
u
s
 
I
F
N
 
t
h
e
r
a
p
y
,
 
n
e
a
r
l
y
 
t
h
r
e
e
-
q
u
a
r
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Appendix 2  
QUOROM flow chart of study inclusion 
(2007 update literature search)
FIGURE 6  QUORUM flow chart. Note: An additional PEG-α-2b study, published in 2005, was identified from the Reference Manager 
database used in our previous assessment report (although it was not actually included in that report). Therefore, the total number of 
PEG-α-2b included studies in the current report was five, and the total number of studies included in the review was eight.
Potentially relevant
papers identified
n = 735
Papers excluded on title
and abstract n = 653:
  • not Hep B (n = 179)
  • not RCT (n = 400)
  • wrong intervention (n = 68)
  • wrong outcome measure (n = 6)
Papers excluded n = 65:
  • not Hep B (n = 2)
  • not RCT (n = 47)
  • irrelevant intervention (n = 5)
  • irrelevant outcome measure (n = 1)
  • conference abstract (n = 10)
Papers retrieved for
more detailed
evaluation
n = 82
Papers included
n = 17
(reporting 8 studies)
• ADV n = 3 studies
 • PEG-α-2b n = 5* studiesDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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S
even fully published RCTs were included in our 
original report:
•	 Four evaluated ADV. In two studies ADV was 
compared with placebo.21,65 (A publication 
reporting long-term follow-up of one of these 
trials was identified by our update search.20 
In the other two studies, ADV, either as 
monotherapy or in combination with LAM, was 
compared with LAM monotherapy in patients 
with LAM resistance.66,67
•	 Three evaluated PEG-α-2a. In two studies, 
the combination of PEG-α-2a and LAM was 
Appendix 3  
Characteristics of RCTs included 
in original assessment report
compared with both agents separately (the 
difference being that one study included 
HBeAg-positive patients, the other HBeAg-
negative patients).50,76 The third study 
compared PEG-α-2a with IFN-α.77
Table 41 provides a general overview of the RCTs 
included in the original systematic review. For 
further detail on the study characteristics and 
results, please consult the original report.12 The 
remainder of the current report focuses on studies 
included from the updated literature search.
TABLE 41  Overview of RCTs included in original systematic review
Study
HBeAg 
status
No. of participants, 
duration of trial (Td), 
additional follow-up (Fd) 
and total duration  Arm 1 Arm 2 Arm 3 Arm 4
ADV studies
Hadziyannis et al., 
200321
Study 438
Negative n = 185
Td = 48 weeksa
Fd = 0 weeks
Total = 48 weeks
ADV 10 mg/
day (n = 123)
Placebo 
(n = 62)
Marcellin et al., 
200365
Study 437
Positive n = 515
Td = 48 weeksb
Fd = 0 weeks
Total = 48 weeks
ADV 10 mg/
day (n = 172)
ADV 30 mg/
day (n = 173)
Placebo 
(n = 170)
Perrillo et al., 
200466
Study 465
Positive n =  95
Td = 52 weeksc
Fd = 0 weeks
Total = 52 weeks
LAM 100 mg/
day + ADV 
10 mg/day 
(n = 46)
LAM 100 mg/
day + 
placebo 
(n = 49)
Peters et al., 200467
Study 461
Positive n =  59
Td = 48 weeks
Fd = 0 weeks
Total = 48 weeks
ADV 10 mg/
day + 
placebo 
(n = 19)
ADV 10 mg/
day + LAM 
100 mg/day 
(n = 20)
LAM 
100 mg/
day + 
placebo 
(n = 19)
Sung et al., 200378 Positive n = 115
Td = 52 weeksd
Fd = 0 weeks
Total = 52 weeks
LAM 100 mg/
day + ADV 
10 mg/day 
(n = 55)
LAM 100 mg/
day + 
placebo 
(n = 57)
continuedAppendix 3
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Study
HBeAg 
status
No. of participants, 
duration of trial (Td), 
additional follow-up (Fd) 
and total duration  Arm 1 Arm 2 Arm 3 Arm 4
PEG-α-2b studies
Marcellin et al., 
200476
Study 241
Negative n =  552 (of whom 
537 were included 
in analyses)
Td = 48 weeks
Fd = 24 weeks
Total =  72 weeks
PEG 180 μg/week + 
placebo (n = 177)
PEG 180 μg/
week + LAM 
100 mg/day 
(n = 179)
LAM 
100 mg/
day 
(n = 181)
Cooksley et al., 
200377
Study 037
Positive n = 194
Td = 24 weeks
Fd = 24 weeks
Total = 48 weeks
IFN 4.5 MIU three 
times/week (n = 51)
PEG 90 μg/
week (n = 49)
PEG 
180 μg/
week 
(n = 46)
PEG 270 μg/
week 
(n = 48)
Lau et al., 200550
Study 240
Positive n = 814
Td = 48 weeks
Fd = 24 weeks
Total =  72 weeks
PEG 180 μg/week + 
placebo/day (n = 271)
PEG 180 μg 
once weekly 
+ LAM 
100 mg 
once daily 
(n = 271)
LAM 
100 mg 
once daily 
(n = 272)
MIU, million international units.
a  After 48 weeks, patients in the ADV group were re-randomised to receive placebo for 48 weeks, or 10 mg ADV for 192 
weeks. Patients in the placebo group received 10 mg ADV for a further 192 weeks. Study due to end June 2005, when 
patients will have received 5 years of treatment.
b  After 48 weeks, patients were reassigned so that the 30 mg ADV group received placebo, the 10 mg ADV group were 
re-randomised to receive either 10 mg ADV or placebo, and the placebo group received 10 mg ADV. After July 2001, the 
double-blind phase of the study was terminated and all groups were assigned to receive 10 mg ADV (open-label) up to 
March 2005, when patients will have received 5 years of treatment.
c  78 patients continued to receive treatment for a further 2 years (Study 493). Study is ongoing.
d  Study continued for a further 52 weeks.
TABLE 41  Overview of RCTs included in original systematic review (continued)DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Reference
Veenstra and colleagues (2007) Cost-effectiveness 
of peginterferon alpha-2a compared with 
lamivudine treatment in patients with HBe-
antigen-positive chronic hepatitis B in the United 
Kingdom.44
Study characteristics
Research question
What are the stated objectives of the evaluation?
•	 To assess the net health consequences, costs, 
and cost-effectiveness of peginterferon 
alpha-2a (40 kDa) for treatment of patients 
with HBeAg-positive CHB, compared with 
lamivudine treatment (p. 632).
Study population
What definition was used for chronic hepatitis B?
•	 The cohort was defined as those with a 
histological diagnosis of CHB, HBeAg +ve for 
more than 6 months, and detectable HBV DNA 
> 500,000 copies/ml.
What are the characteristics of the baseline cohort 
for the evaluation?
Age 32-year-old patients 
Sex 78% male
Race (if appropriate) 87% Asian
Genotype Not specified
Other characteristics Characteristics of the cohort 
were based on patient 
population (n = 542) enrolled 
in a clinical trial (Lau et al.50). 
100% HBeAg+ve
17% with compensated 
cirrhosis or transition to 
cirrhosis
Mean baseline ALT was 110.6 
U/l (> 2 × ULN)
Interventions and comparators
What number of interventions/strategies were 
included?
•	 Two.
Appendix 4  
Data extraction forms – economic evaluations
Was a no treatment/supportive care strategy 
included?
•	 No.
Describe interventions/strategies:
•	 Intervention/strategy 1: PEG-α-2a 180 mg daily 
monotherapy for 48 weeks
•	 Intervention/strategy 2: lamivudine 100 mg 
daily monotherapy up to a maximum of 
4 years or until patients achieve HBeAg 
seroconversion.
Analytical perspective
What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)?
•	 UK NHS perspective.
Study type
Cost-effectiveness/cost-utility/cost-benefit analysis?
•	 CEA (incremental cost per additional life-year 
saved)
•	 CUA (incremental cost per QALY).
Institutional setting
Where is/are the intervention(s) being evaluated 
usually provided?
•	 Not identified. PEG-α-2a is administered 
intravenously, so for some patients the 
treatment may be provided at the institutional 
setting. LAM is an oral medication and can be 
self-administered.
Country/currency
Has a country setting been provided for the 
evaluation? What currency are costs expressed 
in and does the publication give the base year to 
which those costs relate?
•	 Currency is £ sterling in 2005. (Table 2, p. 
635).Appendix 4
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Data sources
Effectiveness
Were the effectiveness data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
Effectiveness data 
at 48 weeks of 
treatment were 
derived from a single 
study
 Lau GK, Piratvisuth T, 
Luo KX, Marcellin P , 
Thongsawat S, Cooksley 
G, et al. Peginterferon alfa-
2a, lamivudine, and the 
combination for HBeAg-
positive chronic hepatitis B. N 
Engl J Med 2005;352:2682–95
Long-term 
effectiveness data 
(seronversion, 
relapse and 
lamivudine resistance 
rates at 2-4 years,) 
were derived from 
combination of 
previous follow-up 
studies
 Non-controlled studies
Liaw YF, Leung NW, Chang 
TT, Guan R, Tai DI, Ng KY, 
et al. Effects of extended 
lamivudine therapy in Asian 
patients with chronic hepatitis 
B. Asia Hepatitis Lamivudine 
Study Group. Gastroenterology 
2000;119:172–80.
Leung NW, Lai CL, Chang 
TT, Guan R, Lee CM, Ng KY, 
et al. Extended lamivudine 
treatment in patients with 
chronic hepatitis B enhances 
hepatitis B e antigen 
seroconversion rates: results 
after 3 years of therapy. 
Hepatology 2001;33:1527–32
Lok AS, Lai CL, Leung N, 
Yao GB, Cui ZY, Schiff ER, 
et al. Long-term safety 
of lamivudine treatment 
in patients with chronic 
hepatitis B. Gastroenterology 
2003;125:1714–22
Expert opinion ×
Give the definition of treatment effect used in the 
evaluation.
•	 Primary treatment effect (p. 633, also one of 
two primary outcomes in the pivotal clinical 
trial)
  – % of patients achieving seroconversion 
(transitioning from CHB state to 
seroconversion state). This can occur 
spontaneously or as a result of treatment.
•	 In addition the following outcomes are used
  – percentage of patients relapsing 
(transitioning from seroconversion state 
back to CHB state). Can occur on an 
annual basis (yet different rates apply 
at 6 months after the treatment and the 
subsequent intervals)
  – percentage of lamivudine patients 
developing resistance (used in the scenario 
analysis)
  – percentage of patients with AEs (from Lau 
and colleagues50).
Give the size of treatment effect used in the 
evaluation.
•	 Not applicable. Serocoversion, relapse and 
resistance are composite, qualitative measures 
of outcome.
Include values used for subgroups (if applicable). 
Indicate the source for individual treatment effects (if 
appropriate).
Intervention costs
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single clinical trial 
used to estimate 
the proportion of 
patients with AEs
 Lau GK, Piratvisuth T, 
Luo KX, Marcellin P , 
Thongsawat S, Cooksley 
G, et al. Peginterferon alfa-
2a, lamivudine, and the 
combination for HBeAg-
positive chronic hepatitis B. N 
Engl J Med 2005;352:2682–95
A review/synthesis 
or combination of 
previous studies is 
used for health-state 
costs
 Produced in
Shepherd J, Jones J, Takeda 
A, Davidson P , Price A. 
Adefovir dipivoxil and pegylated 
interferon alfa-2a for the 
treatment of chronic hepatitis 
B: a systematic review 
and economic evaluation. 
Southampton Health 
Technology Assessments 
Centre (SHTAC); 2005
Bennett WG, Inoue Y, Beck 
JR,Wong JB, Pauker SG, 
Davis GL. Estimates of the 
cost-effectiveness of a single 
course of interferon-alpha 2b 
in patients with histologically 
mild chronic hepatitis C. Ann 
Intern Med 1997;127: 855–65.
Expert opinion 
estimates of 
resources used to 
treat AE associated 
with PEG-α-2a 
treatment
DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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List the direct intervention costs used in the evaluation – include resource estimates (and sources for these 
estimates, if appropriate) as well as sources for unit costs used.
Resource category Type of resources Unit cost estimate Source
Drug costs (weekly) PEG-α-2a 180 mg £132 BNF
LAM 100 mg £20
Health state
Total annual management 
cost Source
Health-state costs 
(range)
Seroconversion £267 (200–334) Shepherd J, Jones J, Takeda A, Davidson 
P , Price A. Adefovir dipivoxil and pegylated 
interferon alfa-2a for the treatment of chronic 
hepatitis B: a systematic review and economic 
evaluation. Southampton Health Technology 
Assessments Centre (SHTAC); 2005
Bennett WG, Inoue Y, Beck JR,Wong JB, 
Pauker SG, Davis GL. Estimates of the cost-
effectiveness of a single course of interferon-
alpha 2b in patients with histologically 
mild chronic hepatitis C. Ann Intern Med 
1997;127:855–65
Chronic hepatitis B £537 (403–671)
Compensated cirrhosis £1138 (854–1422)
Decompensated 
cirrhosis
£9120 (6840–11,400)
Hepatocellular 
carcinoma
£8127 (6095–10,159)
Liver transplantation £36,788.00 (27,561–45,985)
Post-liver transplant £1385 (1039–1731)
Average costs of 
treating side effects 
per patient per year 
of treatment
Not elaborated Unit costs are not presented
PEG-α-2a £6.48
LAM £2.04
BNF unit costs are used for each component 
of treatment of AE
Other direct costs (used 
in scenario analysis)
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) 
study
 Incidence of lamivudine 
resistance 26%/year (Lok AS, 
Lai CL, Leung N, Yao GB, Cui 
ZY, Schiff ER, et al. Long-term 
safety of lamivudine treatment 
in patients with chronic 
hepatitis B. Gastroenterology 
2003;125:1714–22
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used.
•	 The cost of ADV used in the LAM arm as a 
salvage therapy for the patients who developed 
resistance (£73.50 per week).
Indicate the source for individual cost values (if 
appropriate).
Indirect costs (due to lost productivity, 
unpaid inputs to patient care)
Were indirect costs included?
•	 Not applicable.
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued).
•	 Not applicable.
Indicate the source for individual cost values (if 
appropriate).Appendix 4
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Health-state valuations/utilities 
(if study uses quality of life 
adjustments to outcomes)
Were the utility data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
×
A review/synthesis 
or combination of 
previous studies
 Wong JB, Koff RS, Tine F, 
Pauker SG. Cost-effectiveness 
of interferon-alpha 2b 
treatment for hepatitis B 
e antigen-positive chronic 
hepatitis B. Ann Intern Med 
1995;122:664–75
Bennett WG, Inoue Y, Beck 
JR,Wong JB, Pauker SG, 
Davis GL. Estimates of the 
cost-effectiveness of a single 
course of interferon-alpha 2b 
in patients with histologically 
mild chronic hepatitis C. Ann 
Intern Med 1997;127:855–65
Kind P , Hardman G, Macran 
S. UK population norms for 
EQ-5D. CHE Discussion Paper 
172. York: York Centre for 
Health Economics, University 
of York; 1999
Expert opinion ×
List the utility values used in the evaluation.
Seroconversion
UK age-specific utility 
(± 20%)
Chronic hepatitis B 0.87 (0.89–0.97)
Compensated cirrhosis 0.84 (0.82–0.86)
Decompensated cirrhosis 0.46 (0.36–0.56)
Hepatocellular carcinoma 0.41 (0.31–0.51)
Liver transplantation 0.42 (0.32–0.52)
Post-liver transplant 0.62 (0.52–0.72)
An absolute decrease in utility of 0.05 to PEG-α-2a arm 
compared with lamivudine arm was used (Wong JB, Koff RS, 
Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b 
treatment for hepatitis B e antigen-positive chronic hepatitis 
B. Ann Intern Med 1995;122:664–75). 
Indicate the source for individual cost values (if 
appropriate).
Modelling
If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation).
•	 Markov state-transition model.
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original.
•	 Model structure was similar to previously 
published models by Crowley,42 Crowley and 
colleagues43 and Pwu and Chan,49 except that 
Crowley and colleagues did not include health 
states to account for patients receiving a liver 
transplant.
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?
•	 Not explained, but presumably to estimate 
long-term costs and benefits (expressed 
in terms of final rather than intermediate 
outcomes) beyond the timeframe of the clinical 
trial (48-week treatment).
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.
•	 HBeAg seroconversion, HBeAg-positive 
CHB, compensated cirrhosis, decompensated DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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cirrhosis, HCC, liver transplantation, post-liver 
transplantation, and death.
Extract transition probabilities for [natural history/
disease progression] model and show sources (refer 
to Table 1, p. 634).
Disease state 
from To % (range)
Chronic 
hepatitis B
Seroconversion, year 
1, peginterferon a-2a 
(40 kDa)
32.0 (30.0–34.0)
Seroconversion, year 1, 
lamivudine
19.0 (17.0–21.0)
Seroconversion, year 2, 
lamivudine
10.0 (9.5–11.0) 
Seroconversion, year 3, 
lamivudine
6.0 (3.0–9.0) 
Seroconversion, year 4, 
lamivudine
5.0 (2.5–7.5) 
Seroconversion, 
spontaneous
9.0 (6.0–12.0) 
Compensated cirrhosis 6.0 (4.0–8.0) 
Hepatocellular 
carcinoma
0.40 (0.10–0.70)
HBeAg 
seroconversion
Chronic hepatitis B, 
year 5, lamivudine
25.0 (20.0–30.0)
Chronic hepatitis B, 
year 2, peginterferon 
a-2a (40 kDa)
8.0 (3.0–13.0)
Chronic hepatitis B, 
spontaneous relapse
2.9 (1.0–5.0)
Compensated cirrhosis 1.0 (0.5–2.0)
Compensated 
cirrhosis
Decompensated 
cirrhosis
5.0 (3.8–9.5) 
Death 5.0 (3.0–6.5)
Decompensated 
cirrhosis
Hepatocellular 
carcinoma
2.5 (2.0–7.8)
Liver transplantation 3.1 (1.0–10.0)
Death 39.0 (30.0–50.0)
Hepatocellular 
carcinoma
Death 56 (45.0–65.0)
Liver transplantation Not reported
Liver 
transplantation
Post-liver 
transplantation
79.0 (tunnel 
state)
Death 21.0 (15.0–25.0)
Post-liver 
transplant
Death 5.7 (3.0–9.0)
What is the model time horizon? Duration of the 
cycle?
•	 12-month cycle, lifetime duration (not 
specified).
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes?
•	 All costs were discounted at a 6% annual 
rate and outcomes (e.g. QALYs) at 1.5%, in 
accordance with UK guidelines at the time of 
this analysis.
Results/analysis
What measure(s) of benefit were reported in the 
evaluation?
•	 Life-years (LYs), quality-adjusted life years 
(QALYs).
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation.
•	 Treatment with PEG-α-2a compared with 
treatment with LAM is associated with:
•	 Additional discounted life expectancy of 0.39 
and additional quality-adjusted life expectancy 
of 0.30 years.
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.
•	 Lifetime (discounted) costs associated with 
treatment
•	 PEG-α-2a £14,900 per patient
•	 LAM £11,800 per patient.
Synthesis of costs and benefits –are the costs 
and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of 
the results.
•	 The comparative performance of alternative 
treatment strategies was measured by the 
ICER, defined as the additional cost of a 
specific strategy, divided by its additional 
clinical benefit, compared with the next least 
expensive strategy.
•	 Discounted ICER is equal to £7949 (£8000) per 
LY gained.
•	 Discounted ICER is equal to £10,333 (£10,400) 
per QALY gained.Appendix 4
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Give results of any statistical analysis of the results 
of the evaluation.
•	 The cost-effectiveness acceptability curve 
generated from the probabilistic sensitivity 
analysis indicated that there was a greater 
than 95% probability that PEG-α-2a was cost-
effective compared with lamivudine at the 
£30,000 per QALY threshold (95% central 
range of results, £6000–£26,500 per QALY 
gained).
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic]?
•	 One-way and probabilistic sensitivity analyses 
were performed.
•	 ICERs were most sensitive to variation in the 
probability of:
  – developing compensated cirrhosis from 
CHB
  – PEG-α-2a seroconversion rate as observed 
in the clinical trial (Lau and colleagues50)
  – relapse after 4 years of lamivudine 
treatment (i.e. from year 5 on)
  – the probability of developing compensated 
cirrhosis from the seroconversion state.
•	 The ICER for PEGα-2a compared with 
lamivudine monotherapy ranged from 
£8300 to £15,400 per QALY when treatment 
efficacy, drug cost, the health state-transition 
probabilities, utility values and health-state cost 
estimates were varied.
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?
•	 A scenario analysis in which ADV salvage 
treatment was used for lamivudine-resistant 
patients was provided.
•	 Annual seroconversion rates and drug costs 
for lamivudine-treated patients were modified 
based on the proportion of patients (26%, Lok 
and colleagues53), with resistance each year 
rather than explicitly including a resistance 
health state.
•	 The increase in the HBeAg seroconversion rate 
for resistant patients who received ADV salvage 
therapy was obtained from a randomised 
controlled trial of ADV–lamivudine 
combination therapy versus lamivudine 
monotherapy in lamivudine-resistant patients 
(Perrillo and colleagues66) (8% versus 3% 
HBeAg seroconversion at end of 1 year of 
treatment respectively).
•	 Not relevant to structural uncertainty (no new 
state was added) or methodological uncertainty. 
Transition probabilities (parameters of the 
model) were altered.
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis. If so, what were the suggested 
causes?
•	 Treatment with PEG-α-2a compared with 
treatment with LAM and ADV salvage therapy 
is associated with:
  – additional discounted life expectancy of 
0.33 and (versus 0.39 in the base-case 
analysis)
  – additional quality-adjusted life expectancy 
of 0.14 years (versus 0.30 in the base-case 
analysis)
  – the lifetime difference in cost between 
treatments with PEG-α-2a and LAM has 
decreased from £3100 to £875.
•	 The scenario analysis results are:
  – discounted ICER is equal to £2652 per LY 
gained
  – discounted ICER is equal to £6250 not 
(£6100 as reported) per QALY gained.
Conclusions/implications
Give a brief summary of the author’s conclusions 
from their analysis.
•	 Authors suggest that use of PEG-α-2a is 
highly likely to be cost-effective, given certain 
assumptions about disease progression 
and the efficacy and cost of therapy. The 
ICERs were most sensitive to variation in 
the probability of developing compensated 
cirrhosis from CHB, PEG-α-2a seroconversion 
rate, lamivudine treatment durability and 
the probability of developing compensated 
cirrhosis from seroconversion. However, when 
these parameters were varied over a range 
of estimates using one-way and multiway 
sensitivity analyses, the ICER did not exceed 
the £30,000/QALY threshold.
What are the implications of the evaluation for 
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PEG-α-2a is likely to be cost-effective in treatment 
of HBeAg +ve patients who do not develop HBeAg 
–ve disease variant.
  – Uncertainty in relation to applicability of 
the outcomes to HBeAg –ve patients (a 
shortcoming of the study is an exclusion of 
HBeAg –ve state in disease progression).
  – Uncertainty in relation to generalisability 
of the results to England and Wales 
population (87% Asian in the modelled 
cohort, although UK life tables are used). 
In particular, seroconversion rates used in 
years 2–4 are low in comparison to the rate 
reported elsewhere [27–35% at 2 years and 
40% at 3 years (Shepherd and colleagues12, 
Crowley42)].
  – Uncertainty associated with terminating 
LAM maintenance (and hence HBV DNA 
suppression) after 4 years. In particular, 
applying transition probabilities beyond 
4 years of lamivudine treatment. A 25% 
annual relapse rate appears to be a 
conservative estimate in comparison with 
the 35% rate reported in the literature; this 
is five times the rate observed in year 4. 
This may bias the result in favour of PEG-
α-2a.
•	 Although scenario analysis more closely 
approximates the real clinical practice, 
no probabilistic sensitivity analysis was 
performed with respect to parameter estimates 
(seroconversion rates observed in LAM/ADV 
treatment versus LAM monotherapy).
Reference
Sullivan and colleagues (2007) Cost-effectiveness 
of peginterferon alfa-2a compared to lamivudine 
treatment in patients with hepatitis B e antigen 
positive chronic hepatitis B in Taiwan.45 
Study characteristics
Research question
What are the stated objectives of the evaluation?
•	 The objective of our study was to assess the 
net health consequences, costs and cost-
effectiveness of 48 weeks of peginterferon 
alfa-2a for treatment of patients with HBeAg-
positive CHB, compared with 48 weeks of 
lamivudine treatment.
Study population
What definition was used for mild chronic hepatitis 
B?
•	 The hypothetical cohort of patients was based 
on the clinical and demographic characteristics 
of patients in the Lau and colleagues (2005) 
clinical trial.50 The cohort was defined as 
those with a histological diagnosis of CHB, 
HBsAg-positive for more than 6 months, and 
detectable HBV DNA > 500,000 copies/ml.
What are the characteristics of the baseline cohort 
for the evaluation?
Age 32-year-old patients 
Sex 78% male
Race (if appropriate) 87% Asian
Genotype Not specified
Other characteristics Characteristics of the cohort were 
based on the patient population 
(n = 542) enrolled in a clinical 
trial (Lau et al., 200550). 100% 
HBeAg+ve
17% with compensated cirrhosis or 
transition to cirrhosis
Mean baseline ALT was 110.6 U/l 
(> 2 × ULN)
Interventions and comparators
What number of interventions/strategies were 
included?
•	 Two
Was a no treatment/supportive care strategy 
included?
•	 No
Describe interventions/strategies.
•	 Intervention/strategy 1: PEG-α-2a 180 mg daily 
monotherapy for 48 weeks
•	 Intervention/strategy 2: Lamivudine 100 mg 
daily monotherapy for 48 weeks.
Analytical perspective
What is the perspective adopted for the evaluation 
[health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)]?
•	 Taiwan Bureau of National Health Insurance.
Study type
Cost-effectiveness/cost-utility/cost-benefit analysis?
•	 CEA (incremental cost per additional life-year 
saved)Appendix 4
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•	 CUA (incremental cost per QALY).
Institutional setting
Where is/are the intervention(s) being evaluated 
usually provided?
•	 Not identified. PEG-α-2a is administered 
intravenously, so for some patients, the 
treatment may be provided at the institutional 
setting. LAM is an oral medication and can be 
self-administered.
Country/currency
Has a country setting been provided for the 
evaluation? What currency are costs expressed 
in and does the publication give the base year to 
which those costs relate?
•	 The costs are initially expressed in NTD; the 
outcomes are also converted into US$. The 
base year to which all costs are related is not 
indicated, but unit costs for medical procedures 
and intervention medications were expressed 
in NTD as at 2004.
Data sources
Effectiveness
Were the effectiveness data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
Effectiveness data 
at 48 weeks of 
treatment were 
derived from a single 
study
 Lau GK, Piratvisuth T, 
Luo KX, Marcellin P , 
Thongsawat S, Cooksley 
G, et al. Peginterferon alfa-
2a, lamivudine, and the 
combination for HBeAg-
positive chronic hepatitis B. N 
Engl J Med 2005;352:2682–95.
A review/synthesis 
or combination of 
previous studies
 Lok et al., 198783
Crowley, 200042
Pwu and Chan, 200249
van Nunen et al., 200380
Wang et al., 200454
Liaw et al., 1988,79 1986,84 
198987
Lau et al., 199786
Expert opinion  The data selected for use in 
the model were validated 
by eight clinical hepatology 
experts in Taiwan
Give the definition of treatment effect used in the 
evaluation.
•	 Primary treatment effect (p. 633, also one of 
two primary outcomes in the pivotal clinical 
trial) – percentage of patients achieving 
seroconversion (transitioning from CHB 
state to seroconversion state). This can occur 
spontaneously or as a result of treatment.
•	 In addition the following outcome is used:
•	 percentage of patients relapsing (transitioning 
from seroconversion state back to CHB 
state). Can occur first at year 2 (p. 1495). 
The paper did not report the probability of 
relapsing at year 2. After year 3 all patients 
could experience spontaneous seroconversion 
or relapse on an annual basis (Lok and 
colleagues,83)
Give the size of treatment effect used in the 
evaluation.
•	 Not applicable. Seroconversion and relapse are 
composite, qualitative measures of outcome.
Include values used for subgroups (if applicable). 
Indicate the source for individual treatment effects (if 
appropriate).
Intervention costs
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
Cost of HCC was 
obtained from a 
single study
 Wang JD. Estimation of life 
years lost and financial burden 
of major cancer in Taiwan. 
Taipei: Australia–Taiwan 
Clinical Trial Symposium, 
20–21 November 2004
A review/synthesis 
or combination of 
previous studies 
and the Taiwanese 
Government sources
 Liver transplantation costs 
were estimated based on 
the cost of a liver transplant 
surgical procedure and 
treatment costs to avoid 
infections in a Taiwanese 
hospital
Expert opinion  The costs for the disease 
states of CHB, compensated 
cirrhosis and decompensated 
cirrhosis were based on the 
medical resource use reported 
by treating cliniciansDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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List the direct intervention costs used in the evaluation – include resource estimates (and sources for these 
estimates, if appropriate) as well as sources for unit costs used.
Resource category Type of resources
Cost estimate for the overall 
treatment period of 48 weeks Source
Drug acquisition costs PEG-α-2a 180 mg daily NTD203,616 BNHI 2004 Reference List 
for Drugs
LAM 100 mg daily NTD30,912
Health state
Total annual management cost 
(NTD) Source
Health-state costs Seroconversion Not reported (assumed to be zero?) Unit costs from BNHI 2004 
Fee Schedule for Medical 
Service and Reference List 
for Drugs
Wang JD, 2004 (see above)
BNHI 2004 Fee Schedule and 
Chang Gung Hospital data
Chronic hepatitis B $11,806 ($8855–14,758)
Compensated cirrhosis $20,821 ($15,618–26,026)
Decompensated cirrhosis $44,431 ($33,323–55,539)
Hepatocellular carcinoma $96,510 ($72,383–120,638)
Liver transplantation $1,720,632 ($1,290,474–2,150,790)
Post-liver transplant $508,901 ($381,676–636,126)
Indicate the source for individual cost values (if 
appropriate).
Other direct costs (incurred 
directly in treating patients)
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
×
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
•	 Not reported.
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used.
Indicate the source for individual cost values (if 
appropriate)
Indirect costs (due to lost productivity, 
unpaid inputs to patient care)
Were indirect costs included?
•	 Not used.
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued).
Indicate the source for individual cost values (if 
appropriate).
Health-state valuations/utilities 
(if study uses quality of life 
adjustments to outcomes)
Were the utility data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
×
A review/synthesis 
or combination of 
previous studies
 Quality of life (utility) values 
associated with CHB disease 
states were based on data 
obtained from previously 
published economic 
evaluations (Pwu and Chan, 
2002,49 Wong et al., 1995,8 
Bennett et al., 199755
Expert opinion ×Appendix 4
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List the utility values used in the evaluation.
Seroconversion 1.00 (0.98–1.00) (Pwu and Chan49)
Chronic hepatitis B 0.95 (0.9–0.95) (Pwu and Chan49)
Compensated 
cirrhosis
0.9 (0.8–0.92) (Pwu and Chan49)
Decompensated 
cirrhosis
0.54 (0.5–0.65) (Wong et al., 19958)
Hepatocellular 
carcinoma
0.5 (0.3–0.5) (Bennett et al., 199755)
Liver transplantation 0.5 (0.5–0.6) (Bennett et al., 199755)
Post-liver transplant 0.7 (0.6–0.8) (Bennett et al., 199755)
Indicate the source for individual cost values (if 
appropriate).
Modelling
If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation).
•	 Markov state-transition model
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original.
•	 Model structure was similar to previously 
published models by Crowley42 and Pwu 
and Chan,49 except that Crowley did not 
include health states to account for liver 
transplantation.
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?
•	 Not explained, but presumably to estimate 
long-term costs and benefits (expressed 
in terms of final rather than intermediate 
outcomes) beyond the timeframe of the clinical 
trial (48-week treatment).
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.
•	 HBeAg seroconversion, HBeAg-positive 
CHB, compensated cirrhosis, decompensated 
cirrhosis, HCC, liver transplantation, postliver 
transplantation, and death.
Extract transition probabilities for [natural history/
disease progression] model and show sources (or 
refer to table in text).
Disease state 
from To % (range) Source
Chronic 
hepatitis B
Seroconversion, 
year 1, 
peginterferon a-2a
32.1 (30.0–
34.0)
Lau et al., 
200550
Seroconversion, 
year 1, lamivudine
19.1 (17.0–
21.0)
Lau et al., 
200550
Seroconversion, 
spontaneous, years 
3+
7.7 (5.0–9.0) Lok et al., 
198783
Compensated 
cirrhosis
4.4 (3.0–6.0) Liaw et al., 
198879
Hepatocellular 
carcinoma
0.83 (0.20–
1.00)
Liaw et al., 
198684
HBeAg 
seroconversion
Chronic hepatitis 
B, year 2, 
lamivudine
35.0 (30.0–
40.0)
van Nunen 
et al., 2003,80 
Wang et al., 
200454
Chronic hepatitis 
B, year 2, 
peginterferon a-2a
8.0 (3.0–
13.0) 
van Nunen 
et al., 200380
Chronic hepatitis 
B, spontaneous 
relapse
3.0 (2.6–5.0)  van Nunen 
et al., 200380
Compensated 
cirrhosis
1.0 (0.5–1.6) Crowley, 
200042
Compensated 
cirrhosis
Decompensated 
cirrhosis
4.6 (2.3–5.6) Liaw et al., 
198987
Hepatocellular 
carcinoma
2.8 (2.5–5.0) Liaw et al., 
198987
Death 5.1 (3.4–5.1)  Lau et al., 
199786
Decompensated 
cirrhosis
Hepatocellular 
carcinoma 
2.5 (2.0–5.0) Crowley, 
200042
Liver 
transplantation 
1.4 (10.05–
3.10)
Taiwan 
Registry
Death  39.0 (23.5–
40.0)
Crowley, 
200042
Hepatocellular 
carcinoma
Death 37.2 (37.0–
56.0)
Pwu and 
Chan, 200249
Liver 
transplantation
0.08 (0.02-
0.08)
Chen, 200690
Liver 
transplantation
Post-liver 
transplant
85.0 (79.0–
90.0)
Taiwan 
Bureau of 
National 
Health 
Insurance
Death  15.0 (10.0–
21.0)
Post-liver 
transplant
Death, year 2 and 
beyond
1.5 (1.0–5.7) Taiwan 
Bureau of 
National 
Health 
InsuranceDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
145
What is the model time horizon?
•	 Not reported, but appears to be life time.
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes?
•	 All costs and outcomes were discounted at a 3% 
annual rate.
Results/analysis
What measure(s) of benefit were reported in the 
evaluation?
•	 Life-years (LYs), quality-adjusted life years 
(QALYs)
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation.
•	 Treatment with PEG-α-2a compared with 
treatment with LAM is associated with:
  – additional discounted life expectancy of 
0.33
  – additional quality-adjusted life expectancy 
of 0.41 years.
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.
•	 Lifetime (discounted) costs associated with 
treatment
•	 PEG-α-2a NTD355,932 per patient
•	 LAM NTD200,016 per patient.
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of 
the results.
•	 The comparative performance of alternative 
treatment strategies was measured by the 
ICER, defined as the additional cost of a 
specific strategy, divided by its additional 
clinical benefit, compared with the next least 
expensive strategy.
•	 Discounted ICER is equal to NTD466,936 
(NTD472,475) per LY gained.
•	 Discounted ICER is equal to NTD380,619 
(NTD380,250) per QALY gained (US$12,000).
Give results of any statistical analysis of the results 
of the evaluation.
•	 No statistical analysis was reported.
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].
•	 Deterministic (one-way) sensitivity analysis was 
performed and the most influential variables 
were identified with a ‘tornado diagram’.
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?
•	 Parameter uncertainty (assumptions over 
values of parameters in the model, such as 
costs, quality of life or disease progression 
rates) were tested.
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?
•	 Estimates of incremental cost-effectiveness were 
most sensitive to variation in the probability of 
developing compensated cirrhosis from CHB, 
the probability of developing compensated 
cirrhosis from the seroconversion state, and the 
peginterferon alfa-2a efficacy rate.
•	 The ICER for peginterferon alfa-2a compared 
with lamivudine monotherapy ranged from 
NTD313,819 to NTD485,262 per QALY (i.e. 
did not exceed US$15,000) gained despite 
variation in treatment efficacy, drug cost, the 
health-state transition probabilities, utility 
values and health-state cost estimates.
Conclusions/implications
Give a brief summary of the authors’ conclusions 
from their analysis.
•	 The findings suggest that use of peginterferon 
alfa-2a is likely to be cost-effective, given 
certain assumptions about disease progression 
and the efficacy and cost of therapy. The 
cost-effectiveness ratios were most sensitive 
to variation in the probability of developing Appendix 4
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compensated cirrhosis from CHB, the 
probability of developing compensated 
cirrhosis from seroconversion and 
peginterferon alfa-2a efficacy rates. However, 
when these parameters were varied over a 
range of estimates, the ICER did not exceed 
NTD485,000 per QALY.
What are the implications of the evaluation for 
practice?
•	 Although 48 weeks of treatment with 
peginterferon alfa-2a (40KD) compared with 
48 weeks of treatment with lamivudine in 
CHB patients who are HBeAgpositive offers 
life expectancy benefits at a favourable cost-
effectiveness ratio, the implication for clinical 
practice in Taiwan is not clear as the current 
reimbursement guidelines in Taiwan provide 
for 6 months of peginterferon alfa-2a and 12–
18 months of lamivudine.
Reference
Kanwal and colleagues (2006) Treatment 
alternatives for hepatitis B cirrhosis: a cost-
effectiveness analysis.46
Study characteristics
Research question
What are the stated objectives of the evaluation?
•	 An economic analysis is performed to estimate 
the cost-effectiveness of competing strategies 
for the management of cirrhosis as a result of 
chronic HBV with active viral replication.
Study population
What definition was used for mild chronic hepatitis 
B?
•	 No definition was provided for chronic HBV; 
however, the cohort of patients with cirrhosis 
was assumed to have active viral replication at 
the baseline.
What are the characteristics of the baseline cohort 
for the evaluation?
Age 50 years old
Sex Not indicated
Race (if 
appropriate)
Not indicated
Genotype Not indicated
Other 
characteristics
It was assumed that 50% of the 
cohort had compensated cirrhosis and 
the remainder had decompensated 
cirrhosis. Within each treatment 
strategy patients are stratified by stage 
of liver disease (i.e. compensated 
vs decompensated) and separate 
probability estimates are assigned to 
compensated vs decompensated groups
Interventions and comparators
What number of interventions/strategies were 
included?
•	 Six.
Was a no treatment/supportive care strategy 
included?
•	 Yes.
Describe interventions/strategies.
Strategy 1: no pharmacological treatment of 
chronic HBV (‘do nothing’ strategy).
Strategy 2: lamivudine monotherapy 100 mg once 
daily for an indefinite period.
Strategy 3: ADV monotherapy 10 mg once daily for 
an indefinite period.
Strategy 4: lamivudine with crossover to ADV on 
development of resistance (‘ADV salvage’ strategy).
Intervention/strategy 5: entecavir monotherapy 
0.5 mg once daily for an indefinite period.
Intervention/strategy 6: lamivudine with crossover 
to entecavir on development of resistance 
(‘entecavir salvage’ strategy).DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Analytical perspective
What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)?
•	 The perspective adopted was of a (US) third-
party payer.
Study type
Cost-effectiveness/cost–utility/cost–benefit analysis?
•	 Cost–utility analysis. The results are reported 
as the incremental cost per QALY gained 
between the competing strategies.
Institutional setting
Where is/are the intervention(s) being evaluated 
usually provided?
•	 All pharmacotherapies are administered orally.
Country/currency
Has a country setting been provided for the 
evaluation? What currency are costs expressed 
in and does the publication give the base year to 
which those costs relate?
•	 2005 US$ (p. 2080).
Data sources
Effectiveness
Were the effectiveness data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single study ×
A combination of 
previous studies  Yes. A systematic review of 
literature was conducted and 
assessed by three independent 
reviewers according to the 
predefined selection criteria. 
All available data into annual 
probability estimates and 
combined across studies by 
calculating a weighted mean 
using study sample size as the 
weight
Expert opinion ×
Give the definition of treatment effect (outcomes) 
used in the evaluation.
•	 The following efficacy end points are relevant 
to probability estimates used in the evaluation:
progression from compensated to 
decompensated cirrhosis
  – regression (recompensation) from 
decompensated to compensated cirrhosis
  – decomposition following initial 
recompensation
  – progression from cirrhosis to 
hepatocellular carcinoma (for compensated 
cirrhosis only?)
  – developing resistance to initial 
pharmacotherapy
  – developing severe renal side effects (seems 
to be used in ADV patients only)
  – progression to liver transplantation
  – progression to cirrhosis following liver 
transplantation
  – subsequent complications related to 
recurrent HBV post-liver transplantation.
Give the size of treatment effect used in the 
evaluation.
•	 Not applicable. Outcomes are assessed in a 
dichotomous variable (yes/no).
Include values used for subgroups (if applicable). 
Indicate the source for individual treatment effects (if 
appropriate).Appendix 4
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Intervention costs
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
×
A review/synthesis 
or combination of 
previous studies and 
other sources
 Costs for physician services 
and procedures obtained 
from the 2005 American 
Medical Association Current 
Procedural Terminology 
codebook and the 2005 
Medicare Fee Schedule, 
and derived our base-case 
pharmaceutical costs from 
the average wholesale prices 
(AWPs) listed in the 2006 Red 
Book. Because large buying 
consortiums are often capable 
of obtaining prices lower 
than the Red Book AWPs, we 
obtained cost estimates for 
cirrhosis and related health 
states from a published study 
of detailed itemised inpatient 
and outpatient direct costs 
incurred by patients with 
cirrhosis (Bennett et al.55)
Expert opinion ×
List the direct intervention costs used in the 
evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well 
as sources for unit costs used.
Drug costs (Red Book, FDA)  ($)
Cost per month of lamivudine  158
Cost per month of ADV  595
Cost per month of entecavir  720
Cost per 5 ml injection of hepatitis B immune 
globulin (HBIG)
684
Non-drug costs of treatment period 
(American Medical Association, 2004 prices)
Cost per physician visit 52
Cost per set of laboratory tests  80
Cost per abdominal ultrasound 150
Costs of cirrhosis care (Bennett et al.55)
Cost per year of compensated cirrhosis  964
Cost of first year following variceal haemorrhage 
(assuming survival)
22,444
Cost per subsequent year following variceal 
haemorrhage
4393
Cost per year of ascites 4058
Cost of first year of encephalopathy 14,406
Cost per subsequent year following 
encephalopathy
3337
Cost of liver transplantation 127,499
Cost per year of follow-up care post-liver 
transplant
22,266
Cost of hepatocellular carcinoma  38,715
Indicate the source for individual cost values (if 
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Other direct costs (incurred 
directly in treating patients)
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single study  Cost estimates for cirrhosis 
and related health states were 
obtained from a published 
study of detailed itemised 
inpatient and outpatient direct 
costs incurred by patients 
with cirrhosis (Bennett et 
al.55) These 1997 costs were 
updated to 2005 dollars using 
the medical care component 
of the consumer price index
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used.
Cost per year of compensated cirrhosis  $964
Cost of first year following variceal 
haemorrhage (assuming survival)
$22,444
Cost per subsequent year following 
variceal haemorrhage
$4393
Cost per year of ascites $4058
Cost of first year of encephalopathy $14,406
Cost per subsequent year following 
encephalopathy
$3337
Cost of liver transplantation $127,499
Cost per year of follow-up care post-liver 
transplant
$22,266
Cost of hepatocellular carcinoma  $38,715
Indicate the source for individual cost values (if 
appropriate).
Indirect costs (due to lost productivity, 
unpaid inputs to patient care)
Were indirect costs included?
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued).
Indicate the source for individual cost values (if 
appropriate).
Health-state valuations/utilities 
(if study uses quality of life 
adjustments to outcomes)
Were the utility data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single study  Previously established utilities 
for cirrhosis and related 
complications that were 
derived using standard gamble 
elicitations in patients with 
chronic hepatitis C were 
adopted (Chong et al.59)
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
List the utility values used in the evaluation.
Utility of compensated cirrhosis  0.82 (0.80), 
according to Table 
3 (p. 2080)
Utility of decompensated cirrhosis  0.60
Utility following successful liver 
transplant 
0.86
Utility of hepatocellular carcinoma  0.73
Indicate the source for individual cost values (if 
appropriate).
Modelling
If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation).
•	 Markov state-transition model.Appendix 4
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Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original.
•	 The authors used their previously published 
model (Kanwal and colleagues38) for cost-
effectiveness analysis of treatment options in 
compensated hepatitis B to develop a current 
version for the subgroup of hepatitis B patients 
with cirrhosis.
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?
•	 To determine whether and under what 
circumstances the greater therapeutic benefits 
of newer antiviral agents, such as adefovir 
and entecavir, offset their greater cost versus 
lamivudine in the management of chronic 
hepatitis B cirrhosis (by extrapolating 
the outcomes of the clinical trial over the 
long term) (p. 2077), and also to permit 
comparisons between different interventions 
in medicine, using QALYs as a final outcome 
to allow for these comparisons to be made (p. 
2080).
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.
•	 The base-case patient has chronic HBV 
infection, active viral replication and 
clinical cirrhosis (either compensated or 
decompensated) and no previous treatment 
for hepatitis B (see Figure 1, p. 2077, although 
it is a bit confusing, as there is no transition 
from chronic HBV with cirrhosis to either 
decompensated or compensated cirrhosis).
•	 The following health states are used in the 
model:
  – compensated cirrhosis
  – decompensated cirrhosis
  – successful liver transplant
  – hepatocellular carcinoma
  – death.
Extract transition probabilities for [natural history/
disease progression] model and show sources (or 
refer to table in text). 
Estimate, 
%
Weighted 
averages across 
the following 
studies 
(references as 
reported in 
Kanwal et al.46 
are presented)
Transition probabilities used in ‘no treatment’ strategy
Annual rate of mortality 
in compensated cirrhosis
4.9 21–31
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis
7.3 21, 23, 29, 31–34
Annual rate of 
recompensation in 
decompensated cirrhosis
8 37–39
Annual rate of 
decomposition following 
initial recompensation
20 40, 41
Annual rate of mortality 
in decompensated 
cirrhosis
19 21–23, 26, 27, 35
Annual rate of 
progression 
from cirrhosis to 
hepatocellular carcinoma
3.4  21, 25, 29, 35, 36, 
42–45
Annual rate of mortality 
in hepatocellular 
carcinoma
43.3 46–48
Annual rate of receiving 
a liver transplant in 
decompensated cirrhosis
25 49
Annual rate of receiving 
a liver transplant in 
hepatocellular carcinoma
30 49
Annual rate of 
development of 
recurrent HBV following 
successful transplant 
(assuming patients on 
lamivudine and HBIG 
therapy post-transplant)
4.7 50–64
Annual rate of 
progression to 
decompensated 
cirrhosis in patients with 
recurrent HBV following 
successful transplant
24 52, 56, 66
Annual rate of 
progression to 
decompensated cirrhosis 
in patients without 
recurrent HBV following 
successful transplant
7 Not reported
Annual rate of receiving 
a second liver transplant 
in patients with 
recurrent HBV
13 Not reportedDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Estimate, 
%
Weighted 
averages across 
the following 
studies 
(references as 
reported in 
Kanwal et al.46 
are presented)
Annual rate of receiving 
a second liver transplant 
in patients without 
recurrent HBV
1 Not reported
Annual rate of mortality 
following successful 
transplant in patients 
with HBV recurrence 
(adjusted to account 
for decreasing mortality 
over time from 
transplant)
18.8 52, 66–70
Annual rate of mortality 
following successful 
transplant in patients 
with recurrent HBV 
(adjusted to account 
for decreasing mortality 
over time from 
transplant)
5.4  52, 66, 67
Transition probabilities used in LAM monotherapy strategy 
and combination treatment strategy in patients receiving 
LAM
Annual rate of 
developing resistance on 
long-term lamivudine
23 71–85
Annual rate of 
progression from 
compensated to 
decompensated 
cirrhosis with lamivudine 
resistance
8 5, 7, 10, 11, 38, 
86, 87
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis 
without lamivudine 
resistance
2 5, 11, 38, 86, 87
Annual rate of 
recompensation 
in decompensated 
cirrhosis with lamivudine 
resistance
8 Assumption
Annual rate of 
recompensation in 
decompensated cirrhosis 
without lamivudine 
resistance
35 7, 38, 87
Annual rate of 
decomposition following 
initial recompensation 
in decompensated 
cirrhosis with lamivudine 
resistance
25 Assumption
Estimate, 
%
Weighted 
averages across 
the following 
studies 
(references as 
reported in 
Kanwal et al.46 
are presented)
Annual rate of 
decomposition following 
initial recompensation in 
decompensated cirrhosis 
without lamivudine 
resistance
4 7
Annual rate of 
progression 
from cirrhosis to 
hepatocellular carcinoma
1.5 7, 87
Recurrent HBV following 
successful transplant 
with lamivudine 
resistance
80 5, 50, 70, 88
Annual rate of 
developing recurrent 
HBV following successful 
transplant without 
lamivudine resistance
4.7 88
Transition probabilities used in ADV monotherapy strategy 
and ADV salvage therapy
Annual rate of 
developing resistance on 
long-term adefovir
Year 1 0 89
Year 2 2 89
Year 3 5 89
Year 4 8 89
Annual rate of 
developing severe renal 
side effects
2 13, 88, 90, 91
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis 
with adefovir resistance
8 Assumption
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis 
without adefovir 
resistance
2 14, 91, 92
Annual rate of 
recompensation in 
decompensated cirrhosis 
with adefovir resistance 
(equal to corresponding 
variable in LAM arm)
8 AssumptionAppendix 4
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Estimate, 
%
Weighted 
averages across 
the following 
studies 
(references as 
reported in 
Kanwal et al.46 
are presented)
Annual rate of 
recompensation in 
decompensated cirrhosis 
without adefovir 
resistance
33 14, 93
Annual rate of 
decomposition following 
initial recompensation in 
decompensated cirrhosis 
with adefovir resistance 
(equal to corresponding 
variable in LAM arm)
25 Assumption
Annual rate of 
decomposition following 
initial recompensation in 
decompensated cirrhosis 
without adefovir 
resistance
4 91
Annual rate of 
progression 
from cirrhosis to 
hepatocellular carcinoma
1.5 93
Annual rate of 
development of 
recurrent HBV following 
successful transplant 
with adefovir resistance 
(equal to corresponding 
variable in LAM arm)
80 Assumption
Annual rate of 
development of 
recurrent HBV following 
successful transplant 
without adefovir 
resistance (equal to 
corresponding variable in 
LAM arm)
4.7 Assumption
Transition probabilities used in entecavir monotherapy 
strategy and entecavir salvage therapy
Annual rate of 
developing resistance on 
long-term entecavir
Treatment-naive 
patients (years 1 
and 2)
0 12, 109
Treatment-naive 
patients (years 3–10)
1 Assumption
Lamivudine-resistant 
patients years 3–14
7 100
Estimate, 
%
Weighted 
averages across 
the following 
studies 
(references as 
reported in 
Kanwal et al.46 
are presented)
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis 
without entecavir 
resistance(equal to 
corresponding variable in 
LAM/ADV arm)
2 Assumption
Annual rate of 
progression from 
compensated to 
decompensated cirrhosis 
with entecavir resistance 
(equal to corresponding 
variable in LAM/ADV 
arm)
8 Assumption
Annual rate of 
recompensation in 
decompensated cirrhosis 
with entecavir resistance 
(equal to corresponding 
variable in LAM/ADV 
arm)
8 Assumption
Annual rate of 
recompensation in 
decompensated cirrhosis 
without entecavir 
resistance (equal to 
corresponding variable in 
LAM arm)
35 Assumption
Annual rate of 
progression 
from cirrhosis to 
hepatocellular carcinoma 
(equal to corresponding 
variable in LAM/ADV 
arm)
4.7 Assumption
What is the model time horizon?
•	 Lifetime horizon.
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes?
•	 All costs and utility estimates were discounted 
at a rate of 3% per year.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Results/analysis
What measure(s) of benefit were reported in the 
evaluation?
•	 QALYs.
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation.
•	 Not reported separately.
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.
•	 Not reported separately.
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of 
the results.
•	 Adefovir monotherapy versus ‘doing nothing’ 
ICER is $19,731($14,342–$24,224).
•	 Adefovir monotherapy versus entecavir 
monotherapy ICER is $25,626 ($19,637–
$31,184).
•	 ‘Adefovir salvage’ strategy is dominated.
•	 ‘Entecavir salvage’ strategy is dominated.
•	 Lamivudine monotherapy is dominated.
Give results of any statistical analysis of the results 
of the evaluation.
•	 A probabilistic (Monte Carlo) simulation 
under the assumption that all variables were 
triangular.
•	 In distribution was performed to estimate the 
2.5 and 97.5 percentiles for estimated ICERs 
comparing alternative strategies.
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].
•	 Base-case probability estimates were varied 
within the plausible range reported in 
the literature or taken as an assumption. 
In particular, proportion of patients with 
decompensated hepatitis B at baseline was 
varied within 0–100% range. In the sensitivity 
analysis the medication prices from the Red 
Book were substituted for the acquisition costs 
of the Veteran’s Administration (VA) used as a 
proxy for the discounts achieved by large third-
party payers.
•	 A multivariable sensitivity analysis (‘tornado 
analysis’) was performed and the most 
influential variables were rank ordered. One-
way sensitivity analyses on the most influential 
variables were subsequently performed to 
identify the threshold values at which the 
cost-effectiveness order between the strategies 
changes (Table 5, p. 2081).
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?
•	 Parameter uncertainty was tested (ie. 
assumptions about costs, quality of life and 
disease progression rates).
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?
•	 The model outcomes were found to be sensitive 
to the following variables:
  – cost per month of adefovir
  – cost per month of entecavir
  – annual rate of progression from 
compensated to decompensated cirrhosis 
with lamivudine resistance
  – annual rate of progression from 
compensated to decompensated cirrhosis 
with entecavir (no resistance)
  – annual rate of progression from 
compensated to decompensated cirrhosis 
with adefovir (no resistance)
  – annual rate of progression from 
compensated to decompensated cirrhosis 
with adefovir resistance.
Conclusions/implications
Give a brief summary of the authors’ conclusions 
from their analysis.
The most cost-effective strategy in the management 
of HBV cirrhosis remains unclear. We performed 
a comprehensive decision analysis to identify the Appendix 4
154
most cost-effective therapeutic approach under 
varying clinical and budgetary conditions. Our 
analysis has four key findings:
1.  We found that the newer generation of antiviral 
therapies in HBV, including adefovir and 
entecavir, are cost-effective in patients with 
HBV cirrhosis and should be preferred over 
lamivudine monotherapy.
2.  Of the competing new-generation antiviral 
therapies, entecavir appears to be more 
effective yet more expensive than adefovir. 
Specifically, compared with adefovir, treating 
with upfront entecavir cost an additional 
$25,626 to gain one additional QALY – a 
value that falls well within the range of many 
commonly accepted medical interventions.
3.  Selecting between adefovir and entecavir is 
highly dependent on available budgets and 
‘willingness to pay’. For third-party payers 
willing to pay $50,000 per QALY gained for 
entecavir, most (> 60%) patients receiving 
entecavir will fall within the budget. In 
contrast, entecavir is generally not cost-
effective for third-party payers willing to pay 
less than $25,000 per QALY gained.
4.  Our analysis found that initiating upfront 
lamivudine with crossover to adefovir or 
entecavir as ‘salvage’ on emergence of viral 
resistance is not cost-effective in HBV patients 
with cirrhosis. However, when faced with a 
patient who has already developed lamivudine 
resistance, using ‘adefovir salvage’ appears 
more effective and less expensive than 
‘entecavir salvage’ on the basis of current viral 
resistance data.
What are the implications of the evaluation for 
practice?
1.  Both adefovir and entecavir seem to be cost-
effective in hepatitis B patients with cirrhosis.
2.  Of the new agents, entecavir appears more 
effective yet more expensive than adefovir. 
Selecting between these agents completely 
depends upon the available health care budget 
and willingness to pay.
3.  In patients with pre-existing lamivudine 
resistance, it appears more cost-effective 
to start with adefovir than with entecavir, 
as entecavir is associated with higher viral 
resistance than adefovir in the face of previous 
lamivudine resistance.
Critical appraisal
•	 Whether indirect comparison is used 
appropriately, i.e. only the studies that used the 
‘no treatment’ arm as a common comparator 
were included in obtaining probability 
estimates.
•	 Whether homogeneity was addressed in 
calculating probability estimates across the 
studies?
•	 Whether assumptions about transitioning from 
compensated to decompensated cirrhosis are 
well justified?
Reference
Buti and colleagues (2006) Cost-effectiveness 
analysis of lamivudine and adefovir dipivoxil in the 
treatment of patients with HBeAg-negative chronic 
hepatitis B.47
Study characteristics
Research question
What are the stated objectives of the evaluation?
•	 The objective of this study was to analyse the 
cost-effectiveness of long-term therapy (over 4 
years) with adefovir dipivoxil or lamivudine in 
patients with HBeAg-negative CHB in Spain. 
However, the study compared LAM with ADV as a 
salvage therapy treatment algorithm with algorithms 
based on ADV monotherapy.
Study population
What definition was used for mild chronic HBeAg-
negative hepatitis B?
•	 No definition is provided. However from 
Figure 1 (p. 411) it appears that the cohort 
consisted of CHB patients with HBeAg-
negative disease variant and compensated liver 
function.
What are the characteristics of the baseline cohort 
for the evaluation?
•	 The clinical effectiveness data for 100 
patients with chronic HBeAg-negative CHB 
were obtained from the range of trials that 
enrolled patients with different demographic 
characteristics at baseline.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Age Mean age of patients varied from 
45 to 49 years
Sex Proportion of males varied from 
74% to 83%
Race (if appropriate)
Genotype
Other characteristics Proportion of patients with 
cirrhosis, wherever reported, 
varied from 23% to 54% across 
four studies that were used to 
obtain estimates of the outcome
Interventions and comparators
What number of strategies were included?
•	 Two.
Was a no treatment/supportive care strategy 
included?
•	 No.
Describe interventions/strategies.
•	 Intervention/strategy 1: Lamivudine (100 mg 
daily) followed by adefovir dipivoxil (10 mg 
daily) as a salvage therapy for patients 
developing resistance to LAM treatment.
•	 Intervention/strategy 2: Adefovir dipivoxil 
(10 mg daily).
Analytical perspective
What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)?
•	 Spanish Public Health System.
Study type
Cost-effectiveness/cost–utility/cost–benefit analysis?
•	 Cost-effectiveness (incremental cost per 
additional patient with response).
•	 Cost-effectiveness ratios were also calculated.
Institutional setting
Where is/are the intervention(s) being evaluated 
usually provided?
•	 Not applicable. Both interventions are 
administered orally.
Country/currency
Has a country setting been provided for the 
evaluation? What currency are costs expressed 
in and does the publication give the base year to 
which those costs relate?
•	 Spain, 2003 Euros (p. 413).
Data sources
Effectiveness
Were the effectiveness data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single study ×
Combination of 
previous studies  See transition probabilities in 
Table 1 (pp. 412–13)
Expert opinion  See transition probabilities 
in Table 1 (pp. 412–13). The 
methods for obtaining expert 
opinion were not elaborated
Give the definition of treatment effect used in the 
evaluation.
•	 ‘Response to treatment’ defined as a ‘decrease 
of serum HBV DNA to undetectable levels by 
polymerase chain reaction (PCR) assay’ (p. 
411).
•	 In addition, ‘resistance to treatment’ as another 
outcome was used in the model. This was 
defined as as ‘reappearance of HBV DNA in 
serum due to the emergence of drug resistant 
HBV mutants’ (p. 411).
•	 Although not stated anywhere, ‘progressing 
to decompensated liver disease’ is an implicit 
outcome that is applied only to patients who 
received no treatment owing to development of 
resistance to LAM and/or ADV. This outcome 
is not associated with a defined health state but 
is associated with additional costs (Table 2, p. 
414).
Give the size of treatment effect used in the 
evaluation.
•	 Not applicable. Outcomes are assessed in a 
dichotomous variable (yes/no).
Include values used for subgroups (if applicable). 
Indicate the source for individual treatment effects (if 
appropriate).Appendix 4
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Intervention costs
Were the cost (resource use) data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
×
A review/synthesis 
or combination of 
previous studies
 The European 
consensus conference 
and other international 
recommendations were 
taken into consideration in 
estimating the amount of 
resource use
Expert opinion  Was used to estimate the 
frequency of outpatient visits 
and the laboratory tests 
required for each strategy
List the direct intervention costs used in the 
evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well 
as sources for unit costs used.
Resource category Type of resources Unit cost estimate Source
Drug cost (monthly) Lamivudine (100 mg, 28 
tablets) 
€55.59 Medicinal Product Catalogue
Adefovir dipivoxil (10 mg, 
30 tablets)
€428.40
Specialist hepatologist 
consultation
Initial consultation €154.24 Not indicated
Successive consultations €77.41
Pathology investigation Analyses €23.66 Not indicated
Serology €43.73 SOIKOS database 2004
α-fetoprotein €14.29 Not indicated
Radiology investigations Ultrasound scan €62.94 SOIKOS database 2004
Diagnostic tests Biopsy €319.19 SOIKOS database 2004, 
Hospital Vall d’Hebron HBV DNA €101.18
Resistance test €18.00DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Indicate the source for individual cost values (if 
appropriate).
The resources listed in the table above are 
combined in different quantities to obtain the 
aggregated cost of initial assessment, annual 
treatment with LAM, annual treatment with ADV 
and costs incurred when no intervention therapy is 
administered (no active treatment state). See Table 
3, p. 415.
Other direct costs
Were the cost data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
Not clear. Apparently average 
[weighted?] costs associated 
with progressing to a 
decompensated liver disease 
stage were derived using 
epidemiological data from 
unidentified source (footnote 
to Table 2, p. 414). Note: 
Decompensated CHB health 
state is not included in the 
model as presented in Figure 
1 (p. 411)
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used.
•	 Decompensation costs €172.50 applied only 
to a percentage of non-treated patients who 
develop decompensation because of cirrhosis 
(7.3%/year), hepatic encephalopathy (0.4%/
year), varicose haemorrhage (1.1%/year), 
ascites (2.5%/year), hepatocarcinoma (1.6%/
year); the source of these data is not provided.
Indicate the source for individual cost values (if 
appropriate).
Indirect costs (due to lost productivity, 
unpaid inputs to patient care)
Were indirect costs included?
•	 Indirect costs were not included.
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued).
Indicate the source for individual cost values (if 
appropriate).
Health-state valuations/utilities 
(if study uses quality of life 
adjustments to outcomes)
Were the utility data derived from:
Tick
Were the methods for 
deriving these data 
adequately described? 
(Give sources if using data 
from other published 
studies)
A single 
(observational) study
Not applicable
A review/synthesis 
or combination of 
previous studies
×
Expert opinion ×
List the utility values used in the evaluation.
Indicate the source for individual cost values (if 
appropriate).
Modelling
If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation).
•	 A decision-analytic model.
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original.
•	 Appears to be a newly developed model.
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?
•	 Not clearly indicated. Apparently, to help 
decision making in order to optimise resources 
by providing information regarding the costs 
associated with CHB and its progression 
towards more advanced stages, in particular 
with respect to treating HBeAg-negative 
patients with either LAM or AVD (summary of 
objective of the study as described on p. 410).Appendix 4
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What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.
During 4 years the patient may progress through 
the following stages:
•	 Initial treatment with LAM
  – receiving LAM treatment with response
  – continuing LAM treatment with response
  – developing resistance to LAM treatment
  – receiving ADV treatment and continue with 
response (applies to LAM patients who 
developed resistance)
  – developing resistance and no response to 
ADV treatment
  – no active treatment
Also implicitly assumed is the state of 
decompensated liver disease for the proportion of 
patients who receive no treatment.
•	 Initial treatment with ADV
  – receiving ADV treatment and continue with 
response
  – developing resistance and no response to 
ADV treatment
  – no active treatment
Also implicitly assumed is the state of 
decompensated liver disease for the proportion of 
patients who receive no treatment.
Source of data: Expert opinion (not elaborated) 
and published clinical trials.
Extract transition probabilities for [natural history/
disease progression] model and show sources (or 
refer to table in text).
See Table 1, pp. 412–13
Lamivudine as initial treatment
What is the model time horizon?
•	 4 years.
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes?
•	 A 3% discount rate was applied to costs in the 
base-case scenario. Sensitivity analysis used 
undiscounted costs. No discount rate was 
applied to the efficacy and response results as 
these were obtained from figures published in 
clinical studies.
Results/analysis
What measure(s) of benefit were reported in the 
evaluation?
•	 Proportion of patients with response.
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation.
•	 The proportion of patients with response in the 
lamivudine/adefovir arm at the end of year 4 
was 40.4%.
•	 The proportion of patients with response in the 
adefovir dipivoxil arm at the end of year 4 was 
78.0%.
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.
•	 The estimated discounted total cost of 4 years 
of treatment with lamivudine as an initial 
therapy was €11,457.
•	 The estimated discounted total cost of 4 years 
of treatment with adefovir dipivoxil as an initial 
therapy was €21,939.
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost-
effectiveness ratios)? If so, provide a summary of 
the results.
•	 CER (average cost per patient with successful 
therapy response at year 4)
  – €28,375 for the LAM/ADV arm
  – €28,132 for the ADV arm.
•	 ICER (additional cost per patient with response 
in ADV monotherapy arm)
  – €27 872.
Give results of any statistical analysis of the results 
of the evaluation.
•	 No statistical analysis was performed.
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].
•	 Deterministic one-way sensitivity analysis was 
performed (see Table 5, p. 417).DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Disease state from To Transition probability  Source of transition probability
Initial LAM treatment Continued LAM 
treatment with 
response (year 1)
0.73 Tassopoulos NC, et al. Efficacy of lamivudine 
in patients with hepatitis B e antigen-
negative/hepatitis B virus DNA-positive 
(precoremutant) chronic hepatitis B. 
Hepatology 1999;29:889–96
Continued LAM 
treatment with 
response (year 2)
0.58 Lai CL, et al. Prevalence and clinical correlates 
of YMDD variants during lamivudine therapy 
for patients with chronic hepatitis B. Clin Infect 
Dis 2003;36:687–96
Continued LAM 
treatment with 
response (year 3)
0.47 Lai et al., 2003
Continued LAM 
treatment with 
response (year 4)
0.37 Di Marco, 2004; Gaia, 2004; Papatheodoridis, 
2005
Developing resistance 
to LAM (year 1) 
0.27 Tassopoulos et al., 1999 
Developing resistance 
to LAM (year 2)
0.42 Lai et al., 2003
Developing resistance 
to LAM (year 3)
0.53 Lai et al., 2003
Developing resistance 
to LAM (year 4) 
0.63 Di Marco, 2004; Gaia, 2004; Papatheodoridis, 
2005
Develop resistance to 
LAM 
Receive ADV 
treatment and continue 
with response (first 
year after initiation)
0.571 Vassiliadis T, et al. Adefovir dipivoxil added 
to ongoing lamivudine therapy in patients 
with lamivudine resistant hepatitis B e antigen 
negative chronic hepatitis B. Aliment Pharmacol 
Ther 2005;21:531–7
Receive ADV 
treatment
Continue ADV 
treatment with 
response into the 
second and subsequent 
years
0.71 Hadziyannis et al. Long-term therapy with 
adefovir dipivoxil for HBeAg-negative chronic 
hepatitis B. N Engl J Med 2005;352:2673–81 
and panel of experts
Developing resistance 
and no response to 
ADV (first year after 
initiation)
0.429 Vassiliadis et al., 2005 
Developing resistance 
and no response to 
ADV into the second 
and subsequent years
0.29 Hadziyannis et al., 2005
Develop ADV 
resistance 
No treatment 1.0 Panel of experts
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?
•	 No sensitivity analysis in relation to structural 
uncertainty was performed.
Methodological uncertainty was tested by not 
applying a discount rate to the costs (0%), which is 
consistent with the choice of not discounting the 
outcomes.
The uncertainty in relation to the following 
resource use (but not the associated outcomes) was 
investigated:
1.  the dosage of lamivudine was increased from 
100 to 150 mg/dayAppendix 4
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2.  decompensation costs were set to be equal to 
zero
3.  the number of visits and laboratory tests 
investigating adefovir resistance was increased 
from two to four times per year to be equal to 
those treated with lamivudine
4.  the cost of the diagnostic test of HBV drug 
resistance was reduced by half.
In addition a threshold analysis was undertaken by 
varying a single parameter of the model associated 
with clinical effectiveness – the lamivudine arm 
response rate at year 4.
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?
•	 Considering €30,000 a threshold for a 
acceptability of a treatment strategy.
•	 CER and ICER were sensitive (i.e. > threshold) 
to the number of consultations in the ADV 
monotherapy arm and to the size of LAM dose 
in the combination therapy arm.
Conclusions/implications
Give a brief summary of the authors’ conclusions 
from their analysis.
•	 The results indicate that at the end of 
the 4-year treatment, suppression of viral 
replication is achieved in almost twice the 
number of HBeAg-negative patients treated 
with adefovir dipivoxil (monotherapy) 
compared with patients treated with 
lamivudine (as initial treatment followed by 
adefovir as a salvage therapy in patients who 
developed resistance to LAM). Although the 
costs associated with 4 years of therapy with 
adefovir dipivoxil are moreorless double those 
of lamivudine/(ADV), the cost per responding 
patient with adefovir dipivoxil is slightly 
less than with lamivudine/(ADV). This study 
demonstrates that long-term therapy, over 
a period of 4 years, with adefovir dipivoxil 
as first-line treatment for HBeAg-negative 
patients can be considered a cost-effective 
strategy (p. 417).
What are the implications of the evaluation for 
practice?
•	 Hard to tell considering that the model does 
not adequately describe the natural disease 
progression.
•	 In addition to assumptions listed on pp. 411–
412, many other assumptions were made in the 
model.
•	 Meta-analysis of the clinical outcomes across 
the studies using the same end point does not 
seem to have been conducted (simple averages 
are used). This means that the likely sources of 
homogeneity (e.g. differences in the baseline 
characteristics of the patients enrolled in the 
trials that provided inputs in the model) were 
not analysed.
•	 Indirect comparison of alternative therapies 
is used inappropriately. Clinical outcomes 
of LAM and ADV that were evaluated 
independently are used in two arms of the 
model.
•	 To check whether conditional probabilities 
(i.e. observed in LAM-resistant patients) 
were consistently applied to subsequent ADV 
treatment.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Appendix 5 
Transition probabilities used in 
published economic evaluationsAppendix 5
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From To
Intervention
BSC (SHTAC)
BSC (Veenstra 
et al., 200744)
BSC (Sullivan et 
al., 200746)
BSC (Kanwal et 
al., 200538)a
‘Cured’ state 
(HBsAg)
HBsAg # Not used Not used Not used
HCC 0.00005 (Wong et 
al., 19958)
Dead of all causes Life tables
Seroconversion 
(HBeAg)
HBsAg 0.02 (de Franchis 
et al., 20033)
Not used Not used Not used
HBeAg # # # 1.0
CHB 0.03 (Wong et al., 
19958)
0.029 (0.1–5.0) 
(Wong et al., 
19958)
0.03 (0.1–5.0) 
(van Nunen et al., 
200380)
0
CC 0.01 (Liaw et al., 
198879)
0.01 (0.5–2.0) 
(Crowley, 200042)
0.01 (0.5–2.0) 
(Crowley, 200042)
0
HCC 0.001 (Wong et 
al., 19958)
Not used Not used Not used
Dead of all causes Life tables Life tables Life tables Life tables
Chronic hepatitis 
B (CHB)
 HBsAg 0.0175 (Wong et 
al., 19958)
Not used Not used Not used
Seroconversion, 
spontaneous
0.09 (Wong et al., 
19958)
0.09 (6.0–12.0) 
(Wong et al., 
19958)
Seroconversion, 
year 3 + 0.077 
(5.0–9.0) (Lok et 
al., 198783)
0.069 (HBeAg 
+ve), 0.016 
(HBeAg –ve)
CHB # # # #
Compensated 
cirrhosis
0.05 (Liaw et al., 
198879)
0.06 (0.04–0.08) 
(Liaw et al., 
200482)
0.044 (0.03–0.06) 
(Liaw et al., 
198879)
0.03 (HBeAg 
+ve), 0.046 
(HBeAg –ve)
Hepatocellular 
carcinoma
0.005 (Di Bisceglie 
et al., 198881 
and Wong et al., 
19958)
0.004 (0.001–
0.007) (Crowley, 
200042)
0.083 (0.2–01) 
(Liaw et al., 
198684)
0.015 (0.0- 0.1)
Dead (excess 
mortality risk)
0.0035 (Gilead 
Sciences, 
Shepherd et al. 
200612)
Not used Not used Not used
Dead of all causes Life tables Life tables Life tables Life tables
Compensated 
cirrhosis (CC)
Seroconversion, 
spontaneous
0.09 (Wong et al., 
19958)
Not used Not used Not used
Compensated 
cirrhosis
# # # #
Decompensated 
cirrhosis
0.05 (Fattovich et 
al., 199185)
0.05 (0.038–
0.095) (Fattovich 
et al., 199185)
0.046 (0.023–
0.056) (Liaw et al., 
198987)
0.073 (0.035–0.1)
Hepatocellular 
carcinoma
0.025 (Wong et 
al., 19958)
0.025 (0.02–
0.078) (Wong et 
al., 19958)
0.028 (0.025–
0.05) (Liaw et al., 
198987)
0.034 (0.01- 0.12)
Dead (excess 
mortality risk)
0.051 (Lau et al., 
199786)
0.05 (0.03–0.065) 
(Lau et al., 199786)
0.051 (0.03–
0.065) (Lau et al., 
199786)
0.049 (0.02–0.14)DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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From To
Intervention
BSC (SHTAC)
BSC (Veenstra 
et al., 200744)
BSC (Sullivan et 
al., 200746)
BSC (Kanwal et 
al., 200538)a
Dead of all causes Life tables Life tables Life tables Life tables
Decompensated 
cirrhosis (DC)
Decompensated 
cirrhosis
# # # #
Liver transplant 0.03 (Bennett et 
al., 199755)
0.031 (0.01–0.1) 
(Bennett et al., 
1997 55)
0.014 (0.10–0.3) 
(Taiwan Registry)
0.25 (0.0–0.4) (US 
registry for organ 
sharing)
Hepatocellular 
carcinoma
0.025 (assumed 
the same as CC)
0.025 (0.02–
0.078) (assumed 
the same as CC)
0.025 (0.02–0.05) 
(Crowley, 200042)
Dead (excess 
mortality risk)
0.39 (Wong et al., 
19958)
0.39 (0.3–0.5) 
(Wong et al., 
19958)
0.39 (0.23–0.4) 
(Wong et al., 
19958)
0.19 (0.06–0.25)
Dead of all causes Life tables Life tables Life tables –
Hepatocellular 
carcinoma
Liver transplant 0 0 0 0.3 (0.0–0.4) (US 
registry for organ 
sharing)
Hepatocellular 
carcinoma
# # # #
Dead (excess 
mortality risk)
0.56 (Wong et al., 
19958)
0.56 (0.45–0.65) 
(Wong et al., 
19958)
0.37 (0.37–0.56) 
(Pwu and Chan, 
200249)
0.433 (0.2–0.6)
Dead of all causes Life tables Life tables Life tables Life tables
Liver transplant Post-liver 
transplantation 
state
– 0.79 0.85 (Taiwan 
Bureau of National 
Health Insurance)
Not used
Dead 0.21 (Bennett et 
al., 199755)
0.21 (Bennett et 
al., 199755)
0.15 (Taiwan 
Bureau of National 
Health Insurance)
Post-liver 
transplantation 
state
Post-liver 
transplantation 
state
# # # #
Dead 0.057 (Bennett et 
al., 199755)
0.057 (Bennett et 
al., 199755)
0.015 (Taiwan 
Bureau of National 
Health Insurance)
Annual mortality 
rate 0.069 (0.02–
0.12) (US registry 
for organ sharing)
BSC, best supportive care.
a  Transition probabilities used in Kanwal et al.48 are the weighted mean values across various relevant publications.
# indicates the residual probability, i.e. one minus the sum of all the other probabilities for the given health state.Appendix 5
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From To
Intervention
PEG-α-2a (Veenstra 
et al., 200744) PEG-α-2a (SHTAC)
PEG-α-2a (Sullivan 
et al., 200746)
‘Cured’ state (HBsAg) HBsAg Not used # Not used
HCC 0.00005 (Wong et al., 
19958)
Dead of all causes Life tables
Seroconversion 
(HBeAg)
HBsAg Not used 0.02 (de Franchis et 
al., 20033)
Not used
HBeAg # # #
CHB 0.08 (0.3–0.13) (van 
Nunen et al., 200380)
0.09 (as in IFN) (van 
Nunen et al., 200380)
0.08 (0.3–0.13) (van 
Nunen et al., 200380)
CC 0.01 (0.5–2.0) 
(Crowley, 200042)
0.01 (Liaw et al., 
198879)
0.01 (0.5–1.6) 
(Crowley, 2000)42
HCC Not used 0.001 (Wong et al., 
19958)
Not used
Dead of all causes Life tables Life tables Life tables
Chronic hepatitis B 
(CHB)
 HBsAg Not used 0.0175 Not used
Seroconversion, 
spontaneous
Seroconversion, year 
1, 0.32 (0.3–0.34) (Lau 
et al., 200550)
Seroconversion, year 
1, 0.32 (Lau et al., 
2005)50
Seroconversion, year 
1, 0.32 (0.3–0.34) (Lau 
et al., 200550)
CHB # # #
Compensated cirrhosis 0.06 (0.04–0.08) (Liaw 
et al., 200482)
0.05 (Liaw et al., 
198879)
0.044 (0.03–0.06) 
(Liaw et al., 198879)
Hepatocellular 
carcinoma
0.004 (0.001–0.007) 
(Crowley, 200042)
0.005 (Wong et al., 
1995,8 Di Bisceglie et 
al., 198881)
0.083 (0.02–0.1) (Liaw 
et al., 198684)
Dead (excess mortality 
risk)
Not used 0.0035 (Shepherd et 
al., 200612)
Not used
Dead of all causes Life tables Life tables Life tables
Compensated cirrhosis 
(CC)
Seroconversion, 
spontaneous
Not used 0.09 (Wong et al., 
19958)
Life tables
Compensated cirrhosis # # #
Decompensated 
cirrhosis
0.05 (0.038–0.095) 
(Fattovich et al., 
199185)
0.05 (0.038–0.095) 
(Fattovich et al., 
199185)
0.046 (0.023–0.056) 
(Liaw et al., 198987)
Hepatocellular 
carcinoma
0.025 (0.02–0.078) 
(Wong et al., 19958)
0.025 (Wong et al., 
19958)
0.028 (0.025–0.05) 
(Liaw et al., 198987)
Dead (excess mortality 
risk)
0.05 (0.03–0.065) (Lau 
et al., 199786)
0.051 (Lau et al., 
199786)
0.051 (0.03–0.065) 
(Lau et al., 199786)
Dead of all causes Life tables Life tables Not usedDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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From To
Intervention
PEG-α-2a (Veenstra 
et al., 200744) PEG-α-2a (SHTAC)
PEG-α-2a (Sullivan 
et al., 200746)
Decompensated 
cirrhosis (DC)
Decompensated 
cirrhosis
# # #
Liver transplant 0.031 (0.01–0.1) 
(Bennett et al., 199755)
0.03 (Bennett et al., 
199755)
0.014 (0.10–0.3) 
(Taiwan Registry)
Hepatocellular 
carcinoma
0.025 (0.02–0.078) 
(assumed the same as 
CC)
0.025 (assumed the 
same as CC)
0.025 (0.02–0.05) 
(Crowley, 200042)
Dead (excess mortality 
risk)
0.39 (0.3–0.5) (Wong 
et al., 19958)
0.39 (Wong et al., 
19958)
0.39 (0.23–0.4) (Wong 
et al., 19958)
Dead of all causes Life tables Life tables Life tables
Hepatocellular 
carcinoma
Liver transplant 0 0 0
Hepatocellular 
carcinoma
# # #
Dead (excess mortality 
risk)
0.56 (0.45–0.65) 
(Wong et al., 19958)
0.56 (Wong et al., 
19958)
0.37 (0.37–0.56) (Pwu 
and Chan, 200249)
Dead of all causes Life tables Life tables Life tables
Liver transplant Post-liver 
transplantation state
0.79 – 0.85 (Taiwan Bureau 
of National Health 
Insurance)
Dead 0.21 (Bennett et al., 
199755)
0.21 (Bennett et al., 
199755)
0.15 (Taiwan Bureau 
of National Health 
Insurance)
Post-liver 
transplantation state
Post-liver 
transplantation state
# # #
Dead 0.057 (Bennett et al., 
199755)
0.057 (Bennett et al., 
199755)
0.015 (Taiwan Bureau 
of National Health 
Insurance)Appendix 5
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From To
Intervention
LAM (Veenstra 
et al., 200744) LAM (SHTAC)
LAM (Sullivan et 
al., 200746)
LAM (Kanwal et 
al., 200538)a
‘Cured’ state 
(HBsAg)
HBsAg Not used # Not used Not used
HCC 0.00005 (Wong et 
al., 19958)
Dead of all causes Life tables
Seroconversion 
(HBeAg)
HBsAg Not used 0.02 (de Franchis 
et al., 20033)
Not used Not used
HBeAg # # # 1.0
CHB 0.25 (0.2–0.3) 
(van Nunen et al., 
200380)b
0.25 (0.2–0.3) 
(van Nunen et al., 
200380)b
0.25 (0.2–0.3) 
(van Nunen et al., 
200380)b
0
CC 0.01 (0.5–2.0) 
(Crowley, 200042)
0.01 (Liaw et al., 
198879)
0.01 (0.5–1.6) 
(Crowley, 200042)
0
HCC Not used 0.001 (Wong et 
al., 19958)
Not used Not used
Dead of all causes Life tables Life tables Life tables Life tables
Chronic hepatitis 
B (CHB)
 HBsAg Not used 0.0175 (Wong et 
al., 19958)
Not used Not used
Seroconversion, 
spontaneous
Seroconversion, 
year 1, 0.19 
(0.17–0.21) (Lau 
et al., 200550)
Seroconversion 
0.18 (Marcellin et 
al., 2003)88
Seroconversion, 
year 1, 0.19 
(0.17–0.21) (Lau 
et al., 200550)
0.2 (HBeAg +ve), 
0.1 (HBeAg –ve)
Seroconversion, 
year 2, 0.1 (0.095–
0.11) (Liaw et al., 
200051)
Seroconversion, 
year 3, 0.06 
(0.03–0.09) (Liaw 
et al., 200052)
Seroconversion, 
year 4, 0.05 
(0.025–0.075) 
(Liaw et al., 
200053)
CHB # # # #
Compensated 
cirrhosis
0.06 (0.04–0.08) 
(Liaw et al., 
200482)
0.02 additional Tx 
effect (Goodman 
et al., 199989)
0.044 (0.03–0.06) 
(Liaw et al., 
198879)
0.03 (HBeAg 
+ve), 0.046 
(HBeAg –ve)
Hepatocellular 
carcinoma
0.004 (0.001–
0.007) (Crowley, 
200042)
0.005 (Di Bisceglie 
et al.,81 Wong et 
al., 19958)
0.083 (0.02–0.1) 
(Liaw et al., 
198684)
0.015 (0.0–0.1)
Dead (excess 
mortality risk)
Not used 0.0035 (Shepherd 
et al., 200612)
Not used Not used
Dead of all causes Life tables Life tables Life tables Life tables
Compensated 
cirrhosis (CC)
Seroconversion, 
spontaneous
Not used 0.09 (Wong et al., 
19958)
Not used Not used
Compensated 
cirrhosis
# # # #DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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From To
Intervention
LAM (Veenstra 
et al., 200744) LAM (SHTAC)
LAM (Sullivan et 
al., 200746)
LAM (Kanwal et 
al., 200538)a
Decompensated 
cirrhosis
0.05 (0.038–
0.095) (Fattovich 
et al., 199185)
0.018 additional 
effect
0.046 (0.023–
0.056) (Liaw et al., 
198987)
0.073 (0.035–0.1)
Hepatocellular 
carcinoma
0.025 (0.02–
0.078) (Wong et 
al., 19958)
0.025 (Wong et 
al., 19958)
0.028 (0.025–
0.05) (Liaw et al., 
198987)
0.034 (0.01–0.12)
Dead (excess 
mortality risk)
0.05 (0.03–0.065) 
(Lau et al., 199786)
0.051 (Lau et al., 
199786)
0.051 (0.03–
0.065) (Lau et al., 
199786)
0.049 (0.02–0.14)
Dead of all causes Life tables Life tables Life tables Life tables
Decompensated 
cirrhosis (DC)
Decompensated 
cirrhosis
# # # #
Liver transplant 0.031 (0.01–0.1) 
(Bennett et al., 
199755)
0.03 (Bennett et 
al., 199755)
0.014 (0.10–0.3) 
(Taiwan Registry)
0.25 (0.0–0.4) (US 
registry for organ 
sharing)
Hepatocellular 
carcinoma
0.025 (0.02–
0.078) (assumed 
the same as CC)
0.025 (assumed 
the same as CC)
0.025 (0.02–0.05) 
(Crowley, 200047)
Dead (excess 
mortality risk)
0.39 (0.3–0.5) 
(Wong et al., 
19958)
0.195 0.39 (0.23–0.4) 
(Wong et al., 
19958)
0.19 (0.06–0.25)
Dead of all causes Life tables Life tables Life tables
Hepatocellular 
carcinoma
Liver transplant 0 0 0 0.3 (0.0–0.4) (US 
registry for organ 
sharing)
Hepatocellular 
carcinoma
# # # #
Dead (excess 
mortality risk)
0.56 (0.45–0.65) 
(Wong et al., 
19958)
0.56 (Wong et al., 
19958)
0.37 (0.37–0.56) 
(Pwu and Chan, 
200249)
0.433 (0.2–0.6)
Dead of all causes Life tables Life tables Life tables Life tables
Liver transplant Post-liver 
transplantation 
state
0.79 – 0.85 (Taiwan 
Bureau of National 
Health Insurance)
Not used
Dead 0.21 (Bennett et 
al., 199755)
0.021 additional 
effect
0.15 (Taiwan 
Bureau of National 
Health Insurance)
–
Post-liver 
transplantation 
state
Post-liver 
transplantation 
state
# # # #
Dead 0.057 (Bennett et 
al., 199755)
0.057 (0.6) 
(Bennett et al., 
199755)
0.015 (Taiwan 
Bureau of National 
Health Insurance)
Annual mortality 
rate 0.069 (0.02–
0.12) (US registry 
for organ sharing)
a  Transition probabilities used in Kanwal et al.38 are the weighted mean values across various relevant publications.
b  According to van Nunen et al.80 an additional 35% of LAM patients relapsed beyond 6 months of treatment. Veenstra 
et al.44 considered this to be an overestimate and reduced the figure to 25% to account for the potential impact of 
extended (up to 4 years’) therapy on seroconversion durability. In the SHTAC model these rates applied only to patients 
who underwent seroconversion while on LAM treatment and are only applied in the year immediately following 
seroconversion.
# indicates the residual probability, i.e. one minus the sum of all the other probabilities for the given health state.DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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TABLE 42  Utility decrements to age-specific health-state utilities: values used in probabilistic analysis
Mean SE Distribution Alpha Beta
HBsAg/HBeAg seroconverted 0.79 0.0102 Beta 558.6160 148.4929
CHB 0.69 0.0128 Beta 1416.7219 636.4982
Compensated cirrhosis 0.68 0.0128 Beta 908.7808 427.6615
Decompensated cirrhosis 0.35 0.0128 Beta 489.0519 908.2392
Hepatocellular carcinoma 0.42 0.0153 Beta 628.4237 867.8233
Liver transplantation 0.57 0.0128 Beta 595.7397 449.4176
Post-liver transplantation 0.66 0.0153 Beta 909.6367 468.6007
TABLE 43  Health-state cost distributions
Mean SE Distribution Alpha Beta
HBsAg seroconverted 0.00 – – – –
HBeAg seroconverted 289.65 57.93 Gamma 25.0000 11.5861
CHB 583.58 116.72 Gamma 25.0000 23.3433
Compensated cirrhosis 1341.42 231.17 Gamma 33.6726 39.8372
Decompensated cirrhosis 10,750.25 1519.47 Gamma 50.0553 214.7674
Hepatocellular carcinoma 9579.74 1909.83 Gamma 25.1606 380.7444
Liver transplantation 32,215.38 2884.79 Gamma 124.7094 258.3237
11,148.67 2547.97 Gamma 19.1451 582.3234
Post-liver transplantation 1632.58 355.02 Gamma 21.1461 77.2046
Standard error (SE) for HBeAg seroconversion and CHB costs assumed to be 20% of mean value.
Costs of transplant and first year care are estimated separately. Liver transplant cost is the sum of the two values.
TABLE 44  Effectiveness of IFN- α and PEG-α in probabilistic analysis
Parameter Intervention Mean Distribution Parameters
CHB to HBeAg 
seroconverted
IFN-α-2b 13.9% Beta n = 115; r = 16
PEG-α-2b 21.7% Beta n = 115; r = 25
Appendix 6  
Updated parameters in probabilistic 
sensitivity analysisDOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
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Optimal treatment sequence, using the principle of 
extended dominance:
IFN followed by LAM (ICER = £8804 per QALY 
gained relative to best supportive care), IFN 
Appendix 7  
Costs and outcomes of sequential 
treatment strategies – HBeAg-positive 
and HBeAg-negative cohorts
TABLE 46  Costs and outcomes of sequential treatment strategies for patients with HBeAg-negative CHB
Strategy Cost (£) Life expectancy Discounted QALYs
ICER (£ per QALY 
gained)
Best supportive care 16,532 12.46 8.43  
Conventional IFN-α 20,799 13.19 8.96 8040
Conventional IFN-α followed by 
lamivudine
24,378 13.78 9.40 8172
Conventional IFN-α followed by adefovir 
dipivoxil
46,181 14.49 9.92 26,648
Conventional IFN-α followed by 
lamivudine with adefovir salvage
50,737 14.75 10.11 37,419
Pegylated IFN-α 23,279 13.98 9.55 4251
Pegylated IFN-α followed by lamivudine 26,323 14.41 9.86 4239
Pegylated IFN-α followed by adefovir 
dipivoxil
44,132 14.92 10.24 –6432
Pegylated IFN-α followed by lamivudine 
with adefovir salvage
47,529 15.11 10.37 –12,114
TABLE 45  Costs and outcomes of sequential treatment strategies for patients with HBeAg-positive CHB
Strategy Cost (£) Life expectancy  Discounted QALYs
ICER (£ per QALY 
gained)
Best supportive care 10,676 18.12 13.48
Conventional IFN-α 14,632 18.43 13.80 12,215
Conventional IFN-α followed by 
lamivudine
17,232 18.87 14.22 6179
Conventional IFN-α followed by adefovir 
dipivoxil
29,163 19.46 14.76 15,186
Conventional IFN-α followed by 
lamivudine with adefovir salvage
28,961 19.51 14.80 20,412
Pegylated IFN-α 17,972 18.56 13.94 24,873
Pegylated IFN-α followed by lamivudine 20,473 18.99 14.35 26,647
Pegylated IFN-α followed by adefovir 
dipivoxil
31,882 19.55 14.86 27,636
Pegylated IFN-α followed by lamivudine 
with adefovir salvage
31,628 19.60 14.89 27,866
followed by LAM followed by ADV (ICER = 
£20,413 relative to IFN followed by LAM) and 
PEG followed by LAM followed by ADV (ICER = 
£27,856 relative to IFN followed by LAM followed 
by ADV).Appendix 7
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Optimal treatment sequence, using the principle of 
extended dominance:
PEG (ICER = £6056 per QALY gained relative to 
best supportive care), PEG followed by LAM (ICER 
= £9714 relative to PEG) and PEG followed by 
LAM followed by ADV (ICER = £41,560 relative to 
PEG followed by LAM).
This contrasts with the ICERs for the optimal 
treatment sequences derived from the original 
model, which were: PEG (ICER = £2950 per 
QALY gained relative to best supportive care), PEG 
followed by LAM (ICER = £4955 relative to PEG) 
and PEG followed by LAM followed by ADV (ICER 
= £18,039 relative to PEG followed by LAM). 
As with the majority of the analyses reported in 
this update, the scale of difference in the ICERs 
(particularly that for the sequence of PEG followed 
by LAM followed by ADV) is largely accounted 
for by the change in discounting practice. Using 
the same discount rates as in our previous report 
(6% for costs and 1.5% for outcomes), the ICERs 
for these sequences (which remain the optimal 
sequences) are: PEG (ICER = £3914 per QALY 
gained relative to best supportive care), PEG 
followed by LAM (ICER = £5715 relative to PEG) 
and PEG followed by LAM followed by ADV (ICER 
= £20,175 relative to PEG followed by LAM).DOI: 10.3310/hta13350  Health Technology Assessment 2009; Vol. 13: No. 35
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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